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CDK/cyclins play a central role in coordinating cell cycle progression, and in sustaining proliferation of cancer 
cells, thereby constituting established cancer biomarkers and attractive pharmacological targets. In 
particular, CDK4/cyclin D, which is responsible for coordinating cell cycle progression through G1 into S 
phase, is a relevant target in several cancers including melanoma, associated with mutation of CDK4, cyclin 
D, p16
INK4a
 and pRb. 
As there are no sensitive and direct approaches to probe CDK4/cyclin D activity in physiological and 
pathological conditions, the first goal of my thesis has consisted in engineering a fluorescent biosensor to 
probe this kinase in vitro and in cellulo. Once characterized and validated in vitro, the biosensor was applied 
to detect CDK4/cyclin D alterations in biopsies from human skin and melanoma xenografts in fluorescence-
based activity assays, and in living cancer cells by fluorescence microscopy and timelapse imaging. 
Moreover, only few inhibitors are currently available to target CDK4/cyclin D and most of them bind the ATP 
pocket. As such, the second major goal of my thesis project has consisted in identifying non-ATP competitive 
inhibitors, either through rational design of peptides or by screening small molecule libraries. To this aim, 
two fluorescent biosensors were engineered which discriminate compounds that target the interface 
between CDK4 and cyclin D, or that perturb the conformational dynamics of CDK4, respectively, from ATP-
pocket binding compounds. Fluorescence-based screening assays performed with these biosensors lead to 
identification of hits, which were validated and characterized in vitro and in cell proliferation assays, and 
which constitute promising candidates for selective chemotherapy in melanoma. 
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Les CDK/cyclines jouent un rôle majeur dans la progression du cycle cellulaire et dans le maintien de la 
prolifération des cellules cancéreuses, constituant ainsi des biomarqueurs clés et des cibles 
pharmacologiques attractives. Plus particulièrement, l’activité de CDK4/cycline D, kinase responsable de la 
progression de la phase G1 et de la transition G1/S, est dérégulée dans de nombreux cancers dont le 
mélanome. Cette hyperactivation est associée à des mutations, à l’amplification ou à la surexpression de 
CDK4, cycline D, p16
INK4a
 ou encore pRb. 
Comme aucune approche sensible et directe n’existe pour évaluer l’activité de CDK4/cycline D dans des 
conditions physiologiques et pathologiques, le premier objectif de ma thèse a consisté à développer un 
biosenseur fluorescent permettant d’étudier cette kinase in vitro et in cellulo. Une fois caractérisé et validé 
in vitro, le biosenseur a été appliqué à la détection d’altérations de CDK4/cycline D dans des biopsies de 
peau humaine et de xénogreffes de mélanome dans des essais fluorescents d’activité kinase, ainsi que dans 
des cellules cancéreuses vivantes par microscopie de fluorescence et vidéo microscopie. 
Par ailleurs, peu d’inhibiteurs sont actuellement disponibles pour inhiber CDK4/cycline D et la plupart 
d’entre eux ciblent la poche de fixation de l’ATP. C’est pourquoi le second objectif de ma thèse a consisté à 
identifier des inhibiteurs non compétitifs de l’ATP, soit par élaboration rationnelle de peptides, soit par 
criblage de petites molécules. A cette fin, deux biosenseurs fluorescents ont été développés qui permettent 
d’identifier soit des composés ciblant l’interface entre CDK4 et cycline D, soit des inhibiteurs allostériques 
capables de perturber la dynamique conformationnelle de CDK4. Des essais de criblage par fluorescence 
réalisés avec ces biosenseurs ont conduit à l’identification de touches qui ont été validées et caractérisées in 
vitro et dans des essais de prolifération cellulaire, et qui constituent des candidats prometteurs pour une 
chimiothérapie sélective du mélanome. 
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1. CDK/cyclins and cell cycle regulation 
1.1. The cell cycle 
The cell cycle enables all living organisms to grow and divide by generating two daughter cells from 
one mother cell. The rhythm at which cells are renewed varies from one organism to another and 
even from a cell to another. In eukaryotic cells, the cell cycle is controlled by a complex system of 
regulatory enzymes involved in different signaling pathways. The cell cycle is divided into four key 
phases: three interphase phases (G1, S and G2) where the cell grows, accumulates all necessary 
nutrients and synthesizes DNA for cell division, and the mitotic (M) phase where the cell divides into 
two daughter cells (Figure 1) (Harper and Brooks, 2005; Morgan, 1995, 1997; Nurse, 1975). 
 
Figure 1: Eukaryotic cell cycle phases. The cell cycle is divided into four phases : M, G1, S and G2 
(from (Lodish, 2008)). 
The cell cycle starts with G1 phase during which cells grow in size and synthesize proteins and RNA 
that are required for DNA replication.  
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Then, during the synthesis phase, commonly called S phase, chromosomes are replicated, leading to 
the production of two identical chromatids. 
Between DNA replication and mitosis, in G2 phase, cells continue to grow and prepare for mitosis. 
The fourth step of the cell cycle is defined by the mitotic phase (M phase). This phase corresponds to 
the division of one mother cell into two identical daughter cells. It is a four-stage process.  
- During prophase, chromosomes condense and the separation of the two centrosomes induces 
formation of the mitotic spindle.  
- Metaphase is the stage where the condensed chromosomes align in the middle of the cell, the 
nuclear envelope is disassembled and chromosomes are attached to microtubules.  
- During anaphase, the chromatids split, segregate and move toward opposite poles of the cell.  
- Telophase corresponds to the stage where chromosomes reach the centrosomes which lead to 
the formation of the daughter cells’ nuclei.  
- The final stage of mitosis is cytokinesis which is defined by the formation of two daughter cells 
containing the same genetic material (Sagona and Stenmark, 2010).  
Following these 4 stages, if cells lack growth factors and nutrients, they exit the cell cycle and stay in 
a quiescent state which is called the G0 phase. However, this process is reversible and cells can, upon 
growth factor stimulation, reenter the cell cycle. 
Cell cycle checkpoints are essential to ensure that each phase is accurately completed before 
entering the next phase. They are crucial to avoid abnormal events such as mutations which can 
further be implied in tumorigenesis (Lazzaro et al., 2009). Upon detection of DNA damage or 
incomplete processes, checkpoints such as the DNA damage checkpoint and the DNA replication 
checkpoint refrain cell cycle progression to enable repair and correction of these abnormal events or 
induce cell cycle arrest. In 1974, Pardee demonstrated the existence of a G1 checkpoint, also named 
restriction (R) point or point of no return, which occurs 2-3 hours prior to the onset of DNA synthesis 
and from where cells no longer require growth factors to complete the cell cycle and irreversibly 
commit to the cell division process (Pardee, 1974). 
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1.2. The discovery of CDK/cyclins 
In addition to cell cycle checkpoints, network of enzymes that control cell cycle progression were 
discovered through studies in starfish, yeast and Xenopus (Hartwell et al., 1974; Labbe et al., 1988; 
Nurse, 1975). Cyclin-dependent kinases (CDKs) were first identified, described and cloned in the 
1970s–1980s as gene products involved in regulation of the cell division cycle (Hartwell et al., 1974; 
Labbe et al., 1988, 1989; Lee and Nurse, 1987; Lohka et al., 1988; Nurse, 1975). CDK/cyclins form a 
family of serine/threonine proline-directed protein kinases that, by definition, catalyze the transfer 
of a phosphate group from ATP onto a serine or a threonine residue (Figure 2) (Cohen, 2002; Rubin 
and Rosen, 1975).  
 
Figure 2: The phosphorylation process. This reaction is catalyzed by kinases and consists in the 
removal of a phosphate group from ATP, followed by its covalent attachment to amino acids with a 
free hydroxyl group, namely, serine, threonine, and tyrosine. 
CDK/cyclins are heterodimeric complexes which contain a catalytic CDK subunit and a regulatory 
cyclin subunit. These kinases are part of the CMGC sub-family which also contains MAPK (Mitogen-
Activated Protein Kinases), GSK3 (Glycogen Synthase Kinase 3) and CLK (Cdc-like kinases) (Figure 3). 
Substrate
P
Substrate
kinaseOH
ATP ADP
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Figure 3: The kinome tree (adapted from https://www.horizon-genomics.com/available/kinome). 
The human genome harbors 518 genes encoding a kinase domain. 7 kinase sub-families have been 
defined : AGC named after the Protein Kinase A, G, and C families (PKA, PKG, PKC); CMGC for CDK, 
MAPK, GSK3 and CLK; CAMK best known for Calmodulin/Calcium regulated kinases (CAMK) in CAMK1 
and CAMK2 families; CK1 for Cell Kinase 1; STE for Homologs of the yeast STE7, STE11 and STE20 
genes; TK for Tyrosine Kinases; TKL for Tyrosine Kinase-Like proteins. 
After several decades of studies, twenty CDKs and about the same number of cyclins have been 
identified (Malumbres and Barbacid, 2005) (Table 1). Besides a well-known role in cell cycle 
regulation, a wealth of non-cell cycle functions has been reported for CDK/cyclin complexes including 
transcriptional regulation, epigenetics, DNA damage response and repair, neuronal differentiation, 
synaptic trafficking and remodelling, glycogen synthesis and lipogenesis, angiogenesis, 
haematopoiesis, ciliogenesis and spermatogenesis (Figure 4) (Lim and Kaldis, 2013; Prével et al., 
2014a).  
Symbol Synonym Identity to CDK1 (%) Cyclin-binding domain Main activating cyclin 
CDK1 Cdc2, Cdc28 100 PSTAIRE A1, A2, B1, B2 
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CDK2 
 
65 PSTAIRE A1, A2, E1, E2 
CDK3 
 
63 PSTAIRE E1, E2, A1, A2, C 
CDK4 PSK-J3 42 PISTVRE D1, D2, D3 
CDK5 
 
56 PSSALRE p35, p39 
CDK6 
 
43 PLSTIRE D1, D2, D3 
CDK7 
MO15, CAK, 
STK1 
38 NRTALRE H 
CDK8 K35 28 SMSACRE C 
CDK9 
 
34 PITALRE T1, T2, K 
CDK10 
 
37 PISSLRE Unknown 
CDK11 
Cdc2L1, 
Cdc2L2 
26 SMSACRE L1, L2 
PITSLRE 
 
35 PITSLRE Unknown 
PFTAIRE1 Pftk1 44 PFTAIRE Unknown 
PFTAIRE2 
 
41 PFTAIRE Unknown 
PCTAIRE1 Pctk1, Crk5 45 PCTAIRE Unknown 
PCTAIRE2 Pctk2 48 PCTAIRE (Cables1) 
PCTAIRE3 Pctk3 45 PCTAIRE Unknown 
CRK7 CrkRS, CD2L7 17 PITAIRE Unknown 
CHED Cdc2L5 16 PITAIRE Unknown 
CCRK 
 
37 PNQALRE Unknown 
Table 1: The mammalian CDKs and their activating cyclins (adapted from (Malumbres and 
Barbacid, 2005)) 
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Figure 4: Functions of cyclin-dependent kinases. Schematic representation of the functional 
diversity of CDKs and their converging contributions to subsets of biological processes (from 
(Prével et al., 2014a)) 
1.3. The CDK/cyclins involved in cell cycle regulation 
1.3.1.  Roles throughout the cell cycle 
Only four CDKs play a role in the cell cycle. CDK1/cyclin A-B, CDK2/cyclin A-E, CDK4/cyclin D and 
CDK6/cyclin D are in charge of regulating the different cell cycle transitions (Malumbres, 2011; 
Morgan, 1997). The sequential activation of these different CDK/cyclin complexes drives the 
transitions through the different phases of the cell cycle (Figure 5). CDK4-6/cyclin D ensure the 
progression through G1 phase and CDK2/cyclin E is responsible for G1/S transition. CDK2/cyclin A is 
involved in regulation of S phase, CDK1/cyclin A is responsible for progression through G2 phase 
whereas CDK1/cyclin B is activated during mitosis. Finally, besides an essential role in transcription, 
CDK7, in association with cyclin H, forms a complex termed CAK, the CDK-Activating Kinase, which is 
involved in activation of several CDK/cyclins through phosphorylation of the  CDK  activation  loop  
(or  T-loop) (Fisher, 2005).  
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Figure 5: Cell cycle regulation by CDK/cyclins (from (Peyressatre et al., 2015)). 
 Studies on mice have demonstrated that inactivation of genes coding for cell cycle CDKs was not 
lethal, except for CDK1/cyclin B, because of compensatory mechanisms between the different 
complexes (Santamaría et al., 2007; Satyanarayana and Kaldis, 2009; Sherr and Roberts, 2004). 
Surprisingly, these losses of function only affect the development of specialized cell types. The 
examples of CDK4 and CCND1 gene knockouts are detailed in paragraph 2.2. Only the absence of 
CDK1 leads to a cell cycle arrest, meaning that the other CDKs cannot compensate the loss of CDK1 
(Santamaría et al., 2007). 
1.3.2.  Regulation of CDK/cyclins 
Monomeric CDKs are catalytically inactive and acquire basal kinase activity through binding of a 
cyclin partner. Following their assembly into heterodimeric complexes, CDKs are subject to reversible 
activating and inhibitory phosphorylations which complete activation of the kinase (Boutros et al., 
2006; Kaldis, 1999; Morgan, 1995, 1997). They are subject to inhibitory phosphorylation which 
prevents ATP binding, on Thr14 and Tyr15 residues, for CDK1 and CDK2, by Wee1 and Myt1 kinases 
(Coleman and Dunphy, 1994; Morgan, 1997). They are then activated through activating 
phosphorylation of threonine 161 (Thr161 in CDK1) by the CDK-activating kinase CDK7/cyclin H and 
G1
S
G2
M
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(Cell growth)
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dephosphorylation of Thr14 and Tyr15 residues by members of the Cdc25 phosphatase family 
(Boutros et al., 2006; Kaldis, 1999). 
Besides these phosphorylation/dephosphorylation events, CDK/cyclins are also regulated through 
interactions with structural inhibitors called CDK inhibitors (CKIs). The INK4 family of CKIs comprises 
proteins composed of multiple ankyrin repeats (p16INK4a, p15INK4b, p18INK4c and p19INK4d) which 
specifically bind CDK4 and CDK6 and either prevent or compete with cyclin binding (Jeffrey et al., 
2000). CDK/cyclin activity is also regulated by association with the Cip/Kip family of CKIs (p21Cip1, 
p27Kip1, p57Kip2) which bind and maintain CDK/cyclin heterodimers in an inactive form (Sherr and 
Roberts, 1999).  
Figure 6 provides a schematic representation of the general molecular mechanism of assembly and 
regulation of CDK/cyclins, although some variations occur depending on the CDK. 
 
Figure 6: Schematic representation of the general molecular mechanism of assembly and 
regulation of CDK/cyclins (from (Prével et al., 2014a)). 
The mechanism of CDK/cyclin assembly has been described for CDK2/cyclin A and provides key 
information to gain insight into the molecular basis of CDK/cyclin complex activation (Brown et al., 
1999; Hagopian et al., 2001; Jeffrey et al., 1995; Morris et al., 2002; Russo et al., 1996). These studies 
reveal that cyclin binding is a two-step process which consists first in the rapid association between 
the PSTAIRE helix in the N-terminal lobe of CDK2 and the α5 helix of cyclin A (Figure 7). This step 
cdc25
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leads to reorientation of the CDK ATP-binding pocket, aligning it with the catalytic cleft in a position 
which is appropriate for transfer of phosphate onto the substrate. The second step corresponds to a 
slower isomerization of the CDK C-terminal lobe which promotes a conformational switch of an 
activating segment termed the T-loop, partially stabilizing it in a position which favours subsequent 
phosphorylation by CAK. Phosphorylation further displaces the T-loop into a position stabilized 
through interactions between the phosphate group and several residues within the C-lobe of the 
CDK, thereby generating a fully accessible substrate-binding site.   
 
Figure 7: Crystal structure of CDK2/cyclin A (PDB 1QMZ) 
1.4. CDK/cyclins and cancers 
1.4.1.  Definition and hallmarks of cancers 
Cancer is a generic term for a large group of diseases that involve abnormal cell growth with the 
potential to invade or spread to other parts of the body (Hanahan and Weinberg, 2000) 
(http://www.who.int/mediacentre/factsheets/fs297/en/). Other terms used are malignant tumours 
and neoplasms. Cancer can be defined as the rapid generation of abnormal cells that grow beyond 
their usual boundaries, and which can then invade other parts of the body and spread to other 
organs, the latter process is referred to as metastasizing. 
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Hanahan and Weinberg have proposed 6 characteristic features of all cancer cells associated with 
tumor progression (Hanahan and Weinberg, 2000) (Figure 8): 
- self-sufficiency in growth signaling 
- insensitivity to anti-growth signals 
- evasion of apoptosis 
- enabling of a limitless replicative potential 
- induction and sustainment of angiogenesis 
- activation of metastasis and invasion of tissue 
 
Figure 8: Schematic representation of the characteristic features of all cancer cells associated with 
tumor progression (from (Hanahan and Weinberg, 2000)). 
Cancer develops through accumulation of several genomic alterations including mutations, 
amplification and overexpression. Most of these deregulations affect two types of genes, the tumor 
suppressor genes and the proto-oncogenes, which, once altered, act as drivers of cancers (Vogelstein 
et al., 2013; Zhu et al., 2015). A tumor suppressor is a protective gene that normally limits the growth 
of tumors. If a mutation appears in this gene and causes a loss or reduction in its function, the cell 
can progress to cancer, usually in combination with other genetic changes (Sun and Yang, 2010). pRb 
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and p53 are two well-known examples of tumor suppressor proteins which are frequently mutated 
or deleted in cancers. In contrast, a proto-oncogene is a normal gene which, when altered by 
mutation, becomes an oncogene that can contribute to cancer (Croce, 2008). Most normal cells 
undergo apoptosis when critical functions are altered. Activated oncogenes can cause those cells 
designated for apoptosis to survive and proliferate instead. CDK/cyclins are not formally considered 
as oncogenes but highly contribute to sustain proliferation of cancer cells. In the literature, 
CDK/cyclin hyperactivity associated with mutations or aberrant expression has been widely described 
(Figure 8) (Malumbres and Barbacid, 2001, 2007) (COSMIC database 
http://www.sanger.ac.uk/genetics/CGP/cosmic/). 
 
Figure 9: Genetic alterations of G1/S regulators in human cancers. Only alterations that occur in 
more than 10% of primary tumours have been considered. The loci in which specific genetic or 
epigenetic alteration have been defined are in pink. The alterations for which no mechanistic 
explanation has been provided are in yellow. Alterations relevant for tumour prognosis are 
indicated by asterisks (from (Malumbres and Barbacid, 2001)). 
1.4.2.  Causes of cancers 
Both internal factors (including inherited mutations (5-10%), hormone deregulations, and immune 
disorders) and environmental factors promote genetic alterations and constitute the onset of 
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tumorigenesis (Anand et al., 2008; Shang, 2007). The vast majority of cancers, some 90–95% of cases, 
are due to environmental factors (Anand et al., 2008). Common environmental factors that 
contribute to cancer death include tobacco (25–30%), diet and obesity (30–35%), and infections 
(mostly due to viruses such as Human papillomavirus, Epstein Barr virus, Kaposi’s sarcoma-associated 
herpes virus, human T-lymphotropic virus 1, HIV, HBV, and HCV) (15–20%) (Anand et al., 2008). Up to 
10% of total cancer cases may be induced by radiation, both ionizing and nonionizing, typically from 
radioactive substances and ultraviolet (UV), pulsed electromagnetic fields (Belpomme et al., 2007). 
Cancers induced by radiation include some types of leukemia, lymphoma, thyroid cancers, skin 
cancers, sarcomas, lung and breast carcinomas. The remaining percentage (15-20%) is due to other 
factors like stress, physical activity, environmental pollutants or carcinogens such as asbestos (Anand 
et al., 2008; Hodgson and Darnton, 2000). 
1.4.3.  CDK/cyclins as therapeutic targets for cancer therapy 
CDKs, as cancer biomarkers, constitute attractive targets for the development of anti-cancer drugs. 
Over the last two decades, many efforts have been invested to develop potent inhibitors of 
CDK/cyclins (Asghar et al., 2015; Fischer et al., 2003; Garrett and Fattaey, 1999; Lapenna and 
Giordano, 2009). 
Targeting the ATP binding site, essential protein/protein interfaces, hydrophobic pockets or allosteric 
sites which are exposed only in inactive intermediates are part of the strategies developed to inhibit 
CDK/cyclin activity (Cohen and Alessi, 2013; Fang et al., 2013; Liu and Gray, 2006; Pommier and 
Cherfils, 2005). These approaches are detailed below in paragraph 3.  
It has to be mentioned that, despite the large number of CDK inhibitors which are currently 
undergoing clinical trials, only one inhibitor has been approved for clinical use so far. Indeed, on 
February 2015, FDA (Food and Drug Administration) granted approval to Palbociclib, a CDK4/6 
inhibitor for use in combination with letrozole for the treatment of post-menopausal women with 
estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative 
advanced breast cancer (http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm43288 
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6.htm).   
2. CDK4/cyclin D 
2.1. Primary sequences of CDK4 and D-cyclins 
2.1.1.  CDK4 
CDK4, formerly called PSK-J3, is a 34-kDa serine/threonine kinase. CDK4 was first cloned from HeLa 
cells and then from mice cells, based on its homology to mixed oligonucleotide probes representing 
highly conserved regions of other mammalian kinases (Hanks, 1987; Matsushime et al., 1992).  
Figure 10 displays the primary sequence of human CDK4 with its main functional elements such as 
the ATP-binding domain and the T-loop. 
 
Figure 10: Primary sequence of human CDK4 (source: www.uniprot.org/). Functional elements, 
which will be further described, are highlighted as follows : ATP-binding domain ; Inhibitory 
phosphorylation site: Y17 ; Cyclin-binding domain: PISTVRE ; Start and end of the T-loop ; 
Activating phosphorylation site: T172  (adapted from (Lim and Kaldis, 2013)). 
2.1.2. Human D-type cyclins 
Although only one cyclin D has been identified in mice, drosophila and many other organisms, three 
D-type cyclins, cyclin D1, cyclin D2 and cyclin D3, have been found expressed in most human 
proliferating cells (Sherr and Roberts, 2004). All three can bind CDK4 and CDK6 proteins. They are 
closely related as shown in Figure 11 which displays the sequence alignments of these proteins. The 
human cyclin D1 and cyclin D2 proteins are 51% and 62% respectively, identical to human cyclin D3, 
and 62% identical to each other (source: www.uniprot.org/). 
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Figure 11: Sequence alignements between cyclin D1, cyclin D2 and cyclin D3 (source: 
www.uniprot.org/) 
2.1.3.  Cyclin D1 
Compared with cyclin D2 and cyclin D3, the functional characterization of cyclin D1 and its role in 
human cancer have been much more studied and reported in the literature (Musgrove et al., 2011). 
In 1991, human cyclin D1 was first cloned by introducing a cDNA library prepared from a human 
glioblastoma cell line into a budding yeast strain that lacked CLN1 and CLN2 and was conditionally 
deficient for CLN3 function (Xiong et al., 1991). 
Figure 12 displays the primary sequence of human cyclin D1 with its main functional elements 
including the Rb binding domain and the cyclin box. 
 
Figure 12: Primary sequence of human cyclin D1 (source: www.uniprot.org/). Functional elements 
are highlighted as follows (adapted from (Alao, 2007; Musgrove et al., 2011)): 
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LXCXE motif: required for RB binding 
RXXL motif: required for APC (Anaphase Promoting Complex) mediated following genotoxic insult 
degradation (Agami and Bernards, 2000) 
Cyclin box: mediates CDK4 binding and is necessary for interaction with p21, p27 and p57 
LLXXXL motif: C-terminal leucine-rich motif which binds an LXXLL motif in the steroid receptor co-
activators SRC1 and AIB1 (McMahon et al., 1999; Zwijsen et al., 1998) 
T286: residue that, when phosphorylated, triggers ubiquitin-mediated degradation (see paragraph 
2.8) 
2.2. Phenotypes of mice lacking CDK4 or D-cyclins  
As previously described in paragraph 1.3, studies on mice have demonstrated that inactivation of 
genes coding for any interphase CDK was not lethal because of compensatory mechanisms between 
the different complexes (Santamaría et al., 2007; Satyanarayana and Kaldis, 2009; Sherr and Roberts, 
2004). CDK4 knockout in mice only induces abnormal development of β-pancreatic cells and leads to 
insulin-dependent diabetes (Rane et al., 1999). Triple knockout of cyclin D1, D2 and D3 leads to death 
due to anemia and defects in heart development (Kozar et al., 2004). Table 2 reports in details the 
phenotypes of mice with disrupted cyclin D and CDK4 genes. 
Cyclin D1 Viable 
Small body size, hypoplastic retinopathy, 
defective beast lobuloalveolar development 
during pregnancy, and uncharacterized 
neuropathy with altered clasping reflexes 
(Fantl et al., 1995; 
Sicinski et al., 1995) 
Cyclin D2 Viable 
Defective ovarian granulosa cell development 
and female sterility. Males have hypoplastic 
testes but are fertile. Abnormal postnatal 
cerebellar development due to a reduced 
number of granule neurons and loss of stellate 
interneurons. Impaired proliferation of 
peripheral B-lymphocytes 
(Huard et al., 1999; 
Lam et al., 2000; 
Sicinski et al., 1996; 
Solvason et al., 2000) 
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Cyclin D3 Viable 
Hypoplastic thymus with loss of T-cell 
maturation from double-negative (CD4−, 
CD8−) to double-positive (CD4+, CD8+) cells 
due to cytokine-independent defects in pre-
TCR signaling 
(Sicinska et al., 2003) 
Cyclin D2 and 
D3 
(D1 only) 
Embryonic 
lethality 
before 
E18.5 
Death likely is due to severe megaloblastic 
anemia. Other hematopoietic lineages were 
not evaluated. 
(Ciemerych et al., 
2002) 
Cyclin D1 and 
D3 
(D2 only) 
 
Death at 
P1, but a 
few 
survive to 
2 months 
Neuropathy leading to meconium aspiration is 
cause of early death. Survivors fail to thrive 
and exhibit hypoplastic retinas. 
Cyclin D1 and 
D2 
(D3 only) 
Viable but 
die within 
first three 
postnatal 
weeks 
Retarded growth and impaired coordination. 
Inhibited postnatal cerebellar development, 
and hypoplastic retinas 
Cyclins D1, 
D2, 
and D3 (no 
D-type cyclin) 
Dead by 
E16.5 
Severe hematopoietic deficits affecting 
number and proliferative capacity of stem 
cells and multipotential progenitors. Fetal liver 
lacks progenitors and cannot reconstitute 
lymphoid or myeloid function after 
transplantation. Death due to anemia and 
(Kozar et al., 2004) 
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defects in heart development. MEFs can be 
propagated in culture but exhibit greatly 
reduced susceptibility to transformation by 
oncogenic Ras + Myc, E1A, or DN-p53 
Cdk4 Viable 
Small body size. Most males are sterile due to 
hypoplastic testes and low sperm counts. 
Female sterility is due to defects in the 
hypothalmic–pituitary axis, abnormal estrus, 
and failure of corpus luteum. Abnormal 
development of pancreatic-islet cells leads to 
insulin-dependent diabetes within the first 2 
mo of life. MEFs can be propagated in culture 
with decreased ability to enter the cell cycle 
from quiescence; they express aberrantly high 
levels of p21Cip1 and resist transformation by 
oncogenic Ras + DN-p53. 
(Moons et al., 2002; 
Rane et al., 1999; 
Tsutsui et al., 1999; 
Zou et al., 2002)  
Table 2: Phenotypes of mice with disrupted cyclin D and CDK4 genes (from (Sherr and Roberts, 
2004)) 
2.3. Role in the cell cycle 
Under normal conditions, most cells in multicellular organisms remain in a quiescent state (G0 phase) 
and do not divide. Upon stimulation by extracellular signals such as growth factors, cells can reenter 
the G1 phase of the cell cycle. CDK/cyclin complexes involved in the regulation of G1 phase and G1/S 
transition are CDK4-6/cyclin D and CDK2/cyclin E. They have been demonstrated to be involved in the 
G1 checkpoint (or restriction point; see paragraph 1.1) from where cells no longer require growth 
factors to complete the cell cycle and irreversibly commit to the cell division process (Blagosklonny 
and Pardee, 2002). Indeed, the phosphorylation of the members of the retinoblastoma protein family 
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(pRb, p107 and p130) by CDK4-6/cyclin D leads to E2F transcription factor derepression inducing 
transcription of cyclin E which is required for G1/S transition (Ho and Dowdy, 2002) (Figure 13). 
 
Figure 13: Function and regulation of CDK4/cyclin D (from (Peyressatre et al., 2015)). The 
expression of cyclin D (orange) via mitogenic signals leads to its association with CDK4 (blue) and 
formation of the complex. The binding with Cip/Kip proteins (light purple) is required for assembly 
of the complex and its nuclear localization. The activity of CDK4/cyclin D activity is negatively 
regulated by interaction with the INK4 protein family (pink). Once activated, CDK4/cyclin D 
regulates the progression through G1 phase and the transition into S phase. CDK4/cyclin D 
phosphorylates the retinoblastoma protein (Rb) (dark purple) inducing the derepression of E2F 
transcription factors (green) which allows the transcription of genes which are required for G1/S 
transition. 
More recently, it has been shown that CDK4/cyclin D activates pRb by mono-phosphorylation and 
that CDK2/cyclin E executes all the remaining inactivating phosphorylations (Narasimha et al., 2014). 
The complete phosphorylation of pRb then allows for complete release of E2F factors, which may act 
as transcriptional activators (Boonstra, 2003). 
Besides a function in G1 phase progression and G1/S transition, Gabrielli and co-workers have 
reported a role of CDK4, in complex with cyclin D3, in G2/M transition (Gabrielli et al., 1999). They 
have provided evidence for a CDK4/cyclin D3 activity in late S/G2 phase that appears to be required 
for normal cell cycle progression through G2 phase into mitosis. Indeed p16
INK4a accumulation, in 
response to UV radiation, leads to inhibition of CDK4 activity which appears to be involved in the G2 
phase delay observed. 
2.4. Differences between CDK4 and CDK6 
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The human CDK4 and CDK6 proteins are 64% identical to each other (source: www.uniprot.org/). 
Because of this high sequence identity and their similar expression profiles, they have been widely 
thought to act redundantly to regulate the cell cycle through the phosphorylation of pRB. However, 
novel functions of CDK6 have been recently uncovered and several studies highlight differences 
between CDK4 and CDK6. For example CDK6, when proliferation is inappropriate, plays a role in 
halting cellular growth through a mechanism involving the accumulation of the p53 and p130 
growth-suppressing proteins (Nagasawa et al., 2001). Moreover, CDK6 has been found to be involved 
in angiogenesis (Kollmann et al., 2013). Indeed, Kollmann and collaborators have demonstrated that 
CDK6 was part of a transcription complex that induces the expression of the tumor suppressor 
p16INK4a and the pro-angiogenic factor VEGF-A. Differences in subcellular localization and in the 
timing of nuclear localization of CDK4 and CDK6 have also been described (Mahony et al., 1998; 
Nagasawa et al., 1997). Moreover, CDK4 and CDK6 are differently deregulated in cancer cells (Bellail 
et al., 2014; Chilosi et al., 1998; Corcoran et al., 1999; Costello et al., 1997; Dobashi et al., 2004; 
Peyressatre et al., 2015; Puyol et al., 2010; Sotillo et al., 2001a; Wölfel et al., 1995). 
2.5. Other roles of CDK4/cyclin D 
Beyond its role in cell cycle progression, CDK4/cyclin D is also essential for control of metabolic 
processes such as lipid synthesis, glycolysis, and mitochondrial function (Fajas, 2013). For instance, 
Fajas and collaborators have demonstrated an adipogenic role of CDK4 and cyclin D3 through 
positive regulation of PPARγ activity, a ligand-activated transcription factor belonging to the nuclear 
receptor superfamily activity (Abella et al., 2005; Sarruf et al., 2005). 
Moreover, CDK4 is involved in controlling proliferation of specific cell types such as pancreatic β cells 
(Martín et al., 2003). The lack of CDK4 expression in mice leads to insulin-deficient diabetes due to a 
reduced number of pancreatic cells. It has been shown that the CDK4-pRB-E2F1 pathway was 
involved in glucose homeostasis through regulation of the expression of Kir6.2, a key component of 
the KATP channel involved in the regulation of glucose-induced insulin secretion in pancreatic β-cells 
(Fajas et al., 2010). 
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Aggarwal and co-workers have also demonstrated a role of CDK4/cyclin D in epigenetic regulation 
through Mep50 phosphorylation (Aggarwal et al., 2010). Indeed, accumulation of nuclear 
CDK4/cyclin D1 during S-phase triggers increased PRMT5/MEP50 activity, thereby specifically 
reducing CUL4 expression. 
Other functions of cyclin D1 have also been described such as a role in HR-mediated DNA damage 
repair (Jirawatnotai et al., 2011; Li et al., 2010). Indeed, analyses of cyclin D1 interactors have 
revealed a network of DNA repair proteins, including RAD51, a recombinase that drives the 
homologous recombination process (Jirawatnotai et al., 2011). 
Finally, a nuclear role of cyclin D1 in NF-Y, Stat, Creb2, Elk1, Znf423 and Cux1 transcription, 
independent of CDK4, has been discovered by performing a genetic-proteomic screen (Bienvenu et 
al., 2010). 
2.6. Other substrates of CDK4/cyclin D 
CDK4-6/cyclin D complexes are mostly known for their role in G1 phase. Thus, the pRb family 
members (p105Rb, p107, p130Rb2) are the best known substrates for CDK4. However, CDK4/cyclin D 
also phosphorylates other substrates including Smad3, a protein which has a key function in 
mediating the TGF-beta growth-inhibitory response; the DNA replication factor Cdt1; the nucleolar 
transcription factor upstream binding factor (UBF); the bone-specific transcription factor Runx2; and 
possibly the tumour suppressor tuberous sclerosis complex 2 (TSC2) (Bockstaele et al., 2006; Liu et 
al., 2004; Matsuura et al., 2004; Shen et al., 2006; Voit et al., 1999; Zacharek et al., 2005). 
2.7. Regulation of CDK4/cyclin D activity 
The activity of CDK4/cyclin D is regulated by phosphorylation/dephosphorylation events. 
Phosphorylation of residue Tyr17, close to the ATP binding site, maintains CDK4 in an inactive 
conformation (Figure 14). This site of phosphorylation is equivalent to Tyr15 of the well-described 
CDK1 kinase which undergoes inhibitory phosphorylation by WEE1 and MYT1 (Mueller et al., 1995; 
Parker and Piwnica-Worms, 1992). However, these two kinases do not phosphorylate CDK4. Instead, 
phosphorylation of CDK4 on Tyr17 is performed by Src kinases (Martin et al., 2008). Cdc25A 
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phosphatase performs the dephosphorylation of this residue, leading to the partial activation of 
CDK4 (Boutros et al., 2006; Iavarone and Massagué, 1997; Terada et al., 1995). Activating 
phosphorylation on Thr172 residue by the CAK CDK7/cyclin H allows a full activation of CDK4 and this 
is essential to promote G1 progression (Schachter et al., 2013) (Figure 14).  
 
Figure 14: Crystal structure of CDK4, in complex with cyclin D3 (not shown here) (PDB 3G33). The 
functional elements are highlighted as follows: ATP-binding domain; Inhibitory phosphorylation 
site: Y17; Cyclin-binding domain: PISTVRE; Start and end of the T-loop; Activating phosphorylation 
site: T172 
Besides these phosphorylation/dephosphorylation events, CDK4/cyclin D activity is also regulated by 
CKIs (Figure 13). Its activity is inhibited by interaction with the INK4 proteins which can bind both 
monomeric CDK4, preventing its association with cyclin D, and the CDK4/cyclin D complex, forming 
an inactive ternary entity (Jeffrey et al., 2000). CDK4/cyclin D activity is also regulated by association 
with Cip/Kip proteins (Sherr and Roberts, 1999). At low concentration, they act as positive regulators 
by enhancing the binding between CDK4 and cyclin D and the translocation of the dimeric complex 
into the nucleus (LaBaer et al., 1997). Indeed, p21 and p27 contain a NLS sequence (Nuclear 
Localization Sequence) but not cyclin D and CDK4 (Bockstaele et al., 2006; Sherr and Roberts, 1999). 
At higher concentrations, Cip/Kip proteins inhibit CDK4/cyclin D activity. It has to be noted that, 
Y17
T172
PISTVRE domain
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N-ter
C-ter
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through the sequestration of p21 and p27, CDK4/cyclin D plays a second non-catalytic role in G1 
phase progression by facilitating CDK2 activation (Figure 15). Indeed, sequestration by CDK4/cyclin D 
of Cip/Kip proteins, which also bind CDK2/cyclin E, lowers the inhibitory threshold and facilitates 
activation of this complex (Sherr and Roberts, 1999). 
 
Figure 15: Regulation of CDK4/cyclin D and CDK2/cyclin E by Cip/Kip proteins (from (Sherr and 
Roberts, 1999)). Mitogenic signals promote the assembly of active CDK4-6/cyclin D complexes with 
a Cip or Kip protein. Sequestration of Cip/Kip proteins lowers the inhibitory threshold and 
facilitates activation of the CDK2/cyclin E complex. The cyclin D- and E-dependent kinases 
contribute sequentially to Rb phosphorylation, canceling its ability to repress E2F family members 
and activating genes required for entry into S phase. 
Recently, it has been demonstrated that Cip/Kip proteins also play a role in transcriptional regulation 
of genes repressed by p130/E2F4 complexes by recruiting and regulating the activity of specific 
CDK/cyclin complexes on the promoters (Orlando et al., 2015). It is well-known that, during the G1 
phase of the cell cycle, sequential phosphorylation of p130 by CDKs disrupts p130/E2F4 complexes 
allowing gene expression. Orlando and collaborators have demonstrated that, in early and mid G1, 
p27 recruits CDK4/cyclin D2-D3 complexes on the promoters by its amino terminal domain; and in 
late G1, these complexes are substituted by p21/cyclin D1/CDK2. In cells lacking p27, CDK4/cyclin D2-
D3 do not associate to the promoters and phosphorylation of p130 and transcription of target genes 
is increased. In p21 null cells, CDK2/cyclin D1 are not found on the promoters and transcription is 
elevated. 
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2.8. Expression, degradation and subcellular localization 
Regarding D-type cyclin expression, it has been demonstrated that, in Swiss 3T3 cells, different 
mitogenic stimuli could induce disparate responses in cyclin D1 and cyclin D3 expression (Anderson 
et al., 2010). Indeed, activation of the PI3K/AKT/mTOR pathway results in generation of active cyclin 
D3 whereas activation of the Ras/Raf/MEK/ERK pathway leads to cyclin D1 transcription. 
Upon activation of these pathways, D-cyclins are synthesized in the cytoplasm by ribosomes and then 
associate with CDK4 which is, like other CDKs, believed to be continuously expressed. Two 
transcription factors are involved in CDK4 expression. The first one is the zinc finger-homeodomain 
transcription factor, δ-crystallin enhancer factor 1 (δEF1), which has been shown to upregulate CDK4 
transcription via the E2-box element on the CDK4 promoter (Hu et al., 2014). The second one is the 
proto-oncogene c-MYC which has been found to induce a rapid increase in CDK4 mRNA levels 
through four highly conserved c-MYC binding sites within the CDK4 promoter (Hermeking et al., 
2000). In c-Myc-deficient cells, serum-stimulated induction of CDK4 mRNA is attenuated and delayed. 
These cells exhibit an extension of their G1 and G2 phases, leading to an increase in cell-doubling 
time from 18 h to 50 h.  
Once assembled, the CDK4/cyclin D complex shuttles from the cytoplasm into the nucleus, thanks to 
Cip/Kip proteins, to phosphorylate its nuclear substrate Rb (Bockstaele et al., 2006; LaBaer et al., 
1997). 
Cyclin D1 is an unstable protein with a short half-life of 24 min (Alao, 2007; Diehl et al., 1998). Cyclin 
D1 is mainly degraded in the cytoplasm via the 26S proteasome in an ubiquitin-dependent manner 
(Alao, 2007). This mechanism involves cyclin D1 phosphorylation on Thr286 residue by GSK3β 
(glycogen synthase kinase 3β), which promotes relocation of cyclin D1 in the cytoplasm through 
association with the nuclear exportin CRM1 (Chromosome Region Maintenance 1) (Diehl et al., 
1998). Indeed, this phosphorylation induces a conformational change in cyclin D1 that exposes a 
nuclear export sequence (NES) (residues 290 – 295) that is recognized by CRM1 (Alt et al., 2000; 
Benzeno and Diehl, 2004; Moore, 2013). 
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2.9. Structural and mechanistic features of CDK4/cyclin D 
2.9.1.  Assembly and activation of CDK4/cyclin D 
In its monomeric conformation, CDK4, like other mammalian CDKs, is inactive. CDK4 activation 
requires first the binding with its regulatory subunit cyclin D.  
The mechanism of assembly is believed to be similar for the different CDK/cyclin complexes. 
However, some elements of specificity induce differences in substrate recognition and in biological 
and physiological functions. The comparison of CDK2/cyclin A and CDK4/cyclin D crystal structures 
indicate that the interaction between the PISTVRE helix of CDK4 and the α5 helix of cyclin D is 
conserved whereas interactions between the C-terminal lobe of CDK4 and cyclin D are not (Figure 16) 
(Day et al., 2009; Lolli, 2010; Takaki et al., 2009). CDK2/cyclin A displays a “closed” conformation in 
contrast to the “open” conformation of CDK4/cyclin D. Moreover, it has been demonstrated that 
CDK4, although bound to cyclin D1 and phosphorylated on Thr172, is in an inactive conformation 
(Day et al., 2009). It was therefore suggested that substrate binding and association with Cip/Kip 
proteins might induce a closed conformation and favor complete activation (Day et al., 2009; Takaki 
et al., 2009). However, a recent study based on molecular dynamics with excited normal modes 
suggests that a closed conformation may exist in CDK4/cyclin D1, resembling that of CDK2/cyclin A 
(Floquet et al., 2015). 
 
Figure 16: Representation of CDK2/cyclin A (PDB 1QMZ), CDK4/cyclin D1 (PDB 2W99) and 
CDK4/cyclin D3 (PDB 3G33) crystal structures. 
2.9.2. Rb binding 
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The sequence of Rb can be divided in four domains, the N- and C-termini and the pocket A and B 
domains. Numerous studies have demonstrated that the Rb protein interacts with the LXCXE motif 
present in transcription factors and in some cyclins through its B domain (Lee et al., 1998). More 
recently, a site within the C-terminal domain of Rb (amino acids 893 to 910) was found to be 
required for cyclin D1-CDK4-dependent phosphorylation of Rb both in vitro and in cells (Wallace and 
Ball, 2004). 
2.10. CDK4/cyclin D deregulation in cancers 
Deregulation of the p16INK4a / CDK4/6-cyclin D / pRb pathway is one of the most frequent events in 
cancers, suggesting that inhibition of CDK4 activity constitutes a relevant therapeutic target for 
cancer therapy (Musgrove et al., 2011; Sherr, 1996). Figure 17 illustrates the genetic alterations 
found for the different components of this pathway. 
 
Figure 17: Deregulation of CDK4/cyclin D activity in human cancers associated with R24C mutation 
of CDK4, mutation of p16
INK4a
 or Rb, overexpression or amplification of CDK4 or cyclin D 
Genetic inactivation of p16INK4a, inhibitor of CDK4/cyclin D, constitutes one of the most frequent 
mutations in human cancers (Rocco and Sidransky, 2001). Inactivation of p16INK4a gene by deletion, 
mutation or hypermethylation, results in a defective inhibition of CDK4 which leads to a deregulated 
activity (Brown et al., 2004; Kawaguchi et al., 2003; Pinyol et al., 1998; Xing et al., 1999). 
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The loss of Rb protein function by phosphorylation, mutation or viral oncoprotein binding leads to a 
malignant phenotype (Giacinti and Giordano, 2006). Indeed, as a direct consequence of this loss of 
function, E2F transcription factors are released, thus inducing a cell cycle deregulation. This genetic 
alteration is observed in a variety of human tumors, including retinoblastoma, osteosarcoma and 
small-cell lung carcinoma (Horowitz et al., 1990). 
The CDK4 R24C point mutation causes loss of CDK4 binding to p16INK4a, and consequently leads to 
constitutive activation of CDK4 (Wölfel et al., 1995). This mutation has been identified in several 
cancers including familial melanoma and lung cancers (Chawla et al., 2010; Puyol et al., 2010; Sotillo 
et al., 2001a). It has been also described that mice harboring c-myc-3’RR/CDK4R24C and c-myc-
3’RR/p53
+/- phenotypes spontaneously develop B lymphomas, demonstrating a role of CDK4 in the 
development of lymphomas (Fiancette et al., 2011; Vincent-Fabert et al., 2012). In a high percentage 
of liposarcomas and neuroblastic tumours, CDK4 gene is also found to be amplified (Easton et al., 
1998; Tos et al., 2000).  
Cyclin D1 amplification is observed in 5-30% of NSCLC (Non Small Cell Lung Cancer). In 18-76% of 
these cancers, high expression of cyclin D1 has been reported and correlates with a poor prognostic 
for patients (Gautschi et al., 2007; Musgrove et al., 2011). In lung cancer, CDK4 or cyclin D 
overexpression induces apoptosis in cultured cells with normal Rb protein (Dobashi et al., 2004). 
Moreover, NSCLC mediated by KRAS are particularly dependent on CDK4, and targeting this kinase 
has been proposed as therapeutic strategy for this type of cancer which resists to conventional 
therapies because of the lethal interaction between ablation/inhibition of CDK4 and KRAS (Puyol et 
al., 2010).  
High levels of cyclin D1 are also frequently encountered in breast cancers either through genetic 
amplification or overexpression (Gillett et al., 1994). In neuroblastoma, genetic aberrations of cyclin 
D1, including overexpression, have also been reported (Molenaar et al., 2012). In mantle cell 
lymphoma, cyclin D1 is translocated to the IgH promoter (hallmark aberration). These translocations 
are also found in multiple myelomas (Chesi et al., 1996). 
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Table 3 summarizes the deregulations of CDK4 and cyclin D identified in human cancers.  
CDK4 
Amplification 
refractory rhabdomyosarcoma, 
osteosarcoma, glioblastoma 
(Park et al., 2014; Schmidt et al., 
1994; Wei et al., 1999) 
Overexpression 
melanoma (Smalley et al., 2008) 
lung cancer (Dobashi et al., 2004) 
Amplification 
/Overexpression 
osteosarcoma, sporadic breast 
carcinoma, uterine cervix cancer 
(An et al., 1999; Cheung et al., 2001; 
Wunder et al., 1999) 
R24C mutation 
familial melanoma 
(Chawla et al., 2010; Sheppard and 
McArthur, 2013; Sotillo et al., 
2001a, 2001b, 2005; Tsao et al., 
2012; Vidwans et al., 2011; Wölfel 
et al., 1995; Zuo et al., 1996) 
lung carcinoma (Puyol et al., 2010) 
mantle cell lymphoma (Vincent-Fabert et al., 2012) 
38 simple coding 
mutation / 25 missense 
mutations / 12 
synonymous mutations 
wide variety of cancer tissues 
COSMIC database 
http://www.sanger.ac.uk/genetics/ 
CGP/cosmic/ 
Cyclin D Overexpression 
follicular mantle cell lymphoma, 
lung cancer, breast cancer, head 
and neck, esophageal cancer 
(Kim and Diehl, 2009) 
colorectal adenocarcinomas (Seong et al., 1999) 
lung cancer (Dobashi et al., 2004) 
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pancreatic cancer (Gansauge et al., 1997) 
endometrial carcinoma (Moreno-Bueno et al., 2004) 
Amplification 
/overexpression 
head and neck carcinoma 
(Akervall et al., 1997; Meredith et 
al., 1995; Michalides et al., 1997) 
IGH translocation and 
overexpression 
multiple myeloma 
(Bergsagel and Kuehl, 2005; Chesi et 
al., 1996) 
mantle cell lymphoma (Bertoni et al., 2006; Li et al., 1999) 
Mutation that disrupts 
phosphorylation-
dependent nuclear 
export 
esophageal cancer (Benzeno et al., 2006) 
Truncated form (cyclin 
D1b) (A870G 
polymorphism) / Nuclear 
Accumulation 
NSCLC 
(Betticher et al., 1995; Gautschi et 
al., 2007; Li et al., 2008) 
esophageal and prostate cancer 
(Burd et al., 2006; Knudsen et al., 
2006) 
prostate cancer (Comstock et al., 2009) 
breast cancer (Millar et al., 2009) 
Truncated form (cyclin 
D1b) and its co-
expression with cyclin 
D1a 
breast cancer (Abramson et al., 2010) 
cyclin D1a isoforms with 
truncated 3' UTRs, not 
alternatively spliced 
cyclin D1b mRNA 
mantle cell lymphoma (Wiestner et al., 2007) 
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isoforms / alterations of 
CCND1 3' UTR structure 
Table 3 : CDK4 and cyclin D aberrations associated with cancer (from (Peyressatre et al., 2015)) 
2.11. CDK4/cyclin D in melanoma 
Malignant melanoma, which arises from deregulated proliferation of melanocytes, is one of the most 
aggressive malignancies in humans and is responsible for 60–80% of deaths from skin cancers 
(Bandarchi et al., 2010). In the European Union, among all cancers, melanoma is placed seventh in 
terms of incidence (Figure 18). 
 
Figure 18: Incidence and mortality of cancers in the European Union (from http://globocan.iarc.fr/) 
One of the most significant risk factors for melanoma is a family history of the disease. It is estimated 
that approximately 10% of melanoma cases report a first- or second-degree relative with melanoma 
(Hayward, 2003). Moreover, sun exposure has been shown to be a leading risk factor for melanoma 
(Garibyan and Fisher, 2010). 
Melanomas are classified in 4 subtypes, according to their whole-exome sequencing and their 
significant mutated genes (Cancer Genome Atlas Network, 2015): 
- the BRAF subtype which is the largest genomic subtype (52% of samples), defined by the presence 
of BRAF hot-spot mutations 
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- the RAS subtype which represents the second major subtype (28% of samples), defined by the 
presence of RAS hot-spot mutations 
- the NF1 subtype which presents mutations of NF1 (Neurofibromin 1) (14% of samples) 
- the triple Wild-Type Subtype which is characterized by a lack of hot-spot BRAF, N/H/KRAS, or NF1 
mutations. 
Recently, analysis of a whole-exome sequencing data from 121 melanoma tumor/normal pairs 
enabled the discovery of six novel genes (PPP6C, RAC1, SNX31, TACC1, STK19 and ARID2) as potential 
drivers in melanoma (Hodis et al., 2012). 
2.11.1.  Detection of melanomas 
To detect this aggressive cancer, a wide panel of suitable serologic and immunohistochemical 
biomarkers has been described (Utikal et al., 2007). The most widely used serological biomarker 
molecules are the melanocyte lineage/differentiation antigens S100-beta and melanoma inhibitory 
activity (MIA). They serve for early detection of metastasis or tumor relapse since their serum 
concentrations strongly correlate with patients’ tumour load. Some pro-angiogenic factors such as 
VEGF (Vascular Endothelial Growth Factor), cytokines like interleukin-6 (IL-6), HLA molecules or other 
molecules like LDH (Lactate Deshydrogenase) are also used as biomarkers of malignant melanoma 
(Utikal et al., 2007). Besides these serum markers, several immunohistochemical markers have also 
been reported for the detection of malignant melanoma including tumour suppressors, such as 
p16INK4a or pRb, or cell cycle associated proteins such as cyclin D. 
2.11.2.  Most common treatment options for melanoma 
To treat this cancer, several factors have to be considered including the thickness of the primary 
melanoma, the rate of melanoma growth, the presence of specific genetic changes in melanoma 
cells, and also the stage of the melanoma. Earlier stages are often rather easy to treat by surgery. 
However, stage IV which corresponds to metastatic melanoma is incurable. Immunotherapy such as 
Ipilimumab which targets the immune system and targeted drugs like Vemurafenib which targets 
BRAF mutants have shown to be efficient for this stage (Banaszynski and Kolesar, 2013). Indeed, 
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selective BRAF inhibitors including Vemurafenib and Dabrafenib achieved significant response rates 
(~50%) in clinical trials and were recently granted by the FDA for the treatment of malignant BRAF 
V600E/K melanomas (Hertzman Johansson and Egyhazi Brage, 2014). However, a significant number 
of these patients demonstrate intrinsic resistance and do not respond to BRAF inhibitors, and the 
majority of patients who initially respond acquire drug resistance and relapse within 6–12 months 
(Chapman et al., 2011; Long et al., 2012). Hence, new therapeutics targeting different pathways are 
still actively sought for the development of more targeted and more efficient treatments. 
2.11.3.  CDK4/cyclin D : an established biomarker for melanoma 
The p16INK4a / CDK4/6-cyclin D / pRb pathway is deregulated in 90% of melanomas. In human and 
mouse melanoma models, activation of this pathway is tightly related to BRAF and NRAS mutant in 
melanocyte transformation. RAS/RAF/MEK/ERK pathway is deregulated in 65-90% of metastatic 
melanomas, increasing more the p16INK4a / CDK4/6-cyclin D / pRb pathway and therefore cyclin D1 
expression (Chawla et al., 2010; Chin et al., 2006).  
The importance of CDK4 protein in cancers has especially been described following the identification 
of the R24C mutation in the CDK4 locus which predisposes to melanoma (Wölfel et al., 1995; Zuo et 
al., 1996). However, a weak incidence of spontaneous melanomas has been demonstrated in 
CDK4R24C/R24C mice. An increased incidence of spontaneous melanomas occurs in mice expressing the 
HRAS (G12V) oncogene in melanocytes, in a R24C context (Chawla et al., 2010).  
The risk of developing melanomas is also enhanced by CDK4/cyclin D hyperactivation due to cyclin D 
amplification (18% of melanomas) or loss of p16INK4a (deletion of CDKN2A in 50-60% of metastatic 
tumors) (Tsao et al., 2012).  
Thus, this kinase constitutes a key biomarker for the diagnostic of melanomas and a relevant 
therapeutic target (Sheppard and McArthur, 2013). 
3. Inhibitors of CDK/cyclins 
3.1. ATP-competitive compounds 
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For a long time, plant extracts have been used to treat cancer (Mann, 2002). Indeed, the American 
Indians used, for example, extracts from the roots of may apple, Podophyllum peltatum, as an 
effective treatment for skin cancers. This medicine led to identification of a group of anticancer 
agents known as the podophyllins, which include etoposide and teniposide, two topoisomerase 
inhibitors. Other anti-cancer products have been extracted from natural sources including bacteria, 
fungi, marine sponges and plants, such as olomoucine, staurosporine, butyrolactone, flavopiridol, 
meridianin, variolin, hymenialdisine and indirubin (Mann, 2002; Peyressatre et al., 2015). The 
determination of their molecular nature as purine and pyrimidine analogues enabled a better 
understanding of their inhibitory potential (Gray et al., 1998; Noble et al., 2005). These molecules 
were classified as ATP-competitive compounds meaning they could bind the ATP binding site thereby 
inhibiting kinase activity through competition with ATP (Figure 19A). Because toxic side-effects and 
limited selectivity arise with this first generation of compounds, a second generation of synthetic 
ATP-competitive drugs harboring less toxicity and greater efficacy were developed such as RO3306, 
Dinaciclib, PD-0332991 and AT7519 (Table 4) (Malumbres et al., 2008; Sausville, 2002). 
3.2. Non ATP-competitive inhibitors 
Although some of these ATP-competitive compounds are undergoing clinical trials and offer 
promising results for cancer therapy, issues such as lack of efficacy, limited selectivity and emergence 
of acquired drug resistance are frequently associated with these inhibitors (Fang et al., 2013). 
Indeed, the 518 members of the human kinome bear a conserved ATP pocket and it is therefore 
quite difficult to be specific for one kinase in particular by targeting this binding site. Hence, 
alternative approaches that do not target the ATP pocket have been investigated to inhibit 
CDK/cyclin activity. These strategies involve targeting protein/protein interfaces, hydrophobic 
pockets distinct from the ATP-binding pocket, which are exposed only in inactive intermediates, or 
allosteric sites (Cohen and Alessi, 2013; Fang et al., 2013; Liu and Gray, 2006; Pommier and Cherfils, 
2005). 
Peptides targeting protein-protein interfaces (Figure 19B) (Table 4) 
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To inhibit CDK/cyclin activity, an alternative approach consists in interfering with substrate 
recognition or by targeting crucial protein-protein interfaces (PPI). PPI are essential for the assembly 
of the complex. Indeed, the dynamic interactions between the two sub-units enable stabilization or 
modulation of both the conformation and the catalytic function of the complex. Identification of such 
compounds is often led by high throughput screening of small molecule libraries or by rational design 
of peptides mimicking the interfaces (Arkin and Wells, 2004). This approach has been successfully 
used to target different multimeric and multiprotein complexes, such as p53/MDM2 complex (Chène, 
2004). Several peptide inhibitors have been designed to target PPIs between CDKs and substrates, 
between CDKs and cyclins and between CDK/cyclins and p21/p27/p107 proteins that target the 
cyclin-binding groove (Abate et al., 2013; Cirillo et al., 2011; Esposito et al., 2013; Gondeau et al., 
2005; Orzáez et al., 2009). 
Small Molecule non-ATP competitive Inhibitors—Allosteric Inhibitors (Figure 19C) (Table 4) 
Recent efforts to target CDK/cyclins have been invested in the development of compounds which do 
not compete with ATP, and allosteric inhibitors that bind sites which are not conserved across the 
kinome (Eglen and Reisine, 2010). Allosteric sites are only accessible in specific conformations. Thus, 
inhibitors bind and stabilize kinases in an inactive conformation and prevent transition through an 
active state. They are therefore expected to exhibit superior selectivity profiles (Cohen and Alessi, 
2013; Eglen and Reisine, 2010; Fang et al., 2013; Liu and Gray, 2006; Zhang et al., 2009). This class of 
compounds is not simple to design rationally and requires identification of hydrophobic pockets 
distinct from the ATP-binding pocket, which are only exposed in inactive intermediates; or 
identification of allosteric sites. Identification of such compounds is therefore often performed by 
high throughput screening following identification of an allosteric site (Jahnke et al., 2005; Lebakken 
et al., 2012; Liu and Gray, 2006; Prével et al., 2014b). 
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Figure 19: Strategies for targeting cyclin-dependent kinases (from (Peyressatre et al., 2015)).  
(A) ATP-competitive inhibitors. They bind the ATP pocket and compete with ATP binding. 
(B) Protein-protein interface inhibitors. They target essential and specific protein/protein 
interactions either between CDKs and cyclins, or between CDK/cyclins and p21/p27/p107 proteins-
targeting the cyclin-binding groove. The second example represents an inhibitor, C4 peptide, which 
targets the primary interface between CDK2 and cyclin A (more precisely between the “PSTAIRE” 
helix of CDK2 and alpha 5 helix of cyclin A) (Gondeau et al., 2005). 
(C) Non ATP-competitive small molecules. They prevent ATP binding by targeting sites which are 
remote from the ATP pocket, so as to stabilize enzymatically inactive conformations or interfere 
with conformational transitions associated with kinase activation, compete with substrate or ATP 
binding. 
Inhibitor Target References 
ATP-competitive inhibitors   
Roscovitine (purine) CDK5, CDK2, CDK1, CDK7, 
CDK9 
(De Azevedo et al., 1997; Bach 
et al., 2005; Bettayeb et al., 
2008; Chang et al., 1999; 
Demange et al., 2013) 
Staurosporine (alkaloid) CDK1, CDK2, CDK4 (Gadbois et al., 1992; Tamaoki 
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et al., 1986) 
Olomoucine (purine) CDK1, CDK2, CDK5 (Glab et al., 1994) 
Butyrolactone I CDK1 > CDK2 (Kitagawa et al., 1993) 
Flavopiridol CDK2, CDK4, CDK6, CDK9 (Christian et al., 2007; König et 
al., 1997; Lin et al., 2009b; 
Losiewicz et al., 1994; Patel et 
al., 1998) 
Indirubin-5 (purine) CDK1 > CDK2 > CDK5 (Hoessel et al., 1999) 
PD-0322991 (Palbociclib) CDK4, CDK6 (Cen et al., 2012; Fry et al., 
2004; Guha, 2013; Toogood et 
al., 2005) 
Dinaciclib CDK1, CDK2, CDK5, CDK9 (Feldmann et al., 2011; Parry 
et al., 2010; Paruch et al., 
2010) 
AT7519 CDK2, CDK4, CDK5, CDK7, 
CDK9 
(Mahadevan et al., 2011; 
Santo et al., 2010; Squires et 
al., 2009, 2010; Wyatt et al., 
2008) 
Peptide inhibitors targeting protein/protein interfaces  
Interface peptide CDK2/cyclin A (Mendoza et al., 2003) 
C4 peptide derived from cyclin A CDK2/cyclin A (Gondeau et al., 2005) 
Hexapeptide - targets cyclin A surface 
pocket 
CDK2/cyclin A (Canela et al., 2006) 
Spa310 and derivative from p130/pRb 
spacer domain 
CDK2/cyclin A (Bagella et al., 2007; Giordano 
et al., 2007) 
 41 
 
CDK4 derived C-terminal hexapeptide CDK4/cyclin D (Warenius et al., 2011) 
Interface peptides derived from p35 CDK5/p35 (Chin et al., 1999; Shukla et al., 
2013; Sundaram et al., 2013; 
Zheng et al., 2002, 2005, 2010) 
Small molecule non-ATP competitive/allosteric inhibitors  
CPD1 3alpha-amino-5alpha androstane CDK5/p25 (Corbel et al., 2011; Zhang et 
al., 2011) 
Allosteric pocket in CDK2/Cyclin A/p27 CDK2/cyclin A/p27 (Corsino et al., 2009) 
Chrysin-derivative - allosteric site CDK2 and CDK4/CDK6 (Liu et al., 2013) 
Table 4: CDK inhibitors 
3.3. CDK4/cyclin D inhibitors 
As CDK4/cyclin D is a relevant target for anticancer therapy, many efforts have been made to identify 
new and specific inhibitors of this kinase. 
3.3.1. ATP-competitive inhibitors 
In 2000, Barvian and co-workers found that pyrido[2,3-d]pyrimidin-7-one compounds were potent 
inhibitors of CDK/cyclins (Barvian et al., 2000) (Figure 20A). Through screening of a chemical 
compound library, they identified some hits which display modest selectivity for CDK4 versus other 
kinases. Chemical modifications of the original template led to identification of PD 0183812, as a 
potent and highly selective ATP competitive inhibitor of CDK4 and CDK6 kinase activity. Rb positive 
cell lines demonstrated a G1 arrest when treated with PD 0183812 and a reversible block in 
proliferation (Fry et al., 2001) (Figure 20B). 
Based on the recent demonstration that modification of the C2-side chain to a 2-aminopyridine 
provided inhibitors with exquisite selectivity for CDK4/6 in vitro and in cellulo, compound 43 (PD-
0332991) was identified as a drug candidate for the treatment of cancer (Toogood et al., 2005).  
PD-0332991 (now called Palbociclib) is an orally active, highly selective inhibitor of CDK4-6/cyclin D 
that blocks retinoblastoma (Rb) phosphorylation in the low nanomolar range (IC50 = 11 nM) and CDK6 
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(IC50 = 16 nM) (Figure 21). It has no activity against a panel of 36 additional tyrosine and 
serine/threonine kinases. It is a potent antiproliferative agent against retinoblastoma (Rb)-positive 
tumor cells in vitro, inducing an exclusive G1 arrest, with a concomitant reduction of phospho-
Ser780/Ser795 on the Rb protein (Fry et al., 2004). PD-0332991 inhibits MDA-MB-435 breast 
carcinoma cell proliferation with an IC50 of 0.16 µM. A similar value was found for Colo-205 colon 
carcinoma cell line (0.13 µM). In vivo, the therapeutically active doses of PD-0332991 administrated 
per os in mice were 12.5, 37.5, 75 and 150 mg/kg. 
Another inhibitor called 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-
dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) was found to be a potent multikinase inhibitor 
with potent inhibitory activity against the CDK4/cyclin D1 and ARK5 kinases, inducing apoptosis of 
tumor cells at a concentration of approximately 30-100 nM (Reddy et al., 2014). 
Highly selective CDK4 inhibitors have also been identified by modifying a 2-aminoquinazoline scaffold 
(Bathini et al., 2005) (Figure 20C). 
 
Figure 20: Chemical structure scaffolds which led to the development of CDK4/cyclin D inhibitors 
(A) pyrido[2,3-d]pyrimidin-7-one scaffold (Barvian et al., 2000) 
(B) Chemical structure of PD 0183812 (Fry et al., 2001) 
(C) 2-aminoquinazoline scaffold (Bathini et al., 2005) 
Currently, three inhibitors which compete with ATP are currently in clinical trials (Asghar et al., 2015; 
Dickson, 2014; VanArsdale et al., 2015) (Figure 21). Palbociclib has recently been approved by the 
FDA to treat ER+ (HER2-negative) metastatic breast cancer in combination with letrozole, an 
A B C
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aromatase inhibitor (VanArsdale et al., 2015). It is also currently tested for liposarcoma and mantle 
cell lymphoma in phase II or III.  
In vitro studies have demonstrated that another CDK4 inhibitor, Ribociclib (also called LEE011 
(Novartis)), caused G1 arrest and had antitumor activity in several models, including melanoma with 
BRAF or NRAS mutation, breast cancer and neuroblastoma (Infante et al., 2013; Kim et al., 2013; 
Rader et al., 2013). Ribociclib inhibits CDK4 and CDK6 with an IC50 of 10 nM and 39 nM, respectively. 
In cellulo studies have demonstrated that the growth of 12 of 17 neuroblastoma cell lines was 
significantly impaired in response to CDK4/6 inhibition with LEE011 (mean IC50= 30 +/- 68 nM, 
sensitive lines only) (Rader et al., 2013). 
A third CDK4 inhibitor, Abemaciclib (LY2835219 developed by Ely Lilly) is also currently tested in 
phase I for NSCLC and hormone receptor-positive metastatic breast cancer (Asghar et al., 2015). 
Abemaciclib inhibits CDK4 and CDK6 with IC50 values of 2 nM and 10 nM, respectively. The 
proliferation of MDA-MB-361, a breast cancer cell line, was reduced by 50% when treated with 
LY2835219 at 90 +/- 31 nM (Gelbert et al., 2014). Interestingly, this compound has been shown to 
cross the blood-brain barrier and could therefore be potently used for treating brain cancers 
(Sanchez-Martinez et al., 2011). Indeed, the p16INK4a / CDK4/6-cyclin D / pRb pathway is commonly 
altered in glioblastoma multiforme (GBM), mostly by homozygous deletion of CDKN2A/B, genes 
which code for p16INK4a and p15INK4b respectively (He et al., 1995; Jen et al., 1994; Ueki et al., 1996). 
The principle adverse event of these three inhibitors is neutropenia which is probably a result of 
transient growth arrest in hematopoietic precursor cells (Roberts et al., 2012). 
 
Figure 21: Structures of ATP-competitive CDK4/6 inhibitors 
Palbociclib (PD-0332991) Ribociclib (LEE011) Abemaciclib (LY2835219)
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3.3.2. Non ATP-competitive inhibitors 
Regarding non-ATP competitive strategies, Warenius and coworkers have targeted a non-kinase 
domain of CDK4. A hexapeptide deriving from a C-terminal loop outside the kinase domain of CDK4 
and its cyclic derivatives, used at 200 µM, proved to be efficient in killing several cancer cell lines 
whilst sparing keratinocytes and fibroblasts (Figure 22) (Warenius et al., 2011). 
Chemopreventive properties of Chrysin (5,7-dihydroxyflavone), a natural flavonoid widely distributed 
in plants, have been reported against various cancers. A chrysin derivative, referred to as compound 
69407, was found to be an efficient ATP-non competitive inhibitor of CDK2 and CDK4 that binds an 
allosteric pocket in these kinases (Figure 22) (Liu et al., 2013). Results of in vitro kinase assays 
indicated that it inhibited CDK2 and CDK4 kinase activities with IC50 values of 8.3 and 8.4 µM, 
respectively. This compound attenuated cell cycle progression of EGF-stimulated cells at the G1 
phase and inhibited the G1/S transition, causing loss of retinoblastoma phosphorylation by CDK4/6 
and CDK2. It also reduced tumor growth in a mouse xenograft model of human epidermoid 
carcinoma (A431 cells).  
Besides targeting CDK4, some efforts have been invested to target cyclin D. For instance, Tiemann 
and collaborators have downregulated CCND1 and CCND2 expression in two mantle cell lymphoma 
(MCL) cell lines with siRNAs to investigate the cytotoxic effect of combining siRNAs with conventional 
chemotherapeutic agents (Tiemann et al., 2011). They have demonstrated that siRNAs targeting 
cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents (etoposide and 
doxorubicin) in MCL cell lines. The reduction in cyclin D expression by siRNAs resulted in decreased 
IC50 values for both doxorubicin and etoposide. This study highlights the fact that, combination of 
siRNA-mediated inhibition of the D-cyclins, along with chemotherapeutic agents, could potentially be 
used to lower the effective doses of the chemotherapeutic agents and reduce drug-related toxicities. 
Figure 22 summarizes the different strategies developed to inhibit CDK4/cyclin D activity.  
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Figure 22: Inhibitors of CDK4/cyclin D.  
CDK4 targeting: three ATP-competitive inhibitors targeting the ATP binding site, PD-0332991 
(Palbociclib), LEE011 (Ribociclib) and LY2835219 (Abemaciclib) (Asghar et al., 2015; Dickson, 2014; 
VanArsdale et al., 2015); a hexapeptide PRGPRP (Warenius et al., 2011); and a chrysin derivative 
69407 (Liu et al., 2013) 
D-cyclin targeting: downregulation of CCND1 and CCND2 expression by siRNAs (Tiemann et al., 
2011) 
4. Fluorescent biosensors for probing protein kinase activity 
4.1. Concepts around fluorescent biosensors 
4.1.1.  Definition of a biosensor 
Biosensors can be defined as tools which combine a biological or biomimetic element that can probe 
a specific target, with a physicochemical transducer which converts the recognition event into a 
detectable and measurable analytical signal (Lee, 2008) (Figure 23). They allow to monitor target 
proteins in a sensitive, robust, quantitative and reproducible fashion, and respond to target changes 
in a dynamic and reversible fashion. 
PD-0332991
LEE011
LY2835219
Chrysin derivative 69407
PRGPRP 
peptide
siRNA
D-cyclin
CDK4
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Figure 23: Schematic representation of a biosensor. It combines a receptor, sensitive to a specific 
biological target, and a physicochemical transducer. 
In 1962, Clark and Lyons were the first to describe the concept of biosensors with their work on 
electrodes for monitoring glucose concentrations in the blood of patients (Clark and Lyons, 1962). 
Since then, the development of eletrochemical, electronic and microbial biosensors has enabled the 
detection of ions, small molecules, proteins or DNA (Sokolov et al., 2009; Su et al., 2011; Turner, 
2013). A wide variety of optical biosensors have also been developed. In optical biosensor 
technology, the main used biological materials are the optocouple enzyme/substrate, 
antibody/antigen, and nucleic acids/complementary sequences (Dey and Goswami, 2011). The 
mechanism of detection of many optical biosensors is based on the phenomenon of Surface Plasmon 
Resonance (SPR). Binding of a target analyte to a receptor on the surface of thin layer of gold (or 
other materials) leads to changes in the local index of refraction, inducing a change in the resonance 
conditions of the surface. Indeed, a thin layer of gold on a high refractive index glass surface can 
absorb laser light, producing electron waves (surface plasmons) on the gold surface. This 
phenomenon occurs only at a specific incident angle and wavelength and highly depends on the 
surface of the gold. Hence, binding of a target to a receptor on the gold surface produces a 
detectable and measurable signal. Several model membrane systems have been developed for use 
with optical biosensors (Cooper, 2002). 
More recent developments of optical biosensors have been based on fluorescence technologies, and 
have occupied a central role in modern fundamental and biomedical research (Ibraheem and 
Campbell, 2010; Lemke and Schultz, 2011; Morris, 2010; Nhu Ngoc Van and Morris, 2013; Wang et 
al., 2009). 
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4.1.2. What is fluorescence? 
4.1.2.1. History 
 
Figure 24: History of fluorescence: timeline (Brune et al., 1994; Chalfie et al., 1994; Deisseroth, 
2011; Fox and Wood, 1960; Fox et al., 1957; Gilardi et al., 1994; Heim et al., 1995; Herschel, 1845a, 
1845b; Jabłoński, 1933; Matz et al., 1999; Mitchison, 1989; Miyawaki et al., 1997; Ormö et al., 
1996; Romoser et al., 1997; Shimomura et al., 1962; Teale and Weber, 1957; Zemelman et al., 
2002) 
4.1.2.2. Principle of fluorescence 
1845
•Sir John Herschel reports visible emission of aqueous quinine solution (Herschel, 1845a, 1845b).
1852
•George GabrielStokes describes fluorescence as absorption and emission of light.
1871
•Fluorescein is first synthesized by Adolf von Baeyer (von Bayer, A., Chem. Ber., 1871, 5, 255).
1933
•Jablonski diagram describes electronic states of a fluorescent molecule (Jabłoński, 1933).
1950
•The first fluorimeters are commercialized.
1957
•Ultraviolet fluorescence of the three aromaticamino acids is discovered (Teale and Weber, 1957).
1957
•Indocyanine green, the first near-infrared dye, is synthesized (Fox et al., 1957; Fox and Wood,
1960).
1962
•GFP is discovered in Aequorea Victoria (Shimomura et al., 1962).
1989
•The first caged fluorescent probe, a fluorescein derivative, is used for a biological experiment
(Mitchison, 1989).
1994
•Development of synthetic fluorescent probes for biological applications (Brune et al., 1994; Gilardi
et al., 1994)
1996
•The crystal structure of GFP is published (Ormö et al., 1996).
1997
• The first two FRET biosensors are developed to measure changes in Ca2+ concentrations in living
cells (Miyawakiet al., 1997; Romoser et al.; 1997).
1999
•Red fluorescent proteins (DsRed) are discovered in anthozoan corals (Matz et al., 1999).
2002
•An optogenetic tool is described for stimulating groups of genetically designated neurons, based
on the use of light to control neural activity (Zemelman et al., 2002; Deisseroth, 2011)
2008
•Shimomura, Chalfie and Tsien receive the Nobel Prize for the discovery and development of the
green fluorescent protein, GFP (Chalfie et al., 1994; Miyawakiet al., 1997; Heim et al., 1995)
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Figure 25: Different types of luminescence 
Photoluminescence is formally divided into two categories - fluorescence and phosphorescence -
depending on the nature of the excited state (Figure 25 and Figure 26A) (Lakowicz, 1999). It is 
defined as the emission of light from any substance, and occurs from electronically excited states.  
More precisely, this process involves (1) photon absorption by a fluorophore giving an excited state 
and (2) relaxation of the excited state by emission of another photon (Figure 26). When absorbing a 
photon, a molecule gains energy and enters an excited state. One way for this molecule to relax is to 
emit a photon, thus losing its energy.  
Fluorescence is distinct from phosphorescence since the kinetics of emission are much faster in the 
first process. Indeed, fluorescence results of singlet–singlet electronic relaxation (typical lifetime: 
nanoseconds) whereas phosphorescence results of triplet–singlet electronic relaxation (typical 
lifetime: milliseconds to hours). The Jablonski diagram describes these different electronic states and 
transitions upon excitation and relaxation (Figure 26A). 
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Figure 26: Principles of fluorescence 
(A) Jablonski energy diagram of fluorescence 
(B) General excitation and emission spectrum of a fluorophore 
Molecules that can absorb light and emit fluorescence are called fluorophores and are characterized 
by a spectrum of light absorption and emission. Fluorophores typically contain several combined 
aromatic groups, or plane or cyclic molecules with several π bonds (Lakowicz, 1999). 
Their electronic state transitions are correlated with a particular wavelength (λ) and energy (E) 
required for their excitation. The wavelength of light is inversely proportional to its energy and can 
be illustrated by a simple equation E=hc/λ where h is Planck's constant with a value of 6.626.10-34 J.s 
and c is the speed of light with a constant value of 3.108 m/s. Each fluorophore is defined by its 
maximum absorbance wavelength λabs and its emission wavelength λem. Because of a partial loss of 
energy, an emitted photon carries less energy and is characterized by a longer wavelength than that 
of the excitation photon. The difference between emitted photon energy and excited photon energy 
is named “Stokes shift” and varies according to the solvent polarity (Figure 26B) (Lakowicz, 1999; 
Stokes, 1852). This cycle of excitation-emission events can be repeated until the fluorophore is 
damaged. This phenomenon, due to extended illumination, is called photobleaching. Other 
photophysical properties allow to characterize a fluorophore. The molar extinction coefficient (ε) is 
related to the capacity of a fluorescent molecule to absorb photon energy at a given wavelength. The 
quantum yield (Φ) corresponds to the capacity of a fluorophore to re-emit absorbed energy and is 
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equal to the number of emitted photons divided by the number of absorbed photons. Fluorescence 
lifetime (τ) is defined as the average time the fluorophore stays in its excited state before emitting a 
photon, tipically between 0.1 and 100 ns.  
4.1.2.3. Principle of FRET 
Förster Resonance Energy Transfer (FRET) is a mechanism which involves energy transfer between 
two fluorophores (Förster, 1948). A donor fluorophore, in its electronic excited state, can transfer 
energy to an acceptor fluorophore through non-radiative dipole-dipole coupling. Three conditions 
are required for efficient FRET between donor and acceptor: overlap between donor emission 
spectrum and acceptor absorption spectrum; alignment of the transition dipole moments of the 
donor and acceptor fluorophores; and distance between fluorophores (Förster, 1948; Lakowicz, 
1999; Stryer and Haugland, 1967). The latter is crucial for FRET and generally comprised around 1 to 
10 nm. FRET between a donor and an acceptor promotes increase in fluorescence intensity of 
acceptor and decrease in intensity of donor fluorescence associated with decrease in lifetime of the 
donor. This technology is frequently used to measure protein-protein interactions, conformational 
changes or protein activation (Ibraheem and Campbell, 2010; Lakowicz, 1999; Lavis and Raines, 2008; 
Lemke and Schultz, 2011; Stryer and Haugland, 1967; Wang et al., 2009). 
4.1.2.4. Principle of solvatochromism 
Some fluorophores are sensitive to changes in their local environment such as pH, viscosity and 
solvent polarity. This sensitivity to changes of solvent polarity is called solvatochromism. It is defined 
as the ability of a chemical substance to change color due to a change in solvent polarity, which leads 
to stabilization of either ground or excited state of the fluorophore, which consequently affects the 
energetic gap between these states (Reichardt, 1994). The Imperiali group has provided a detailed 
description of this phenomenon (Figure 27) (Loving et al., 2010).  
 51 
 
 
Figure 27: Origin of solvatochromism effects on fluorescence (from (Loving et al., 2010)) 
Upon absorption of a photon of appropriate energy, the fluorophore is promoted to an excited 
singlet state and adopts a dipole moment that differs significantly from that of the ground state. To 
accommodate this larger dipole, the molecules of the solvent sphere reorient dipoles, resulting in a 
more ordered arrangement. This step is named solvent relaxation and leads to a decrease in energy 
of the excited singlet state, which reduces the energetic gap between these states. Finally, when the 
fluorophore returns to the ground state by emission of a photon, the latter is of a much longer 
wavelength, i.e. a much lower energy, than that which was originally absorbed during excitation.  
Incorporation of this type of fluorophores into biological systems can therefore provide information 
on local changes in environment of probes such as conformational changes, switches between 
active/inactive conformations, activity or protein-protein interactions. Hence, they have been widely 
used for the development of fluorescent biosensors (Loving et al., 2010).  
A large number of solvatochromic fluorescent probes have been developed including PRODAN, 
Coumarin derivatives, Dansyl derivatives and Merocyanines such as Brooker’s Merocyanine (Brooker 
et al., 1951; Loving et al., 2010; Reichardt, 1994). 
4.2. Fluorescence imaging for monitoring protein kinase activity 
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Due to the importance of CDK/cyclins as cancer biomarkers, efficient approaches for probing kinase 
activity are required.  
Currently, the most developed approaches to study kinase activity are based on radioactivity or 
antigenic approaches which require specific antibodies that recognize phosphorylated residues (Jia et 
al., 2008).  
In in vitro radioactive-based assays, kinase activity is correlated with incorporation of radiolabelled 
phosphate into kinase substrates and therefore requires the use of enzymatically active kinases. 
Radioactive product analysis is performed by scintillation proximity assay, autoradiography or gel-
permeation (Ma et al., 2008; Sittampalam et al., 1997). Although these radioactive methods have 
been widely used in laboratories, they are laborious and time-consuming. Moreover, they do not 
allow to follow the reaction kinetics and further lack the physiological cellular environment. Cell-
based methods have been developed to incorporate 32P directly into cells. Nevertheless, these 
approaches are end-point, poorly sensitive, require cell lysis and substrate protein isolation and 
purification (Nhu Ngoc Van and Morris, 2013). 
Non radioactive cell-based assays have been implemented to probe kinase activity, using an ELISA 
(enzyme-linked immunosorbent assay) approach that employs phosphorylation-specific antibodies 
(Ma et al., 2008; Versteeg et al., 2000).  
Another in cellulo method, based on the use of a fluorogenic peptide substrate (rhodamine 110, bis 
peptide amide) has been developed (Kupcho et al., 2003). In its unphosphorylated form, the peptide 
is cleaved, thereby releasing free rhodamine 110. In its phosphorylated form, it is prevented from 
cleavage and the compound remains as a non fluorescent peptide conjugate. 
Unfortunately, none of these methods allow for real-time studies and provide real insights into the 
dynamics and enzymatic kinetics of the targeted kinase in its native environment. 
Fluorescence imaging is particularly well suited to address this challenge. It allows visualization of 
dynamic processes in living cells overtime, thereby providing precious information on subcellular 
localization, behavior of intracellular targets or protein/protein interactions (Chudakov et al., 2010; 
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Morris, 2010; Weissleder and Ntziachristos, 2003). Fluorescence imaging technology displays many 
advantages such as high intrinsic sensitivity and selectivity, high spatial and temporal resolution, non 
destructive imaging, broad spectrum wavelengths and real-time kinetic analysis.  
Fluorescent biosensors of protein kinases offer precious means of probing enzymatic activities in a 
continuous fashion in vitro, and in real time in living cells, and to study the kinetics of kinase 
activation, as well as the response to protein kinase inhibition (Bastiaens and Pepperkok, 2000; 
Lippincott-Schwartz and Patterson, 2003; Lippincott-Schwartz et al., 2001; Nhu Ngoc Van and Morris, 
2013). They also allow to monitor conformational changes of protein kinases (Tarrant and Cole, 
2009). Additionally, they provide a sensitive means of visualizing shuttling between different 
subcellular compartments with high spatial and temporal resolution (Giepmans et al., 2006).  
With the aim of monitoring protein kinase activity, two types of fluorescent biosensors have been 
developed: genetically-encoded biosensors and non genetic protein/peptide biosensors. 
4.3. Genetically-encoded fluorescent biosensors 
4.3.1.  Discovery of AFPs - Development of genetic fluorescent biosensors  
Green Fluorescent Protein (GFP) (λexc = 395 nm; λem = 508 nm) has been the first auto-fluorescent 
protein (AFP) to be discovered. It has been isolated from bioluminescent jellyfish Aequorea Victoria 
in 1962 (Shimomura et al., 1962). Crystal structure of GFP, published in 1996 by Örmo and co-
workers, showed that a fluorescent group imidazolinone was trapped inside a “barrel” formed by 
eleven beta-sheets (Ormö et al., 1996). 
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Figure 28: Crystal structure of Green Fluorescent Protein. A fluorescent group imidazolinone is 
trapped inside a “barrel” formed by eleven beta-sheets (PDB 1EMA) (Ormö et al., 1996)  
A panel of GFP derivatives including Cyan Fluorescent Protein (CFP) and Yellow Fluorescent Protein 
(YFP) has been generated by mutations leading to modifications of colors and spectral properties 
(Pakhomov and Martynov, 2008). These fluorescent reporters have been widely used to obtain many 
physiological information such as protein localization in living cells (Bastiaens and Pepperkok, 2000; 
Lippincott-Schwartz and Patterson, 2003; Lippincott-Schwartz et al., 2001; Wouters et al., 2001).  As 
AFPs are very robust with respect to genetic fusions to their N- and C-termini, they can be genetically 
fused to any protein targets (Frommer et al., 2009). Hence, they have led to the development of a 
wide panel of genetically-encoded fluorescent biosensors, allowing the monitoring of numerous 
biological processes in cellulo such as kinase activity (Nhu Ngoc Van and Morris, 2013). 
Three sub-families of genetic fluorescent biosensors, FRET-based fluorescent biosensors, biosensors 
based on BiFC (Bimolecular Fluorescence Complementation) and pH-sensitive biosensors, will be 
further described in the following paragraphs. 
4.3.2.  FRET-based fluorescent biosensors for probing protein kinase activity 
To monitor protein kinase activity, FRET-based fluorescent biosensors incorporate a pair of 
genetically-encoded AFPs together with a kinase-specific substrate sequence and a Phospho Amino 
Acid Binding Domain (PAABD) which recognizes phosphorylated residues in the substrate domain 
(Aye-Han et al., 2009; Ibraheem and Campbell, 2010; VanEngelenburg and Palmer, 2008). So that, 
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when the substrate sequence is phosphorylated upon addition of active kinase, the PAABD 
recognizes this phosphorylation site and undergoes a conformational change, thereby altering the 
distance between AFPs and the orientation relative to one another. Phospho-tyrosine residues are 
recognized by proteins with modular Src-homology 2 (SH2) and phosphotyrosine-binding (PTB) 
domains while pSer/Thr-binding proteins and domains currently include 14-3-3, WW domains and 
forkhead-associated domains (Lu et al., 1999; Yaffe, 2002; Yaffe and Elia, 2001; Yaffe and Smerdon, 
2001).  
Two different types of FRET biosensors have been implemented for probing kinase activity: single-
chain and two-chain biosensors (Figure 29). 
 
Figure 29: FRET-based biosensors of kinase activity 
(A) Intramolecular FRET: a single-chain biosensor bears a pair of AFPs 
(B) Intermolecular FRET: two-chain biosensors in which the two AFPs are genetically fused with 
two different proteins 
These approaches have been used in cellulo to probe activity of both tyrosine and serine/threonine 
kinases such as Protein Kinase A (PKA); Protein Kinase C (PKC); Src, Epidermal Growth Factor 
Receptor (EGFR) and Abl tyrosine kinases; and ERK and JNK MAP kinases (Fosbrink et al., 2010; Ting 
et al., 2001; Violin et al., 2003; Zhang et al., 2001); for review (Nhu Ngoc Van and Morris, 2013)). 
A. intramolecularFRET-based biosensors
B. intermolecular FRET-based biosensors
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Regarding CDK/cyclin kinases, only one FRET-based genetic biosensor has been described to probe 
CDK1/cyclin B activity so far, which is further detailed in paragraph 5.1 (Gavet and Pines, 2010). 
4.3.3.  Biosensors based on BiFC (Bimolecular Fluorescence Complementation) 
The strategy of Bimolecular Fluorescence Complementation is based on the intrinsic ability of some 
fluorescent protein variants, when expressed in a split form tagged to a pair of interacting proteins, 
to refold properly into the β-barrel structure and thus reconstitute the fluorescent form of the 
protein (Ibraheem and Campbell, 2010). Based on this technology, two-chain biosensors have been 
engineered in which the molecular recognition element is fused to one fragment of the fluorescent 
protein and the analyte protein to the other (Figure 30). 
To date, no BiFC-based biosensors have been reported to probe protein kinase activity. 
 
Figure 30: Biosensors based on BiFC, in which two fragments of a split AFP are brought together as 
a consequence of target recognition, or in this case phosphorylation, thereby reconstituting the 
intact and fully fluorescent protein. 
4.3.4.  pH-sensitive biosensors 
This class of biosensors is based on the use of auto-fluorescent proteins whose spectral properties 
vary according to the pH (Ibraheem and Campbell, 2010). Figure 31 provides an example of a pair of 
AFPs whose the acceptor is sensitive to pH. At low pH, spectral properties of the acceptor 
fluorophore make the FRET impossible. A FRET signal is only obtained at high pH. 
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Figure 31: pH-sensitive biosensors. In this example, the acceptor fluorophore is sensitive to pH 
4.3.5.  Pros and cons of genetically-encoded fluorescent biosensors 
Genetic biosensors are regarded as easy to engineer and transfect. However, they display some 
drawbacks such as limitation to in cellulo applications, heterogeneous expression in a population of 
cells, lack of control over expression, large size and sometimes mislocalization (Ciruela, 2008; 
Giepmans et al., 2006; Morris, 2010; Waters, 2007, 2009). Moreover, FRET fluorescence intensity is 
often not easy to be analyzed with a microscope because it depends on excitation intensity, 
photobleaching of fluorescent chromophores, and absorption by the sample. To circumvent these 
barriers, fluorescence lifetime imaging (FLIM) is commonly used, although this technique remains 
technically challenging (Wallrabe and Periasamy, 2005). In contrast to intensity-based FRET 
measurements, the FLIM-based FRET measurements are insensitive to photobleaching, 
concentration of fluorophores and biosensors, excitation power, and can thus filter out artifacts 
introduced by variations in the concentration and emission intensity across the sample (Berezin and 
Achilefu, 2010). 
4.4. Non genetic peptide/protein fluorescent biosensors 
4.4.1.  Principle 
This second strategy is based on the coupling of small synthetic probes onto peptides or proteins. In 
the case of protein kinases, protein/peptide sequences are often derived from domains that 
recognize specific targets such as substrate sequences surrounding a phosphorylation site. Upon 
phosphorylation of the substrate sequence by target kinase, the spectral properties of the synthetic 
donor
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probe are altered directly or indirectly through intramolecular conformational changes or recognition 
of a PAABD. 
Three different approaches have been developed to monitor protein kinase activity. 
4.4.2.  Biosensors based on environmentally-sensitive probes 
This first class of biosensors is based on probes that are sensitive to changes in their local 
environment such as pH, viscosity and solvent polarity (solvatochromism; defined above in paragraph 
4.1.2.4). 
Different approaches have been employed to reach this goal: phosphorylation itself or recognition 
and binding of the phosphorylation site by a PAABD (Figure 32) (Lu et al., 1999; Yaffe, 2002; Yaffe and 
Elia, 2001; Yaffe and Smerdon, 2001). Several examples are given in the following reviews : (Chen et 
al., 2004; Lawrence and Wang, 2007; Nhu Ngoc Van and Morris, 2013; Sharma et al., 2008). 
The position of the fluorescent probe is essential and varies between biosensors: on the 
phosphorylatable residue itself, immediately adjacent to the residue or proximal to it (i.e., 2–5 
residues away). 
 
Figure 32: Environmentally sensitive peptide-based kinase biosensors 
(A) by phosphorylation itself (Yeh et al., 2002) 
(B) upon binding of a phosphopeptide recognition domain, such as SH2 for phosphotyrosine (Wang 
and Lawrence, 2005) 
4.4.3.  Biosensors based on chelation-enhanced fluorescence (CHEF) 
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Some fluorophores have the ability to coordinate metal ions such as Ca2+, Mg2+ and Zn2+. Proximal 
phosphorylation of the peptide substrate increases the number of negative charges thereby 
improving the chelation of these cations. Metal-ion-induced, chelation-enhanced fluorescence 
(CHEF) technology relies on fluorophores whose electronic structure and consequently spectral 
properties are modified upon chelation (Haas and Franz, 2009). Lawrence and collaborators have 
implemented a family of PKC substrates through incorporation of a Ca2+-sensitive fluorophore 
containing a tetracarboxylate chelating site which had been previously developed by the group of 
Tsien (Figure 33A) (Chen et al., 2002; Minta et al., 1989). Imperiali and coworkers have designed a 
peptide biosensor, based on CHEF technology, to selectively report on kinase phosphorylation. The 
originality of the approach is the use of the Sox (sulfonamide-oxine) dye as a solvatochromic probe 
which derives from 8-hydroxyquinoline (Shults et al., 2003). Upon phosphorylation of the Sox-
containing peptide, the chromophore binds Mg2+ and undergoes CHEF. A Recognition-Domain-
Focused (RDF) has been engineered with extended binding sequences and added to the sensor to 
increase the specificity of recognition. This biosensor has shown to be efficient for probing a panel of 
kinases such a PKC, Pim2, Akt1, MK2, PKA, Abl, Src, and IRK in cell extracts (Figure 33B) (Luković et al., 
2008). 
 
Figure 33: Chelation-enhanced fluorescence 
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(A) PKC biosensor based on a Ca
2+
-chelation sensitive fluorescent probe incorporated close to the 
phosphorylation site (Chen et al., 2002) 
(B) Recognition-domain-focused (RDF) Sox biosensor (Luković et al., 2008) 
4.4.4.  Biosensors based on quenching/unquenching strategies 
The first strategy for quenching/unquenching fluorescent probes is based on the photophysical 
properties of aromatic amino acids including tyrosine and tryptophan. Indeed, due to the presence of 
π/π stacking interactions between aromatic groups, they constitute potent tools for quenching 
organic dyes. In particular, tryptophan has been used in a numerous assays for inter- and 
intramolecular fluorescence quenching of organic dyes (Marmé et al., 2003). 
A similar approach has been developed by Lawrence and collaborators that uses the 
phosphorylatable tyrosine residue as a quencher that silences the fluorescence of a proximal 
fluorophore. Upon phosphorylation, the π/π stacking interactions are disrupted, thereby inducing a 
complete enhancement of fluorescence (Figure 34A) (Wang et al., 2006a). 
As this strategy is only applicable to residues containing tyrosine groups, the group of Lawrence has 
developed the “deep quench” strategy for serine and threonine residues. It is based on the addition 
of a quencher in solution to prevent the fluorophore from emission. Upon phosphorylation, the 
quencher is displaced because of binding of a phosphorecognition domain to the phosphorylated 
serine or threonine residue. This binding then promotes significant fluorescence enhancement of the 
environmentally sensitive probe (Figure 34B) (Sharma et al., 2007). This approach has been 
successfully implemented for monitoring PKA activity in mitochondria using Coumarin as fluorescent 
probe, Acid Green 27 as quencher and 14-3-3 domain as PAABD (Agnes et al., 2010). 
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Figure 34: Quenching/unquenching strategies: 
(A) applied for monitoring tyrosine kinase activity 
(B) applied for monitoring serine/threonine kinase activity 
4.4.5.  Photoactivation strategies 
With the aim of optimizing the signal-to-noise (S/N) ratio, controlling the timing observation of the 
reaction and increasing the intensity of the response, photoactivation strategies have been 
implemented by “caging” the phosphorylatable residue with a photo-labile group which can be 
released upon UV irradiation. Phosphorylation by the kinase is only possible after photoactivation 
(Figure 35). This strategy allows a reduction of non-specific basal fluorescence and offers a better 
spatio-temporal resolution. Moreover, it allows control of activation of the biosensor over time (Lee 
et al., 2009). 
 
Figure 35: Light-activation strategies 
4.4.6.  Pros and cons of non genetic protein/peptide fluorescent biosensors 
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This type of biosensors displays many advantages including versatility in design and engineering and 
large choice of the nature and position of incorporation of the fluorescent probe. Moreover, peptides 
and proteins can be easily obtained by chemical synthesis or recombinant protein expression and 
purification. Finally, handling and storage of peptides are simple and up-scaling is quite 
straightforward.  
However, the main issue is their inability to cross cell membranes, which is why they require means 
for efficient internalization in living cells and in vivo (Kurzawa et al., 2010). This may be addressed 
through microinjection or administration thanks to cell-penetrating peptides (CPPs) such as PEP and 
CADY2 (Kurzawa et al., 2010; McNeil, 2001). For instance, microinjection has been used to internalize 
a biosensor capable of visualizing the changing activation of endogenous, unlabeled Cdc42 in living 
cells (Nalbant et al., 2004). In addition, the cell-penetrating peptide TAT has been used to internalize 
in living cells a non genetic fluorescent biosensor for dynamic monitoring of phosphorylation by Abl 
kinase based on fluorescence lifetime imaging microscopy (FLIM) (Damayanti et al., 2013). Non-
covalent strategies that form CPP/protein or CPP/peptide complexes have also been developed to 
deliver biosensors in living cells for probing CDK/cyclins (Kurzawa et al., 2011; Van et al., 2014).  
4.5. Fluorescent biosensors for HTS of protein kinase inhibitors 
Several strategies have been developed for high throughput screening (HTS) of chemical compound 
libraries in view of identifying novel inhibitors of protein kinases (Ahsen and Bömer, 2005; Allen et 
al., 2006; Hanson and Hanson, 2008; Taylor, 2010; Wolff et al., 2006; Zaman et al., 2003). The first of 
these were essentially based on conventional activity-based assays described above in paragraph 4.1. 
To replace these time consuming and invasive techniques and perform HTS assays, several 
fluorescence-based approaches have been developed such as scintillation proximity, FRET, 
fluorescence polarization, luminescence and AlphaScreen assays (Ahsen and Bömer, 2005; Zaman et 
al., 2003). More specifically, fluorescent biosensors have been implemented to monitor protein 
kinase activity in high content and high throughput screening formats (Chen et al., 2004; González-
Vera, 2012; Lawrence and Wang, 2007; Morris, 2013; Nhu Ngoc Van and Morris, 2013; Sharma et al., 
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2008; Tarrant and Cole, 2009; Zhang and Allen, 2007). They offer precious tools for screening in living 
cells thereby assessing inhibitor potential in a physiological environment (Carpenter, 2007; Hanson 
and Hanson, 2008; Lang et al., 2006; Taylor, 2010; Wolff et al., 2006; Zanella et al., 2010). 
Four classes of fluorescent biosensors, illustrated in Figure 36, have been developed for HTS/HCS 
applications: genetically-encoded FRET biosensors, environmentally-sensitive biosensors, positional 
biosensors and FLiK (Fluorescent Labels in Kinases). The first two biosensors have been described in 
detail in paragraphs 4.3 and 4.4. Positional biosensors are genetic fusions of an AFP that bear a 
subcellular localization sequence (generally NLS (Nuclear Localization Sequence) or NES (Nuclear 
Exclusion Sequence)). Exposure of this sequence is modulated in response to target 
activation/inhibition. Thus, they give information on the target activation/inhibition through changes 
in their subcellular localization and constitute potent tools for HCS (Figure 36-2A). 
Most of the strategies described above contain a PAABD and led to identification of ATP-competitive 
compounds. Therefore, with the aim of screening allosteric inhibitors which bind and stabilize only 
the inactive conformation of kinases, FLiK (Fluorescent Labels in Kinases) biosensors have been 
developed (Figure 36-2C). They contain a kinase scaffold in which fluorescent probes are introduced 
into specific positions and serve as sensors of ligands that bind a specific conformational state. FLiK 
assays have been successfully applied to identify inhibitors of p38αMAPK, Src and Abl through HTS 
assays (Getlik et al., 2012; Schneider et al., 2012; Simard et al., 2009a, 2009b, 2009c, 2010; Zhang et 
al., 2010). 
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Figure 36: Fluorescent Biosensors used for HTS (from (Prével et al., 2014a)) 
1. Schematic representation of a fluorescent biosensor  
2. Different examples of fluorescent biosensors – A: Positional biosensors convey information on 
the activity of the target through changes in their subcellular localization. B: Activity-based 
biosensors. C: Conformation-sensitive FLIK (fluorescent labels in kinases)-based approach  
Specific criteria are required for successful application of fluorescent biosensors to HTS. Biosensors 
should be highly specific and sensitive, they should respond in a dynamic and reversible fashion 
leading to robust and reproducible signals. Calculation of the Z-factor enables to assess a HTS assay. 
Indeed, it takes into account the difference between positive and negative controls, the signal-to-
noise (S/N) ratio and the variability of the assay (Ahsen and Bömer, 2005; Allen et al., 2006; Inglese et 
al., 2007; Sui and Wu, 2007; Zaman et al., 2003; Zhang et al., 1999). Z-factor is equal to ͳ െ ଷሺ஺శା஺షሻ஻శି஻ష , 
where A+ and A- correspond to the standard deviations of positive and negative controls, whilst B+ 
and B− are the average responses for positive and negative controls. An assay is considered suitable 
for a screen if the Z factor is greater than 0.5 (Inglese et al., 2007; Prével et al., 2014b; Zhang et al., 
1999). 
Table 5 provides a panel of examples of fluorescent biosensors validated or implemented in HTS 
assays. 
 
Target 
activation
/inhibition
Nucleus
Cell membrane
Positional biosensors 
Allosteric 
modulator
conformation A conformation B
Kinase 
scaffold
Conformation-selective biosensors
kinase
P
Substrate Phosphorylated
substrate
Activity-based biosensors
Fluorescence emission
Receptor 
moiety
target
Fluorescent 
probe
Biosensor
1 2A
2C2B
 65 
 
Biosensor 
Name 
Biosensor Type Target 
Z 
factor 
Dye / Probe Comments References 
PKA 
Genetic, 
positional 
PKA 
 
GFP-NLS-NES cellular assay 
 
GPCR 
Genetic, 
positional 
GPCR 
 
GFP cellular assay 
(O’Dowd et 
al., 2007) 
PPIB 
Genetic, 
positional 
P53/hDM2 0,64 
GFP-NLS-p53 / 
mRFP-NLS-NES-
hDM2 
high content screen 
for protein/protein 
interaction 
inhibitors 
(Dudgeon et 
al., 2010) 
EGFRB 
Genetic, 
positional 
EGFR 0,56 GFP-EGFR 
high content screen 
for modulators of 
EGFR function 
(Antczak et 
al., 2012) 
       
AKAR 2 Genetic, FRET PKA < 0.5 
FRET couple of 
AFPs 
HTS 
(Allen et al., 
2006) 
AKAR 3 Genetic, FRET PKA 0,84 
FRET couple of 
AFPs 
HTS 
(Allen et al., 
2006) 
Pickles Genetic, FRET Bcr-Abl 
 
FRET couple of 
AFPs 
Proposed for HTS / 
HCS 
(Lu and 
Wang, 2010; 
Mizutani et 
al., 2010) 
C3 Genetic, FRET Caspase 3 0,87 
FRET couple of 
AFPs 
HTS performed to 
identify anticancer 
compounds from 
Chinese medicine 
(Tian et al., 
2007) 
       
Kinase 
Chemosensors 
Environmentally-
sensitive 
Akt, MK2, PKA 
 
SOX 
(sulfonamide 
oxine) 
Validation for 
multiplex screening 
using cell extracts 
(Shults et al., 
2005) 
Sox 
Chemosensor 
Environmentally-
sensitive 
Serine/threonine 
Protein kinases  
SOX 
(sulfonamide 
oxine) 
Proposed for HTS 
(Shults et al., 
2006) 
ERK1/2 
chemosensor 
Environmentally-
sensitive 
ERK1/2 
 
SOX 
(sulfonamide 
oxine) 
Proposed for HTS 
using cell extracts 
(Luković et 
al., 2009) 
p38α 
chemosensor 
Environmentally-
sensitive 
p38 alpha 
 
SOX 
(sulfonamide 
oxine) 
Proposed for HTS 
(Stains et al., 
2011) 
Bcr-Abl & Lyn 
Biosensors 
Environmentally-
sensitive 
Bcr-Abl & Lyn 
  
Proposed for HTS 
(Wang et al., 
2010) 
       
DFG Biosensor FLIK P38α 
 
Acrylodan 
validation with 
focused library of 
pyrazolourea 
derivatives 
(Simard et al., 
2009b) 
DFG Biosensor FLIK P38α 
 
Acrylodan 
HTS performed on 
35000 compounds 
(Simard et al., 
2009a) 
P-loop 
Biosensor 
FLIK P38α 
 
Acrylodan 
validation with 
library of DFG-in or -
(Simard et al., 
2010) 
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out conformation 
ligands 
MAPK Insert 
Biosensor 
FLIK P38α >0.7 Acrylodan 
validation with 
library of 2-
arylquinalozines 
(Getlik et al., 
2012) 
DFG Biosensor FLIK cSrc 
 
Acrylodan 
 
(Simard et al., 
2009c) 
Myristate 
Pocket 
FLIK Abl >0.84 Acrylodan amenable to HTS 
(Schneider et 
al., 2012) 
Table 5: Fluorescent biosensors validated and/or implemented in HTS assays (from (Prével et al., 
2014b)) 
4.6. In vivo applications – Development of near-infrared probes 
Two issues in fluorescence imaging have to be taken into account for the development of fluorescent 
biosensors in vivo. The first one is photobleaching and phototoxicity induced by the excitation light 
(Hoebe et al., 2007). The second drawback is absorption/autofluorescence of tissues in visible 
spectrum (especially from 400 nm to 600 nm) which results from absorbers like water, hemoglobins 
and lipids (Weissleder and Ntziachristos, 2003). The use of InfraRed (IR) and Near InfraRed (NIR) 
probes has been considered as one of the key strategies to circumvent this issue (Frangioni, 2003, 
2008; Koide et al., 2012; Lin et al., 2009a; Lukinavičius et al., 2013; McCann et al., 2011; 
Shcherbakova et al., 2012; Shcherbo et al., 2010; Subach et al., 2011). 
NIR light displays many advantages compared to visible light including minimal photodamage to 
biological samples, deep tissue penetration, and low background autofluorescence of biomolecules 
in the NIR range, so that high contrast can be obtained between the imaging probe and background 
tissue. While a wide panel of NIR fluorescent probes has been developed, most of them display 
limitations for bioimaging. Indeed, they suffer from photobleaching, or do not emit adequate 
fluorescence in aqueous media due to molecular stacking or poor water-solubility (Ho et al., 2006; 
Marx, 2015). So far, only cyanine dyes (Cy5 and Cy7) have been widely used for the development of 
NIR fluorescent biosensors (Mishra et al., 2000; Peng et al., 2011). In the past few years, silica-
containing rhodamine (SiR) fluorophores have been developed and constitute a novel class of NIR 
fluorophores which present superior characteristics for in vivo fluorescence imaging and live-cell 
super-resolution microscopy (Koide et al., 2012; Lukinavičius et al., 2013; McCann et al., 2011). 
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4.7. Fluorescent biosensors as diagnostic tools – biomedical applications 
Through all the examples mentioned in the previous sections, fluorescent biosensors, be they genetic 
or non genetic, have proven their utility and their efficiency in vitro and in cellulo. 
In recent years, they have also been a source of inspiration for biomedical applications, including 
diagnostic assays, in the development of complementary assays or as alternatives to the more 
traditional antigenic and/or genomic approaches (MayC Morris, 2012).  
For example, a genetically-encoded FRET biosensor that reports on Bcr-Abl kinase activity has been 
applied to identify cancer cells from CML (Chronic Myeloid Leukemia) patients and to monitor drug 
response and resistance (Lu and Wang, 2010; Mizutani et al., 2010; Tunceroglu et al., 2010). Two 
peptide fluorescent biosensors have also been implemented to simultaneously visualize the tyrosine 
kinase activities of both Abl and Lyn in cells from CML patients (Wang et al., 2010). This last example 
demonstrates that fluorescent biosensors can be applied for multiplex screening. In the same assay, 
it becomes possible to use several biosensors coupled to different fluorescent probes. In drug 
discovery programmes, it therefore allows to monitor several targets simultaneously and gain 
information on the specificity of drugs (Carlson and Campbell, 2009; Piljic and Schultz, 2008; Welch et 
al., 2011). 
For a completely different biomedical application, a fluorescently-labeled peptide biosensor that 
binds preferentially to nerves has been injected in mice and allows the visualization of peripheral 
nerves during surgery. It offers a promising means for developing image-guided surgery by 
facilitating surgical repair of injured nerves and by helping prevent accidental transection (Whitney et 
al., 2011).  
In 2014, Griss and collaborators have developed semisynthetic bioluminescent biosensors that 
enable to measure precisely drug concentrations (Methotrexate and Cyclosporin A) in human blood 
samples, directly by spotting minimal volumes on paper and recording the signal using a simple 
point-and-shoot camera (Griss et al., 2014). In 2015, Courbet and co-workers have developed 
bacterial biosensors to detect pathological biomarkers (nitrogen oxides and glucose) in human urine 
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and serum via amplifying genetic switches and logic gates (Courbet et al., 2015). These last two 
examples constitute a major breakthrough in drug and biomarker monitoring and, more generally, in 
diagnostic assays. 
5. Biosensors to probe CDK/cyclins 
5.1. A FRET-based biosensor for probing CDK1/cyclin B1 activity 
Only one genetic FRET biosensor has been described to probe the activity of CDK1/cyclin B1 so far 
(Gavet and Pines, 2010). This biosensor was engineered through incorporation of a pair of 
genetically-encoded AFPs together with a PAABD derived from the Polo Box Domain (PBD) of Polo-
Like Kinase 1 (Plk1) and a CDK1-specific substrate sequence which derives from the 
autophosphorylation site of cyclin B1. The biosensor was introduced into HeLa cells through 
electroporation. When the substrate sequence was phosphorylated by active CDK1/cyclin B1, the 
PAABD recognized this phosphorylation site and underwent a conformational change, thereby 
inducing a 15% FRET increase between mCerulean (λexc = 433 nm; λem = 475 nm) and YPet56 (λexc 
= 517 nm; λem = 530 nm). It has proved to be a potent tool for probing CDK1/cyclin B1 and allowed 
to demonstrate that this complex was activated just before the disassembly of nuclear envelope, 
thereby initiating the events of prophase (Figure 37). 
 
Figure 37: HeLa cells expressing the CDK1/cyclin B1 activity biosensor (from (Gavet and Pines, 
2010)). (A) Intensity-modulated display representation of the FRET dynamics during mitotic 
progression. (B) Average curve of the quantification of the emission ratio over time in 6 different 
cells. Quantification curves demonstrate that CDK1/cyclin B1 is activated just before the 
A B
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disassembly of nuclear envelope (NEBD). At this stage, the greatest FRET signal enhancement is 
obtained (15%). 
5.2. CDKSENS, CDKACT and CDKCONF to probe CDK/cyclins 
Three classes of non genetic biosensors, CDKSENS, CDKACT and CDKCONF, have been designed in our 
team (Figure 38).  
 
Figure 38: The three families of non genetic fluorescent biosensors developed in the team: (A) 
CDKSENS; (B) CDKACT; and (C) CDKCONF. 
5.2.1.  CDKSENS 
The team has developed a family of fluorescent peptide biosensors, CDKSENS, that reports on the 
relative abundance of CDK/cyclins (Kurzawa et al., 2011). CDKSENS is a family of biligand peptides 
composed of a CDK-binding sequence and a cyclin-binding sequence, and bearing a unique cysteine 
which is coupled with an environmentally-sensitive probe whose fluorescence increases in a sensitive 
fashion upon recognition of its targets (Figure 38A). 
CDKSENS displays a biligand affinity for recombinant CDKs and cyclins in vitro and retains 
endogenous CDK/cyclin complexes from cell extracts. Cy3-labelled CDKSENS, when introduced into 
living cells through complexation with the cell-penetrating carrier CADY2, reports on the relative 
abundance of CDK/cyclins through fluorescence imaging and ratiometric quantification. The 
biosensor further allows for detection of differences between different healthy and cancer cell lines, 
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thereby enabling to distinguish cells that express high levels of these heterodimeric kinases, from 
cells that present decreased or defective assemblies. 
5.2.2. CDKACT 
Few years later, the team has designed a family of fluorescent peptide/peptide biosensors, CDKACT, 
that reports on CDK/cyclin activity through changes in fluorescence of an environmentally-sensitive 
probe (Van et al., 2014). CDKACT biosensors contain a substrate sequence and a Phospho Amino Acid 
Binding Domain (PAABD) that recognizes the phosphorylated substrate sequence. The substrate 
sequence contains a unique cysteine, proximal to the phosphorylation site, onto which an 
environmentally-sensitive cyanine fluorescent probe is coupled. The PAABD derives from the Polo 
Box Domain (PBD) of Plk1 in which all cysteine residues were mutated to serines. Upon 
phosphorylation by CDK/cyclins, the biosensor undergoes a conformational change, thereby altering 
the spectral properties of the fluorescent dye (Figure 38B).  
CDKACT allows a comparison of enzymatic activity of recombinant kinases (25-40% fluorescence 
enhancement), probing endogenous activities in lysates from healthy and cancer cell lines in a 
sensitive and quantitative fashion (60% fluorescence enhancement in HeLa cell extracts) and 
monitoring inhibition by small molecules.  
Cy5-labelled CDKACT, when fused with a red fluorescent protein and introduced into living cells 
through complexation with the cell-penetrating carrier PEP1, allows to monitor the oscillatory 
activity of CDK/cyclins throughout the cell cycle by time-lapse imaging and ratiometric fluorescence 
quantification (Cy5/RFP ratio). 
5.2.3. CDKCONF 
With the aim of identifying allosteric inhibitors of CDK2, the team has developed a protein biosensor, 
CDKCONF, based on FLiK (Fluorescent Labels in Kinases) technology (see paragraph 4.5). The 
biosensor contains a CDK2 kinase scaffold in which fluorescent probes are introduced into specific 
positions and serve as sensors of ligands that bind a specific conformational state of CDK2 (Figure 
38C). CDKCONF has been implemented for screening the French National Chemical Compound 
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Library (18480 compounds) (Tcherniuk et al., in revision). The screening led to identification of 
compounds that interfere with the T-loop of CDK2 and selectively inhibit CDK2 activity and cancer 
cell proliferation. 
  
 72 
 
Objectives
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My thesis comprises two parts, the first concerning the development of a fluorescent biosensor for 
probing CDK4/cyclin D activity; the second devoted to the identification of CDK4/cyclin D inhibitors, 
either by screening small molecule libraries or through rational design of peptides. 
1. Development of a fluorescent biosensor for probing CDK4/cyclin D activity 
Currently, kinase activity is largely detected by radioactivity or antibody-based approaches. However, 
these approaches do not provide real insights into the dynamics and enzymatic kinetics of the target 
kinase in its native environment. As such, my first goal was to develop a non genetic fluorescent 
biosensor that could monitor CDK4/cyclin D activity. Different protein and peptide variants of the 
biosensor were characterized in vitro using recombinant CDK4/cyclin D and cell extracts derived from 
melanoma cell lines in which CDK4/cyclin D is deregulated. The biosensor was then applied to detect 
CDK4/cyclin D alterations in biopsies from human skin and melanoma xenografts in fluorescence-
based activity assays and in living cancer cells through fluorescence microscopy and timelapse 
imaging.  
2. Identification of CDK4/cyclin D inhibitors 
A. Identification of non-ATP competitive compounds targeting CDK4/cyclin D 
To this aim, two fluorescent biosensors were engineered to identify competitors of essential 
protein/protein interfaces between CDK4 and cyclin D, and allosteric inhibitors that perturb the 
conformational dynamics of CDK4, respectively. Once validated, the biosensors were implemented to 
screen two small molecule libraries. Hits were characterized in fluorescence titration and activity 
assays so as to determine their mechanism of action and their ability to inhibit CDK4/cyclin D, as well 
as in proliferation assays in melanoma cell lines. 
B. Development of peptide inhibitors that target the CDK4/cyclin D interface 
The second objective of this section was to develop peptide inhibitors that interfere with essential 
protein/protein interactions between CDK4 and cyclin D. The mechanism of action of these peptides 
was determined in vitro in binding/dissociation assays, using recombinant CDK4 and cyclin D. Their 
 74 
 
inhibitory potential towards CDK4 activity was characterized in fluorescence-based activity assays, as 
well as in proliferation assays in melanoma cell lines following cell-penetrating peptide-mediated 
delivery. 
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Results 
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1. Development of a fluorescent biosensor for probing CDK4/cyclin D activity 
1.1. Concept 
A generic fluorescent protein/peptide biosensor family, CDKACT, was previously developed by the 
team for probing CDK/cyclin activity in vitro and in living cells (Van et al., 2014). In order to generate 
a fluorescent biosensor which would respond specifically to CDK4/cyclin D, we designed a new family 
of CDKACT derivatives with a substrate specific to CDK4.  
This novel family of biosensors consists of three domains: 
- a Phospho Amino Acid Binding Domain (PAABD) which recognizes pSer ou pThr 
- a CDK4-specific substrate sequence derived from the retinoblastoma protein (Rb), from residue 
790 to 801, which is specifically phosphorylated by CDK4/cyclin D (S795 residue) (Grafstrom et al., 
1999). A unique cysteine was introduced at position -2 relative to the phosphoserine for labelling 
with a synthetic environmentally-sensitive fluorescent probe (YKFCSSPLRIPG).  
- a short glycine-rich linker to ensure flexibility between the two domains. 
So that, phosphorylation of the substrate sequence by active CDK4/cyclin D induces an 
intramolecular conformational change due to recognition of the phosphorylated sequence by the 
PAABD which alters the local environment of the probe and consequently its spectral properties 
(Figure 39). 
Three variants of CDK4 biosensors were designed: a recombinant protein and two synthetic peptides, 
which bear the same substrate sequence combined with different PAABDs via a short/long linker. 
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Figure 39: The biosensor consists of a CDK4-specific substrate sequence derived from pRb in which 
a cysteine residue was introduced at position -2 relative to the SP phosphorylation site (795), and a 
phospho amino acid-binding domain (PAABD) which recognizes the substrate sequence 
phosphorylated by CDK4/cyclin D kinase. 
1.2. CDKACTRb 
1.2.1. Design 
First, a 57 kDa GST-CDKACTRb protein biosensor was developed, containing a PAABD derived from 
the Polo Box Domain of Plk1 (García-Alvarez et al., 2007), from residue 367 to 603 (237 amino acids) 
in which all cysteine residues were mutated to serines (materials and methods) (Figure 40A). 
CDKACTRb therefore contained a single cysteine, close to the phosphorylation site, for labeling with 
fluorescent probes such as Cy3 (Figure 40B). 
 
Figure 40: (A) Crystal structure of the Polo Box Domain of Plk1 in complex with a Cdc25 
phosphopeptide (PDB 20JS). (B) Chemical structure of Cy3-iodoacetamide. 
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1.2.2. Biosensor engineering 
CDKACTRb protein biosensor was engineered by recombinant protein technology in fusion with a 
GST tag (materials and methods). It was expressed in E.coli and expression was verified by SDS-PAGE 
(57 kDa). It was purified by affinity on glutathione sepharose and gel filtration chromatography 
(Figure 41) (materials and methods).  
 
Figure 41: Expression and purification of GST-CDKACTRb. M: marker protein; I: protein induction; 
After Gel Filtration (GF) B9-B11: Protein fractions from gel filtration FPLC purification. 
1.2.3.  CDK4, cyclin D1 and CIV engineering 
In order to characterize the biosensor in vitro, recombinant CDK4 and cyclin D1 proteins were 
produced. Activation of the complex was achieved using the CDK-activating kinase CIV of 
Saccharomyces cerevisiae. CDK4, cyclin D1 and CIV were constructed by recombinant protein 
technology in fusion with a GST tag (materials and methods). They were expressed in E.coli and 
expression was verified by SDS-PAGE (GST-CDK4 and GST-cyclin D1: 59 kDa; GST-CIV: 67 kDa) (Figure 
42). They were purified by affinity and gel filtration chromatography (Figure 42) (materials and 
methods). GST-CDK4 / GST-cyclin D complex was formed following individual purification of each 
subunit and incubation of stoechiometric concentrations, then further incubated with 50 nM CIV to 
ensure its activation. 
I
97
66
45
30
After 
GF
kDa
57 kDa
B9 B10 B11M
 79 
 
 
Figure 42: Expression and purification of GST-CDK4, GST-cyclin D1 and GST-CIV. (A) CDK4 - M: 
marker protein; NI: before induction; I: protein induction. (B) cyclin D1 - M: marker protein; NI: 
before induction; I: protein induction. (C) Protein fractions from gel filtration FPLC purification M: 
Marker protein. (D) CIV - M: marker protein; NI: before induction; I: protein induction; protein 
fractions after GST-Trap; After Gel Filtration (GF) : protein fractions from gel filtration FPLC 
purification. 
1.2.4.   In vitro characterization with recombinant CDK4/cyclin D 
In order to validate the ability of CDKACTRb to report on CDK4/cyclin D phosphorylation in vitro and 
further characterize this protein biosensor, spectrofluorimetric experiments were performed in 96-
well plates in standard kinase assay conditions for 50 min at 30°C in the presence of 0.5 mM ATP and 
5 mM MgCl2. CDKACTRb was labeled with the fluorescent probe Cy3. Fluorescence emission of Cy3-
labelled CDKACTRb was measured at 570 nm following excitation at 544 nm on a PolarstarTM 
fluorimeter. Since the fluorescently-labeled biosensor has a basal fluorescence, responses of the 
biosensor resulting from incubation with recombinant proteins and inhibitors are always obtained 
following subtraction of background fluorescence of Cy3-CDKACTRb alone. 
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The first experiment was performed using 50 nM CDKACTRb-Cy3, 50 nM CDK4/cyclin D1 and 50 nM 
CIV. A specific CDK4/6 inhibitor, PD-0332991 (also called Palbociclib) was used at 20 µM to inhibit 
CDK4 activity. The results showed that the addition of active CDK4/cyclin D1 led to a 15% 
enhancement of the fluorescence intensity of the biosensor, after 50 min (3000s) of reaction (Figure 
43B). Upon addition of 20 µM of PD-0332991, the fluorescent signal of the biosensor was decreased 
by 5%. This experiment indicates that CDKACTRb biosensor reports on CDK4/cyclin D1 kinase activity 
in vitro. The weak increase in fluorescence of Cy3-CDKACTRb could be explained by the presence of 
the GST-tag in CDK4, cyclin D and CDKACTRb. As GST-tag has a tendency to dimerize, it could induce 
the formation of homo/heterodimers between the biosensor itself, CDK4 itself, cyclin D itself or 
between the biosensor and the kinase, consequently preventing a robust fluorescent signal. 
 
Figure 43: CDKACTRb-Cy3 (50 nM) fluorescence was monitored over time upon incubation with 50 
nM active recombinant CDK4/cyclin D1 and 50 nM CIV +/- 20 µM PD-0332991. (A) Fluorescence 
emission of Cy3-CDKACTRb alone or upon incubation with active CDK4/cyclin D1 was measured at 
570 nm following excitation at 544 nm. (B) Relative increase in fluorescence of the biosensor 
incubated with kinase following subtraction of background fluorescence of Cy3-CDKACTRb alone. 
1.2.5. In extracto characterization 
To assess the ability of CDKACTRb to report on the activity of endogenous CDK4/cyclin D, a 
melanoma cell line A375, in which CDK4/cyclin D is hyperactivated, was used as a source of 
endogenous kinase. A375 cell extracts were prepared from subconfluent cell cultures and then dosed 
at 280 nm to calculate the total protein concentration.  
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The working concentration window was determined by testing different concentrations of both the 
biosensor and A375 cell extracts. The first series was set up with a fixed concentration of 20 µg of 
proteins from A375 cell extracts and increasing concentrations of Cy3-labelled CDKACTRb (10, 25 and 
50 nM). Figure 44A presents fluorescence emission at 570 nm of CDKACTRb-Cy3 overtime following 
excitation at 544 nm. In Figure 44B, maximal fluorescence of the biosensor at the end of the reaction 
(3000s) is represented in a linear plot as a function of its concentration. The results demonstrated 
that, in standard kinase assay conditions at 30°C, in the presence of 0.5 mM ATP and 5 mM MgCl2, 
fluorescence emission increased in a dose-dependent fashion (30 - 90% enhancement) within a 
window of 10 - 50 nM CDKACTRb-Cy3. By enhancing biosensor concentration from 10 nM to 25 nM, 
the fluorescence intensity strongly increased from 30 to 70%. Upon enhancement of the biosensor 
concentration from 25 nM to 50 nM, the fluorescence intensity was slightly amplified, suggesting 
that saturation has been reached for this concentration of cell extracts. 
The second series of experiments was set up with a fixed concentration of 25 nM of Cy3-labelled 
CDKACTRb and increasing concentrations of 5 - 100 µg proteins from A375 cell extracts (Figure 
44C/D/E). The fluorescence emission of CDKACTRb increased in a dose-dependent fashion (30-100% 
enhancement) within a window of 5 - 20 µg proteins. Upon addition of higher concentrations of A375 
cell extracts (40 - 100 µg), there was a drop in the fluorescent signal compared to that obtained with 
20 µg (Figure 44E). This reduction in fluorescence could be explained by the presence of 
phosphatases whose concentrations are enhanced upon addition of increasing cell extracts 
concentrations. Indeed, as phosphatases remove phosphate groups, the substrate sequence is no 
longer phosphorylated, resulting in a shift of the biosensor from closed to open conformation which 
leads to a return to basal fluorescent signal. Another explanation could be that the excess of extracts 
shields the biosensor and leads to its aggregation. 
Taken together, we observed that the greatest fluorescence enhancement was obtained with 25 - 50 
nM CDKACTRb-Cy3 and 20 µg A375 cell extracts. 
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Figure 44: Determination of working concentrations of Cy3-CDKACTRb and A375 cell extracts in 
real-time fluorescent assays. The fluorescent signal after subtraction of the background 
fluorescence of Cy3-CDKACTRb alone is presented.  
(A) 20 µg A375 cell extracts and increasing concentrations of CDKACTRb-Cy3 (10 - 50 nM) 
(B) The linear plot represents the maximal fluorescence of the biosensor (at 3000s) as a function of 
its concentration upon addition of 20 µg A375 cell extracts. 
(C) 25 nM CDKACTRb-Cy3 and increasing concentrations of A375 cell extracts (5 - 20 µg) 
(D) 25 nM CDKACTRb-Cy3 and increasing concentrations of A375 cell extracts (20 - 100 µg). 
(E) The linear plot represents the maximal fluorescence of the biosensor (25 nM) (at 3000s) as a 
function of A375 cell extract concentrations. 
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Response of CDKACTRb upon inhibition of CDK4/cyclin D activity with PD-0332991  
The assays were performed in standard kinase assay conditions with 25 nM CDKACTRb-Cy3, 10 µg 
A375 cell extracts and different concentrations of PD-0332991 (from 0 to 100 µM). Figure 45A shows 
that addition of A375 cell extracts led to a 80% enhancement of the fluorescence intensity of the 
biosensor. The addition of increasing concentrations of PD-0332991 reduced the fluorescent signal of 
the biosensor in a dose-dependent fashion. The maxima of the curves at the end of the reaction are 
represented in a histogram (Figure 45B). Curve fitting of these points allowed the determination of 
an IC50 value of PD-0332991 in melanoma cell extracts, equal to 5.9 µM (Figure 45C) (see materials 
and methods for the IC50 equation used). Unlike standard IC50 values which are determined using the 
purified recombinant kinase alone (11 nM for PD-0332991 towards CDK4), this value reflects the 
inhibitory efficiency of PD-0332991 towards endogenous CDK4/cyclin D in a more physiological 
context. 
 
Figure 45: Real-time fluorescence assays with A375 melanoma cell extracts as source of 
endogenous CDK4/cyclin D and CDKACTRb-Cy3 in the presence of different concentrations of PD-
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0332991. The fluorescent signal after subtraction of the background fluorescence of CDKACTRb 
alone is presented.  
(A) Relative increase in the fluorescence of 25 nM CDKACTRb-Cy3 incubated with 10 µg A375 cell 
extracts +/- different concentrations of PD-0332991 (CDK4/6 inhibitor)  
(B) Histogram representing the fluorescent signal at the endpoint of the assay (4000s). The 
fluorescent signal of CDKACTRb-Cy3 incubated with cell extracts without PD-0332991 was regarded 
as 100%.  
(C) Curve fitting and IC50 determination of PD-0332991 on CDK4/cyclin D activity in melanoma cell 
extracts. 
Selectivity and Specificity of CDKACTRb 
To assess the selectivity and specificity of CDKACTRb for CDK4/cyclin D, different inhibitors were 
tested: some CDK/cyclin inhibitors including Roscovitine (CDK1/2/5/7/9), RO3306 (CDK1) and AT7519 
(CDK2/4/5/9); and some inhibitors of kinases not related to CDK/cyclins such as Src (PP2), PKA (H89), 
MEK (U0126). The assays were performed as described above with 25 nM CDKACTRb-Cy3, 10 µg 
A375 cell extracts and different concentrations of inhibitors (from 0 to 20 µM). 
These experiments demonstrated that there were no significant changes of the fluorescence 
intensity of CDKACTRb when adding these inhibitors at different concentrations, compared to PD-
0332991 (Figure 46A and B). 
Taken together, these data provide evidence that CDKACTRb reports specifically on endogenous 
CDK4/cyclin D activity. 
 
Figure 46: CDKACTRb-Cy3 (25 nM) fluorescence was monitored over time upon incubation with 10 
µg A375 cell extracts +/- different inhibitor concentrations (0 - 20 µM). The fluorescent signal was 
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obtained following subtraction of background fluorescence of Cy3-CDKACTRb alone and the 
histogram represents the fluorescent signal at the endpoint of the assay (4000s). 
(A) CDK/cyclin inhibitors: PD-0332991 (CDK4/6 inhibitor), Roscovitine (CDK1/2/5/7/9 inhibitor), 
RO3306 (CDK1 inhibitor) and AT7519 (CDK2/4/5/9 inhibitor) 
(B) Inhibitors of other kinases: PP2 (Src inhibitor), U0126 (MAPK inhibitor) and H89 (PKA inhibitor). 
Profiling CDK4/cyclin D activity in different cancer cell lines 
CDKACTRb was used to compare differences in endogenous CDK4/cyclin D activity in cell extracts 
derived from different human cancer cell lines including cervical cancer HeLa, melanoma A375, lung 
carcinoma A549 and acute T cell leukemia Jurkat. Cell extracts were prepared and their 
concentration was normalized at 280 nm. Western blot analysis of these extracts allowed to compare 
the abundance of CDK4 and cyclin D1. The results in Figure 47A showed that cyclin D1 levels were 
comparable between the different cell types while CDK4 was significantly more abundant in HeLa 
than in A375, A549 and Jurkat cell extracts. Figure 47B represents CDK4 levels relative to cyclin D 
levels. Fluorescent kinase assays were performed to measure CDK4/cyclin D activity in 10 μg cell 
extracts from these four cell lines using 25 nM CDKACTRb-Cy3 (Figure 47C). Figure 47D represents 
the fluorescent signal of the biosensor at the endpoint of five independent assays. The results 
showed that CDKACTRb fluorescence intensity measured in cell extracts, in response to CDK4/cyclin 
D activity, was comparable in the four cell lines. These similar response profiles differ from the 
protein expression profiles revealed by Western blotting. This difference can be explained by 
analysing the genotypes of these strains. Indeed, unlike HeLa and Jurkat cell lines which bear wild-
type CDK4, p16INK4A and pRb, A375 and A549 cell lines harbour a mutation of p16INK4A, the 
endogenous inhibitor of CDK4 which leads to unrestricted activity of CDK4. Thus, even if CDK4 is less 
abundant in A375 and A549 than in HeLa, CDKACTRb highlights kinase hyperactivation in these two 
cell lines that harbour molecular alterations converging on CDK4/cyclin D activity. 
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Figure 47: CDKACTRb-Cy3 reports on differences in CDK4/cyclin D activity of different cancer cell 
lines. Cell extracts from HeLa, A375, A549 and Jurkat cell lines were normalized at 280 nm and used 
for Western blotting and fluorescence kinase assays.  
(A) Western blotting of CDK4 and cyclin D1 in HeLa, A375, A549 and Jurkat cancer cell lines. 
(B) Quantification of CDK4/cyclin D1 levels. The ratio CDK4/cyclin D1 in HeLa cell extracts was 
regarded as 1. 
(C) Example of response of 25 nM CDKACTRb-Cy3 upon incubation with 10 µg cell extracts from 
different cancer cell lines: Hela, A375, A549 and Jurkat. The fluorescent signal was obtained 
following subtraction of background fluorescence of Cy3-CDKACTRb alone. 
(D) Histogram representing the fluorescent signal at the endpoint of 5 independent assays (4000s). 
The fluorescent signal of CDKACTRb-Cy3 incubated with HeLa cell extracts was regarded as 100%. 
1.3. WWRb 
In order to probe CDK4/cyclin D activity routinely in cell extracts derived from melanoma cells and 
biopsies and in cellulo, we decided to generate a peptide version of CDKACTRb, WWRb, which was 
smaller, easier to manipulate and which could be easily stored without suffering degradation. 
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WWRb is a 44 amino acid peptide, whose PAABD derived from the WW domain of Pin1, from residue 
10 to 39 (30 amino acids) (Figure 48). This WW domain was previously used in a hybrid biosensor to 
probe CDK9 activity (Anai et al., 2007). 
 
Figure 48: Crystal structure of the WW Domain of Pin1 (green) in complex with a phosphopeptide 
(magenta) (PDB 1F8A). 
1.3.1.  In extracto characterization 
Determination of the working concentration window 
WWRb was first tested upon incubation with melanoma cell extracts, in real time fluorescence assays 
using the same conditions as for CDKACTRb. Hence, WWRb was labeled with the fluorescent probe 
Cy3. Spectrofluorimetric experiments were performed in 96-well plates in standard kinase assay 
conditions for 1h at 30°C in the presence of 0.5 mM ATP and 5 mM MgCl2. Given the predetermined 
optimal conditions for assays with CDKACTRb, the first experiment was performed using 25 - 50 nM 
WWRb-Cy3 and 20 - 40 µg A375 cell extracts. Fluorescence emission of Cy3-labelled WWRb was 
measured at 570 nm following excitation at 544 nm on a ClariostarTM fluorimeter. As for CDKACTRb, 
the response of Cy3-WWRb was obtained following subtraction of background fluorescence of Cy3-
WWRb alone (Figure 49A). This experiment indicated that Cy3-labelled WWRb responded to the 
addition of cell extracts with 50% fluorescence enhancement, irrespective of the concentration of 
biosensor and cell extracts (Figure 49B). These data revealed that Cy3-labelled WWRb biosensor did 
not respond in a dose-dependent fashion to different concentrations of melanoma cell extracts.  
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Moreover, a second experiment, performed using 20 - 40 µg BSA instead of A375 cell extracts, 
demonstrated that the biosensor also responded to the addition of BSA (Figure 49C). These data 
indicated that Cy3-labelled WWRb biosensor did not respond specifically to CDK4 activity. 
In the protein biosensor comprising a large PAABD derived from Plk1, the Cy3 dye responded to 
CDK4 activity. However, since Cy3 does not respond in WWRb, we hypothesized that this fluorophore 
was not suited for probing phosphosubstrate recognition by WW domain. 
 
Figure 49: The response of 25 nM and 50 nM Cy3-WWRb upon incubation with different 
concentrations of A375 cell extracts or BSA (20 - 40 µg) was monitored in real time fluorescent 
assays. (A) Fluorescence emission of Cy3-WWRb alone or upon incubation with cell extracts was 
measured at 570 nm following excitation at 544 nm. (B) Fluorescent signals were obtained 
following subtraction of background fluorescence of WWRb-Cy3 alone. (C) Fluorescence emission 
of Cy3-WWRb alone or upon incubation with BSA was measured at 570 nm following excitation at 
544 nm and fluorescent signals were obtained following subtraction of background fluorescence of 
WWRb-Cy3 alone. 
Response of WWRb when labeled with different fluorescent probes 
Given these unconclusive results, WWRb was labelled with TAMRA and compared with Cy3. A set of 
experiments in which 50 nM Cy3-WWRb and TAMRA-WWRb was incubated with 20 µg proteins from 
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A375 cell extracts was performed and PD-0332991 was used at 20 µM to inhibit CDK4 activity. The 
results from two independent experiments are presented in Figure 50. They demonstrated that, 
whether labeled with Cy3 or TAMRA, WWRb did not respond in a robust and reproducible fashion to 
the addition of A375 cell extracts, with or without addition of PD-0332991. This high variability 
renders the biosensor impossible to use with either of these probes. 
 
Figure 50: The response of 50 nM Cy3-WWRb (left panel) and TAMRA-WWRb (right panel) upon 
incubation with 20 µg A375 cell extracts and 20 µM PD-0332991 were monitored in real time 
fluorescence assays. Two independent experiments are shown (B&C for Cy3-WWRb and E&F for 
TAMRA-WWRb). The fluorescent signal was obtained following subtraction of background 
fluorescence of WWRb-Cy3 or WWRb-TAMRA alone. Chemical structures of Cy3 and TAMRA are 
presented in panels A and D. 
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Two other probes, Texas Red and FITC, were then tested for labeling WWRb. The same experiments 
as above were performed and results are shown in Figure 51. They revealed that, whether labeled 
with Texas Red or FITC, the biosensor responded in a robust and dose-dependent fashion to the 
addition of 20 - 40 µg A375 cell extracts (from 60 to 80% enhancement for Texas Red-WWRb and 
from 50 to 80% enhancement for FITC-WWRb). Moreover, they responded much less to the addition 
of 40 µg BSA (30% enhancement) compared to that of cell extracts. However, the inhibition of 
CDK4/cyclin D activity by PD-0332991 did not affect the fluorescence intensity of WWRb labeled with 
Texas Red or FITC, suggesting that they are again not responding specifically to CDK4.  
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Figure 51: Responses of 50 nM Texas Red-WWRb (A) and FITC-WWRb (B) upon incubation with 20 - 
40 µg A375 cell extracts or BSA and 20 µM PD-0332991 were monitored in real time fluorescent 
assays. The fluorescent signal was obtained following subtraction of background fluorescence of 
WWRb-Texas Red or WWRb-FITC alone. Chemical structures of Texas Red and FITC are shown 
together with corresponding curves. 
Taken together, these data demonstrated that, irrespective of the fluorescent probe chosen for 
labeling WWRb, it did not respond specifically to CDK4/cyclin D activity when incubated with total 
proteins from cell extracts. This lack of specific response might be associated with a lack of 
conformation of WW domain in lysis buffer which is used for cell extract preparation and which 
contains detergents. 
1.3.2. In vitro characterization 
To validate this hypothesis, WWRb biosensor was tested in vitro with recombinant CDK4/cyclin D1. 
The experiment was performed with 150 nM TAMRA-WWRb, 75 nM CDK4/cyclin D1, 50 nM CIV and 
10 µM PD-0332991 to inhibit CDK4 activity (Figure 52). Analysis of changes in fluorescence intensity 
showed that the biosensor responded to the addition of both monomeric CDK4 and dimeric 
CDK4/cyclin D1 through a net increase in relative fluorescence intensity (60 and 65%, respectively). 
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Relative increase in fluorescence further reached 75% when CDK4/cyclin D1 was pre-incubated with 
the CDK-activating kinase CIV (to phosphorylate the activation loop), but was reduced to 45% upon 
incubation with PD-0332991 (Figure 52). These data demonstrate that WWRb is capable of reporting 
on kinase activity of recombinant CDK4/cyclin D1, and that the signal observed can be uncoupled 
into a kinase binding step, which induces a first net increase in biosensor fluorescence (60%  and 65% 
for the monomeric and the dimeric form, respectively), followed by a phosphotransfer step (10% 
additional contribution). The net decrease in fluorescence observed upon addition of PD-0332991 
suggests that the inhibitor, when bound to the ATP pocket, prevents substrate phosphorylation but 
also modifies CDK4/cyclin D conformation, therefore reducing binding of the substrate to its kinase.   
This experiment and the in extracto data suggest that WWRb responds to CDK4/cyclin D activity in 
vitro but is not sensitive and specific enough to be implemented for further experiments. 
 
Figure 52: Fluorescence profile of 150 nM TAMRA-labelled WWRb peptide biosensor incubated 
with 75 nM recombinant GST-CDK4, GST-CDK4/GST-cyclin D1 or GST-CDK4/cyclin D1 pre-incubated 
with CIV to phosphorylate Thr172 +/- 10 µM PD-0332991. The fluorescent signal after subtraction 
of the background fluorescence of WWRb-TAMRA alone is presented. 
1.4. WWshortRb 
We therefore designed another peptide biosensor, WWshortRb, containing an artificial shorter 
PAABD sequence derived from the interface of the WW domain of Pin1 with a phosphopeptide 
substrate. This artificial domain was designed through analysis of the crystal structure of WW Pin1 
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complexed to a phosphopeptide substrate (PDB 1F8A) revealing that the residues which are critical 
for the interaction with the phosphosubstrate are Arg14, Arg17, Tyr23 and Phe25, as well as Trp34 
(GWEKRMSRSSGRVYYFNHITNASQWERPSG) (Figure 53). A short peptide derivative of this WW 
domain (WWshort) was therefore synthesized which comprises these key residues in the linear order 
of appearance that mimicks the interface (Phe25, Arg14, Tyr23, Arg17) interspaced by small 
uncharged amino acids, and which ends with Trp34 followed by the same five amino acids as in the 
native WW domain of Pin1  (GFARVYMSRSSGWERPSG). 
 
Figure 53: The Arg, Tyr, Phe and Trp residues at the interface between Pin1 WW domain (green) 
that recognize a phosphorylated peptide (yellow) are highlighted in pink (Arg14 and Arg 17) and 
orange (Tyr23, Phe25 and Trp34) (PDB 1F8A). 
1.4.1.  Titration experiments to validate the use of the WWshort PAABD 
In order to validate the use of this novel shorter peptide sequence WWshort as PAABD, titration 
experiments were performed between the CDK4-specific Rb substrate peptide in its phosphorylated 
and unphosphorylated form labeled with FITC. 200 nM FITC-labelled peptides were titrated with 
increasing concentrations of WWlong (PAABD of WWRb) or WWshort (PAABD of WWshortRb) (from 
0 to 3 µM). The results revealed that the WWshort peptide interacts with the phosphorylated form 
of Rb substrate peptide with a dissociation constant value of 80 +/- 37 nM, similar to the WWlong 
peptide (118 +/- 37 nM) (Figure 54A). In comparison the WWshort and WWlong peptides bound the 
unphosphorylated substrate peptide with significantly lower dissociation values 628 +/- 109 nM and 
675 +/- 260 nM, indicating that they preferentially bind the phosphorylated substrate, as expected 
from a PAABD (Figure 54B). Moreover, in both cases, the WWshort peptide promoted greater 
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fluorescence enhancement of the fluorescently-labelled Rb substrate than its native counterpart, 
suggesting it was better suited as a PAABD for a biosensing application. 
 
Figure 54: Fluorescence titration of 200 nM FITC-labelled phospho-Rb (A) and Rb (B) peptides. Both 
the WWlong peptide and the WWshort peptide interacted preferentially with the phospho-Rb 
substrate peptide. In both cases, the WWshort peptide promoted greater fluorescence 
enhancement of the fluorescently-labelled Rb substrate than the WWlong peptide. 
The WWshortRb biosensor was synthesized, with the WWshort peptide followed by the CDK4-
specific Rb substrate sequence. To verify that the Rb substrate peptide could bind the recombinant 
form of CDK4, fluorescence titration assays were performed with 200 nM FITC-labelled Rb substrate 
peptide and increasing concentrations of GST-CDK4 or GST-CDK4/GST-cyclin D1 (from 0 to 200 nM). 
The experiments revealed that it bound monomeric GST-CDK4 with a dissociation constant of 30 +/- 
5 nM and its affinity increased to 7 +/- 3 nM when the kinase was complexed to cyclin D1 (Figure 55). 
This result is in line with studies showing that the substrate preferentially binds the catalytic cleft of 
heterodimeric CDK2/cyclin A, which is conformationally more favourable than that of monomeric 
CDK2. 
A B
Concentration (nM)
0 2000 4000
R
e
la
tiv
e
 F
lu
o
re
s
c
e
n
c
e
0
1
2
3
4
5
WWLong Peptide
WWShort Peptide
Concentration (nM)
0 2000 4000
R
e
la
ti
v
e
 F
lu
o
re
s
c
e
n
c
e
1
1,2
1,4
1,6
1,8
2
2,2
2,4
2,6
2,8
3
WWLong Peptide
WWShort Peptide
 95 
 
 
Figure 55: Fluorescence titration of FITC-labeled Rb substrate peptide (200 nM) with monomeric 
GST-CDK4 and GST-CDK4/cyclin D1 complex. The Rb peptide interacts preferentially with the 
heterodimeric complex than with the monomeric GST-CDK4. 
1.4.2. In extracto characterization 
Choice of the probe 
WWshortRb was first tested in real time fluorescence assays using the same conditions as CDKACTRb. 
Hence, WWshortRb was labeled with the environmentally-sensitive fluorescent probe Cy3. 
Spectrofluorimetric experiments were performed in 96-well plates in standard kinase assay 
conditions for 1h at 30°C in the presence of 0.5 mM ATP and 5 mM MgCl2. The first experiment was 
performed using 50 nM WWshortRb-Cy3 and 20 µg A375 cell extracts. Fluorescence emission of Cy3-
labelled WWshortRb was measured at 570 nm following excitation at 544 nm on a ClariostarTM 
fluorimeter. This experiment revealed that Cy3-labelled WWshortRb did not respond in a robust and 
reproducible fashion to the addition of cell extracts and the fluorescent signal of the biosensor was 
only amplified by 5% (Figure 56). 
Instead of Cy3, TAMRA was then tested for labeling WWshortRb. The same experiment as above was 
performed and results demonstrated that TAMRA-labelled WWshortRb responds robustly to the 
addition of A375 cell extracts (Figure 56). The fluorescent signal of the biosensor is amplified by 20% 
alter 1h of reaction. Based on these results, TAMRA was further used for labeling WWshortRb.  
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Figure 56: Real-time fluorescence assays with 20 µg A375 melanoma cell extracts as source of 
endogenous CDK4/cyclin D and 50 nM WWshortRb labeled either with TAMRA (blue) or Cy3 (red). 
The fluorescent signal after subtraction of the background fluorescence of WWshortRb alone is 
presented. 
In order to determine the appropriate working window for TAMRA-labelled WWshortRb, different 
concentrations of both the biosensor and A375 cell extracts were tested. The first experiment was 
set up with a fixed concentration of 40 µg of proteins from A375 cell extracts and increasing 
concentrations of TAMRA-labelled WWshortRb, between 50 and 200 nM. The results showed that 
fluorescence emission increased in a dose-dependent fashion (10 - 40% enhancement) within a 
window of 50 - 150 nM WWshortRb-TAMRA (Figure 57A). At 50 nM, the biosensor started to display 
fluorescence enhancement, whilst at 200 nM, there was a drop in the fluorescent signal compared to 
that of 150 nM. It was hypothesized that this reduction in fluorescence was due to homoquenching 
between probes at this concentration of biosensor.  
The second experiment was set up with a fixed concentration of 150 nM TAMRA-labelled 
WWshortRb and increasing concentrations of proteins from A375 cell extracts (from 10 to 100 µg) 
(Figure 57B). The results indicated that the biosensor displayed the greatest fluorescence increase 
within a window of 40 – 100 µg cell extracts (40% enhancement). The fact that any additional 
fluorescence increase was observed upon incubation with more than 40 µg cell extracts suggested 
that, a 1:1 stoichiometry is reached between the biosensor and the kinase at this threshold 
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concentration. The same experiment was performed using increasing concentrations of BSA instead 
of A375 cell extracts (Figure 57C). No fluorescence enhancement was observed with BSA, revealing 
that the biosensor did not respond to the addition of irrelevant proteins. 
In conclusion, the greatest fluorescence enhancement was obtained with 150 nM TAMRA-labelled 
WWshortRb and 40 µg proteins from A375 cell extracts. 
 
Figure 57: Determination of working concentrations of WWshortRb and A375 cell extracts in real 
time fluorescent assays. Fluorescence emission of TAMRA-WWshortRb was measured at 570 nm 
following excitation at 544 nm. The fluorescent signal was obtained following subtraction of 
background fluorescence of TAMRA-WWshortRb alone and the histograms represent the 
fluorescent signal at the endpoint of the assay (5000s). 
(A) Assays with 40 µg A375 cell extracts and increasing concentrations of TAMRA-WWshortRb 
(B) Assays with 150 nM of TAMRA-WWshortRb and increasing concentrations of proteins from 
A375 cell extracts. 
(C) Assays with 150 nM of TAMRA-WWshortRb and increasing concentrations of BSA. 
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The response of 150 nM TAMRA-WWshortRb was then compared to other peptides labeled with 
TAMRA upon incubation with 40 µg melanoma cell extracts. The incubation with A375 cell extracts 
resulted in a robust increase in fluorescence of TAMRA-WWshortRb (30%) whereas TAMRA-labelled 
Rb substrate peptide and TAMRA-labelled MP26 peptide (an irrelevant peptide that does not bind 
CDKs or cyclins) did not exhibit any change in fluorescence (Figure 58A and B). These experiments 
showed that the increase in fluorescence of TAMRA-WWshortRb was not a response of the probe 
itself. Moreover they demonstrated the requirement of the PAABD for robust response to CDK4 
kinase activity in cell extracts.  
The response of TAMRA-WWshortRb was then compared to Dylight650-WWshortRb. While the 
incubation with A375 cell extracts resulted in a robust increase in fluorescence of TAMRA-
WWshortRb (30%), the Dylight650-labelled WWshortRb peptide barely responded to CDK4 activity in 
cell extracts (10% enhancement) (Figure 58C). This result indicated that the response of WWshortRb 
was associated with the sensitivity of the dye conjugated to the peptide, as previously shown with 
Cy3-labelled WWshortRb. Moreover, as Dylight650 (λexc = 652 nm; λem = 672 nm) and TAMRA (λexc 
= 540 nm; λem = 565 nm) have different spectral properties, the Dylight650-labelled WWshortRb 
peptide constitutes a useful negative control. 
 99 
 
 
Figure 58: Fluorescence of 150 nM TAMRA-labelled WWshortRb peptide biosensor was monitored 
over time upon incubation with 40 µg A375 cell extracts and compared to (A) 150 nM TAMRA-
labelled MP26 peptide; (B) 150 nM TAMRA-labelled Rb substrate peptide; (C) 150 nM Dylight650-
labelled WWshortRb. The fluorescent signal was obtained following subtraction of background 
fluorescence of TAMRA-labelled or DyLight650-labelled WWshortRb alone. 
Response of WWshortRb upon incubation with A375 cell extracts +/- siRNA targeting CDK4 
To verify whether the biosensor was sensitive to CDK4 expression in cells, an experiment was 
performed, in standard kinase assay conditions, with 150 nM WWshortRb-TAMRA and 40 µg cell 
extracts from A375 cells that had been treated or not with siRNA targeting CDK4. Western blotting 
was performed in parallel to assess the efficacy of the siRNA. After 48h of treatment, CDK4 levels 
were decreased by 45% compared with that of the control sample (Figure 59A & B). The activity 
assay showed that the fluorescence response of WWshortRb was reduced (25%) upon incubation 
with extracts from A375 cells that had been treated with siRNA compared with extracts from 
untreated A375 (30% enhancement) (Figure 59C & D). The correlation between Western blot and the 
activity fluorescent curves demonstrates the sensitivity of the sensor for CDK4. 
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Figure 59: Real time fluorescence of TAMRA-labelled WWshortRb upon incubation with A375 cell 
extracts +/- siRNA targeting CDK4. 
(A) Western blotting of CDK4 in A375 cells treated or not with siRNA targeting CDK4; (B) 
Quantification of CDK4/Tubulin levels. 
(C) Fluorescent kinase assays with 150 nM WWshortRb-TAMRA and 40 µg cell extracts from A375 
cells treated or not with siRNA targeting CDK4. The fluorescent signal was obtained following 
subtraction of background fluorescence of WWshortRb-TAMRA alone; (D) The histogram 
represents the fluorescent signal at the endpoint of the assay (5000s) 
Identification of fractions containing CDK4 activity from A375 cell extracts fractionated by gel 
filtration chromatography 
To assess whether the biosensor could be exploited to discriminate between fractions which 
contained CDK4 or not, real time fluorescence assays were performed with 150 nM WWshortRb-
TAMRA and A375 cell extracts fractionated by gel filtration chromatography (Superose 6). Results 
presented in Figure 60 demonstrate that only fractions containing CDK4 (as detected by Western 
blotting) promoted a significant increase in WWshortRb biosensor fluorescence. Calibration of the 
Superose 6 column with Dextran, Conalbumin, Ovalbumin and Carboxic anhydrase allowed to 
determine the molecular weight of proteins contained in the different fractions. This experiment 
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provides further evidence of the utility of WWshortRb to distinguish all fractions in which CDK4 is 
active or not. 
 
Figure 60: Fluorescence of 150 nM TAMRA-labelled WWshortRb biosensor upon incubation with 
fractions of A375 cell extracts purified by gel filtration chromatography (Superose 6). The 
fluorescent signal was obtained following subtraction of background fluorescence of TAMRA-
WWshortRb alone and the histogram represents the fluorescent signal at the endpoint of the assay 
(5000s). At the bottom, Western blotting of CDK4 in the different fractions is presented. 
Response of WWshortRb upon incubation with A375 cell extracts +/- ATP/MgCl2 
To further validate that observed fluorescence enhancement was associated with kinase activity, a 
set of assays was performed in which 150 nM WWshortRb-TAMRA was incubated with 40 µg A375 
cell extracts in the presence or absence of 0.5 mM ATP and 5 mM MgCl2. Figure 61A shows the 
fluorescent signal of the biosensor in both conditions, revealing that the maximal fluorescence of 
WWshortRb-TAMRA was reduced in the absence of ATP/MgCl2 (10% fluorescence decrease). The 
difference in WWshortRb response in the presence or absence of ATP/MgCl2 corresponds to the 
phospho-transfer contribution (10% delta) (Figure 61B). 
These data demonstrate that, when the phosphotransfer reaction is prevented, binding of CDK4 
kinase to the Rb substrate sequence is responsible for a first increase in fluorescence, which is then 
further enhanced by phosphorylation. This experiment therefore demonstrates that WWshortRb is 
capable of reporting on kinase activity of CDK4/cyclin D in melanoma cell extracts, and that the signal 
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observed can be uncoupled into a kinase binding step which induces a first partial increase in 
biosensor fluorescence, followed by a phosphotransfer step.  
 
Figure 61: Response of 150 nM WWshortRb upon incubation with 40 µg A375 cell extracts +/- 
ATP/MgCl2. Fluorescence emission of TAMRA-WWshortRb was measured at 570 nm following 
excitation at 544 nm on Clariostar
TM
 fluorimeter.  
(A) The fluorescent signal after substraction of the background fluorescence of WWshortRb alone 
is presented. 
(B) The curve displays the contribution of the phosphotransfer step in the fluorescence response of 
WWshortRb. The kinetic curve in the absence of ATP/MgCl2 was subtracted from the curve in the 
presence of ATP/MgCl2.  
Response of WWshortRb upon addition of different kinase inhibitors 
Experiments were performed in standard kinase assay conditions with 150 nM WWshortRb-TAMRA 
and 40 µg cell extracts from A375 cells treated with different concentrations of PD-0332991, 
LY2835219 or Roscovitine (from 0 to 20 µM).  
Figure 62 shows that the addition of increasing concentrations of CDK4/6 inhibitors PD-0332991 and 
LY2835219 decreased the fluorescent signal of the biosensor in a dose-dependent fashion whereas 
no significant fluorescence decrease was detected upon the addition of Roscovitine, inhibitor of 
CDK1/2/5/7/9. Taken together, these results and those obtained with the protein biosensor suggest 
that the CDK4-specific Rb substrate sequence enables both biosensors to be selective and specific for 
CDK4/cyclin D. 
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Figure 62: Fluorescence of 150 nM TAMRA-labelled WWshortRb biosensor was monitored over 
time upon incubation with 40 µg cell extracts from A375 cells treated with different concentrations 
PD-0332991 (A & B), LY2835219 (C & D) or Roscovitine (E & F) (from 0 to 20 µM). The fluorescent 
signal was obtained following subtraction of background fluorescence of TAMRA-WWshortRb 
alone and the histograms represent the fluorescent signal at the endpoint of the assay (5000s). 
Since DMSO, in which all stock solutions of inhibitors were made, could affect the fluorescence of the 
biosensor alone, emission fluorescence of WWshortRb-TAMRA at 570 nm following excitation at 544 
nm was measured in presence of different concentrations of DMSO. A range from 0 to 0.2% was 
tested, which corresponds to the residual concentrations of DMSO found after dilution of the 
inhibitors in a standard kinase assay. PD-0332991, LY2835219 and Roscovitine were also tested at 
A B
C D
0
10
20
30
40
50
0 µM 5 µM 10 µM 20 µM
re
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 (
%
)
concentration of LY2835219
-10
0
10
20
30
40
50
0 2000 4000 6000
re
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 (
%
)
t (s)
0 µM
5 µM
10 µM
20 µM
0
10
20
30
40
50
60
0 2000 4000 6000
re
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 (
%
)
t (s)
0 µM
1 µM
5 µM
10 µM
20 µM
E F
-20
-10
0
10
20
30
40
50
0 2000 4000 6000
re
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 (
%
)
t (s)
0 µM
1 µM
5 µM
10 µM
20 µM
0
10
20
30
40
50
0 µM 1 µM 5 µM 10 µM 20 µM
re
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 (
%
)
concentration of PD-0332991
0
10
20
30
40
50
60
0 µM 1 µM 5 µM 10 µM 20 µM
re
la
ti
v
e
 f
lu
o
re
s
n
c
e
n
c
e
 (
%
)
concentration of Roscovitine
 104 
 
concentrations that were used to inhibit CDK4/cyclin D (from 0 to 20 µM). Histograms in Figure 63 
correspond to the average emission fluorescence at 570 nm of duplicate experiments with standard 
deviation bars. The fluorescent signal of WWshortRb-TAMRA alone was arbitrarily considered as 1. 
These experiments provided evidence that neither PD-0332991, LY2835219, Roscovitine nor DMSO 
had any significant effect on the fluorescence of WWshortRb-TAMRA. 
 
Figure 63: Effects of PD-0332991 (A), LY2835219 (B), Roscovitine (C) and DMSO (D) on the 
fluorescence of WWshortRb-TAMRA. 
1.4.3. Characterization of recombinant CDK4 kinase activity 
WWshortRb was then implemented to monitor response to recombinant CDK4 kinase in vitro in the 
presence of ATP and MgCl2, following labelling with TAMRA. The experiment was performed with 150 
nM TAMRA-WWshortRb, 75 nM CDK4/cyclin D1 and 50 nM CIV. PD-0332991 was used at 10 µM to 
inhibit CDK4 activity. Analysis of changes in fluorescence intensity showed that the biosensor 
responded to the addition of CDK4/cyclin D1 through a net increase in relative fluorescence intensity 
(65%) over time, whereas incubation with monomeric CDK4 had much less incidence on fluorescence 
increase (only 40%) (Figure 64). Relative increase in fluorescence further reached 75% when 
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CDK4/cyclin D1 was pre-incubated with the CDK-activating kinase CIV (to phosphorylate the 
activation loop), but was reduced to a similar level as inactive (unphosphorylated) CDK4/cyclin D1 
(55%) upon incubation with PD-0332991 (Figure 64).  
These data demonstrate that WWshortRb is capable of reporting on kinase activity of recombinant 
CDK4/cyclin D1, and that the signal observed can be uncoupled into a kinase binding step which 
induces a first increase in biosensor fluorescence, followed by a phosphotransfer step. The difference 
in WWshortRb response when incubated with inactive or active CDK4/cyclin D1 corresponds to the 
phospho-transfer contribution (10% delta). This result is in line with that obtained upon incubation of 
the biosensor with 40 µg A375 cell extracts in the presence or absence of ATP/MgCl2 (Figure 61). The 
same phospho-transfer contribution (10% delta) is found in this experiment. 
 
Figure 64: Typical fluorescence profile of 150 nM TAMRA-labelled WWshortRb peptide biosensor 
incubated with 75 nM recombinant GST-CDK4, GST-CDK4/GST-cyclin D1 or GST-CDK4/cyclin D1 pre-
incubated with CIV to phosphorylate Thr172 +/- 10 µM PD-0332991. (A) The fluorescent signal was 
obtained following subtraction of background fluorescence of TAMRA-WWshortRb alone (B) The 
histogram represents the fluorescent signal at the endpoint of the assay (5000s). 
1.4.4. Profiling CDK4/cyclin D activity in healthy and cancer cell lines 
To ask whether WWshortRb could be implemented to compare CDK4 activity between different cell 
lines, real time fluorescence assays were performed with 150 nM WWshortRb-TAMRA and 40 µg 
proteins from different cell extracts. The human melanoma A375 cell line was first compared with a 
healthy human fibroblast cell line. Figure 65A and B present the fluorescence emission of TAMRA-
WWshortRb at 570 nm following excitation at 544 nm.  The addition of A375 cell extracts promoted a 
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significant 45% increase in WWshortRb fluorescence whereas only a 30% fluorescence increase was 
detected upon the addition of fibroblast cell extracts. The reaction rate was calculated over the first 
15 min of the reaction and revealed that the kinetics of phosphorylation of the biosensor are much 
faster upon incubation with A375 than fibroblast cell extracts (Figure 65C). Then, A375 melanoma 
cell line was compared with different melanoma cell lines harbouring different combinations of wild-
type or loss-of function p16INK4A (the endogenous inhibitor of CDK4), wild-type or mutated CDK4 
(R24C mutation which prevents the binding of p16INK4A), BRaf and NRas (Figure 65E/F). Fluorescent 
profiles of the WWshortRb revealed the highest CDK4 activity in A375 (CDKN2A loss of function, BRaf 
V600E), Mewo (CDKN2A loss of function, Wt CDK4) and SK-MEL28 (R24C CDK4, BRaf V600E) cell lines 
(about 40% enhancement), followed by SK-MEL2 (NRas mutation (Q61R)) (25%) and MV3 (20%). The 
reaction rate was calculated over the first 15 min of the reaction and revealed that the kinetics of 
phosphorylation of the biosensor are similar in A375, Mewo, SKMEL28 and SKMEL2 cell extracts and 
much slower upon incubation with MV3 cell extracts (Figure 65G). These response profiles are 
consistent with the genotypes of these strains in which loss of function of CDKN2A or mutation of the 
R24C CDK4 mutant both lead to unrestricted, constitutive activity of CDK4. However, they do not 
coincide with Western blot profiles, which only provide limited information on CDK4 protein levels 
(Figure 65D/H). Indeed, overall CDK4 activity is associated with expression levels but also with CDK4 
regulation in the p16INK4A / CDK4/6-cyclin D / pRb pathway. 
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Figure 65: Real time fluorescence of 150 nM TAMRA-labelled WWshortRb peptide biosensor upon 
incubation with 40 µg cell extracts from different cell lines. The fluorescent signal was obtained 
following subtraction of background fluorescence of TAMRA-WWshortRb alone and the histogram 
represents the fluorescent signal at the endpoint of the assay (5000s). The reaction rate was 
calculated from the linear slope of the reaction during the first 15 min (900s). 
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(E, F & G) A375, Mewo, SK-MEL2, SK-MEL28, MV3 melanoma cell lines 
(D) Western blotting profiles of CDK4 and actin in A375, SKMEL28, Mewo, SK-MEL2, MV3 and 
fibroblasts 
(H) Quantification of CDK4/actin levels 
1.4.5. Implementation of WWshortRb biosensor to probe CDK4 activity in skin 
biopsies 
Since WWshortRb peptide biosensor responded to CDK4 activity in melanoma cell extracts and 
reported on differences between cell lines with different p16INK4A and CDK4 genotypes, its application 
to quantify CDK4 activity in skin biopsies was further investigated (materials and methods). Skin 
biopsies for kindly provided by Dr. Laurent Meunier (CHU, Nîmes). First, the response of 150 nM 
WWshortRb-TAMRA was calibrated using different concentrations of total healthy skin samples, 
relative to A375 cell extracts (Figure 66A and B). Fluorescence emission of TAMRA-WWshortRb 
increased in a dose-dependent fashion (5 - 30% enhancement) within a window of 10 - 100 µg skin 
samples. However, with 150 µg proteins from skin samples, the fluorescence intensity of the 
biosensor started to decrease (20%). This reduction in fluorescence at this high concentration of cell 
extracts may be explained by the presence of many phosphatases which dephosphorylate the 
biosensor. It could also be due to the presence of many proteins extracted from skin cells such as 
hair follicles, nerves, sweat glands and small blood capillaries but also by the presence of 
extracellular matrix proteins such as collagen, which can together alter the fluorescent signal of the 
biosensor. 
As with melanoma cell extracts, WWshortRb fluorescence was decreased by addition of 20 µM PD-
0332991, especially upon incubation with 100 µg skin samples (Figure 66C). It suggests that 100 µg of 
cell extracts provide the optimal concentration of CDK4 kinase to be phosphorylated by 20 µM PD-
0332991. 
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Figure 66: Real time fluorescence of 150 nM TAMRA-labelled WWshortRb upon incubation with 
healthy skin biopsies. The fluorescent signal was obtained following subtraction of background 
fluorescence of TAMRA-WWshortRb alone. 
(A) Concentration-dependent response of healthy skin samples (from 10 to 150 µg). 
(B) Results at the endpoint of the assay (5000 s) are presented as histograms corresponding to the 
average of duplicate experiments with standard deviation bars. Healthy skin samples are 
compared to 50 µg A375 cell extracts. 
(C) Fluorescence response of TAMRA-WWshortRb peptide to 50, 100 and 150 µg healthy skin 
samples treated with PD-0332991. The histogram represents the fluorescent signal at the endpoint 
of the assay (5000s). 
The biosensor was then applied to detect differences in CDK4 activity in the dermis and epidermis, 
and found that it was essentially present in the latter (Figure 67A). A 25% fluorescence enhancement 
occurred with the epidermis lysate whereas only a 5% increase was observed with the dermis lysate, 
consistent with the fact that rapidly dividing cells are found in the epidermis. As the protein 
concentration was very low after epidermis lysis, the experiment was only performed with 50 µg 
proteins. WWshortRb was further implemented to compare pathological skin biopsies, first eczema, 
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a skin inflammation, in which no hyperactivity of CDK4 was monitored, then psoriasis, a proliferative 
skin pathology in which CDK4 activity was found to be significantly downregulated (Figure 67B). 
 
Figure 67: Real time fluorescence of 150 nM TAMRA-labelled WWshortRb upon incubation with 
healthy and pathological skin biopsies. The fluorescent signal was obtained following subtraction 
of background fluorescence of TAMRA-WWshortRb alone and the histogram represents the 
fluorescent signal at the endpoint of the assay (5000 s). 
(A) Differential response of the biosensor upon incubation with 50 µg dermis and epidermis cell 
extracts 
(B) Comparative response between 100 µg lysate prepared from healthy, eczema and psoriasis 
biopsies (100 µg A375 cell extracts was used as a control). 
1.4.6. Implementation of WWshortRb biosensor to probe CDK4 activity in tumour 
xenograft lysates 
The biosensor was then applied to detect CDK4 activity in melanoma xenograft extracts. The 
melanoma cell line A375 was implanted subcutaneously into the flank of nude mice by Véronique 
Josserand and Julien Vollaire (Institut Albert Bonniot, Grenoble). After 24 days, mice were then 
treated daily orally either with the CDK4 inhibitor PD-0332991 at 150 mg/kg for 3 or 7 days, or 75 
mg/kg for 7 days (as described in (Fry et al., 2004)), or with the CDK2/5/7/9 inhibitor Roscovitine at 
50 mg/kg for 5 or 11 days. Biopsies of the xenografted tumours were lysed and total proteins were 
normalized by spectrophotometric dosage at 280 nm and incubated with TAMRA-labelled 
WWshortRb peptide biosensor. These experiments revealed a slight reduction in CDK4 activity in the 
xenografts after a 3-days treatment with 150 mg/kg PD-0332991 which is more significant after 7 
days of treatment in two of the three experiments (Figure 68A, blue and green histogrammes). 
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Importantly, no specific decrease in CDK4 protein levels was observed, nor any growth inhibition of 
the tumour xenografts (Figure 68B and Annex A). 
 
Figure 68: Response of WWshortRb peptide biosensor to A375 xenografts treated with PD-
0332991.  
(A) Fluorescence of 150 nM TAMRA-labelled WWshortRb peptide biosensor following incubation 
with 50 µg total proteins extracted from A375 xenografted tumour biopsies from mice treated with 
PD-0332991 at 150 mg/kg for 3 or 7 days, or with 75 mg/kg for 7 days in three independent 
experiments. Control: mock treated xenografts. The histogram represents the fluorescent signal at 
the endpoint of the assay (5000s). 
(B) Western blot of CDK4 levels in biopsies of the first experiment. 
To minimize any differences that might be associated with tumoral heterogeneity, the experiment 
was repeated by normalizing the response of WWshortRb in lysates prepared from different 
melanoma xenografts to the proportion of cancer cells (A375 luciferase) (Figure 69). Indeed, as 
proteins from stromal cells are also present in cell extracts and since each tumor behaves and grows 
differently, the ratio between hyperactive CDK4 kinase in cancer cells and its activity in non-cancer 
cells was likely to vary in the different melanoma xenografts. These experiments revealed a 
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systematic reduction of CDK4 activity after seven days treatment 150 mg/kg and 75 mg/kg PD-
0332991 than after three days with 150 mg/kg, although no growth inhibition of the tumour 
xenografts was observed (Figure 69A and Annex A). In contrast, treatment of A375 xenografted 
tumours with 50 mg/kg Roscovitine, whether for 5 or 11 days, had no significant effect on 
WWshortRb fluorescence, although the latter treatment clearly affected tumour growth, consistent 
with the inhibitory action of this compound towards CDKs other than CDK4/6 (Figure 69B and Annex 
A). 
 
Figure 69: Fluorescence of 150nM TAMRA-labelled WWshortRb peptide biosensor following 
incubation with cell extracts from A375 xenografted tumour biopsies from mice treated either (A) 
with PD-0332991 at 150 mg/kg for 3 or 7 days or at 75mg/kg for 7days; or (B) with Roscovitine at 
50 mg/kg for 5 or 11 days. Histogrammes represent the fluorescent signal at the endpoint of the 
assays (5000s), performed in duplicate from each of the three mouse xenografts, normalized to 
luciferase activity of A375 cells, and relative to control (untreated) tumour samples. 
Taken together the results show that WWshortRb peptide biosensor can be implemented to quantify 
CDK4/Cyclin D kinase activity in skin biopsies and melanoma xenografts. 
1.4.7.  Application of WWshortRb to probe CDK4/cyclin D activity in living cells  
Fixed cell imaging – Upright acquisitions  
In order to monitor CDK4/cyclin D activity in living cells, TAMRA-labelled WWshortRb was 
internalized into A375 melanoma cells. TAMRA-WWshortRb was overlaid onto asynchronized A375 
cells for 30min followed by 1h recovery at 37°C (addition of DMEM supplemented with 10% FCS), cell 
fixation and Hoechst staining. Figure 70A presents images of fluorescent acquisitions of Hoechst, 
TAMRA and overlay Hoechst-TAMRA. Surprisingly, unlike most peptides, the fluorescently-labelled 
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peptide was able to penetrate into living cells alone and thus did not require facilitated delivery for 
efficient internalization into living cells. In order to understand this result, we attempted to 
internalize TAMRA-MP26, TAMRA-Rb substrate and DyLight650-WWshortRb into cells. Neither MP26 
nor Rb substrate could cross cell membranes alone (Figure 70A). However, DyLight650-WWshortRb 
entered living cells alone (Figure 70B). These results reveal that WWshortRb bears an inherent ability 
to cross cell membranes.  
 
Figure 70: Internalization of TAMRA-WWshortRb, TAMRA-Rb substrate, TAMRA-MP26 (A) and 
DyLight650-WWshortRb (B) into A375 melanoma cells. Fluorescently-labelled peptides (2 µM) 
were overlaid onto asynchronized A375 cells followed by 30min incubation at 37°C, 1h recovery at 
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37°C, cell fixation and Hoechst staining. Fluorescent micrographs were acquired with a 63X 
objective. 
(A) Fluorescent acquisitions of Hoechst, TAMRA with a 63X objective and overlay Hoechst-TAMRA.  
(B) Fluorescent acquisitions of Hoechst, DyLight650 with a 63X objective and overlay Hoechst- 
DyLight650. 
To verify that the internalization of WWshortRb did not affect the localization of CDK4, indirect 
immunofluorescence was performed in A375 melanoma cells using anti-CDK4 and Alexa488-
conjugated anti-rabbit antibody (materials and methods). TAMRA-WWshortRb and Dylight650-
WWshortRb were co-internalized into asynchronized A375 cells followed by cell fixation, 
immunofluorescence and Hoechst staining. Figure 71 presents images of fluorescent acquisitions of 
Hoechst, Alexa488, TAMRA and Dylight650. This experiment showed that TAMRA-WWshortRb and 
Dylight650-WWshortRb were efficiently co-internalized into cells and did not affect the localization 
of CDK4.  
 
Figure 71: Indirect immunofluorescence of CDK4 protein and co-internalization of TAMRA-
WWshortRb and DyLight650-WWshortRb into A375 melanoma cells. Fluorescently-labelled 
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WWshortRb (2 µM) was overlaid onto asynchronized A375 cells followed by 30min incubation at 
37°C, 1h recovery at 37°C, cell fixation, immunofluorescence and Hoechst staining. Fluorescent 
micrographs were acquired with a 63X objective. 
In order to investigate the ability of the biosensor to detect inhibition of CDK4/cyclin D, melanoma 
cells (A375) were treated 24h with different concentrations of PD-0332991 (0.5, 1, 10 and 20 µM). 
WWshortRb-TAMRA (2 µM) was then overlaid onto A375 cells for 30min followed by 1h recovery at 
37°C, cell fixation and Hoechst staining. Figure 72A presents images of fluorescent acquisitions of 
Hoechst, TAMRA and overlay Hoechst-TAMRA. The histogram that is presented in Figure 72B 
corresponds to the average fluorescence ratio of the TAMRA-labelled biosensor over the Hoechst 
staining of three different fields of one experiment with standard deviation bars. These results 
showed that the addition of increasing concentrations of PD-0332991 enhanced the fluorescent 
signal of the biosensor in a dose-dependent fashion (fluorescence enhancement from 1 to 47). Thus, 
these experiments suggest that WWshortRb reports on CDK4/cyclin D activity in living cultured cells. 
Unlike in extracto experiments that demonstrated a decrease in fluorescence intensity of 
WWshortRb upon addition of PD-0332991, an increase of fluorescence upon addition of this inhibitor 
was observed in in cellulo experiments. These seemingly contradictory results could be explained by 
a difference in the environment of the probe in intact cells vs in cell extracts. As the probe is sensitive 
to the environment, we hypothesized it might behave differently in a living cells than in lysis buffer.  
Moreover, Western blot analysis of cell extracts from these cells demonstrated that the addition of 
increasing concentrations of PD-0332991 led to degradation of CDK4 (Figure 72C). 
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Figure 72: Internalization of TAMRA-WWshortRb into A375 melanoma cells treated with PD-
0332991. Cells were treated with different concentrations of PD-0332991 (0.5, 1, 10, 20 µM) for 
24h. WWshortRb-TAMRA (2 µM) was then overlaid onto asynchronized A375 cells followed by 
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30min incubation at 37°C, 1h recovery at 37°C, cell fixation and Hoechst staining. Fluorescent 
micrographs were acquired with a 63X objective. 
(A) Fluorescent acquisitions of Hoechst, TAMRA with a 63X objective and overlay Hoechst-TAMRA. 
(B) Histogram representing the fluorescence average ratio TAMRA/Hoechst of triplicate 
experiments with standard deviations as a function of PD-0332991 concentration. The ratio 
TAMRA/Hoechst in untreated A375 cells was regarded as 1. 
(C) Western blotting profiles of CDK4 and tubulin in A375 cells with different concentrations of PD-
0332991 
In order to confirm this result, the same experiment was repeated. However, no fluorescence 
enhancement of the biosensor was observed upon addition of increasing concentrations of PD-
0332991 (Figure 73). Moreover, indirect immunofluorescence, performed in these cells using anti-
CDK4 and Alexa488-conjugated anti-rabbit antibody, revealed neither a reduction in CDK4 protein 
levels nor mislocalization of CDK4 (Figure 73A). This suggests that the fluorescence enhancement of 
the biosensor obtained in the first experiment was maybe due to the presence of a contaminant 
which led to CDK4 degradation and stimulated fluorescence. 
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Figure 73: Indirect immunofluorescence of CDK4 protein and internalization of TAMRA-
WWshortRb into A375 melanoma cells treated with 10 µM and 20 µM PD-0332991 for 24h. 
TAMRA-labelled WWshortRb (2 µM) was overlaid onto asynchronized A375 cells followed by 
30min incubation at 37°C, 1h recovery at 37°C, cell fixation, immunofluorescence and Hoechst 
staining. Fluorescent micrographs were acquired with a 63X objective. 
(A) Fluorescent acquisitions of Hoechst, TAMRA and Alexa488 with a 63X objective. 
(B) Histogram representing the fluorescence average ratio TAMRA/Hoechst of three different fields 
of one experiment with standard deviation bars as a function of PD-0332991 concentration. The 
ratio TAMRA/Hoechst in untreated A375 cells was regarded as 1. 
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TAMRA-WWshortRb and DyLight650-WWshortRb were internalized into A375 living cells for time-
lapse acquisitions. DyLight650-WWshortRb served as a negative control since the probe was 
unresponsive in activity assays when coupled with the biosensor. Time-lapse imaging was performed 
over a window of 10-15h. Video stacks for each parameter were built from these acquisitions for 
signal analysis using Metamorph software. Images in Figure 74 show that both TAMRA-WWshortRb 
and DyLight650-WWshortRb were well internalized into A375 cells.  
 
Figure 74: Co-internalization of WWshortRb-TAMRA and WWshortRb-DyLight650 into 
asynchronous A375 cells. Live cell imaging acquisitions were set up automatically for 10h with an 
inverted microscope equipped with 40X objectives for cell morphology (Phase), TAMRA and 
DyLight650 signals. Images of representative time points are presented (0, 140, 260, 380 and 500 
min). 
Ratiometric quantification of fluorescence in living cells 
In order to determine the response of WWshortRb to CDK4/cyclin D activity in living cells, fluorescent 
signals of TAMRA and DyLight650 were acquired over time and used to determine the response of 
the biosensor. Single cells (dividing and non-dividing) were chosen in the regions of interest (ROI) in 
the images of TAMRA to ensure absence of aggregates and transferred to the two other stacks of the 
same time point for fluorescence intensity measurement.  
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The ratio of TAMRA/DyLight650 fluorescent signals was determined from individual cells in which 
changes in fluorescence of TAMRA correspond to CDK4/cyclin D activity and those of DyLight650 
serve as an intracellular fluorescent control. After background subtraction, average fluorescent 
intensity of each ROI was measured for both TAMRA and DyLight650 using Metamorph software 
(annex B).  
Figure 75 shows representative average fluorescent intensity of TAMRA and DyLight650 and the 
representative ratiometric quantification of TAMRA/DyLight650 signal obtained from three dividing 
and non-dividing cells. First, we observed that no fluorescence enhancement of DyLight650-
WWshortRb was observed. It therefore constitutes an appropriate negative control in living cells. 
However, we then observed that the fluorescence of TAMRA-WWshortRb kept increasing over time, 
irrespective from cell division, suggesting that after initial response (> 300 min) the biosensor might 
be trapped, degraded, or somehow not responding appropriately to CDK4 activity. 
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Figure 75: Representative ratiometric quantification of TAMRA/DyLight650 signal in A375 living 
cells internalized with WWshortRb-TAMRA and WWshortRb-DyLight650 followed by time-lapse 
acquisition in which phase, TAMRA and DyLight650 were imaged. Average fluorescent intensity of 
TAMRA and DyLight650 was measured from ROIs of individual cells. 
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The experiment was repeated to compare the response of WWshortRb in asynchronized and 
synchronized A375 cells. Cells were synchronized in S phase by addition of hydroxyurea for 24h and 
then released for 10h (materials and methods). In parallel, an experiment was performed with A375 
cells treated with 10 µM PD-0332991 or Roscovitine for 24h. Ratiometric quantification of 
TAMRA/DyLight650 signal in A375 non-dividing cells is presented in Figure 76. A reduction of 
TAMRA/DyLight650 ratio was observed in cells treated with PD-0332991 and Roscovitine, indicating 
that TAMRA-WWshortRb reports a decrease of CDK4 activity. These results are in line with the fact 
that PD-0332991 inhibits CDK4 activity and that Roscovitine induces a cell cycle arrest which 
indirectly leads to an inactive CDK4. Synchronized cells displayed a lower TAMRA/DyLight650 ratio 
than asynchronized cells. This result suggests that CDK4 is more active in asynchronized than in 
synchronized cells which, after a 10h S phase release, should be in G1 phase. 
Analysis of the curves indicates that the reaction can be divided in two phases: before and after three 
hours of reaction. Indeed, we first observe a significant increase in the fluorescence of the biosensor 
and then a linear response after three hours of reaction. Given this linearity and since the biosensor 
fluorescence never decreases or reaches a plateau could suggest that the biosensor is not reliable 
after several hours of internalization. It is possible that, once internalized into cells, the peptide is 
rapidly sequestered or metabolized, leading to a release of free probe and thus an inappropriate 
response of the biosensor. 
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Figure 76: Ratiometric quantification of TAMRA/DyLight650 signal in A375 non-dividing cells 
internalized with WWshortRb-TAMRA and WWshortRb-DyLight650 followed by time-lapse 
acquisition in which phase, TAMRA and DyLight650 were imaged. The ratio at the beginning of the 
acquisition was regarded as 100%. The data presented correspond to the average ratiometric 
quantification of TAMRA/DyLight650 signal of three different cells with standard deviation bars. 
2. Identification of non-ATP competitive compounds targeting CDK4/cyclin D 
Alternative approaches that do not target the ATP pocket have been investigated to inhibit 
CDK4/cyclin D activity, by targeting either protein/protein interfaces or allosteric sites (Figure 77). As 
such, two strategies were developed, either by rational design of peptides or by high throughput 
screening of small molecules libraries thanks to fluorescent biosensors, based on CDK4 kinase 
scaffold.  
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Figure 77: Two strategies to inhibit CDK4/cyclin D: with protein/protein interface (PPI) compounds 
or with allosteric T-loop modulators (crystal structure of CDK4/cyclin D3 (PDB 3G33))  
A. Identification by screening of non-ATP competitive compounds 
To this end, two fluorescent biosensors were designed: 
- CDKCONF4A, for identifying compounds that can target the interface between the PISTVRE helix in 
the N-terminal lobe of CDK4 and the complementary α5 helix of cyclin D (Figure 77 and Figure 78A). 
Indeed, this interaction is critical for assembly of the functional heterodimeric kinase (Day et al., 
2009; Takaki et al., 2009). 
- CDKCONF4B, sensitive to conformational changes of CDK4, for identification of allosteric 
modulators of the CDK4 activation loop (or T-loop) (Figure 77 and Figure 78B). 
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Figure 78: Development of two fluorescent biosensors for identifying CDK4/cyclin D inhibitors by 
screening. (A) CDKCONF4A to identify compounds that might interfere with the PISTVRE helix/α5 
helix interface; (B) CDKCONF4B to identify allosteric modulators of CDK4/cyclin D 
2.1. Design and engineering of CDKCONF4A and CDKCONF4B 
The CDK4 sequence comprises 4 cysteines whose thiol groups are available for specific conjugation to 
fluorescent probes. CDKCONF4A and CDKCONF4B were engineered by site-directed mutagenesis of 
cysteine codons in mouse CDK4 cDNA so as to obtain a CDK4 sequence bearing only two cysteines, 
close to the targeted zone of interest (materials and methods and annex C) (Figure 79). 
For CDKCONF4A, cysteine residues 202 and 215 were mutagenized to serine, so as to yield a mutant 
bearing only two cysteine residues, 78 and 135, spanning the PISTVRE helix of CDK4 (Figure 79A).  
For CDKCONF4B, cysteine residues 78, 135 and 215 were mutagenized to serine and serine residue 
189 was mutagenized to cysteine so as to obtain a mutant that contained only two cysteine residues, 
189 and 202, spanning the T-loop of CDK4 (Figure 79B). 
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Figure 79: Design of CDKCONF4A (A) and CDKCONF4B (B): position of the cysteines on which 
fluorescent probes were coupled. 
The two biosensors were expressed in fusion with a GST tag in E.coli and expression was verified by 
SDS-PAGE (59 kDa) (materials and methods) (Figure 80A/B). They were purified by affinity and gel 
filtration chromatography which yielded 80 μg pure CDKCONF4A and 240 μg pure CDKCONF4B from 
1L of bacterial induction (average of 3 purifications) (materials and methods) (Figure 80C/D). 
 
Figure 80: Expression and purification of GST-CDKCONF4A and GST-CDKCONF4B (A) Expression of 
CDKCONF4A M: Marker protein; NI: Before induction; I: Protein induction (B) Purification of 
CDKCONF4A: protein fraction from gel filtration chromatography M: Marker protein (C) Expression 
of CDKCONF4B M: Marker protein; NI: Before induction; I: Protein induction (D) Purification of 
CDKCONF4B: protein fraction from gel filtration chromatography M: Marker protein 
CDKCONF4A and CDKCONF4B were then coupled, on cysteine residues, with the fluorescent probe 
Cy3, which yielded 50 μg Cy3-CDKCONF4A and 160 μg Cy3-CDKCONF4B (average of 3 experiments).       
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2.2. Characterization of CDKCONF4A and CDKCONF4B 
To validate the use of Cy3-labelled CDKCONF4A, cyclin D1 protein and an irrelevant peptide derived 
from the T-loop of CDK4 (sequence: SYQMALEPGC) were used as positive and negative control 
respectively. Titration assays demonstrated that cyclin D1 promoted 80% fluorescence enhancement 
whereas the peptide did not affect the fluorescent signal of the biosensor (Figure 81A). 
The retinoblastoma protein Rb, main substrate of CDK4/cyclin D, and an irrelevant peptide derived 
from the PISTVRE helix (PISTVRE peptide) (sequence: GGGCPISTVREVALLRRL) were used as positive 
and negative control respectively for CDKCONF4B biosensor. While Rb promoted a significant 
enhancement of Cy3-labelled CDKCONF4B biosensor fluorescence, the peptide barely affected the 
biosensor fluorescence (Figure 81B). 
 
Figure 81: Characterization of Cy3-labelled CDKCONF4A (A) and 4B (B): titration assays using 
positive and negative controls.  
2.3. Implementation, miniaturization and optimization of the assay 
Prior to the screen, stability assays and downscaling experiments were performed to establish the 
best conditions for a miniaturized assay in 96-well plates and optimized so as to obtain a robust and 
reproducible signal (materials and methods). For both biosensors, optimal screening conditions were 
established as follows: 25 nM CDKCONF biosensor in 50 mM KH2PO4/K2HPO4, pH 6.4, 500 mM NaCl; 
1% DMSO; controls at 2 µM; for 5 hours at room temperature in the dark (Figure 82). In these 
conditions, the addition of cyclin D1 led to a 1.3 fold fluorescence enhancement of CDKCONF4A with 
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a Z factor equal to 0.89. For CDKCONF4B, the biosensor fluorescence was amplified to 1.8 fold by 
positive control (retinoblastoma protein) with a Z factor equal to 0.68. Calculation of Z-factor values 
allows us to assess the validity of the assays. Indeed, it takes into account the difference between 
positive and negative controls, the signal-to-noise (S/N) ratio and the variability of the assay Z-factor 
is equal to ͳ െ ଷሺ஺శା஺షሻ஻శି஻ష , where A+ and A- correspond to the standard deviations of positive and 
negative controls, whilst B+ and B− are the average responses for positive and negative controls. For 
both biosensors, the Z factor value, which was greater than 0.5, allows to consider the assays suitable 
for screening. 
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Figure 82: Miniaturization of the assay. Fluorescence of 25 nM Cy3-labelled CDKCONF4A (A) and 
CDKCONF4B (B) with 2 µM positive and negative control over time; Fluorescence of 25 - 100 nM 
Cy3-labelled CDKCONF4A (C) and CDKCONF4B (D) with 2 µM positive and negative control after 5h; 
Fluorescence of 25 nM Cy3-labelled CDKCONF4A (E) and CDKCONF4B (F) with positive and negative 
control (0.25 - 2 µM) after 5h. The fluorescent signal of CDKCONF4A/B-Cy3 alone at t=0h was 
regarded as 100%. 
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2.4. Screening of two small molecule libraries 
Both biosensors were then implemented to screen two libraries of small chemical compounds: the 
National Chemical Essential (CNE) Library (480 compounds at 10 µM) and a library from Strasbourg 
(640 molecules at 10 µM) (collaboration with Dr Frédéric Bihel, Faculty of Strasbourg) (materials and 
methods). The screen was performed on a TECAN Freedom EvoTM Robot at the MRI platform in 
Montpellier with the help of Dr. Julien Bellis. Figure 83 and Table 6 summarize the results of the 
screening assays (see annex D for details). Screens were performed with positive and negative 
controls as well as PD-0332991 since the biosensors CDKCONF4A and CDKCONF4B were designed to 
discriminate against ATP competitors. Importantly, screens confirmed that both biosensors were 
insensitive to PD-0332991. 
The increase in fluorescence of each compound was calculated with reference to the basal 
fluorescence of Cy3-labelled CDKCONF4A or CDKCONF4B biosensor alone and was expressed as the 
relative percentage of increase. A molecule was considered a hit when induced amplification of Cy3-
labelled CDKCONF4A/B biosensor fluorescence to a similar extent as positive control (annex D). 
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Figure 83: Results of the hits retained in the screens performed with 25 nM Cy3-labelled 
CDKCONF4A and CDKCONF4B and compounds from the libraries at 10 µM: (A) hits identified in the 
CNE with CDKCONF4A; (B) hits identified in the CNE with CDKCONF4B; (C) hits identified in the 
library from Strasbourg with CDKCONF4A; (D) hits identified in the library from Strasbourg with 
CDKCONF4B. The fluorescent signal of CDKCONF4A/B-Cy3 alone was regarded as 100%. 
 CDKCONF4A CDKCONF4B 
Pre-screen Z factor = 0.89 Z factor = 0.68 
CNE 15 hits 
Z factor = -0.36 
9 hits 
Z factor = 0.71 
Strasbourg 2 hits 
Z factor = 0.23 
2 hits 
Z factor = 0.76 
Table 6: Results of the screening assays 
In parallel, the intrinsic fluorescence of the library compounds at 570 nm following excitation at 544 
nm was determined. In both libraries, no compounds exhibited autofluorescence at these 
wavelengths (Figure 84). 
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Figure 84: Determination of the intrinsic fluorescence of the library compounds at 570 nm 
following excitation at 544 nm, to eliminate autofluorescent compounds. Here is given an example 
of results obtained from one plate of compounds. The fluorescence of each compound was 
calculated with reference to the basal fluorescence of Cy3-labelled CDKCONF4A biosensor alone. 
2.5. Characterization of hits 
2.5.1.  In vitro characterization 
Confirmation of hits identified in the screens from powder stocks 
 Hits identified in both screens were obtained from source laboratories (annex D) and powder stocks 
were resuspended in DMSO. They were retested manually in duplicate to confirm they were positive 
hits with a fresh batch of Cy3-labelled CDKCONF4A and CDKCONF4B biosensor (Figure 85). 4 hits 
from the CNE promoted a fluorescence enhancement of Cy3-CDKCONF4A, AB-00016193, LPS401, 
LPS853 and ICMR-04-E10, whilst 2 compounds slightly amplified the fluorescent signal of Cy3-
CDKCONF4B, CEsr-1409000 and LPS401. 
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Figure 85: Confirmation of hits identified in the screens at 10 µM with a fresh batch of Cy3-labelled 
CDKCONF4A (A) and CDKCONF4B (B) biosensors. Compounds identified with both biosensors are in 
purple, compounds identified only with CDKCONF4A are in blue and compounds identified only 
with CDKCONF4B are in orange. The fluorescent signal of CDKCONF4A/B-Cy3 alone was regarded 
as 100%. 
Dose response of CDKCONF4A/B-Cy3 to hits identified in the two libraries 
Since few hits promoted a fluorescence increase of the biosensors at 10 µM, the response of Cy3-
labelled CDKCONF4A and CDKCONF4B was therefore investigated using different concentrations of 
compounds (examples are given in Figure 86). While a response of CDKCONF4A/B-Cy3 was obtained 
with AB-00015228, AB-00015203, AB-00016193, LPI2148 and LPI2251 at 10-5M in the original screen, 
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the biosensors only responded to these compounds when diluted at 10-4M in this experiment. This 
difference can be explained by the use of fresh powder stocks of compounds. However, Cy3-
CDKCONF4A responded to ICMR-04-E10 and LPS853 in a dose-dependent fashion (Figure 86A/B), and 
LPS401 promoted a dose-dependent response of both Cy3-CDKCONF4A and Cy3-CDKCONF4B (Figure 
86E/F). 
 
Figure 86: Dose response of Cy3-labelled CDKCONF4A to (A) ICMR-04-E10 and (B) LPS853. Dose 
response of Cy3-labelled CDKCONF4A (left panel) and CDKCONF4B (right panel) to (C & D) AB-
00015228, AB-00015203, AB-00016193 and (E & F) LPI2148 and LPI2251, from the library of 
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Strasbourg, and LPS401, which respond to both biosensors. Compounds were tested at 10
-4
, 10
-5
, 
10
-6
, 10
-7
 and 10
-8
M. The fluorescent signal of CDKCONF4A/B-Cy3 alone was regarded as 100%. 
Given the robust response of Cy3-CDKCONF4A/B to LPI2148 and LPI2251 at 10-4M and since we 
started a close collaboration with Dr. Frédéric Bihel, the chemist who synthesized these compounds, 
we decided to focus only on these two hits to further in vitro characterization, with respect to their 
identification by CDKCONF4A as PPI inhibitors. 
Identification of PISTVRE helix binders 
To verify whether these hits might bind the PISTVRE helix of CDK4 directly, a peptide derived from 
this helix, named PISTVRE peptide, was labelled and a fluorescence titration assay was performed 
using, as a positive control, a peptide named D1 which derived from the complementary interface, 
the α5 helix of cyclin D1 (Figure 87). TP2Rho was used as fluorescent probe because of its important 
fluorescence enhancement upon interaction with targets (Dr Florence Mahuteau-Betzer, Institut 
Curie) (Dumat et al., 2012, 2013). One of these compounds, LPI2251 indeed enhanced the 
fluorescence of TP2Rho-labelled PISTVRE significantly and in a dose-dependent fashion, whereas the 
other, LPI2148 (which will not be described any further) did not.  
 
Figure 87: (A) Design of two peptides derived from the CDK4/cyclin D1 interface (B) Fluorescence 
binding assay of LPI2148 and LPI2251 (at 5 and 10 µM), compared to D1 peptide, with 200 nM 
TP2Rho-PISTVRE peptide. The increase in fluorescence of each compound was calculated with 
reference to the basal fluorescence of TP2Rho-labelled PISTVRE peptide (regarded as 1). 
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To further explore the chemical and structural determinants of LPI2251 involved in the interaction 
with the PISTVRE helix, a family of derivatives was synthesized in the team of Dr. Frédéric Bihel. Their 
general structure is shown in Figure 88. 
 
Figure 88: The general structure of LPI2251 derivatives 
Dose response of CDKCONF4A-Cy3 to LPI2251 derivatives 
The ability of LPI derivatives to enhance fluorescence of Cy3-labelled CDKCONF4A was examined 
(Figure 89). All the compounds, except for LPI2183, promoted a similar fluorescence enhancement of 
Cy3-labelled CDKCONF4A at 5 µM and 10 µM as the positive control (D1 peptide). Only MED0128 
induced a greater fluorescence enhancement at 5 µM and 10 µM than that of D1 peptide. 
 
Figure 89: Fluorescence binding assay of LPI2251 derivatives (at 1, 5 and 10 µM) with 200 nM Cy3-
CDKCONF4A. The increase in fluorescence of each compound was calculated with reference to the 
basal fluorescence of Cy3-CDKCONF4A, regarded as 100%. 
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Dose response of TP2Rho-PISTVRE peptide to LPI2251 derivatives 
Then, their ability to enhance fluorescence of TP2Rho-PISTVRE peptide was investigated. Three 
compounds LPI2252, LPI2466 and RF1210 induced a similar response of the CDK4-derived PISTVRE 
peptide compared to the original hit LPI2251 (Figure 90). 
 
Figure 90: Fluorescence binding assay of LPI2251 derivatives (at 5 and 10 µM) with 200 nM TP2Rho-
PISTVRE peptide. The increase in fluorescence of each compound was calculated with reference to 
the basal fluorescence of TP2Rho-labelled PISTVRE peptide, regarded as 1. 
In order to assess that the increase in fluorescence was indeed due to interaction between the 
PISTVRE peptide and LPI derivatives and not a response of the fluorescent probe TP2Rho itself, a 
control experiment was performed with an irrelevant peptide, MP26, labeled with TP2-Rho (Figure 
91). Unfortunately, upon incubation with LPI derivatives, a similar fluorescence enhancement was 
observed with TP2Rho-MP26 compared to TP2Rho-PISTVRE, indicating that TP2Rho binds LPI 
compounds. 
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Figure 91: Fluorescence control assay with 200 nM TP2Rho-MP26 peptide and LPI2251 derivatives 
(at 5 and 10 µM). The increase in fluorescence of each compound was calculated with reference to 
the basal fluorescence of TP2Rho-labelled MP26 peptide, regarded as 1. 
The fluorescent probe Cy5 was then tested in fluorescence binding assay of LPI2251, LPI2252, 
LPI2466 and RF1210 (at 5 and 10 µM) with 200 nM PISTVRE peptide. Cy5-labelled PISTVRE peptide 
responded to these compounds in a dose-dependent fashion, whilst a much lower increase in 
fluorescence of Cy5-MP26 was observed (Figure 92). This experiment suggested that Cy5 could be 
used for fluorescence binding assays since this fluorescent probe did not bind LPI compounds. 
 
Figure 92: Fluorescence binding assay of LPI2251 derivatives (at 5 and 10 µM) with 200 nM Cy5-
PISTVRE peptide and Cy5-MP26. The increase in fluorescence of each compound was calculated 
with reference to the basal fluorescence of Cy5-labelled PISTVRE or MP26, regarded as 100%. 
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Fluorescence titration assays of PISTVRE peptide with LPI derivatives were performed to determine 
the dissociation constant values of the compounds (Figure 93A). LPI2252, LPI2466 and RF1210 
interacted with TP2Rho-PISTVRE peptide with affinities in the micromolar range, similar to that of the 
complementary peptide derived from the interface of cyclin D1 (D1 peptide) (dissociation constant 
values of 17 µM for D1 peptide, 3.35 µM for LPI2466, 17 µM for RF1210 and 34 µM for LPI2252). 
Then, to verify that these compounds could bind the α5 helix peptide of cyclin D1, fluorescence 
titration assays of D1 peptide with LPI derivatives were performed (Figure 93B). Compared to the 
PISTVRE peptide, LPI2466, RF1210 and LPI2252 indeed bound the interface of cyclin D1, yet with 
much lower affinity (dissociation constant values of 180 nM for PISTVRE, 6.88 µM for LPI2466, 21 µM 
for RF1210 and 47 µM for LPI2252). 
 
Figure 93: (A) Fluorescence titration of 200 nM PISTVRE peptide-TP2Rho with D1 peptide, LPI2251, 
LPI2252, LPI2466 and RF1210. ND: Not Determined - No Kd value could be calculated for LPI2251 
(B) Fluorescence titration of 200 nM D1 peptide-TP2Rho with the PISTVRE peptide, LPI2251, 
LPI2252, LPI2466 and RF1210. 
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Determination of the intrinsic fluorescence of the library compounds at 614 nm following excitation 
at 510 nm  
Importantly, autofluorescence of the LPI derivatives was examined and none of these compounds 
emitted any fluorescence at 614 nm when excited at 510 nm compared to TP2Rho-PISTVRE peptide 
(Figure 94). 
 
Figure 94: Determination of the intrinsic fluorescence of the library compounds at 614 nm 
following excitation at 510 nm, to eliminate autofluorescent compounds. 
2.5.2. In cellulo characterization 
CNE compounds 
The ability of the different CNE compounds (AB-00015228 / AB-00015203 / AB-00016193 / ICMR-04-
E10 / LPS 401 / LPS853 / Cesr-1409000) to inhibit cell growth was examined on the A375 melanoma 
cell line which harbours a wild-type CDK4 but a loss of function of CDKN2A (p16INK4A) and the V600E 
BRaf mutation. Compounds were tested at 10-6, 10-7, 10-8 and 10-9 M and relative cell growth was 
measured at 6, 12, 24h (Figure 95) (materials and methods). This experiment showed that any 
compound promoted a significant decrease in the number of cells under these conditions. 
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Figure 95: Proliferation inhibition studies of the CNE compounds in melanoma A375 cell line at 6, 
12, 24 and 48h. 
LPI derivatives 
Since the LPI derivatives provided promising results in vitro, their ability to inhibit proliferation of 
melanoma cells was investigated. To this aim, the efficiency of the different compounds at 1 µM and 
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10 µM was first examined on the A375 melanoma cell line (Figure 96). While no compound inhibited 
A375 cell proliferation at 1 µM, one compound, LPI2192, promoted efficient cell growth inhibition at 
10 µM at 24 and 48h (Figure 96A).  
 
Figure 96: Proliferation inhibition studies of the LPI derivatives in melanoma A375 cell line at 1 µM 
(left panel) and 10 µM (right panel) at 24 and 48h. 
The dose-dependent inhibitory potency of the most efficient compounds in vitro in binding and 
titration assays and/or in cellulo (LPI2192 / RF1210 / LPI2251 / LPI2252 / MED0128) was then 
investigated on the melanoma (A375) and fibroblast cell lines and compared to PD-0332991 (Figure 
97). Table 7 provides the IG50 values of the compounds determined for A375 at 48h (materials and 
methods and annex E). IG50 were all in the micromolar range and comparable with that of PD-
0332991. One compound, LPI2192, had a significant inhibitory potency on fibroblasts, suggesting that 
it could alter the proliferation of healthy cells. It is therefore more relevant to focus on compounds 
which only alter cancer cells such as RF1210, LPI2251, LPI2252 and MED0128. 
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Figure 97: Proliferation inhibition studies in A375 melanoma (left panel) and fibroblast (right panel) 
cell lines at 48h of the most promising LPI derivatives: (A) LPI2192, (B) RF1210, (C) LPI2251, (D) 
LPI2252, (E) MED0128 and (F) PD-0332991 as control. 
 
Table 7: Inhibition constants (IG50) of LPI compounds in A375 cell line. 
Proliferation assays were then performed in different melanoma cell lines bearing wild-type p16INK4A, 
BRAF and CDK4 (Mewo cells), the NRAS Q61R mutation (SK-MEL2 cell line) or the R24C CDK4 and 
BRAF V600E mutation (SK-MEL28 cell line). Table 2 lists the genetic alterations identified for the 
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RF1210 13.6 +/- 0.4
LPI2251 17.6 +/- 0.5
LPI2252 17.9 +/- 2.2
MED0128 20.7 +/- 0.8
PD-0332991 18.7 +/- 0.4
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different components of the p16INK4A / CDK4/6-cyclin D / pRb pathway and for BRAF and NRAS in 
A375, Mewo, MV3, SK-MEL2 and SK-MEL28 cell lines. 
 
Table 8: Genetic alterations identified in A375, Mewo, MV3, SK-MEL2 and SK-MEL28 cell lines (ND: 
data not found). 
We decided to focus on RF1210 because it proved to be one of the most potent compounds in vitro 
in binding and titration assays. The IG50 values of RF1210 are similar between the different 
melanoma cell lines, from 10 µM to 13.6 µM (Table 9 and annex E). They are similar to the IG50 values 
obtained with PD-0332991 (from 10.7 µM to 18.7 µM). 
 
Table 9: Inhibition Constants (IG50) of PD-0332991 and RF1210 in different melanoma cell lines. 
Combined administration of RF1210 with other drugs 
Finally, proliferation assays were performed to investigate whether RF1210 and LPI2252 could 
cooperate with other drugs in promoting efficient inhibition of A375 melanoma cell proliferation. 
Indeed, at suboptimal concentrations of 10 µM RF1210 and LPI2252, the combination of these 
compounds with CDK4 inhibitors such as PD-0332991 and LY2835219 proved to inhibit proliferation 
of A375 cells more efficiently than either compound alone (Figure 98 and Table 10). Cooperation was 
CDKN2A CDK4 Rb BRAF NRAS 
A375 mutated (E61Stop, Loss of function) WT WT V600E WT
Mewo mutated (R80Stop, Loss of function) WT WT WT WT
MV3 ND ND ND WT WT
SK-MEL2 WT WT WT WT mutated (Q61R)
SK-MEL28 WT R24C WT V600E WT
IG50 (PD-0332991) (µM) IG50 (RF1210) (µM)
A375 18.7 +/- 0.4 13.6 +/- 0.4
MV3 11.0 +/- 0.8 10.8 +/- 4.4
SKMEL2 10.7 +/- 1.6 10.1 +/- 1.0
SKMEL28 11.5 +/- 3.2 12.0 +/- 0.2
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also observed with LEE011, another CDK4 inhibitor, but also with drugs not related to CDK4 such as 
Paclitaxel and Methotrexate which are commonly used for treatment of cancer.  
 
Figure 98: Cooperation between (A) RF1210 (10 µM) and PD-0332991 (10 µM); (B) RF1210 (10 µM) 
and LY2835219 (15 µM); LPI2252 (10 µM) and PD-0332991 (10 µM); LPI2252 (10 µM) and 
LY2835219 (15 µM) at 48h in A375 cell line. 
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Table 10: Proliferation inhibition studies in melanoma A375 of (A) RF1210 (10 µM) and (B) LPI2252 
(10 µM) in combination with other drugs at 48h. 
B. Development of peptide inhibitors that target the CDK4/cyclin D 
interface 
2.6. Concept and design 
Peptides were designed to target the interface between CDK4 and cyclin D through structural 
analysis of the helices involved in the protein-protein interaction (PPI) (Figure 99).  
Cooperation
–RF1210
Degree of 
inhibition (%)
10 µM RF1210 46.2
15 µM LEE011 20.5
15 µM LY2835219 58.6
15 µM Paclitaxel 48.4
15 µM Methotrexate 31.4
10 µM PD-0332991 36.0
RF1210 + LEE011 73.4
RF1210 + LY2835219 92.0
RF1210 + Paclitaxel 72.4
RF1210 + Methotrexate 58.0
RF1210 + PD-0332991 71.7
Cooperation
–LPI2252
Degree of 
inhibition (%)
10 µM LPI2252 23.7
15 µM LEE011 20.5
15 µM LY2835219 58.6
15 µM Paclitaxel 48.4
15 µM Methotrexate 31.4
10 µM PD-0332991 36.0
LPI2252 + LEE011 37.7
LPI2252 + LY2835219 84.5
LPI2252 + Paclitaxel 73.2
LPI2252 + Methotrexate 48.8
LPI2252 + PD-0332991 55.6
A B
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Figure 99: Design of peptides that can target the interface between the PISTVRE helix of CDK4 and 
the α5 helix of cyclin D (crystal structure of CDK4/cyclin D1 (PDB 2W99)). 
In the team, this strategy was already implemented for targeting the interface between CDK2 and 
cyclin A (Gondeau et al., 2005). Given the success of this work, two peptides were designed to target 
the interface between the PISTVRE helix of CDK4 and the α5 helix of cyclin D1: one peptide, named 
D1, derived from the α5 helix sequence; and the other, PISTVRE, derived from the PISTVRE helix 
sequence (Table 11). A cysteine residue was introduced in both peptide sequences for labeling with 
fluorescent probes. 
Peptide Derived from Sequence 
PISTVRE PISTVRE helix of CDK4 H-GGGCPISTVREVALLRRL 
D1 α5 helix of cyclin D1 SIRPEELLQMELLLVNKLKWNLC 
Table 11: Amino acid sequence of the two peptides that have been designed to target the 
CDK4/cyclin D interface 
2.7. In cellulo characterization 
Proliferation assays were performed in A375 melanoma cells to determine the ability of the two 
peptides to inhibit cell proliferation. These peptides were delivered into cells using the cell 
penetrating peptide CADY2 (Figure 99) (Kurzawa et al., 2010). CADY2 is an amphipathic peptide that 
can interact with proteins and peptides and deliver them efficiently into living cells. This strategy has 
α5 helix
CDK4
cyclin D1
PISTVRE helix
PPI inhibitors
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already been implemented to deliver peptide inhibitors targeting a PPI (eg MP51) (Kurzawa et al., 
2010). 
 
Figure 100: Delivering into cells of PISTVRE and D1 peptides thanks to the cell-penetrating peptide 
CADY2. 
The PISTVRE peptide inhibited A375 cell proliferation similarly than PD-0332991 with a 22% and 27% 
decrease in melanoma cell growth at 10-6M and 10-7M, respectively (Figure 101 A&B). The D1 peptide 
was more efficient at 10-6M with a 56% decrease in melanoma cell growth and was comparable to 
PISTVRE at 10-7M (22% decrease) (Figure 101 C&D). At 10-6M and 10-7M, neither PISTVRE nor D1 
inhibit melanoma cell growth when administrated alone, without facilitated delivery (Figure 101 
E&F). 
peptide CADY2
cell membrane
nanoparticle
nucleus
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cycD
CDK4
cycD
CDK4
CDK4
cycD
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Figure 101: Proliferation inhibition studies of PISTVRE and D1 peptides at 10
-6
M (left panel) and 10
-
7
M (right panel) in A375 melanoma cell lines at 24 and 48h. (A & B) PISTVRE/CADY2 (ratio 1/20) 
compared to PD-0332991; (C & D) D1/CADY2 (ratio 1/20) compared to PD-0332991; (E & F) PISTVRE 
and D1 peptides administrated without CADY2. 
2.8. In vitro characterization 
Some variants of PISTVRE were generated in order to determine the minimal sequence that can 
efficiently target the interface. Shorter and longer sequences derived from the CDK4/cyclin D 
interface were synthesized to investigate whether N- and C-terminal extensions could favour 
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interactions (Figure 102 and Table 12). For each variant, an N-terminal acetylated derivative was also 
synthesized so as to cap the N-terminus and prevent its recognition by the proteolytic machinery. 
 
Figure 102: Design of PISTVRE variants. They all contain the sequence corresponding strictly to 
helical region and additional amino acids that are thought to be involved in the main interactions 
between CDK4 and cyclin D (crystal structure of CDK4/cyclin D1 (PDB 2W99)). These amino acids 
are highlighted with circles. 
PISTVRE 
helix
PISTVRE 
helix
α5 helix
α3 helix
CDK4
cyclin D 
α5 helix
α3 helix
α5 helix
C-ter
extension
N-ter
extension
PISTVRE 
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Table 12: Sequence of the PISTVRE variants. They contain the original PISTVRE sequence and N-
terminal and/or C-terminal extensions. 
In order to determine the best derivative, binding assays of the variants (from 0 to 3000 nM) with 
500 nM TAMRA-labelled D1 peptide were performed (Figure 103). Dissociation constant (Kd) values 
demonstrated that the shorter PISTVRE variant, PISTVRE-A, bound with the greatest affinity (Kd = 172 
+/- 113 nM).  
sequence
D1 SIRPEELLQMELLLVNKLKWNLC
PISTVRE H-GGGCPISTVREVALLRRL
Ac-PISTVRE Ac-GGGCPISTVREVALLRRL
PISTVRE-A H-CPISTVREVALLRRL 
Ac-PISTVRE-A Ac-CPISTVREVALLRRL
PISTVRE-B H-CPISTVREVALLRRLEAFE
Ac-PISTVRE-B Ac-CPISTVREVALLRRLEAFE 
PISTVRE-C H-GGGCPISTVREVALLRRLEAFE
Ac-PISTVRE-C Ac-GGGCPISTVREVALLRRLEAFE
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Figure 103: Binding assays of the PISTVRE variants (from 0 to 3000 nM) with 500 nM TAMRA-
labelled D1 peptide. (A) Binding curves; (B) Constant dissociation (Kd) values calculated for the 
different variants. 
Further experiments will include studies of the interaction with cyclin D1 protein to characterize the 
affinity and the specificity of interaction between the PISTVRE peptide and the α5 helix of cyclin D1, 
taking into account the whole environment surrounding this interface and all the secondary 
interactions existing at this interface. 
  
sequence Kd (nM)
PISTVRE H-GGGCPISTVREVALLRRL 1757 +/- 1007
PISTVRE-A H-CPISTVREVALLRRL 172 +/- 113
PISTVRE-B H-CPISTVREVALLRRLEAFE 1016 +/- 581
PISTVRE-C H-GGGCPISTVREVALLRRLEAFE 9498 +/- 16655
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Discussion & Perspectives 
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1. Development of a fluorescent biosensor for probing CDK4/cyclin D activity 
1.1. Assessment 
We have developed a CDK4-specific fluorescent peptide biosensor, WWshortRb, which comprises a 
substrate sequence derived from Rb and a newly designed phosphorecognition domain. This 
biosensor binds CDK4 and reports on the enzymatic activity of recombinant CDK4/cyclin D kinase in 
vitro through changes in fluorescence intensity. It is also well suited to probe CDK4 activity in cell 
extracts, skin biopsies, melanoma xenograft lysates and living cells, thereby providing a scaled and 
predictive readout of this cancer biomarker for diagnostic purposes.  
Moreover, WWshortRb biosensor provides sensitive means of comparing CDK4 activity between 
different melanoma cell lines that harbour molecular alterations converging on CDK4/cyclin D 
activity, and of quantifying differences which cannot be identified by simple analysis of protein 
kinase expression levels.  
WWshortRb has also proved to be efficient in extracto to quantify alterations in CDK4 activity 
following treatment with selective inhibitors or siRNA in a more physiologically-relevant environment 
than in buffer containing purified recombinant kinase. It therefore offers promising perspectives for 
drug discovery programs since it could enable to monitor the progression of melanoma and to 
monitor response to CDK4 inhibitors over time. 
1.2. Biosensor design and importance of PAABD 
We first generated a CDK4-specific fluorescent protein biosensor, CDKACTRb, which contains a CDK4-
specific substrate sequence and a PAABD derived from the PBD of Plk1.  
Despite the very promising results obtained in vitro and in extracto, we investigated an alternative 
strategy, the development of a peptide biosensor, WWRb, which offers a more practical handling and 
cellular delivery. WWRb contains the same substrate sequence as CDKACTRb but a different PAABD, 
derived from the WW domain of Pin1. This switch between protein and peptide allowed to highlight 
the importance of the phospho-recognition domain for the proper functioning of the biosensor. 
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Indeed, while the Pin1 WW domain had been successfully used in a hybrid biosensor to probe CDK9 
activity (Anai et al., 2007), it did not seem to be functional in WWRb upon incubation of cell extracts. 
Since the lack of response of WWRb was observed with different probes in extracto and as the 
biosensor responded to recombinant CDK4/cyclin D in vitro, we hypothesized that the presence of 
lysis buffer, which contains detergents, prevented a proper folding of the WW domain.  
This lack of functionality led to the design of a new shorter phosphorecognition domain, WWshort, 
derived from the interface of the WW domain of Pin1 with a phosphopeptide substrate. We found 
that the WWshort interacted better than the WWlong with Rb substrate and phospho-Rb substrate. 
Moreover, WWshortRb responded to CDK4/cyclin D in vitro and in extracto, validating the use of this 
artificial PAABD. 
Thanks to WWshortRb biosensor, we are able to dissect the two steps involved in protein kinase 
phosphorylation. First, the kinase binds independently of the presence of ATP/MgCl2, followed by the 
phosphotransfer reaction itself which is dependent on ATP/MgCl2. 
1.3. Sensitivity of the biosensors - Importance of the probe 
First of all, it has to be noted that, compared to radioactive assays in which micromolar 
concentration of reagents are needed, only nanomolar concentrations are required in fluorescence-
based assays. For instance, WWshortRb biosensor displayed a high sensitivity to recombinant 
CDK4/cyclin D activity in fluorescent assays, which were performed with 150 nM of biosensor and 75 
nM recombinant protein. CDKACTRb was used at lower concentrations (50 nM) and exhibited greater 
fluorescence compared to peptide variants in extracto (see in extracto experiments). However, as the 
fluorescent probe was not the same, it is difficult to provide a quantitative comparison. 
In extracto studies performed with WWRb and WWshortRb have demonstrated that the choice of 
the probe was essential to monitor response of the biosensor. The size and structure of the probe 
was crucial in these dynamic systems. For WWshortRb, TAMRA was the only probe suited to report 
on a conformational change. This result was an advantage for in cellulo experiments and ratiometric 
quantification since WWshortRb could be labelled with either a responsive or unresponsive probe 
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and co-internalized in living cells. Compared to TAMRA, Cy3 and DyLight650 display a higher 
extinction coefficient which allows better detection at low concentrations. However, WWshortRb 
only responds to CDK4 activity when labeled with TAMRA. Our hypothesis is that the size of the 
fluorophores plays a crucial role in the response of the biosensor. Indeed, DyLight650, a stable 
sulfonate derivative of Cy5, and Cy3 are much larger than the tetramethylrhodamine TAMRA. As the 
fluorophore is close to the phosphorylation site, it can be hypothesized that a large fluorophore 
sterically prevents the complete conformational change upon phosphorecognition. 
The maximal fluorescence enhancement of TAMRA-WWshortRb biosensor observed was 40% upon 
phosphorylation by CDK4/cyclin D. This limitation in fluorescence enhancement may be due to the 
fact that TAMRA is not extremely sensitive in comparison with other dyes. It could therefore be 
interesting to test fluorophores such as merocyanine or DMN4 which could allow to get a more 
robust increase in fluorescence (Gulyani et al., 2011; Loving and Imperiali, 2008). However, it is not 
certain that changing the probe will improve the fluorescence enhancement. Indeed, it is possible 
that the interaction between the PAABD and the phosphorylated residue does not lead to enough 
changes in the surrounding environment in terms of pH or solvent polarity to increase the 
fluorescent signal more than 40%.  
Moreover, additionally to fluorescence enhancement, it is important to analyze the kinetics of the 
curves obtained under different treatments or conditions. Indeed, WWshortRb response overtime 
provides precious information on the phosphorylation rate and allows to assess the efficacy of an 
inhibitor for example. 
Even though TAMRA is not highly sensitive, TAMRA-labelled WWshortRb biosensor allows to 
compare CDK4 activity between different melanoma cell lines, and to quantify differences which 
cannot be identified by simple analysis of protein kinase expression levels. TAMRA-WWshortRb is 
therefore sensitive enough to highlight kinase hyperactivation in cell lines that harbour molecular 
alterations converging on CDK4/cyclin D activity. 
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Finally, cellular internalization and live cell imaging were performed with WWshortRb biosensor 
which exhibited alterations in fluorescent intensity at 2 μM in response to CDK4/cyclin D activity. It is 
a much lower concentration compared to that of other peptide biosensors such as NBD-based PKC 
biosensor or mero53-based Src biosensor, microinjected into cells at 200 µM and 40 μM, respectively 
(Gulyani et al., 2011; Yeh et al., 2002). The fact that WWshortRb crosses cell membranes alone allows 
to treat much more cells compared to microinjection and to prevent them from stress due to this 
technique. 
1.4. Specificity of the biosensors 
In extracto studies demonstrated that CDKACTRb reported on endogenous CDK4 activity from 
melanoma cell extracts in a dose-dependent fashion, since addition of increasing concentrations of 
PD-0332991 reduced the fluorescent signal of CDKACTRb accordingly. In contrast other CDK 
inhibitors and other protein kinase inhibitors had no significant effect on CDKACTRb fluorescence. 
The full spectrum of protein kinase inhibitors have not been screened but, as CDKACTRb did not 
respond to those tested and given the CDK4-specific substrate sequence contained in the biosensor, 
we can infer it responds specifically to CDK4 activity in cell extracts. However, its specificity has not 
been investigated in cellulo and could differ from that obtained in extracto. 
Regarding WWshortRb, its fluorescence was decreased upon incubation or treatment of cells with 
the CDK4 inhibitors PD-0332991 and LY2835219, but not upon addition of Roscovitine, which 
preferentially inhibits CDK1, CDK2, CDK5, CDK7 and CDK9. We observed a residual fluorescence 
response of WWshortRb upon addition of high concentrations of PD-0332991 whereas no residual 
fluorescence was observed following addition of 20 µM LY2835219. This suggests that PD-0332991 is 
not as potent as LY2835219 to inhibit CDK4/cyclin D activity in melanoma cell extracts. This result 
highlights the utility of the biosensor to compare, in a cellular context, the efficacy of CDK4 inhibitors 
which display a similar IC50 value in vitro (2 and 11 nM for LY2835219 and PD-0332991, respectively). 
Likewise, the biosensor reported on a reduced CDK4 activity in A375 cells in which CDK4 protein 
levels were reduced following treatment with siRNA targeting CDK4. Finally, WWshortRb peptide 
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biosensor was implemented to identify fractions bearing CDK4 activity following fractionation of 
A375 cell extracts by gel filtration chromatography. Taken together, these experiments reveal that 
WWshortRb constitutes a specific tool to quantify CDK4 activity in melanoma cell extracts following 
treatment with selective inhibitors or downregulation of kinase levels by RNA silencing. 
1.5. Application of WWshortRb to probe CDK4 activity in skin biopsies and in 
tumour xenograft lysates 
We have shown that WWshortRb reports on CDK4/cyclin D in skin biopsies and that CDK4 was 
essentially active in the epidermis, compared to the dermis, consistent with the fact that rapidly 
dividing cells are found in the epidermis. The biosensor further reported a similar CDK4 activity in 
eczema skin biopsies compared to healthy samples, whereas a significant downregulation of CDK4 
activity was found in psoriasis, skin pathology in which cells are renewed excessively. WWshortRb 
allows to demonstrate for the first time a deregulation of CDK4 in psoriasis. This discovery could 
further help to treat this pathology and understand why ultraviolet B (UVB) phototherapy is an 
effective treatment for psoriasis. Indeed, it has been demonstrated that p16INK4a accumulation, in 
response to UV radiation, leads to inhibition of CDK4 activity which appears to be involved in the G2 
phase cell cycle arrest (Gabrielli et al., 1999; Pavey et al., 2001). 
Finally, WWshortRb was applied to quantify CDK4/cyclin D kinase activity in melanoma xenograft 
lysates from mice treated with PD-0332991. However, we realized that it was essential to normalize 
lysates prepared from different melanoma xenografts to the proportion of cancer cells (A375 
luciferase). Indeed, as stromal cells are also present in the tumour, the lysate contains normal and 
hyperactive proteins, such as CDK4/cyclin D. Since each tumor behaves and grows differently, the 
ratio between hyperactive and normal protein expression level changes, resulting in an inaccurate 
normalization.  
1.6. Application of WWshortRb to probe CDK4/cyclin D activity in living cells 
Internalization of WWshortRb 
 160 
 
One of the major drawbacks of peptide/protein-based biosensors is the requirement of effective 
delivery strategies for in cellulo and in vivo studies and applications, as cellular membranes constitute 
barriers. However, although we did not identify any obvious sequence that could confer a cell-
penetrating ability to WWshortRb, we found that it could cross cell membranes alone. This result 
renders imaging experiments more straightforward since the labeled peptide biosensor does not 
require any additional preparation. However, the stability of the peptide biosensor for in vivo 
applications has to be investigated. Indeed, peptides are subject to degradation by proteases and 
WWshortRb is completely unprotected since it does not require cell-penetrating peptides to facilitate 
its delivery. Some strategies to improve its stability should be considered (see future developments). 
Ratiometric quantification of fluorescence in living cells 
Time-lapse acquisitions were performed following co-internalization of TAMRA-WWshortRb and 
DyLight650-WWshortRb into A375 melanoma cells. DyLight650-WWshortRb was confirmed to be 
unresponsive in living cells and therefore constituted an appropriate negative control. Ratiometric 
quantification of TAMRA/DyLight650 signal demonstrated that TAMRA-WWshortRb fluorescence was 
significantly decreased upon addition of PD-0332991, which inhibits CDK4 activity, and Roscovitine, 
which arrests the cell cycle in a phase where CDK4 is not active. However, the linearity of the signal 
after three hours of reaction suggests that the biosensor is not responding properly after 200 min.  
This data show that WWshortRb is not really well suited for in cellulo applications and should rather 
be applied in vitro in which it proved to be highly efficient.  
1.7. Future developments 
WWshortRb biosensor constitutes a first-of-a kind tool for detection of a relevant enzymatic 
biomarker, whose predictive value complements immunological approaches for identification of 
serological and histological markers. We can therefore anticipate it will enable to establish a 
diagnostic assay for early-stage detection of melanoma onset, providing information on CDK4 activity 
which complement data on biomarker expression levels, obtained from immunological approaches. 
Moreover, as the biosensor exhibits a sensitive response to CDK4 inhibition by specific CDK4 
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inhibitors, it represents a powerful technology for drug discovery programmes, to monitor the 
response to treatment and to assess the efficacy of new generations of CDK4 inhibitors. WWshortRb 
could also be applied to probe CDK4 activity in other cancers such as Non Small Cell Lung Cancer 
NSCLC) and lymphoma in which the p16INK4A/CDK4/cyclin D/Rb pathway is also deregulated.  
WWshortRb constitutes a potent alternative tool to radioactivity or antibody-based approaches to 
probe CDK4 activity in vitro. Moreover, it reports on enzymatic activities in complex biological 
samples such as the cellular cytoplasm or the tumoral environment. To our knowledge, WWshortRb 
constitutes the first chemical tool applied to quantify kinase activities in skin or tumour biopsies. 
 
As previously mentioned, the technology might be further improved through incorporation of more 
sensitive or solvatochromic dyes, such as merocyanine or DMN4, to obtain greater enhancement in 
fluorescence (Gulyani et al., 2011; Loving and Imperiali, 2008). Moreover, the contribution of CDK4 
binding to the biosensor contributes to a large increase in fluorescence compared to phosphorylation 
itself. It might therefore be relevant to investigate the use of a probe which would only respond to 
phosphorylation, such as the solvatochromic Sox (sulfonamide-oxine) dye, which binds Mg2+ and 
undergoes chelation-enhanced fluorescence (CHEF) upon phosphorylation (Shults et al., 2003). 
However, despite this large contribution of binding in WWshortRb fluorescence, the biosensor 
responds to inhibitors such as PD-0332991.  We hypothesize that the inhibitor, when bound to the 
ATP pocket, prevents the substrate phosphorylation but also modifies CDK4/cyclin D conformation, 
therefore reducing the binding of the substrate to its kinase.   
With the aim of optimizing the signal-to-noise (S/N) ratio, controlling the timing observation of the 
reaction and increasing the intensity of the biosensor response, photoactivation strategies could be 
implemented by “caging” the phosphorylatable residue with a photo-labile group which can be 
released upon UV irradiation. This strategy has previously been proposed in the development of 
other biosensors (Dai et al., 2007; Veldhuyzen et al., 2003; Wang et al., 2006b). 
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Furthermore, efforts have to be made to improve the stability of WWshortRb, especially for in vivo 
applications. For instance, chemical modifications of the peptide sequence could be made to prevent 
proteolysis such as incorporation of non-natural amino acids or incorporation of pseudo-peptide 
bonds (Gentilucci et al., 2010). Moreover, formulations with carriers such as microparticles, 
nanoparticles, liposomes or carbon nanotubes, which are used for facilitated delivery could also be 
tested with WWshortRb (Patel et al., 2014). 
2. Identification of non-ATP competitive compounds targeting CDK4/cyclin D 
A. Identification by screening of non-ATP competitive compounds 
2.1. Assessment 
Several ATP-competitive inhibitors of CDK4 tested in clinical trials, such as Palbociclib (PD-0332991), 
Ribociclib (LEE011) and Abemaciclib (LY2835219), exhibit promising perspectives for Rb-positive 
melanomas. However, response to these inhibitors is associated with loss, or functional 
downregulation of p16INK4A, most likely because this endogenous inhibitor of CDK4/cyclin D prevents 
their binding within the ATP pocket of CDK4. As such, and since the classical mechanism of action of 
ATP-competitive inhibitors is notorious for its lack of selectivity, alternative strategies to target CDK4 
kinase function should provide new avenues to develop therapeutics for melanoma.  
We have engineered two fluorescent biosensors, CDKCONF4A and CDKCONF4B, to identify 
competitors of essential protein/protein interfaces between CDK4 and cyclin D, and allosteric 
inhibitors that perturb the conformational dynamics of CDK4, respectively. These tools enabled to 
establish assays for screening of chemical compound libraries, thereby leading to identification of 
hits with promising potential for selective chemotherapeutic application for melanoma based on 
postscreen characterization in vitro and in cellulo. 
2.2. Implementation of an HTS assay 
CDKCONF4A and CDKCONF4B biosensors were applied to screen the National Chemical Essential 
Library and a library from the Faculty of Pharmacy of Strasbourg (Laboratoire d’innovation 
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thérapeutique; collaboration Dr. F. Bihel) in a high throughput format. Prior to HTS, I spent a lot of 
time performing stability assays and downscaling experiments in order to establish the best 
conditions for a miniaturized assay in 96-well plates. Positive and negative controls were validated in 
fluorescent binding assays. Conditions of the assay were then optimized in a time and concentration 
dependent fashion so as to obtain a robust and reproducible signal at lower cost and with a 
manageable quantity of proteins. The assay was assessed by calculating the Z-factor whose value 
must be above 0.5 to lead HTS assays.  
For the screening of the CNE with CDKCONF4A, the positive control (cyclin D1) did not respond as 
well as expected, leading to a negative Z-factor value. This result can be explained by the fact that 
different batches of both biosensor and positive control were prepared and used for prescreening 
assays and the screen itself. Although protein expression and purification was verified by SDS-PAGE, 
recombinant proteins are not always expressed in the same way, for example because of a 
temperature change that leads to a misfolded protein which will be less soluble. Since some CNE 
compounds promoted a significant increase in fluorescence of Cy3-CDKCONF4A, we decided to retain 
15 hits, despite the lack of positive control. Importantly, the two biosensors did not respond to PD-
0332991, proving that they could discriminate against ATP analogues. Finally, 4% CNE compounds 
and 0.3% molecules from Strasbourg were retained with both biosensors. 
2.3. Post-screen characterization  
Hits identified in the screen were retested manually from fresh powder stocks resuspended in DMSO 
to confirm they were positive with a fresh batch of Cy3-labelled CDKCONF4A/B biosensor. This 
validation did not allow to reconfirm all the hits. It is probably due to the fact that fresh powders 
were used instead of stock solutions used in the screens. Indeed, unlike fresh powders which 
normally contain only pure product, solutions from the 96-well plates might contain secondary 
products resulting from molecule degradation since they were frozen and thawed several times. 
Thus, a response of the biosensor obtained from the screen could potentially be promoted by a 
secondary product instead of the compound itself. 
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In vitro characterization 
Since a close collaboration started with Frédéric Bihel, the post-screen characterization mainly 
focused on the two hits identified in the library from Strasbourg and on their mechanism of action at 
the CDK4/cyclin D interface. This work is in part summarized in a manuscript (see section “Articles in 
preparation”). 
Fluorescence titration assays were performed in order to verify whether these two hits might 
interact with a peptide derived from the PISTVRE helix of CDK4. The evidence that only one hit could 
bind this peptide led to the characterization of a family of compounds derived from LPI2251. 
Unfortunately, the first set of experiments performed to validate binding involved the use of a 
fluorescent probe TP2Rho, which yielded misinterpreting results. However, docking and mutagenesis 
experiments revealed that LPI2251 derivatives bound a new pocket below the PISTVRE helix of CDK4 
and not far from the T-loop (cf manuscript in section “Articles in preparation”). The position of this 
new pocket could explain why the two original hits were retained in the screen with both 
CDKCONF4A and CDKCONF4B. We have therefore identified allosteric small molecule inhibitors 
which can potentially target the CDK4/cyclin D interface, perturb the association between CDK4 and 
cyclin D and indirectly modulate the T-loop and prevent the binding of the substrate. We can also 
hypothesize that the binding site of LPIs is close enough to the T-loop to directly modulate this latter. 
In cellulo characterization 
LPI derivatives were found to inhibit melanoma cell proliferation (A375 cells) with an efficacy in the 
same range as PD-0332991. Moreover, RF1210 promoted efficient inhibition of different melanoma 
cell lines harbouring different combinations of wild-type or loss-of function p16INK4A (the endogenous 
inhibitor of CDK4), wild-type or mutated CDK4 (R24C mutation which prevents the binding of 
p16INK4A), BRaf and NRas, with IG50 values from 10 µM to 13.6 µM. 
RF1210 and LPI2252 further cooperated with CDK4 inhibitors and also with traditional anticancer 
inhibitors at sub-IC50 concentrations, suggesting that it could provide real benefit for the treatment 
of melanoma. Moreover, this finding suggests that dual targeting of CDK4 kinase with an ATP-
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competitive and a non-ATP-competitive inhibitor may provide a more effective means of targeting its 
function in melanoma, thereby offering new therapeutic perspectives to target the 
p16INK4A/CDK4/cyclin D/Rb pathway in this deadly disease.  
2.4. Future developments 
Some LPI derivatives, such as RF1210 and LPI2252, constitute promising small molecules to target 
CDK4/cyclin D and inhibit its activity. Additional in vitro experiments have to be performed to fully 
understand their mechanism of action at the CDK4/cyclin D interface.  
The CNE hit compounds remain to be characterized with respect to their inhibitory potential and 
mechanism of action towards CDK4. Some of them, such as LPS401 and ICMR-04-E10, displayed 
promising preliminary results in binding assays with CDKCONF4A. It would also be interesting to test 
other cell lines to characterize the inhibitory potential of the hits in different cancer cells such as Non 
Small Cell Lung Cancer (NSCLC) cells in which the CDK4 pathway is also deregulated. 
The CDKCONF technology, which was previously successfully implemented to identify allosteric 
inhibitors of CDK2, was demonstrated to be a powerful tool to identify non-ATP competitive 
inhibitors of CDK4. This strategy could therefore be applied to other CDK kinases and also be 
extended to other kinases. Rauh and co-workers have previously developed biosensors based on FLiK 
(fluorescent labels in kinases) to identify non-ATP inhibitors of Akt (Fang et al., 2015). All these 
examples illustrate the potency of FLiK (fluorescent labels in kinases)-based approaches for drug 
discovery programmes. 
B. Development of peptide inhibitors that target the CDK4/cyclin D interface 
2.5. Assessment 
To target the CDK4/cyclin D interface, we have developed an approach based on rational design of 
peptides. Following analysis of the interaction between the PISTVRE helix of CDK4 and the α5 helix of 
cyclin D, we designed two peptides, PISTVRE and D1. We found that they efficiently inhibit melanoma 
cell growth when administrated with the cell-penetrating peptide CADY2. Moreover, fluorescent 
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binding assays of the PISTVRE variants with the D1 peptide suggested that the shorter PISTVRE 
variant, PISTVRE-A, bound with the greatest affinity. 
2.6. Future developments 
The mechanism of action of the PISTVRE variants, with an emphasis on PISTVRE-A, remains to be 
determined in vitro in competition and dissociation assays, using recombinant CDK4 and cyclin D1, 
and their inhibitory potential towards CDK4 kinase activity will be characterized in activity and 
proliferation assays. The most potent derivatives could further be optimized in terms of stability and 
cellular uptake with the aim of undertaking in vivo experiments. 
2.7. Comparison of the two strategies 
During my thesis, I have developed two different strategies to inhibit CDK4/cyclin D activity. The 
screening approach is in a much more advanced stage than the rational approach. Nevertheless, 
some features can already be compared. In terms of time and costs, the rational strategy is much less 
time consuming and expensive. Indeed, miniaturization and optimization of a HTS assay take time 
and require small molecule libraries which can be expensive. However, the screening strategy allows 
the identification of several hits, with different chemical structures, and offers the possibility to 
optimize the hits by synthesizing derivatives. Moreover, no facilitated delivery is required to 
internalize small molecules. However, peptides can also be optimized in size and the generation of 
mutants allows identification of essential amino acids. They can also be improved in terms of cellular 
uptake. Compared to peptides, small hydrophobic molecules can be difficult to characterize in vitro, 
in binding assays, as they easily stick to fluorescent probes.  
Finally, our screening approach, coupled with docking experiments, led to an unexpected discovery, 
the identification of a novel allosteric pocket, which is not to be expected with a rational approach.  
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Materials and methods 
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1. Design of protein biosensors 
1.1. CDKACTRb biosensor  
CDKACTRb is a derivative of CDKACT, a biosensor previously developed by the team for probing 
CDK/cyclin activity in vitro and in living cells (Van et al., 2014). 
CDKACTRb was engineered by replacing the substrate sequence of CDKACT derived from histone H1 
by a substrate sequence derived from the retinoblastoma protein (Rb), which is specifically 
phosphorylated by CDK4/cyclin D (S795 residue) (Grafstrom et al., 1999). The proline at position -2 
relative to the SP phosphorylation site was replaced by a cysteine group (YKFCSSPLRIPG).  
CDKACTRb contains the same PAABD as CDKACT which derived from the Polo Box Domain of Plk1 
(García-Alvarez et al., 2007), from residue 367 to 603 (237 amino acids) in which all cysteine residues 
were mutated to serines (GEVVDSHLSDMLQQLHSVNASKPSERGLVRQEEAEDPASIPIFWVSKWVDYSDK 
YGLGYQLSDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITP
REGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILSPLMAAVTYIDEKRDFRTYRLSLLEEYGSSKELASRL
RYARTMVDKLLSSRSASNRLKAS). 
It also contains a short glycine-rich linker to ensure flexibility between the two domains 
(EFPGAGGTGGLPGG). 
The complete sequence of CDKACTRb is as follows:  
GEVVDSHLSDMLQQLHSVNASKPSERGLVRQEEAEDPASIPIFWVSKWVDYSDKYGLGYQLSDNSVGVLFNDSTRL
ILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAII
LHLSNGSVQINFFQDHTKLILSPLMAAVTYIDEKRDFRTYRLSLLEEYGSSKELASRLRYARTMVDKLLSSRSASNRLKA
S EFPGAGGTGGLPGG YKFCSSPLRIPG 
1.2. CDKCONF4A biosensor  
The cDNA sequence of mouse CDK4 was cloned into the pGex6P1 vector (GE Healthcare) 5’BamHI 3’ 
EcoRI. Cysteine residues 202 and 215 were mutagenized to serine, so as to yield a mutant bearing 
only two cysteine residues, 78 and 135, spanning the PISTVRE helix of CDK4 (annex C).  
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1.3. CDKCONF4B biosensor  
The cDNA sequence of mouse CDK4 was cloned into the pGex6P1 vector (GE Healthcare) 5’BamHI 3’ 
EcoRI. Cysteine residues 78, 135 and 215 were mutagenized to serine and serine residue 189 was 
mutagenized to cysteine so as to yield a mutant bearing only two cysteine residues, 189 and 202, 
spanning the T-loop of CDK4 (annex C). 
2. Design and synthesis of peptides 
2.1. Peptide biosensors for probing CDK4/cyclin D activity 
Peptides were synthesized by GLS Biochem and purified to 95%. 
The long WW peptide, WWRb, was derived from the native WW domain of Pin1 previously described 
by Anai et al. to generate a phosphopeptide hybrid biosensor (residues 6-39) (Anai et al., 2007). The 
shorter version, WWshortRb, was derived from the residues that line the interface with the 
phosphopeptide in the crystal structure of WW Pin1 complexed to a phosphopeptide substrate (PDB 
1F8A). The residues that are critical for the interaction with the phosphosubstrate are Arg14, Arg17, 
Tyr23 and Phe25, as well as Trp34 (GWEKRMSRSSGRVYYFNHITNASQWERPSG). WWshortRb therefore 
comprised these key residues in the linear order of appearance that mimicks the interface (Phe25, 
Arg14, Tyr23, Arg17) interspaced by small uncharged amino acids, and which ends with Trp34 
followed by the same five amino acids as in the native WW domain of Pin1  
(GFARVYMSRSSGWERPSG). 
The Rb substrate peptide was derived from the retinoblastoma protein (Rb) sequence, which is 
specifically phosphorylated by CDK4/cyclin D (S795 residue) (Grafstrom et al., 1999). A unique 
cysteine was introduced at position -2 relative to the phosphoserine for labelling with a synthetic 
environmentally-sensitive fluorescent probe. A phosphorylated form of this peptide was also 
synthesized. 
MP26 peptide is a non-binder of CDK/cyclins and was used as an irrelevant peptide (Kurzawa et al., 
2011). 
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Peptide name Sequence 
Number of 
Amino 
Acids 
Molecular 
weight 
(g/mol) 
WW long GWEKRMSRSSGRVYYFNHITNASQWERPSG 30 3587.9 
WW short GFARVYMSRSSGWERPSGG 19 2087.3 
Rb substrate GGYKFCSSPLRIPG 14 1481.7 
PhosphoRb 
substrate YKFCSpSPLRIPG 
12 1446.6 
WWRb GWEKRMSRSSGRVYYFNHITNASQWERPSGGGYKFCSSPLRIPG 44 5051.6 
WWshortRb GFARVYMSRSSGWERPSGGYKFCSSPLRIPG 31 3436.9 
MP26 VESSDTIDNVKSKIQDKEGC 20 2195.3 
Table 13: Sequence, number of amino acids and molecular weight of the peptides that have been 
used in activity assays 
2.2. Peptides that target the interface between CDK4 and cyclin D 
The PISTVRE peptide was derived from the PISTVRE helix domain of CDK4 whilst the D1 peptide was 
derived from the α5 helix domain of cyclin D1. They were synthesized by GLS Biochem and purified to 
95%. A peptide derived from the T-loop of CDK4 and used as negative control for CDKCONF4A was 
also synthesized by GLS Biochem and purified to 95%. PISTVRE variants were synthesized at the 
IBMM facility. Solid-phase peptide synthesis (SPPS) on a Rink amide resin using Fmoc- protected 
amino acid was performed for synthesizing them (purity > 98%).  
Peptide name Sequence 
Number of Amino 
Acids 
Molecular 
weight (g/mol) 
PISTVRE H-GGGCPISTVREVALLRRL  18 1897.2 
D1 SIRPEELLQMELLLVNKLKWNLC 23 2783.3 
irrelevant peptide derived 
from the T-loop of CDK4 
SYQMALEPGC 10 1098.2 
Ac-PISTVRE Ac-GGGCPISTVREVALLRRL  18 1939.2 
PISTVRE-A H-CPISTVREVALLRRL  15 1726.1 
Ac-PISTVRE-A Ac-CPISTVREVALLRRL  15 1768.1 
PISTVRE-B H-CPISTVREVALLRRLEAFE  19 2202.6 
Ac-PISTVRE-B Ac-CPISTVREVALLRRLEAFE  19 2244.6 
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PISTVRE-C H-GGGCPISTVREVALLRRLEAFE  22 2373.7 
Ac-PISTVRE-C Ac-GGGCPISTVREVALLRRLEAFE  22 2415.7 
Table 14: Sequence, number of amino acids and molecular weight of the peptides developed to 
target CDK4/cyclin D interface. 
3. Molecular biology : site-directed mutagenesis 
3.1. PCR 
Site-directed mutagenesis was performed according to the QuickChangeTM protocol (Stratagene). 
Primers were designed so as to introduce the desired mutation sites in the middle of the primer of 
about 45 bp.  
50 μL PCR reaction was prepared as follows: 36 μL distilled H2O; 5 μL Buffer PFU 10X; 2 μL forward 
primer (100 ng/μL); 2 μL reverse primer (100 ng/μL); 2 μL dNTP (5 mM); 2 μL DNA template (5 ng/μL); 
1 μL Pfu DNA Polymerase (3 units/μL; Promega). 
PCR reactions were performed on a thermocycler (T-personal CombiTM; Biometra) starting with 
denaturation of DNA template at 95°C for 3 min followed by 15 cycles: 95°C for 30s (Denaturation); 
55°C for 1 min (Annealing); 72°C for 2 min/kb (Extension/Elongation). Reactions were terminated by 
the addition of an extension step at 72°C for 10 min. PCR products were then stored at 4°C. 
Dpn I restriction enzyme (20 units/μL; BioLabs) was added at 37°C for 1h to digest the parental DNA 
template. 
3.2. DNA plasmid transformation 
Library competent E.coli DH5α were purchased from Invitrogen for transformation of mutagenesis 
products. Competent cells were removed from -80°C and thawed on ice. 2 µL of plasmid containing 
at least 100ng DNA was mixed with 50 µL competent bacteria. The mixture was incubated on ice for 
20min before heat shock at 42°C for 45s. 300 µL LB Broth was then added and the culture was 
incubated at 37°C for 1h before spreading onto LB plates (50 µg/mL ampicilline) (annex F). The plates 
were incubated at 37°C overnight for colony growth. 
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Single colonies picked, grown in 3 mL LB + Ampicilline (50 µg/mL), then DNA was extracted by 
miniprep (QIAGEN kits) and sequenced by Eurofins MWG. 
3.3. Preparation of competent E.coli BL21 for protein induction 
E.coli BL21 pLysS codon + cells were grown in 100ml LB broth (annex F) until 0D600 reached 0,6. Cells 
were harvested by centrifugation at 4500 rpm, at 4°C for 15min. The cell pellet was re-suspended in 
5ml ice cold TSS buffer (10 mL LB; 10% PEG 3000-8000; 50 mM MgCl2; 5% DMSO; filter through 0.2 
µm), aliquoted into 200 µL aliquots, and flash frozen in liquid nitrogen. Competent cells were then 
stored at –80°C until needed. 
4. Protein Engineering 
4.1. Induction of CDKACTRb 
A single colony of E. coli BL21 transformed with pGex6P1-CDKACTRb was picked and grown into 50 
mL LB + Amp (50 µg/mL) at 37oC, under agitation, overnight. The overnight culture was diluted into 1 
L LB/Amp broth and incubated in the same conditions until OD(600) reached 0.6 (for 2-3h), at which 
point 0.5 mM IPTG was added. The temperature was then reduced to 20oC and the culture was 
incubated overnight for expression of soluble recombinant GST-CDKACTRb. Cells were then 
harvested by centrifugation at 4000 rpm for 20 min (TX-1000 rotor, Thermo Scientific). The cell pellet 
was resuspended in 30 mL TBS lysis buffer (annex F) and stored at -80oC until the next manipulation. 
CDKACTRb expression was verified by comparing a fraction of non-induced and induced cultures by 
SDS-PAGE prior to purification. 
4.2. Purification of CDKACTRb 
Bacterial lysate 
Bacterial cell pellets were thawed and lysed by sonication. Supernatant was recovered by 
centrifugation at 13000 rpm for 30min (F15-8x50cy rotor, Thermo Scientific) and then filtered 
through 0,45 µm and 0,2 µm membranes (Millipore) prior to chromatography purification. 
Glutathione sepharose resin equilibration 
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1 mL glutathione sepharose HP (High Performance) was prepared for each 30 mL bacterial lysate as 
follows: the slurry was washed in 30 mL H2O; centrifuged 3000 rpm for 5 min (F15-8x50cy rotor, 
Thermo Scientific); and resin was washed and equilibrated 15 min in 30 mL TBS buffer (twice) then 
centrifuged 3000 rpm for 5min. 
GST Batch purification 
The supernatant containing GST-CDKACTRb was incubated with 1 mL equilibrated resin at 4°C for 3h, 
then centrifuged at 3000 rpm for 5min and washed with 30mL cold TBS buffer followed by 
centrifugation at 3000 rpm for 5min (F15-8x50cy rotor, Thermo Scientific) (twice). The supernatant 
was then removed and GST-CDKACTRb was eluted on Econocolumns using 3-4 mL freshly prepared 
50 mM glutathione in TBS buffer. 1 mL fractions were recovered in eppendorf tubes. Eluted 
fragments were checked on SDS-PAGE to select those containing GST-CDKACTRb. 
FPLC purification 
Selected samples were centrifuged for 5 min at 13000 rpm in microcentrifuge to remove any 
precipitate. Remaining supernatant was injected onto a Gel Filtration column Superdex 75 (GE 
Healthcare) connected to an FPLC system (FPLC ÄKTA, GE Healthcare). Peak fractions were eluted in 
TBS buffer (flow rate 1 mL/min) and verified on SDS-PAGE to identify those containing GST-
CDKACTRb. 
4.3. Induction of CDK4, CDKCONF4A and B, cyclin D1 and CIV 
Recombinant GST-CDK4, GST-CDKCONF4A/B, GST-cyclin D1 and GST-CIV, the CDK-activating kinase of 
Saccharomyces cerevisiae, were expressed in E. coli by IPTG induction as described above except for 
the buffer (PBS) (annex F).  
4.4. Purification of CDK4, CDKCONF4A and B, cyclin D and CIV 
Bacterial lysate 
Bacterial cell pellets were retrieved from -80oC, thawed and lysed by sonication. Supernatant was 
recovered by centrifugation at 13000 rpm for 30 min and then filtered through 0,45 µm and 0,2 µm 
membranes (Millipore). 
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FPLC purification 
The supernatant was purified on High Performance Glutathione Sepharose (GE Healthcare) in PBS 
buffer and eluted with 50 mM glutathione in the same buffer, followed by gel filtration 
chromatography on Superdex75 (FPLC ÄKTA, GE Healthcare). 
GST-CDK4 / GST-cyclin D1 complex was formed following individual purification of each subunit and 
incubation of stoichiometric concentrations, then further incubated with CIV to ensure its activation. 
5. Biochemistry 
5.1. SDS-PAGE (SDS-polyacrylamide Gel Electrophoresis) 
Sample preparation  
To verify the induction of GST-CDK4, GST-cyclin D1, GST-CIV and GST-CDKACTRb, 1 mL of bacterial 
culture were taken before and after IPTG induction.  After centrifugation for 5 min at 10000 rpm in 
microcentrifuge, the bacterial pellet was resuspended in 50 µL H2O + 50 µL Laemmli buffer (annex F) 
and then sonicated for 20 s. Samples were then heated at 95oC for 5 min and loaded on SDS-PAGE. 
SDS-PAGE 
4% acryl/bisacryl stacking gels and 15% acryl/bisacryl running gels were prepared (annex F) and run 
using Biorad equipments (Mini-PROTEAN Tetra Cell). Denatured protein samples and Protein Marker 
(Low Molecular Weight Calibration Kit, Amersham) were loaded onto gel and run at 250V for 1 h. 
Gels were stained with Coomassie Brilliant Blue (annex F) for 2 min and then destained in water 
before observing the protein bands. 
5.2. Western-Blotting 
Sample preparation  
See paragraph 9.2 for cell extract preparation. Protein concentration was determined by measure of 
OD(280) using a spectrophometer NanodropTM (Thermo Scientific) with BSA standard curve. 
Normalization to obtain 25 µg proteins was made by dilution in PBS lysis. After addition of Laemmli 
buffer, samples were heated at 95oC for 5 min and loaded on SDS-PAGE. 
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SDS-PAGE 
4% acryl/bisacryl stacking gels and 15% acryl/bisacryl running gels running gels and were prepared 
(annex F) and run using Biorad equipments (Mini-PROTEAN Tetra Cell). Denatured protein samples 
and pre-stained protein marker (PageRulerTM Plus Prestained Protein Ladder; Life Technologies) were 
loaded onto gel and run at 90 V for 15 min and 140 V for 1h15. 
Protein transfer 
Proteins were then transferred to a PVDF membrane (Membrane Immobilon-P, PVDF; Merck 
Millipore) for 2h at 100 V using a cold transfer buffer (annex F) and a liquid blotting system (Biorad). 
Blocking step 
 5% skimmed milk (Régilait) was prepared in PBS with 0,1% Tween and membranes were blocked by 
incubation for 1h.  
Incubation with the primary antibody 
 Antibodies against CDK4 (C22, sc-260; Santa Cruz), cyclin D1 (C20, sc-717; Santa Cruz) and anti-
tubulin (Amersham, N356) were diluted 1/500 in PBS tween. The membrane was incubated with the 
corresponding primary antibody overnight followed by 3 washes for 10 min in PBS tween. 
Incubation with the secondary antibody 
Horseradish peroxidase (HRP)-conjugated anti-mouse (Amersham, NXA931) or anti-rabbit 
(Amersham, NA934) antibodies were diluted 1/10000 in blocking solution. The membrane was 
incubated for 60 min followed by 3 washes for 5 min in PBS tween. 
Detection 
 ECL (Amersham; GE Healthcare) was added onto the membrane and incubated for 2 min. 
Chemiluminescence was detected using a chemiluminescence imaging camera (Chemi-Smart 5000; 
Vilber Lourmat). 
6. Thiol labeling of peptide/protein with fluorescent probe 
Proteins and peptides were fluorescently labelled using maleimide or isothyocyanate probes on the 
thiol group of cysteine residues at pH 7,0 as described by Molecular ProbesTM. 
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Fluorophores stocks were prepared at a concentration of 2*10-3 M in DMSO and stored at -20°C. 
Peptides were prepared at a concentration of 10-3M (in H2O, 1% DMSO) and then diluted at 10
-4M in 
PBS before labeling. 
Fluorophores were added at 2-10 fold greater excess concentration and labelling was performed 
overnight at 4°C or by microwave radiation for 10-20 s. Peptides and proteins were further purified 
on NAP5 columns (GE Healthcare) in PBS to remove excess label. Absorbance of labelled 
protein/peptide were measured on NanodropTM (Thermo Scientific) at appropriate wavelengths (see 
table) followed by calculation of the molar concentration using the Beer-Lambert law defined as A= 
ε*l*C where A corresponds to the Absorbance, ε is the molar extinction coefficient, l corresponds to 
the path length of the beam of light through the material sample, whilst C is the concentration. 
 
Molar extinction 
coefficient Ɛ  
(M-1.cm-1) 
λabs (nm) λem (nm) supplier 
TAMRA 61000 540 565 FluoProbes 
Cy3 150000 544 570 GE Healthcare 
Cy5 250000 649 670 GE Healthcare 
FITC 70000 495 520 FluoProbes 
Texas Red 85000 592 614 Life technologies 
DyLight650 250000 652 672 Life technologies 
TP2Rho 58900 510 614 
Florence 
Mahuteau, Curie 
Institute, Paris 
Table 15: Spectral properties of the fluorescent probes that were used  
7. Real-time fluorescence kinase assays 
Fluorescence kinase assays were performed in 96-well plates in a thermostated chamber (PolarstarTM 
or ClariostarTM, BMG) at 30°C in 200mL PBS buffer supplemented with 5 mM MgCl2, 0.5 mM ATP, 
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except when stated otherwise. In all experiments, relative fluorescence was calculated following 
subtraction of fluorescently-labelled CDKACTRb, WWRb or WWshortRb fluorescence from 
fluorescence values obtained in the presence of protein kinases, inhibitors or cell extracts. 
Inhibition assays were performed in the same conditions as above except the addition of 0 - 20 µM 
CDK inhibitor: PD-0332991 (Palbociclib; SelleckChem), LY2835219 (Abemaciclib; Euromedex), LEE011 
(Ribociclib; Euromedex), Roscovitine (SelleckChem), RO3306 (Calbiochem) and AT7519 (Euromedex); 
or inhibitors of kinases not related to CDK/cyclins: PP2 (Sigma), H89 (Euromedex) and U0126 
(Euromedex).  
All stock inhibitor solutions were made in DMSO and diluted in PBS to the desired concentration 
freshly prior to use. 
8. Fluorescence titration experiments 
Fluorescence titration assays were performed in 96-well plates using a ClariostarTM 
spectrofluorimeter (BMG) at room temperature for 40 min in 200 µL PBS (Sigma). The fluorescence 
of 200 nM FITC-labelled Rb substrate peptide with WWlong and WWshort was acquired at 495 nm 
following excitation at 520 nm. The fluorescence of 200 nM Cy3-labelled CDKCONF4A/B biosensor 
with positive and negative controls, PD-0332991 or small molecules was acquired at 570 nm 
following excitation at 544 nm. The fluorescence of 200 nM TP2-Rho-labelled PISTVRE peptide with 
D1 peptide, PD-0332991 or small molecules was acquired at 614 nm following excitation at 510 nm. 
The fluorescence of 200 nM TP2-Rho-labelled D1 peptide with PISTVRE peptide, PD-0332991 or small 
molecules was acquired at 614 nm following excitation at 510 nm. The fluorescence of 500 nM 
TAMRA-labelled D1 peptide with PISTVRE variants was acquired at 570 nm following excitation at 
544 nm. Data analysis was performed using the GraFit Software (Erathicus Ltd) and curve fitting was 
performed using a quadratic equation, as described in (Gondeau et al., 2005). The quadratic equation 
is defined as ܨ ൌ ܨ݉ܽݔ െ ሺܨ݉ܽݔ െ ܨ݉݅݊ሻ כ ሺሺሺܭ݀ ൅ ݈ ൅ ݌ሻ െ ටሺඥ௄ௗା௟ା௣ሻ;ିସכ௟כ௣ሻሻଶכ௣ ሻ where F 
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corresponds to the fluorescence, whilst Kd is the dissociation constant, p is the fluorescent peptide 
concentration and l is the ligand/substrate or partner. 
9. Cell biology 
9.1. Cell lines and cell culture 
Cell culture media, serum and antibiotics were purchased from Invitrogen. A375, HeLa, A549 and 
Jurkat cell lines were purchased from ATCC. Human fibroblast, SK-MEL2, MV3 and Mewo cell lines 
were kindly provided by Dr. Pauline Henri (IBMM, Montpellier). SK-MEL28 cell line was kindly 
provided by Dr. Céline Gongora (IRCM, Montpellier). All cell lines were cultured in DMEM/RPMI + 
Glutamax supplemented with 10% FCS, 100 units/mL penicillin (G sodium salt) and 100 µg/mL 
streptomycin at 37°C in an atmosphere containing 5% CO2. For microscopy experiments, DMEM 
without phenol red was used. 
Melanoma cell lines used: 
 
CDKN2A CDK4 Rb BRAF NRAS 
A375 mutated (E61Stop, Loss of function) WT WT V600E WT 
Mewo mutated (R80Stop, Loss of function) WT WT WT WT 
MV3 ND ND ND WT WT 
SK-MEL2 WT WT WT WT mutated (Q61R) 
SK-MEL28 WT R24C WT V600E WT 
Table 16: Genetic alterations identified for the different components of the p16
INK4a 
/ CDK4/6-cyclin 
D / pRb pathway and for BRAF and NRAS in A375, Mewo, MV3, SK-MEL2 and SK-MEL28 cell lines 
(ND: data not found). 
9.2. Cell extract preparation 
Cells were grown to 90% confluence, washed with PBS then harvested by scraping in PBS followed by 
centrifugation for 10 min at 10000 rpm in microcentrifuge at 4°C. Cell pellets were then lysed in PBS 
lysis buffer (annex F) through 21G and 26G gauge needle (Terumo) syringing, respectively. 
Supernatant was collected following centrifugation of cell extracts for 10 min at 13000 rpm at 4°C. 
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Protein concentration was determined by measuring OD(280) using a spectrophotometer 
NanodropTM (Thermo Scientific) with BSA standard curve, followed by normalization through dilution 
on PBS lysis buffer to the same concentration before further use. 
9.3. Fractionation of A375 cell extracts 
Fractionation of A375 cell extracts prepared from 5 million cells in 500µL PBS lysis buffer was 
performed by gel filtration chromatography on a Superose 6 10/300 GL column (GE Healthcare). 500 
µL fractions were eluted in PBS buffer (50 mM KH2PO4/K2HPO4, pH 7.4, 150 mM NaCl) (flow rate 0.3 
mL/min) and 50 µL were used for kinase activity assays. 
9.4. Drug treatment for activity assays 
Unsynchronized cells were cultured to subconfluency (60-70%). 0-20 μM inhibitor (PD-0332991, 
LY2835219, Roscovitine, RO3306, AT7519, H89, U0126 and PP2) were added and the cells were 
further incubated for 24 hours followed by washing with PBS. Cell extracts were then prepared as 
described in paragraph 9.2. 
9.5. Cell synchronization experiments 
Unsynchronized cells were cultured to subconfluency (60-70%). For S phase synchrony, cell medium 
was replaced by medium containing 2 mM hydroxyurea (Sigma) for 24h. Cells were then washed 
twice with fresh medium and either directly harvested or incubated with fresh medium for 10h.  
9.6. CDK4 knock-down by addition of siRNA 
Internalization of siRNA in cells was performed using CADY peptide (amino acid sequence: Ac-
GLWRALWRLLRSLWRLLWRA-Cy) (Crombez et al., 2009). CADY is an amphipathic cell penetrating 
peptide which forms non covalent complexes with siRNAs. Ratios used of CADY/siRNA were 20/1 and 
40/1. The siRNA targeting CDK4 is a pool of 4 siRNA and was purchased from Santa Cruz (sc-29261). 
Unsynchronized cells were cultured until 60% of confluence. Stock solutions of CADY (1 mM) were 
prepared in H2O and homogeneised by vortexing and then sonicated in a small bath sonicator for 10 
min. CADY solution was then diluted in Volvic water to obtain a concentration of 2 µM (for 20/1 
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ratio) and 4 µM (for 40/1 ratio). The CDK4 siRNA was diluted in PBS (Sigma) to obtain a concentration 
of 100 nM. The solution of CADY was gently added to an equivalent volume of siRNA and mixed by 
gently tapping the tube. The mixture was incubated at 37°C for 30 min. Cells were then washed with 
PBS (Sigma) twice before addition of the CADY/siRNA solution. After incubation of 5 min, DMEM 
without serum was added for 2h followed by addition of DMEM and serum to obtain a medium 
containing 10% FBS. Cells were then incubated 24 and 48h. 
9.7. Proliferation assays 
Proliferation assays were performed in 96-well plates. The day before addition of inhibitors, cells 
were seeded at a density of 10000-15000 cells/well.  
Then, either 0 - 75 µM small molecules in DMEM or peptides (targeting the CDK4/cyclin D interface) 
complexed to CADY2 peptide (amino acid sequence: Ac-GLWWRLWWRLRSWFRLWFRA-Cy) (Kurzawa 
et al., 2010) were added onto cells. CADY2 is an amphipathic cell penetrating peptide which forms 
non covalent complexes with proteins and peptides. CADY2 solutions were prepared as described for 
CADY. Peptides were added at 1 µM and CADY2/peptide ratio used was 20/1.  
Cells were further incubated for 6-48 hours and then washed twice with PBS. Fixation was performed 
by incubation in 4% PFA (diluted in PBS) for 10 min at room temperature followed by addition of 
crystal violet (Sigma) for 30 min (Gillies et al., 1986). Cells were then washed three times with H2O 
before addition of 10% acetic acid. Relative cell growth is obtained for each well by measurement of 
OD(595) using a ClariostarTM spectrofluorimeter (BMG). 
Data analysis was performed using the GraFit Software (Erathicus Ltd) and IG50 values were 
determined using the equation ݕ ൌ ோ௔௡௚௘ଵାቀ ೣ಺಴ఱబቁೞ ൅ ܤܽܿ݇݃ݎ݋ݑ݊݀ where Range is the fitted uninhibited 
value minus the background, and s is a slope factor (annex E). This equation assumes that y falls with 
increasing x. 
9.8. Peptide internalization 
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Labeled WWshortRb peptide was prepared in PBS at a concentration of 2 μM. A375 cells were grown 
on coverslips or 6 well plates to 80% confluence. Cells were then washed twice with PBS. 200 μL of 
peptides were gently overlaid onto cells and incubated for 30 min at 37°C in an atmosphere 
containing 5% CO2. DMEM was then added followed by an additional incubation in the same 
conditions for 1h. Cells were washed extensively before fixing (coverslips) or performing time lapse 
acquisition (6 well plates). 
Co-internalization of WWshortRb-TAMRA and WWshortRb-DyLight650 into A375 cells were 
performed as follows: WWshortRb-DyLight650 was first internalized into A375 cells by overlaying the 
biosensor onto cells followed by 30 min of incubation at 37°C in an atmosphere containing 5% CO2. 
DMEM was then added followed by an additional incubation in the same conditions for 30 min. Cells 
were washed extensively 3 times with PBS followed by application of WWshortRb-TAMRA and 
additional incubation of 30 min in the same conditions. DMEM was then added followed by 
additional incubation in the same conditions for 30 min. Cells were again washed extensively 3 times 
with PBS, then replaced in DMEM for 1h at the same conditions before performing time lapse 
acquisition.  
9.9. Cell fixation and Hoechst staining 
Fixation was performed by incubation in 4% PFA (diluted in PBS) for 5 min at room temperature 
followed by 3 washes in PBS. Hoechst 33342 (Sigma) diluted in H2O (1 μg/mL) was added to stain 
nuclei at room temperature for 5 min and then washed twice in PBS. Coverslips were then fixed on 
microscope slides (Superfrost™; Thermo Scientific) with Mowiol for fluorescent microscopy 
acquisitions. 
9.10. Indirect immunofluorescence 
Fixation was performed by incubation in 4% PFA (diluted in PBS) for 5 min at room temperature 
followed by 3 washes in PBS. Blocking buffer was added at room temperature for 1 h and then cells 
were incubated overnight at 4°C with anti-CDK4 (C22, sc-260; Santa Cruz) diluted 1/500 in blocking 
solution. Cells were washed three times with PBS for 15 min and then incubated for 1h at room 
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temperature with Alexa488-conjugated anti-rabbit antibody followed by 3 washes in PBS for 15 min. 
Hoechst 33342 (Sigma) diluted in H2O (1 μg/mL) was added to stain nuclei at room temperature for 5 
min and then washed twice in PBS. Coverslips were then fixed on microscope slides (Superfrost™; 
Thermo Scientific) with Mowiol for fluorescent microscopy acquisitions. 
10. Preparation of cell extracts from skin biopsies 
Skin biopsies were kindly provided by Dr. Laurent Meunier (CHU, Nîmes). 
Epidermis and dermis were separated by addition of thermolysine (0.5 mg/mL diluted in PBS (Sigma)) 
for 3h at 37°C. Total proteins were extracted from frozen skin biopsies by addition of a total 
extraction buffer (annex F) through Ultra TurraxTM grinding and normalized following 
spectrophotometric dosage at 280 nm. 
11. A375 xenografts in mice 
In vivo experiments were performed by Véronique Josserand and Julien Vollaire at the Albert Bonniot 
institute in Grenoble. All animal experiments were conducted in agreement with the Principles of 
Laboratory Animal Care (National Institutes of Health publication no. 86-23, revised 1985) and 
approved by the regional ethics committee. Female 6 weeks old NMRI nude mice (Janvier, Le Genest- 
Isle, France) were anesthetized (isoflurane/oxygen 3.5 % for induction and 1.5 % thereafter) and 
3.106 A375 cells in 200 µL phosphate-buffered saline were implanted subcutaneously into the flank. 
After 24 days, tumors had reached 257 ± 64 mm3, mice were then treated daily orally with 150 mg/kg 
or 75 mg/kg PD-0332991 (diluted in sodium lactate buffer 50 mM) for 7 days, or 150 mg/kg for 3 
days, or through intraperitoneal injection with Roscovitine (also diluted in sodium lactate buffer 50 
mM) at 50 mg/kg for 5 or 11 days. Mice were then sacrificed and tumors were collected and frozen.  
In the first set of experiments, tumors samples were lysed and total proteins were extracted by 
addition of a total extraction buffer (annex F) and grinding with an Ultra TurraxTM, then normalized 
following spectrophotometric dosage at 280 nm. In the second set of experiments, total proteins 
were extracted by addition of a luciferase cell culture lysis reagent (annex F) and normalized to the 
proportion of cancer cells (A375 luciferase) (Victor3 V luminescence microplate reader, Perkin Elmer). 
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12. Fluorescence Microscopy 
12.1. Upright acquisitions – fixed cell imaging 
Internalization experiments of WWshortRb were performed in fixed A375 cells. The images were 
acquired with a Leica DM6000 microscope equipped with a Coolsnap HQ2 camera and 63X objectives 
and piloted by Metamorph software. 
12.2. Time-lapse acquisition – live cell imaging 
A375 melanoma cells internalized with WWshortRb were subjected to time-lapse acquisition for live 
cell imaging. The plates of cells was placed in an incubation chamber containing 5% CO2 and 
thermostated at 37°C. Video microscopy acquisitions were set up automatically with an Olympus 
IX83 inverted microscope equipped with a sCMOS Andor Zyla 5.5 camera and 40X objectives for 5-
10h.  
The biosensor WWshortRb was labeled either with TAMRA or DyLight650 and the two solutions were 
co-internalized sequentially into A375 cells. WWShortRb-DyLight650 served as negative control since 
the probe was unresponsive in activity assays when coupled with the biosensor. Multiple positions 
and parameters, including phase for cell morphology and DyLight650 or TAMRA fluorescence, for 
either the responsive or unresponsive WWshortRb biosensor, were acquired every 20 min. 
Fluorescence intensity of both fluorophores was analyzed for ratiometric quantification of 
TAMRA/DyLight650 signals. 
12.3. Image analysis and ratiometric quantification 
Upright acquisitions – fixed cell imaging 
Images analysis was performed using the ImageJ software. The fluorescent signal of the TAMRA-
labelled biosensor was quantified and compared by determination of the ratio TAMRA-Hoechst. 
Region of interest (ROI) comprising three or four cells was created for each image (Hoechst and 
TAMRA) to determine the fluorescence intensity. Then, background fluorescence was subtracted in 
all images. The ratio “TAMRA” / “Hoechst” was then calculated. Final histograms that are presented 
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correspond to the average fluorescence ratio of the TAMRA-labelled biosensor over the Hoechst 
staining of nuclei in three different fields.  
Time-lapse acquisitions – live cell imaging 
Ratiometric fluorescence intensity quantification was performed for live cell imaging. Using 
MetaMorph software, stacks of images (Phase, DyLight650 and TAMRA) were built up to quantify 
fluorescent signals over time. Background signal of DyLight650 and TAMRA stacks was subtracted by 
elimination of the signal of a blank region that did not contain any cells. A region of interest (ROI) 
delimiting single cells on the phase stacks at each time point was transferred to DyLight650 and 
TAMRA stacks of the same time point (after background subtraction). Average fluorescence intensity 
was determined at each time point (annex B). The ratio of the fluorescent signal of TAMRA-
WWshortRb biosensor over that of the control DyLight650-WWshortRb was calculated representing 
relative responses of the biosensor to CDK4 activity in living cells over time. 
13. Automated High Throughput Screen conditions and hit validation 
CDKCONF4A and CDKCONF4B biosensors were applied to screen two libraries: the National Chemical 
Essential Library (480 compounds) and a library from Strasbourg (640 compounds, Dr. F. Bihel, Fac. 
Pharma, Strasbourg) in a high throughput format. Prior to HTS, stability assays and downscaling 
experiments were performed to establish the best conditions for a miniaturized assay in 96-well 
plates on PolarstarTM (BMG Labtech) and optimized so as to obtain a robust and reproducible signal. 
Performance criteria for reproducibility, sensitivity (in the presence of DMSO), tolerance, robustness 
and best response over time were established with: 
- 10 µM PD-0332991, the ATP-competitive inhibitor of CDK4  
- 2 µM cyclin D1 and 2 µM retinoblastoma protein, as positive control of CDKCONF4A and 
CDKCONF4B respectively, that promotes significant enhancement of Cy3-labelled biosensor 
fluorescence 
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Optimal screening conditions were established as follows: 25 nM freshly purified Cy3-labelled 
CDKCONF4A/B biosensor in 50 mM KH2PO4/K2HPO4, pH 6.4, 500 mM NaCl, 1% DMSO, for 5 hours at 
room temperature in the dark.  
For CDKCONF4A, these conditions led to a 1.3 fold fluorescence enhancement by positive control 
(cyclin D1) with a Z factor equal to 0.89. For CDKCONF4B, these conditions led to a 1.8 fold 
fluorescence enhancement by positive control (retinoblastoma protein) with a Z factor equal to 0.68. 
Z-factor is equal to ͳ െ ଷሺ஺శା஺షሻ஻శି஻ష , where A+ and A- correspond to the standard deviations of positive 
and negative controls, whilst B+ and B− are the average responses for positive and negative controls. 
The screen itself was performed in 96-well black Greiner Bio One plates. Compounds from the library 
were used at 10-5 M final concentration against 25 nM Cy3-labelled CDKCONF4A/B biosensor in 50 
mM KH2PO4/K2PO4, pH 6.4, 500 mM NaCl and fluorescence emission of Cy3 was measured at 570 
nm following excitation at 550 nm after 5 hours. The screen was performed on a TECAN Freedom 
EvoTM Robot. In parallel, the intrinsic fluorescence of the library compounds at 570 nm following 
excitation at 550 nm was determined, to eliminate autofluorescent compounds. The increase in 
fluorescence of each compound was determined relative to the basal fluorescence of Cy3-labelled 
CDKCONF4A/B biosensor alone. A molecule was considered a hit when it was not autofluorescent, 
yet induced amplification of Cy3-labelled CDKCONF4A/B biosensor fluorescence to a similar extent as 
positive control (annex D). Hits identified in the screen were retested manually from fresh powder 
stocks resuspended in DMSO in duplicate to confirm they were positive hits with a fresh batch of 
Cy3-labelled CDKCONF4A/B biosensor.  
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Growth curves of A375 xenografts treated with PD-0332991 or Roscovitine 
Growth curves of A375 xenografts implanted in mice and treated with PD-0332991 at 150 mg/kg for 
3 or 7 days, or with 75 mg/kg for 7 days, or Roscovitine at 50 mg/kg for 5 or 11 days. Control : mock 
treated mice. Arrows indicate time of treatment. 
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  dividing cell 
time (min) TAMRA DyLight650 
ratio 
TAMRA/Dylight650 
0 151.83 57.32 2.65 
20 153.30 49.09 3.12 
40 153.16 44.95 3.41 
60 147.04 42.53 3.46 
80 145.01 38.53 3.76 
100 153.61 40.27 3.81 
120 162.93 39.42 4.13 
140 172.91 40.31 4.29 
160 167.20 39.78 4.20 
180 180.19 40.05 4.50 
200 186.55 40.38 4.62 
220 196.70 40.69 4.83 
240 212.12 42.46 5.00 
260 228.77 44.20 5.18 
280 241.03 48.63 4.96 
300 264.63 63.69 4.16 
320 253.89 54.98 4.62 
340 271.49 63.22 4.29 
360 275.62 65.59 4.20 
380 273.33 61.37 4.45 
 
  cell after division 
time (min) TAMRA DyLight650 
Ratio 
 TAMRA/Dylight650 
0 158.68 66.15 2.40 
20 190.62 95.40 2.00 
40 162.25 71.71 2.26 
60 166.69 52.16 3.20 
80 165.32 44.33 3.73 
100 173.47 39.71 4.37 
120 189.73 42.46 4.47 
140 206.02 43.74 4.71 
160 207.49 42.00 4.94 
180 206.03 39.79 5.18 
200 211.71 39.18 5.40 
220 214.78 39.10 5.49 
240 215.42 38.56 5.59 
260 220.65 39.08 5.65 
280 226.70 39.36 5.76 
300 231.93 41.01 5.66 
320 229.83 38.59 5.96 
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340 238.53 40.88 5.84 
360 239.92 42.39 5.66 
380 246.57 40.25 6.13 
400 251.69 41.22 6.11 
420 249.72 40.99 6.09 
440 249.58 40.50 6.16 
460 253.79 41.66 6.09 
 
  cell after division 
time (min) TAMRA DyLight650 
ratio  
TAMRA/Dylight650 
0 74.24 44.36 1.67 
20 84.44 45.17 1.87 
40 88.61 47.36 1.87 
60 94.28 48.23 1.95 
80 102.56 47.30 2.17 
100 115.46 49.41 2.34 
120 122.69 49.37 2.49 
140 132.18 49.85 2.65 
160 131.32 49.17 2.67 
180 148.08 51.06 2.90 
200 153.86 49.98 3.08 
220 154.93 49.40 3.14 
240 167.28 48.03 3.48 
260 180.57 48.25 3.74 
280 190.18 48.37 3.93 
300 192.34 47.44 4.05 
320 201.27 48.39 4.16 
340 201.69 47.77 4.22 
360 204.61 48.62 4.21 
380 210.72 48.57 4.34 
400 214.27 48.63 4.41 
420 218.02 50.29 4.34 
440 219.13 48.34 4.53 
460 224.42 49.70 4.52 
480 230.26 51.04 4.51 
500 232.32 51.40 4.52 
520 233.54 51.15 4.57 
540 234.74 51.00 4.60 
560 237.73 51.69 4.60 
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Nucleotide sequence of mouse CDK4 (Source : UniProtKB - P30285) 
ATGGCTGCCACTCGATATGAACCCGTGGCTGAAATTGGTGTCGGTGCCTATGGGACGGTGTACAAAGCCCGAGAT
CCCCACAGTGGCCACTTTGTGGCCCTCAAGAGTGTGAGAGTTCCTAATGGAGGAGCAGCTGGAGGGGGCCTTCCC
GTCAGCACAGTTCGTGAGGTGGCCTTGTTAAGGAGGCTGGAGGCCTTTGAACATCCCAATGTTGTACGGCTGATG
GATGTCTGTGCTACTTCCCGAACTGATCGGGACATCAAGGTCACCCTAGTGTTTGAGCATATAGACCAGGACCTG
AGGACATACCTGGACAAAGCACCTCCACCGGGCCTGCCGGTTGAGACCATTAAGGATCTAATGCGTCAGTTTCTA
AGCGGCCTGGATTTTCTTCATGCAAACTGCATTGTTCACCGGGACCTGAAGCCAGAGAACATTCTAGTGACAAGT
AATGGGACCGTCAAGCTGGCTGACTTTGGCCTAGCTAGAATCTACAGCTACCAGATGGCCCTCACGCCTGTGGTG
GTTACGCTCTGGTACCGAGCTCCTGAAGTTCTTCTGCAGTCTACATACGCAACACCCGTGGACATGTGGAGCGTT
GGCTGTATCTTTGCAGAGATGTTCCGTCGGAAGCCTCTCTTCTGTGGAAACTCTGAAGCCGACCAGTTGGGGAAA
ATCTTTGATCTCATTGGATTGCCTCCAGAAGACGACTGGCCTCGAGAGGTATCTCTACCTCGAGGAGCCTTTGCC
CCCAGAGGGCCTCGGCCAGTGCAGTCAGTGGTGCCAGAGATGGAGGAGTCTGGAGCGCAGCTGCTACTGGAAATG
CTGACCTTTAACCCACATAAGCGAATCTCTGCCTTCCGAGCCCTGCAGCACTCCTACCTGCACAAGGAGGAAAGC
GACGCAGAGTGA 
 
Amino acid sequence of mouse CDK4 (Source : UniProtKB - P30285) 
MAATRYEPVAEIGVGAYGTVYKARDPHSGHFVALKSVRVPNGGAAGGGLPVSTVREVALLRRLEAFEHPNVVRLM
DVCATSRTDRDIKVTLVFEHIDQDLRTYLDKAPPPGLPVETIKDLMRQFLSGLDFLHANCIVHRDLKPENILVTS
NGTVKLADFGLARIYSYQMALTPVVVTLWYRAPEVLLQSTYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGK
IFDLIGLPPEDDWPREVSLPRGAFAPRGPRPVQSVVPEMEESGAQLLLEMLTFNPHKRISAFRALQHSYLHKEES
DAE 
 
Design of primers for CDKCONF4A and CDKCONF4B  
CDKCONF4A 
C202S forward GACATGTGGAGTGTTGGCTCTATCTTTGCAGAGATGTTTCGT 
 reverse ACGAAACATCTCTGCAAAGATAGAGCCAACACTCCACATGTC 
C215S forward CGTCGAAAGCCTCTCTTCTCTGGAAACTCTGAAGCCGAC 
 reverse GTCGGCTTCAGAGTTTCCAGAGAAGAGAGGCTTTCGACG 
 
CDKCONF4B 
C78S forward GTCCGGCTGATGGACGTCTCTGCCACATCCCGAACTGAC 
 reverse GTCAGTTCGGGATGTGGCAGAGACGTCCATCAGCCGGAC 
C135S forward GATTTCCTTCATGCCAATTCCATCGTTCACCGAGATCTG 
 reverse CAGATCTCGGTGAACGATGGAATTGGCATGAAGGAAATC 
S189C forward CCTGAAGTTCTTCTGCAGTGTACATACGCAACACCCGTG 
 reverse CACGGGTGTTGCGTATGTACACTGCAGAAGAACTTCAGG 
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Compounds identified in the screens: names, origin and response to CDKCONF4A and/or 
CDKCONF4B 
Compound Name 
Molecular 
weight  (g/mol) 
Lab Source Identified with 
ICMR-04-E10 516 ICMR-Reims 
 
CDKCONF4A 
ICMR-04-F03 300 ICMR-Reims CDKCONF4A and B 
        
U181-10-12-L-F07 476.44 
Université Claude 
Bernard -Lyon 
CDKCONF4A 
U181-03-13-L-H10 290.29 
Université Claude 
Bernard -Lyon 
CDKCONF4B 
U181-10-08-L-D11 252.27 
Université Claude 
Bernard -Lyon 
CDKCONF4B 
        
AB-00015228 427.56 ICSN CDKCONF4A and B 
AB-00016193 549.06 ICSN CDKCONF4A 
AB-00015203 412.54 ICSN CDKCONF4A and B 
        
LSP 03-M-002-E05 214.35 Paris, Saint-Pères 
 
CDKCONF4B 
LSP 04-L-001-D07 331.22 Paris, Saint-Pères CDKCONF4B 
        
AB-00008525 389.26 Lille CDKCONF4A 
        
JP00465 400.48 
Université Joseph 
Fourier, Grenoble 
CDKCONF4A 
        
CEsr-1409000 339.4 Université de Caen CDKCONF4A 
CEsr-1837000 258.3 Université de Caen CDKCONF4A 
CEmr-1278100 362.3 Université de Caen CDKCONF4A 
        
AB-00025980 294.27 Institut Curie CDKCONF4A 
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AB-00031272 235.24 Institut Curie CDKCONF4A 
        
LPS401 285.39 LPS Strasbourg 
 
CDKCONF4A and B 
LPS853 361.37 LPS Strasbourg CDKCONF4A 
LPS4056 297.32 LPS Strasbourg CDKCONF4B 
        
LPI2148 418.92 
Strasbourg (F. 
Bihel) 
CDKCONF4A and B 
LPI2251 565 
Strasbourg (F. 
Bihel) 
CDKCONF4A and B 
 
Results of the screen performed with Cy3-CDKCONF4A and compounds from the CNE 
 CDKCONF4A plate position  value standard deviation 
Above 115% 
1 B5 119.147 12.894 
1 C8 116.755 4.211 
2 C5 129.098 23.633 
4 B8 136.483 4.254 
4 C8 116.027 4.629 
4 E9 116.890 1.470 
4 G9 119.556 1.949 
5 B10 119.116 3.697 
5 G10 119.653 3.129 
6 C8 115.004 4.629 
6 E9 119.962 1.470 
6 E10 124.227 0.168 
7 F9 119.488 0.771 
8 B4 128.714 1.419 
8 G9 118.357   
Between 105 and 115% 
1 C5 108.361 2.370 
1 D8 105.429 2.329 
1 E4 106.601 6.904 
1 F9 105.114 1.034 
1 F11 109.144 4.308 
2 C7 110.115 6.435 
2 C8 109.685 7.035 
2 C11 108.951 9.438 
2 D3 107.033 0.922 
2 D5 105.411 4.546 
2 D7 106.274 3.893 
2 D8 105.790 5.520 
2 E4 108.033 1.540 
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2 E5 109.683 1.404 
2 E6 105.409 2.649 
2 F5 107.736 0.052 
2 F8 111.740 2.816 
2 F9 111.932 13.825 
3 B9 109.933 6.221 
3 B10 112.803 3.587 
3 B11 113.148 3.243 
3 C6 107.984 3.244 
3 C7 114.375 2.839 
3 D5 110.085 5.116 
3 D9 107.202 3.706 
3 E4 110.297 5.328 
3 F7 105.097 1.071 
3 F8 105.285 0.488 
4 B4 108.380 2.035 
4 B10 106.747 3.697 
4 B11 108.313 3.540 
4 C5 105.649 4.133 
4 C7 108.819 3.092 
4 C9 106.740 0.395 
4 C10 105.205 2.678 
4 D8 106.293 5.891 
4 D9 107.319 5.915 
4 E5 105.337 6.573 
4 E8 105.440 1.004 
4 E10 106.737 0.168 
4 F9 106.933 4.575 
4 G4 109.271 0.568 
4 G5 106.353 8.319 
5 C7 107.131 3.092 
5 C8 109.907 4.629 
5 C9 107.548 0.395 
5 D3 105.751 1.255 
5 D5 110.713 2.661 
5 D8 106.797 5.891 
5 E8 105.636 1.004 
5 F4 113.824 0.888 
5 F5 112.540 3.874 
5 F7 106.159 2.977 
5 F8 105.517 1.535 
5 G3 112.411 2.063 
6 C2 114.962 1.267 
6 C7 105.436 3.092 
6 E4 105.223 0.454 
6 E8 112.349 1.004 
6 G9 106.207 1.949 
7 B3 112.741 19.944 
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7 B8 105.316 1.095 
7 C10 106.387 6.893 
7 D4 108.091 3.701 
7 E7 112.045 8.275 
7 F8 107.216 5.671 
7 F10 108.850 0.435 
7 G11 105.429 11.113 
8 B8 111.655   
8 B9 105.737   
8 B10 105.616   
8 C5 109.481 0.030 
8 C8 106.220   
8 C9 108.696   
8 D5 105.344 1.329 
8 D8 112.560   
8 D9 105.435   
8 D10 106.159   
8 E4 106.250 1.117 
8 E7 107.065   
8 E8 106.159   
8 E9 108.152   
8 F6 106.944 0.181 
8 F7 108.696   
8 G7 107.548   
8 G8 109.481   
Between 80 and 90% 
1 B9 89.512 2.711 
1 D2 87.591 3.108 
1 D3 80.268 3.442 
1 D6 80.531 1.287 
1 E6 89.039 2.238 
1 E9 89.106 0.667 
1 G3 87.865 3.885 
1 G10 81.215 2.022 
2 B2 84.825 2.628 
2 B4 89.831 4.596 
2 B5 85.882 4.216 
2 B7 88.775 2.567 
2 B9 87.124 1.356 
2 C3 89.883 1.247 
2 F2 83.418 3.007 
3 C10 80.247 1.592 
3 C11 84.991 3.529 
3 F3 86.846 3.408 
4 F7 80.855 2.977 
4 G10 83.983 3.129 
5 B2 89.063 0.654 
5 D2 88.202 1.707 
5 G2 88.816 3.971 
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5 G5 86.981 8.319 
5 G6 81.903 0.993 
6 B11 83.123 3.540 
6 E2 82.214 1.446 
6 G4 89.401 0.568 
7 F3 89.061 5.043 
7 F6 87.303 1.822 
7 G2 88.342 0.610 
7 G6 89.807 0.626 
8 B2 89.553 2.536 
8 B3 80.767 0.030 
8 D4 89.825 0.513 
8 D7 87.923   
8 E11 89.493   
Between 70 and 80% 
1 C9 75.871 2.269 
1 E11 76.603 6.477 
1 F6 76.698 4.910 
1 F8 76.414 1.269 
1 G5 72.569 5.466 
1 G6 75.282 3.594 
2 E8 72.518 0.224 
2 F10 71.085 1.263 
3 E2 73.588 0.829 
3 E5 77.791 2.791 
5 G9 72.468 1.949 
5 G11 75.159 5.154 
6 B7 73.763 1.104 
6 D5 74.400 2.661 
Below 70% 
1 B6 59.971 6.923 
1 B7 66.032 1.598 
2 E11 64.484 1.389 
2 G5 54.585 0.148 
3 C4 65.264 0.044 
3 E3 69.692 1.525 
4 F8 67.453 1.535 
7 G3 68.750 5.835 
Table 17 : The increase in fluorescence of each compound was calculated with reference to the 
basal fluorescence of Cy3-labelled CDKCONF4A biosensor alone and was expressed as the 
percentage of increase. Only compounds that promoted an increase in fluorescence greater than 
115% were considered as hits. 
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Results of the screen performed with Cy3-CDKCONF4B and compounds from the CNE 
CDKCONF4B plate position  value 
standard 
deviation 
Above 120% 
3 B7 124.620 12.603 
3 B10 122.257 12.233 
4 B8 126.571 7.432 
4 E9 121.455 2.008 
5 G3 125.194 3.682 
5 F5 123.288 4.845 
5 G8 120.769 3.585 
5 B10 122.854 13.516 
6 E10 121.249 4.308 
Between 110 and 
120% 
1 B2 113.488 9.958 
1 B4 112.593 8.109 
1 B8 119.913 10.031 
1 B10 114.559 9.382 
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1 E10 111.059 4.308 
1 B11 113.111 7.228 
2 E7 111.765 4.635 
2 D8 110.368 1.575 
3 B2 111.132 10.951 
3 B5 110.010 9.137 
3 D7 113.496 2.023 
3 B8 116.525 12.057 
3 B9 114.725 8.687 
3 B11 119.670 13.934 
4 C7 116.813 3.513 
4 D7 111.982 1.317 
4 C9 110.790 2.635 
4 F9 111.481 0.941 
4 C10 110.194 4.308 
4 C11 111.418 1.129 
5 F4 119.832 0.194 
5 E5 110.788 4.877 
5 D6 115.310 20.478 
5 B7 118.005 3.083 
5 C7 114.696 2.487 
5 D7 119.574 2.132 
5 E7 117.216 4.942 
5 F7 117.797 2.552 
5 C8 114.632 1.260 
5 E8 111.079 1.195 
5 F8 115.924 0.484 
5 C9 116.925 1.873 
5 E9 110.982 0.904 
5 D10 116.990 4.308 
5 E10 112.468 4.308 
5 F10 114.115 4.308 
6 C2 111.543 0.582 
6 C4 110.165 4.108 
6 C7 113.595 3.001 
6 D7 110.716 0.674 
6 F7 110.808 2.113 
6 C8 115.248 0.000 
6 E9 111.911 0.827 
6 D10 119.290 4.308 
6 D11 112.278 4.133 
7 D7 110.066 1.748 
7 E7 112.086 3.888 
7 C10 112.447 4.308 
Between 80 and 90% 
1 F2 87.853 6.088 
1 C6 85.941 2.000 
1 D6 83.382 0.559 
1 E6 87.029 3.206 
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1 F8 82.118 2.176 
1 C9 81.529 0.588 
1 E9 83.971 0.147 
1 G10 86.029 4.308 
2 B2 81.543 0.097 
2 B3 89.975 1.146 
2 B4 88.760 0.395 
2 F4 82.828 3.238 
2 B5 88.823 0.066 
2 G6 86.809 0.891 
2 E8 83.541 1.664 
2 C9 87.611 2.882 
3 E2 82.126 1.510 
3 F5 87.017 1.329 
3 D6 82.760 0.030 
3 E6 87.077 1.872 
3 F6 86.141 1.419 
3 G6 87.953 0.936 
3 C10 80.707 4.308 
3 C11 85.145 2.778 
4 C2 88.739 0.784 
4 B6 87.935 6.419 
4 G6 86.857 0.031 
4 F7 88.959 0.376 
4 B9 88.547 4.741 
4 G10 86.575 4.308 
5 G6 83.204 0.452 
5 G9 83.721 0.517 
5 G11 83.818 1.195 
6 E2 88.151 1.745 
6 E5 83.435 1.255 
6 B7 86.088 0.478 
6 B9 85.360 0.739 
6 B11 81.804 2.519 
7 F3 87.161 2.110 
7 F6 87.191 2.140 
7 E10 86.618 4.308 
8 B2 88.969 3.525 
8 D3 89.971 0.860 
8 F3 89.341 0.344 
8 D4 88.195 1.261 
8 F4 88.166 1.347 
8 D6 89.370 1.003 
8 G6 85.587 3.410 
8 G10 88.682 4.308 
Between 70 and 80% 
1 D3 70.824 2.941 
1 G5 77.382 2.676 
1 B6 77.124 1.830 
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1 F6 70.088 2.088 
1 G6 75.529 2.118 
1 E11 78.412 0.647 
2 C3 75.936 1.426 
2 F10 74.242 4.308 
2 E11 71.955 1.664 
3 F3 71.679 0.181 
3 C4 77.264 10.094 
3 E5 78.321 0.634 
6 D5 75.964 3.368 
8 B9 75.160 0.490 
8 E11 72.894 1.834 
Below 70% 
2 F2 59.358 2.139 
2 G5 69.370 0.000 
3 E3 35.085 4.710 
4 F8 65.339 0.345 
7 G3 64.286 0.995 
8 B3 52.440 0.692 
Table 18 : The increase in fluorescence of each compound was calculated with reference to the 
basal fluorescence of Cy3-labelled CDKCONF4B biosensor alone and was expressed as the 
percentage of increase. Only compounds that promoted an increase in fluorescence greater than 
120% were considered as hits 
 
 
 205 
 
 
 
 
 206 
 
 
 
 
 207 
 
 
Results of the screen performed with Cy3-CDKCONF4A and compounds from Strasbourg 
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Proliferation inhibition studies of LPI2192, LPI2550, RF1210, LPI2251, LPI2252, MED0128 and PD-
0332991 in A375 cell line 
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Proliferation inhibition studies of PD-0332991 and RF1210 in melanoma cell lines (A375, MV3, 
SKMEL2 and SKMEL28) 
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PBS buffer 
50 mM KH2PO4/K2HPO4, pH 6.4 
500 mM NaCl 
 
TBS buffer 
50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
 
PBS/TBS lysis buffer 
PBS/TBS buffer 
+ 0.1 % NP40 
+ 3.3 mM PMSF 
+ 0.33 mg/mL lysozyme 
 
LB broth 
10 g/L Tryptone 
10 g/L NaCl  
5 g/L yeast extract 
 
TSS buffer (filter through 0.2 µm) 
10 mL LB 
10 % Polyethylene glycol 3000 - 8000 
50 mM MgCl2 
5 % DMSO 
 
LB/amp broth 
LB broth 
+ 50 mg/L ampicillin 
 
LB/amp plates 
LB broth 
+ 15 g/L Agar 
Autoclave for 20min 
Let the solution cool to 50°C 
In a sterile atmosphere, add 100 mg/L 
ampicillin and pour ~25 mL of LB agar per 10 
cm Petri dish 
When LB agar is solidified, invert the plates, 
seal with parafilm and store at 4°C 
 
Laemmli buffer 2.5X 
1 mL Bromophenol Blue 2 % (diluted in 
ethanol 96%) 
15 mL glycerol 100 % 
1.54 g DTT 
10 mL SDS 20 % 
8 mL Tris 1M pH=6.8 
46 mL H2O 
 
SDS-PAGE mix 15% (200mL) 
75 mL Acrylamide/Bis-Acrylamide (37,5/1) mix  
50 mL Tris 1.5 M pH=8.8  
73 mL H2O 
2 mL SDS 10 % 
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SDS-PAGE stack 4% (200mL) 
22 mL Acrylamide 
13 mL Bis-Acrylamide 
25 mL Tris 1 M pH=6.8 
2 mL SDS 10 % 
138 mL H2O 
 
Coomassie Brilliant Blue 
6 g Brilliant Blue R (Sigma Aldrich) 
Add 100 mL acetic acid to solubilize the 
powder 
Add 300 mL ethanol 96% 
Add 600 mL H2O 
 
Transfer buffer 
144 g glycine 
30.2 g Tris-Base 
900mL H2O 
 
Blocking buffer 
PBS buffer 
4 % BSA 
4 % goat serum 
0.1 % triton X-100 
Filter through 0.2 µm 
 
 
 
PBS lysis buffer 
PBS pH 7.4 (Sigma) 
0.2 % NP40 
2 mM PMSF 
1 mM EDTA 
CompleteTM protease inhibitors (Roche) 
 
PBS lysis buffer + phosphatase inhibitors 
PBS lysis buffer 
+ 500 mM NaF 
+ 10 mM Na3VO4 
 
Total extraction buffer  
50 mM Trizma Base 
0.5 M NaCl 
5 mM EDTA 
0.6 % NP40 
 
Luciferase cell culture lysis reagent 
25 mM Tris-phosphate (pH 7.8) 
2 mM DTT 
2 mM EDTA 
10 % glycerol 
1 % Triton X-100 
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1. Introduction 
1.1. CDK4/cycline D 
1.1.1. CDK4/cycline D dans le cycle cellulaire 
Les CDK/cyclines forment une famille de protéines kinases hétérodimériques constituées d’une sous-
unité catalytique, la CDK (Cyclin-Dependent Kinase) et d’une sous-unité régulatrice, la cycline. Leur 
rôle majeur est d’assurer la régulation des différentes transitions du cycle cellulaire (Malumbres, 
2011; Morgan, 1997). La phase G1, phase de croissance cellulaire et de réponse aux stimuli 
extracellulaires (facteurs de croissance), et la transition G1/S sont régulées par le complexe 
CDK4/cycline D. En effet, une fois actif, ce complexe phosphoryle les membres de la famille des 
protéines du rétinoblastome (pRb, p107 et p130), induisant une dérépression des facteurs de 
transcription E2F et permettant ainsi la transcription de la cycline E, nécessaire pour la transition 
entre la phase G1 et la phase S (Ho and Dowdy, 2002) (Figure 1). Une phosphorylation 
supplémentaire de pRb par le complexe CDK2/cycline E permet la libération complète des facteurs 
E2F, et donc leur action maximale comme activateurs transcriptionnels (Boonstra, 2003). 
L’activité de CDK4/cycline D est régulée à plusieurs niveaux, via l’expression et la dégradation de 
cycline D mais aussi par interaction avec les inhibiteurs de CDK (CKI) (les protéines INK4 et les 
protéines Cip/Kip). CDK4/cycline D subit également une succession de phosphorylations et 
déphosphorylations qui conduit au final à l’activation complète du complexe (Boutros et al., 2006; 
Iavarone and Massagué, 1997; Jeffrey et al., 2000; Martin et al., 2008; Schachter et al., 2013; Sherr 
and Roberts, 1999; Terada et al., 1995). 
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Figure 1: Fonction et régulation de CDK4/cycline D (source (Peyressatre et al., 2015)). L’expression 
de cycline D (orange) via des signaux mitogènes conduit à son association avec CDK4 (bleu) et à la 
formation du complexe dimérique. L’interaction avec les protéines Cip/Kip (violet clair) favorise 
l’assemblage du complexe et sa localisation nucléaire. L’activité de CDK4/cycline D est 
négativement régulée par interaction avec la famille de protéines INK4 (rose). Une fois actif, le 
complexe CDK4/cycline D régule la progression de la phase G1 et la transition G1/S. CDK4/cycline D 
phosphoryle la protéine du rétinoblastome (Rb) (violet foncé), ce qui induit la dérépression des 
facteurs de transcription E2F (vert), permettant ainsi la transcription de gènes essentiels à la 
transition G1/S. 
1.1.2. Aspects structuraux et mécanistiques 
Le mécanisme d’assemblage des CDK/cyclines a été décrit pour CDK2/cycline A (Brown et al., 1999; 
Hagopian et al., 2001; Jeffrey et al., 1995; Morris et al., 2002; Russo et al., 1996). On estime que ce 
mécanisme est commun pour toutes les CDK/cyclines même s’il existe des déterminants de 
spécificité qui font que chaque CDK s’associe de manière préférentielle avec un partenaire cycline et 
que chaque complexe possède des substrats différents des autres, une fonction biologique et 
physiologique différentes. La première étape du mécanisme consiste en l'association rapide entre 
l'hélice PSTAIRE de CDK2 et l’hélice α5 de cycline A. Cette association conduit à la réorientation de la 
poche ATP de CDK2 et à son alignement avec le site catalytique dans une position favorable au 
transfert du phosphate au substrat.  La deuxième étape correspond à l’isomérisation lente du lobe C-
terminal de CDK2 qui conduit à un changement conformationnel de la boucle d’activation (ou boucle 
T). Cette dernière est ainsi stabilisée dans une position qui permet sa phosphorylation par la CAK 
(Cyclin-Activating Kinase). Cette phosphorylation induit le déplacement de la boucle T dans une 
Rb
E2F
Rb
P
E2F transcription
CDK4
+ Cip/Kip
CDK4CDK4
INK4
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position stabilisée par des interactions entre le groupe phosphate et plusieurs résidus du lobe C-
terminal de CDK2, générant ainsi un site complètement accessible pour le substrat.  
Les structures cristallographiques de CDK2/cycline A et CDK4/cycline D montrent que l’interaction 
entre l’hélice PISTVRE de CDK4 et l’hélice α5 de cycline D est conservée alors que les interactions 
entre le lobe C-ter de CDK4 et cycline D ne le sont pas (Figure 2) (Day et al., 2009; Lolli, 2010; Takaki 
et al., 2009). CDK2/cycline A est dans une conformation fermée contrairement à celle ouverte de 
CDK4/cycline D. De plus, la structure cristallographique du complexe CDK4/cycline D1 montre que 
CDK4, même liée à cycline D1 et phosphorylée sur la tyrosine 172 de la boucle T, est dans une 
conformation dite inactive (Day et al., 2009). La fixation du substrat et l’association avec les protéines 
Cip/Kip seraient donc nécessaires pour favoriser son activation complète (Day et al., 2009; Takaki et 
al., 2009). Cependant, une étude récente de dynamique moléculaire suggère qu’une conformation 
fermée, similaire à celle de CDK2/cycline A, peut exister pour CDK4/cycline D1 (Floquet et al., 2015). 
 
Figure 2: Représentation des structures cristallographiques de CDK2/cycline A (PDB 1QMZ) et 
CDK4/cycline D (PDB 3G33) 
1.1.3. Dérégulation de CDK4/cycline D dans les cancers 
Parmi les CDK/cyclines, CDK4/cycline D est le complexe qui présente le plus d’aberrations dans les 
cancers humains (Lapenna and Giordano, 2009; Malumbres and Barbacid, 2001). La dérégulation de 
la voie p16INK4A / CDK4-6 / cycline D / Rb est l’un des évènements les plus fréquents dans les cancers 
et suggère que l’inhibition de l’activité kinase dépendante de cycline D constitue une cible 
thérapeutique en tant que traitement anticancéreux (Musgrove et al., 2011; Sherr, 1996). 
CDK2 
cycline A 
CDK4 
cycline D 
PISTVRE 
α 5 α 5 PSTAIRE 
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Cas particulier du mélanome 
Le mélanome, qui se développe aux dépens des mélanocytes, est l’un des cancers humains les plus 
agressifs et est responsable de 60 à 80% des décès par cancers de la peau  (Bandarchi et al., 2010). 
CDK4/cycline D est un biomarqueur avéré pour le mélanome. En effet, la voie p16INK4A / CDK4-6 / 
cycline D / Rb est dérégulée dans 90% des mélanomes. Dans les modèles de mélanomes humains et 
murins, l’activation de cette voie est étroitement liée à la mutation de BRAF et NRAS dans la 
transformation des mélanocytes. La voie RAS/RAF/MEK/ERK est dérégulée dans 65% à 90% des 
mélanomes métastatiques, augmentant davantage la voie p16INK4A / CDK4-6 / cycline D / Rb qui elle-
même accroît l’expression de cycline D1 (Chawla et al., 2010; Chin et al., 2006). L’importance de la 
protéine CDK4 dans les cancers a particulièrement été décrite suite à l’identification de la mutation 
R24C dans le locus de CDK4 qui empêche la fixation de l’inhibiteur endogène p16INK4A et prédispose 
au mélanome (Wölfel et al., 1995; Zuo et al., 1996). Cependant, une très faible incidence de 
mélanomes spontanés a été constatée chez des souris CDK4R24C/R24C. Une incidence accrue de 
mélanomes spontanés survient chez les souris exprimant l’oncogène HRAS (G12V) dans les 
mélanocytes, dans un contexte R24C (Chawla et al., 2010). 
Le risque de développer un mélanome est aussi augmenté par l’hyperactivation de CDK4/cycline D 
due à l’amplification de cycline D (18% des mélanomes) ou à la perte de l’inhibiteur p16INK4A (délétion 
de CDKN2A dans 50-60 % des tumeurs métastatiques) (Tsao et al., 2012). 
Cette kinase constitue donc un biomarqueur clé pour le diagnostic du mélanome et une cible 
thérapeutique pertinente (Sheppard and McArthur, 2013). 
1.1.4. Inhibiteurs de CDK4/cycline D 
À ce jour, la plupart des inhibiteurs des CDK/cyclines développés inhibent l’activité kinase en 
interférant avec le site de liaison de l’ATP des CDK (Bruyère and Meijer, 2013; Lapenna and Giordano, 
2009). Trois inhibiteurs spécifiques de CDK4-6/cycline D ciblant le site de liaison de l’ATP sont 
actuellement en essais cliniques : le composé LEE011 (Ribociclib), le composé LY2835219 
(Abemaciclib) et surtout le PD-0332991 (Palbociclib) (Asghar et al., 2015; Dickson, 2014; VanArsdale 
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et al., 2015). Ce dernier cible spécifiquement CDK4/cycline D1 et CDK6/cycline D2 avec un IC50 de 11 
et 16nM respectivement. En 2015, PD-0332991 est devenu le premier inhibiteur de CDK/cyclines à 
être approuvé par la FDA (Food and Drug Administration) pour son utilisation en association avec le 
létrozole dans le traitement de première intention de femmes ménopausées atteintes d’un cancer du 
sein RE+ et HER2- de stade avancé (http://www.fda.gov/Drugs/InformationOnDrugs/Approved 
Drugs/ucm432886.htm).   
Des stratégies alternatives ne ciblant pas la poche ATP ont été explorées pour inhiber la fonction des 
CDK/cyclines, en interférant par exemple avec la reconnaissance du substrat ou en ciblant les 
interfaces protéine/protéine essentielles (PPI) qui sont essentielles dans l’assemblage des complexes. 
Le criblage haut débit de banques de petites molécules ou le design rationnel de peptides mimant les 
interfaces rendent possible l’identification de tels composés (Arkin and Wells, 2004). Cette approche 
a été utilisée avec succès pour cibler différents complexes multimériques ou multiprotéiques, dont le 
complexe p53/MDM2 (Chène, 2004). 
Des approches permettant l’identification d’inhibiteurs allostériques de kinases ont également été 
développées (Eglen and Reisine, 2010). Ces composés sont souvent plus spécifiques que les 
inhibiteurs ATP compétitifs puisqu’ils se lient sur des sites qui ne sont pas conservés chez toutes les 
kinases et qui sont accessibles seulement dans certaines conformations. Les inhibiteurs allostériques 
lient et stabilisent des kinases en conformation inactive et empêchent les transitions vers une 
conformation active. Cette classe de composés reste très difficile à concevoir d’un point de vue 
rationnel et requiert l’identification de poches allostériques ou de sites accessibles seulement dans 
des intermédiaires inactifs. L’identification de ces composés se fait donc le plus souvent par criblage 
haut débit  (Jahnke et al., 2005; Lebakken et al., 2012; Liu and Gray, 2006; Prével et al., 2014b). 
1.2. Développement de biosenseurs fluorescents pour étudier l’activité 
kinase 
1.2.1. Concept de biosenseurs fluorescents 
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Compte tenu de l’importance des CDK/cyclines comme biomarqueurs en cancérologie, des 
approches efficaces et sensibles permettant de suivre l’activité de ces kinases sont requises. 
Actuellement, les seules méthodes permettant de mesurer l’activité des CDK/cyclines sont la 
radioactivité et les approches antigéniques (Jia et al., 2008). Ces tests biochimiques utilisent des 
enzymes recombinantes purifiées et/ou des substrats artificiels et sont basés sur la mesure de 
l’incorporation de phosphate radioactif dans des substrats de kinases ou sur l’utilisation d’anticorps 
qui reconnaissent des résidus phosphorylés spécifiques. Or ces méthodes requièrent de fortes 
concentrations en substrat et en enzyme et ne permettent pas de mesure en temps réel. Elles 
nécessitent également la fixation ou l’extraction de protéines cellulaires. C’est pourquoi le 
développement de nouvelles approches suffisamment sensibles et non-invasives est nécessaire pour 
évaluer qualitativement et quantitativement l’activité kinase des complexes CDK/cyclines dans leur 
environnement natif. 
Les biosenseurs fluorescents permettent de répondre à ces nouveaux challenges. Ils sont capables de 
mesurer de façon sensible les changements de fluorescence associés à la phosphorylation du 
substrat par la kinase. Ils fournissent des informations cinétiques sur l’activité kinase in vitro et in 
cellulo et permettent d’évaluer l’effet d’un inhibiteur sur la kinase (Nhu Ngoc Van and Morris, 2013). 
Ils permettent de visualiser des processus dynamiques dans les cellules vivantes en continu et en 
temps réel, fournissant ainsi des informations précieuses sur la localisation subcellulaire, le 
comportement intracellulaire de cibles ou encore les interactions protéine/protéine (Chudakov et al., 
2010; Morris, 2010; Weissleder and Ntziachristos, 2003). Ils constituent également des outils 
puissants pour détecter les changements conformationnels des kinases (Tarrant and Cole, 2009). Les 
biosenseurs fluorescents offrent de nombreux avantages tels qu’une grande sensibilité et sélectivité 
intrinsèque, une grande résolution spatiale et temporelle, une imagerie non-invasive et un large 
spectre de longueurs d’ondes. 
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Deux familles de biosenseurs fluorescents ont été développées : les biosenseurs génétiques, conçus à 
partir de protéines auto-fluorescentes (AFP) et les biosenseurs non génétiques, basés sur le couplage 
de petites sondes fluorescentes synthétiques sur des protéines ou des peptides.  
1.2.2. Biosenseurs fluorescents génétiquement codés 
Les biosenseurs génétiquement codés les plus connus sont ceux basés sur le FRET (Förster Resonance 
Energy Transfer) entre un couple d’AFP. Ils sont constitués d’un PAABD (Phospho Amino Acid Binding 
Domain) fusionné avec une AFP, qui reconnaît les résidus phosphorylés, et d’un domaine substrat 
spécifique d’une protéine kinase fusionné avec une autre AFP. Lorsque la kinase phosphoryle son 
substrat, le résidu phosphorylé est reconnu par le PAABD, ce qui induit un changement de 
conformation qui altère la distance et l’orientation des deux AFP. Ces biosenseurs ont été appliqués 
avec succès à l’étude de l’activité de nombreuses kinases. Un biosenseur a été développé pour 
étudier l’activité de CDK1/cycline B1 (Gavet and Pines, 2010). Pour l’heure, c’est le seul biosenseur 
génétique à avoir été conçu pour étudier l’activité d’un complexe CDK/cycline. Les biosenseurs 
génétiques sont considérés comme faciles à manipuler et à transfecter dans les cellules. Cependant, 
ils présentent certains inconvénients tels qu’une utilisation limitée aux applications in cellulo, une 
expression difficile à contrôler et hétérogène au sein d’une population de cellules, une taille 
importante et parfois une mauvaise localisation cellulaire (Giepmans et al., 2006; Morris, 2010). 
1.2.3. Biosenseurs fluorescents non génétiques 
Les biosenseurs non génétiques sont généralement constitués d’un scaffold peptidique ou protéique 
sur lequel est couplé une petite sonde fluorescente synthétique. Dans le cas des protéines kinases, 
les séquences peptidiques ou protéiques dérivent souvent de domaines qui reconnaissent 
spécifiquement une kinase, comme par exemple des séquences substrats contenant un site de 
phosphorylation. Suite à la phosphorylation de la séquence substrat par la kinase, les propriétés 
spectrales sont altérées directement ou indirectement par des changements de conformation 
intramoléculaires et/ou la reconnaissance du PAABD.  
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Les biosenseurs non-génétiques présentent certains avantages tels qu’une versatilité dans le design 
et une production aisée par synthèse chimique ou par purification de protéine recombinante. De 
plus, ils peuvent être utilisés in vitro, in cellulo and in vivo. Cependant, l’inconvénient majeur de ces 
outils est leur inaptitude à franchir les membranes cellulaires. La microinjection ou l’internalisation 
grâce à des peptides auto-pénétrants tels que PEP and CADY2 peuvent permettre de résoudre ce 
problème (Kurzawa et al., 2010; McNeil, 2001). 
1.2.4. Biosenseurs fluorescents utilisés pour le criblage HTS/HCS 
Les biosenseurs décrits précédemment, ainsi que les biosenseurs basés sur la technologie FLiK 
(Fluorescent Labels in Kinases) et les biosenseurs positionnels, ont été appliqués au criblage de 
banques de petites molécules dans le but d’identifier de nouveaux inhibiteurs de protéines kinases 
(Ahsen and Bömer, 2005; Allen et al., 2006; Hanson and Hanson, 2008; Prével et al., 2014b; Taylor, 
2010; Wolff et al., 2006; Zaman et al., 2003). Les biosenseurs positionnels sont composés d’une AFP 
qui contient une séquence de localisation nucléaire (NLS) ou d’exclusion nucléaire (NES). L’exposition 
de cette séquence est modulée en réponse à l’activation/inhibition de la kinase cible. Ainsi, ils 
donnent des informations sur les changements subcellulaires de la cible. 
La plupart des stratégies décrites précédemment contiennent un PAABD et conduisent souvent à 
l’identification de molécules compétant avec l’ATP. Dans le but d’identifier des inhibiteurs 
allostériques qui lient et stabilisent les kinases dans une conformation inactive, les biosenseurs FLiK 
ont été développés. Ils contiennent un scaffold kinase dans lequel des sondes fluorescentes sont 
introduites à des positions stratégiques et permettent de « senser » les ligands qui lient un état 
conformationnel spécifique. Ces biosenseurs ont été appliqués avec succès pour l’identification  par 
criblage HTS/HCS (High Throughput Screening/High Content Screening) d’inhibiteurs de p38αMAPK, 
Src and Abl (Getlik et al., 2012; Schneider et al., 2012; Simard et al., 2009a, 2009b, 2009c, 2010; 
Zhang et al., 2010). 
1.2.5. Biosenseurs fluorescents non génétiques développés au laboratoire pour 
étudier les CDK/cyclines 
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CDKSENS 
L’équipe a développé une famille de biosenseurs peptidiques fluorescents permettant d’étudier 
l’abondance des CDK/cyclines (Kurzawa et al., 2011). Ces peptides biligands sont constitués d’une 
séquence substrat spécifique d’une CDK et d’une séquence de liaison à une cycline. Ils contiennent 
une unique cystéine qui, une fois couplée à une sonde fluorescente sensible à l’environnement, 
permet d’assurer la reconnaissance spécifique et affine des CDK/cyclines en complexe. L’abondance 
des CDK/cyclines a pu être déterminée in vitro mais également in cellulo en associant le biosenseur 
avec le peptide vecteur CADY2. 
CDKACT 
Une famille de biosenseurs fluorescents peptidiques et protéiques a été développée dans notre 
laboratoire de façon à étudier l’activité des CDK/cyclines. Ils contiennent un domaine de liaison aux 
acides aminés phosphorylés (PAABD) et un domaine substrat. Ils sont capables, lorsqu’ils sont 
couplés à des sondes fluorescentes sensibles à l’environnement,  de détecter des altérations dans 
l’activité de ces kinases in vitro, mais également in cellulo lorsqu’ils sont associés à des stratégies de 
vectorisation basées sur des peptides vecteurs (Van et al., 2014). 
CDKCONF 
Dans le but d’identifier des inhibiteurs allostériques de CDK2, l’équipe a développé un biosenseur 
protéique basé sur la technologie FLiK (Fluorescent Labels in Kinases). Ce biosenseur contient un 
scaffold de CDK2 dans lequel des sondes fluorescentes sont introduites à des positions spécifiques et 
servent à détecter des ligands se liant à une conformation spécifique de CDK2. CDKCONF a été 
appliqué au criblage de la chimiothèque nationale (18480 composés) et a permis d’identifier des 
composés capables d’inhiber l’activité de CDK2 en interférant avec la boucle T.  
2. Objectifs 
Le premier objectif de ma thèse a porté sur le développement et l’application d’un biosenseur 
fluorescent permettant d’étudier l’activité de CDK4/cycline D. Ce biosenseur a été caractérisé in vitro 
et in extracto puis appliqué à la détection d’altérations de CDK4/cycline D dans des biopsies de peau 
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humaine et de xénogreffes de mélanome dans des essais fluorescents d’activité kinase, ainsi que 
dans des cellules cancéreuses vivantes par microscopie de fluorescence et vidéo-microscopie. 
Le deuxième objectif de ma thèse a consisté à identifier des inhibiteurs non compétitifs de l’ATP, soit 
par élaboration rationnelle de peptides, soit par criblage de petites molécules. A cette fin, deux 
biosenseurs fluorescents ont été développés qui permettent d’identifier respectivement des 
composés ciblant l’interface entre CDK4 et cycline D ou des inhibiteurs allostériques capables de 
perturber la dynamique conformationnelle de CDK4. Des essais de criblage par fluorescence réalisés 
avec ces biosenseurs ont conduit à l’identification de touches qui ont été validées et caractérisées in 
vitro et dans des essais de prolifération cellulaire, et qui constituent des candidats prometteurs pour 
une chimiothérapie sélective du mélanome. 
3. Résultats 
3.1. Développement d’un biosenseur fluorescent pour étudier l’activité de 
CDK4/cycline D 
Une famille de biosenseurs fluorescents a été développée pour suivre spécifiquement l’activité de 
CDK4/cycline D in vitro et in cellulo. Ils sont constitués de trois domaines:  
- un domaine de liaison aux acides aminés phosphorylés (Phospho Amino Acid Binding Domain 
PAABD) qui est capable de reconnaître pSer et pThr.  
- une séquence substrat qui dérive de la protéine du rétinoblastome (Rb) (résidus 790 à 801) et qui 
est spécifiquement phosphorylé par CDK4 (résidu Ser795) (Grafstrom et al., 1999). Une cystéine 
unique proche du site de phosphorylation permet de coupler une sonde fluorescente fonctionnalisée 
(maléimide ou iodoacétamide ou isothiocyanate) (YKFCSSPLRIPG). 
- un linker peptidique court qui lie les deux domaines précédents et confère une certaine flexibilité. 
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Trois variants ont été conçus: une forme protéique (57 kDa) et deux formes peptidiques (44 et 31 
acides aminés). Ils diffèrent selon l’origine et la taille du PAABD mais contiennent la même séquence 
substrat. 
Les biosenseurs sont couplés à une sonde fluorescente sensible à l’environnement et permettent de 
suivre l’activité de CDK4/cycline D par mesure de changements de fluorescence. Leur mode d’action 
est le suivant : la phosphorylation d’un résidu sérine dans le domaine substrat (Rb) du biosenseur par 
CDK4/cycline D entraîne un changement conformationnel dû à l’interaction préférentielle du PAABD 
avec le substrat phosphorylé. Ce repliement du PAABD sur le substrat phosphorylé modifie 
l’environnement de la sonde fluorescente à proximité du site de phosphorylation, ce qui induit une 
variation de fluorescence. 
3.1.1. CDKACTRb 
Un biosenseur protéique de 57 kDa, GST-CDKACTRb, a d’abord été développé. Il contient un PAABD 
dérivé du domaine Polo Box de Plk1 (García-Alvarez et al., 2007), comprenant les résidus 367 à 603 
(237 acides aminés) et dans lequel toutes les cystéines ont été mutées en sérines. CDKACTRb ne 
possède qu’une seule cystéine, proche du site de phosphorylation, pouvant être couplée avec des 
sondes fluorescentes telles que la cyanine 3. 
Le biosenseur a été exprimé chez E.coli sous forme de fusion GST, purifié par chromatographie FPLC, 
puis marqué avec Cy3. Des expériences de spectrofluorimétrie ont été réalisées en incubant le 
biosenseur avec le complexe recombinant CDK4/cycline D ou des extraits cellulaires issus de lignées 
cellulaires de mélanome (A375) en présence d’ATP/MgCl2. Afin de vérifier que les changements de 
fluorescence observés étaient bien associés à une activité kinase, l’inhibiteur compétiteur de l’ATP 
PD-0332991, spécifique de CDK4 et CDK6, était également ajouté à la kinase recombinante ou aux 
extraits cellulaires. Afin de déterminer sa sélectivité et sa spécificité vis-à-vis d’autres kinases et 
d’autres complexes CDK/cyclines, le biosenseur a également été caractérisé in vitro en utilisant 
différents inhibiteurs de kinases. Toutes ces expériences ont montré que CDKACTRb-Cy3 rapporte 
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spécifiquement l’activité du complexe recombinant in vitro et l’activité de CDK4/cycline D endogène 
dans des extraits cellulaires de mélanome.  
3.1.2. WWRb 
Afin d’étudier l’activité de CDK4/cycline D dans des biopsies de peau et in cellulo, un biosenseur 
peptidique plus court et plus facile à manipuler et à stocker a été généré. WWRb est un peptide de 
44 acides aminés dont le PAABD dérive du domaine WW de Pin1 (résidus 10 à 39) (Lu et al., 1999; 
Macias et al., 2000). 
Des expériences de spectrofluorimétrie ont été réalisées en incubant le biosenseur avec des extraits 
cellulaires issus de lignées cellulaires de mélanome (A375) en présence d’ATP/MgCl2 et en ajoutant 
l’inhibiteur PD-0332991. Des expériences contrôles dans lesquelles le biosenseur était incubé avec de 
la BSA à la place des extraits cellulaires ont également été menées. Bien que WWRb ait été testé avec 
différentes sondes fluorescentes (Cy3, TAMRA, FITC, Texas Red), il n’a jamais répondu 
spécifiquement à l’activité de CDK4/cycline D in extracto. En effet, le biosenseur était soit insensible 
à l’ajout de PD-0332991, soit répondait à la présence de BSA, soit répondait de manière aléatoire. 
Nous avons alors émis l’hypothèse que le tampon de lyse utilisé pour faire les lysats cellulaires 
empêchait le repliement du PAABD, certainement à cause de la présence des détergents. 
Pour valider cette hypothèse, WWRb, marqué avec la sonde fluorescente TAMRA, a ensuite été testé 
en présence de la protéine recombinante CDK4/cycline D et de l’inhibiteur PD-0332991. Cette 
expérience a démontré que le biosenseur était capable de rapporter l’activité de CDK4/cycline D in 
vitro.  
Au vu des résultats obtenus in extracto, nous avons considéré que le biosenseur WWRb n’était pas 
assez sensible et spécifique pour être utilisé par la suite. 
3.1.3. WWshortRb 
Nous avons donc développé un second biosenseur peptidique, plus court (31 acides aminés), 
WWshortRb, dont le PAABD a été conçu après analyse de la structure cristallographique du domaine 
WW de Pin1 avec un phosphopeptide (PDB 1F8A). Cette étude a révélé que certains résidus étaient 
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essentiels à l’interaction : Arg14, Arg17, Tyr23, Phe25 et Trp34. Le PAABD qui a été développé, 
appelé WWshort, comprend donc ces résidus clés (Phe25, Arg14, Tyr23, Arg17), inter-espacés par 
des petits acides aminés non chargés, et termine par le résidu Trp34 suivi des cinq acides aminés 
contenus dans la séquence native du domaine WW de Pin1 (GFARVYMSRSSGWERPSG). 
Des titrations de fluorescence réalisées avec WW ou avec WWshort ont démontré que WWshort 
interagissait mieux avec le peptide substrat Rb que WW et qu’il interagissait encore plus 
préférentiellement avec le substrat phosphorylé. 
WWshortRb a ensuite été caractérisé in extracto et in vitro. Nous avons démontré que WWshortRb, 
marqué avec la sonde fluorescente TAMRA, était capable de rapporter l’activité du complexe 
CDK4/cycline D recombinant ou endogène. Nous avons également montré que WWshortRb 
répondait spécifiquement à CDK4/cycline D in extracto puisque seul l’ajout d’inhibiteurs spécifiques 
de CDK4 tels que PD-0332991 ou LY2835219 entraînait une diminution de la fluorescence du 
biosenseur. 
Alors que WWshortRb répond à l’activité de CDK4 lorsqu’il est marqué avec TAMRA, il ne répond pas 
s’il est couplé avec DyLight650. Ainsi, comme Dylight650 (λexc = 652 nm; λem = 672 nm) et TAMRA 
(λexc = 540 nm; λem = 565 nm) possèdent des propriétés spectrales différentes, WWshortRb-
DyLight650 peut être utilisé comme contrôle négatif. 
WWshortRb a ensuite été utilisé pour comparer l’activité de CDK4/cycline D dans différentes lignées 
de mélanome. L’analyse du profil fluorescent de WWshortRb a montré que l’activité kinase de CDK4 
était plus importante dans les lignées cellulaires A375 (perte de fonction CDKN2A, BRaf V600E), 
Mewo (perte de fonction CDKN2A, Wt CDK4) et SK-MEL28 (R24C CDK4, BRaf V600E) (augmentation 
d’environ 40%) comparée à la lignée SK-MEL2 (mutation NRas (Q61R)) (25% d’augmentation) et MV3 
(20% d’augmentation). Ces réponses corrèlent avec les génotypes des lignées cellulaires dans 
lesquelles la perte de fonction de CDKN2A ou la mutation R24C de CDK4 conduit à une hyperactivité 
de CDK4. Pour autant ces résultats ne coïncident pas avec les profils de Western blot qui fournissent 
seulement une information sur l’abondance de CDK4. En effet, l’activité de CDK4 est associée au 
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niveau d’expression de CDK4 mais également à sa régulation au sein de la voie p16INK4A / CDK4-6 / 
cycline D / Rb. 
WWshortRb a aussi été appliqué à la détection d’altérations de CDK4/cycline D dans des biopsies de 
peau humaine. Il a permis de mettre en évidence une activité plus forte de CDK4 dans l’épiderme 
que dans le derme, ce qui s’explique par le fait que de nombreuses cellules en division se trouvent 
dans l’épiderme. La réponse de WWshortRb a également été étudiée en l’incubant avec des extraits 
cellulaires provenant de biopsies de peau saine et de peau présentant une pathologie telle que 
l’eczéma et le psoriasis. Alors qu’une activité similaire de CDK4 a été observée dans les biopsies de 
peau saine et à eczéma, une activité beaucoup plus faible a été trouvée dans les biopsies de peau 
présentant un psoriasis. 
WWshortRb a également été appliqué à la détection d’altérations de CDK4/cycline D dans des 
xénogreffes de mélanome provenant de souris traitées quotidiennement ou non avec l’inhibiteur PD-
0332991. Les biopsies de xénogreffes ont été lysées et les extraits ont été incubés avec WWshortRb-
TAMRA. Ces expériences ont montré une réduction plus forte de l’activité de CDK4 dans les 
xénogreffes traitées avec 150 mg/kg PD-0332991 pendant 7 jours plutôt que 3 jours. 
Enfin, la capacité de WWshortRb à rapporter l’activité de CDK4 in cellulo a été examinée. Nous avons 
démontré que le biosenseur, marqué avec TAMRA ou DyLight650, franchissait les membranes 
cellulaires tout seul et n’avait donc pas besoin d’être associé à une stratégie de délivrance telle que 
les peptides vecteurs. Des expériences de vidéo-microscopie ont confirmé que le fait que 
WWshortRb-DyLight650 constituait un bon contrôle négatif in cellulo et qu’il permettait une 
quantification ratiométrique de la réponse du biosenseur. Dans des cellules vivantes de mélanome 
traitées avec PD-0332991 et Roscovitine, WWshortRb-TAMRA a montré qu’il était capable de 
détecter une inhibition de l’activité de CDK4/cycline D. Cependant, après plusieurs heures 
d’acquisition, la linéarité de réponse du biosenseur suggère qu’il ne répond plus de manière fiable à 
sa phosphorylation par CDK4/cycline D. 
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3.2. Identification d’inhibiteurs non compétitifs de l’ATP ciblant 
CDK4/cycline D 
Dans le but de développer des inhibiteurs de CDK4/cycline D non compétitifs de l’ATP, des approches 
alternatives ciblant des interfaces protéine/protéine ou des sites allostériques ont été envisagées. 
Ces stratégies reposent soit sur la conception rationnelle de peptides, soit sur l’élaboration de 
biosenseurs fluorescents permettant de cribler des banques de petites molécules.  
A. Identification par criblage 
3.2.1. Développement de biosenseurs fluorescents - Criblage de chimiothèques 
Deux biosenseurs fluorescents permettant une approche aléatoire par criblage ont été conçus:  
-un biosenseur permettant d’identifier des inhibiteurs d’interface entre l’hélice PISTVRE de CDK4 et 
l’hélice α5 de cycline D (CDKCONF4A) 
-un biosenseur sensible aux changements conformationnels de CDK4 permettant d’identifier des 
modulateurs allostériques de la boucle T de cette kinase (CDKCONF4B).  
La séquence de CDK4 contient 4 cystéines dont les groupes thiol sont disponibles pour le couplage 
avec des sondes fluorescentes. CDKCONF4A et CDKCONF4B ont été générés à partir d’une 
construction plasmidique codant pour GST-CDK4 de souris. Pour CDKCONF4A, deux cystéines 
proches de l’hélice PISTVRE ont été conservées (Cys 78 et 135). Dans le cas de CDKCONF4B, deux 
cystéines proches de la boucle T ont été utilisées (Cys 202 et 189, la deuxième étant introduite par 
mutagenèse dirigée). 
La cycline D et le substrat Rb ont été utilisés comme contrôle positif de l’interaction pour 
CDKCONF4A et CDKCONF4B respectivement, afin de valider le biosenseur puis d’optimiser les 
conditions d’essai pour le criblage. Tout le processus d’optimisation et de criblage a été effectué sur 
un robot (TECANTM Freedom EVO) de la plateforme MRI au CRBM à Montpellier (collaboration J. 
Bellis et V. Georget). 
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Deux banques ont été criblées : la Chimiothèque Nationale Essentielle (CNE) (480 composés) et une 
banque de molécules provenant de la faculté de pharmacie de Strasbourg (collaboration avec le Dr. 
Frédéric Bihel) (640 molécules). Le criblage de la CNE a permis d’identifier 15 hits pour CDKCONF4A 
et 9 hits pour CDKCONF4B (pourcentage de retenus < 4%). Le criblage de la banque de Strasbourg a 
permis d’identifier deux hits, les mêmes pour CDKCONF4A et CDKCONF4B (pourcentage de retenus < 
1%). 
3.2.2. Caractérisation in vitro des hits identifiés 
Des poudres fraîches des molécules identifiées à la suite du criblage ont été envoyées par les 
laboratoires d’origine et resuspendues dans du DMSO. Les hits ont ensuite été retestés 
manuellement pour confirmer les résultats du criblage.  Seulement quelques composés de la CNE ont 
pu être validés et gardés pour la suite de l’étude (ICMR-04-E10, LPS401, LPS853). Les deux composés 
de Strasbourg ont été caractérisés au regard de leur identification par CDKCONF4A comme 
inhibiteurs d’interface.  Pour vérifier s’ils étaient capables d’interagir avec l’hélice PISTVRE de CDK4, 
des tests d’interaction ont été menés avec le peptide PISTVRE, qui dérive de cette hélice, marqué 
avec une sonde fluorescente, et le peptide D1, qui dérive de l’hélice α5 de cycline D, comme contrôle 
positif. Un seul des composés, LPI2251, a montré une réelle interaction avec PISTVRE. Une 
collaboration avec Dr. Frédéric Bihel a alors débuté afin de tester différents dérivés de ce composé et 
d’identifier les variants permettant de cibler le plus efficacement possible CDK4/cycline D. Le même 
test d’interaction a été effectué entre ces 15 molécules et le peptide PISTVRE. Trois de ces composés 
ont induit un changement de fluorescence significatif qui indique qu’ils interagissent avec l’hélice 
PISTVRE de CDK4. 
3.2.3. Caractérisation in cellulo des hits identifiés 
Des tests de prolifération sur cellules de mélanome (A375) et sur cellules saines (fibroblastes) ont été 
réalisés afin d’évaluer la capacité des 15 molécules de Strasbourg à réduire la croissance cellulaire.  
Les IG50 des six composés les plus prometteurs sont tous compris entre 2.9 et 20,7µM et sont 
comparables à la valeur obtenue pour PD-0332991 (18,7µM). Un seul des composés, LPI2192, a 
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également eu un effet sur la prolifération des fibroblastes sains. Il a donc été écarté de la suite de 
l’étude. 
Des tests de prolifération ont également été menés avec un des composés, RF1210, sur d’autres 
lignées de mélanome (SK-MEL2, SK-MEL28, Mewo, MV3) présentant différentes altérations de la voie 
p16INK4A / CDK4-6 / cycline D / Rb. Les valeurs des IG50 sont similaires entre les différentes lignées, de  
10µM à 13,6µM, et sont comparables à celles obtenues avec PD-0332991 (de 10,7µM à 18,7µM). 
Enfin des tests de synergie ont été réalisés afin de déterminer si RF1210 and LPI2252 pouvaient 
coopérer avec d’autres drogues et inhiber plus efficacement la prolifération des cellules de 
mélanome A375. Ces expériences ont montré qu’à des concentrations sous-optimales de RF1210 et 
LPI2252 (10µM), l’ajout d’un inhibiteur de CDK4 tel que PD-0332991 réduisait le nombre de cellules 
plus significativement que le composé seul. Cette coopération a été observée avec d’autres 
inhibiteurs de CDK4 (LEE011 et LY2835219), mais aussi avec d’autres drogues fréquemment utilisées 
dans le traitement du cancer telles que le Paclitaxel et le Methotrexate. 
B. Conception rationnelle de peptides ciblant l’interface entre CDK4 et 
cycline D 
3.2.4. Concept et design 
Des peptides ont été conçus pour cibler l’interface entre les deux sous-unités du complexe 
CDK4/cycline D. Dans notre laboratoire, cette stratégie a déjà été développée pour cibler 
l’interaction première entre CDK2 et cycline A (Gondeau et al., 2005). Au vu du succès de cette 
approche, deux autres peptides ont été élaborés pour cibler l’interface entre CDK4 et cycline D1 : un 
peptide nommé D1, qui dérive de l’hélice α5 de cycline D1 et un peptide nommé PISTVRE dérivant de 
l’hélice PISTVRE de CDK4.  
3.2.5. Caractérisation in cellulo  
Des tests de prolifération sur cellules de mélanome A375 ont été mis en place afin de déterminer 
l’effet de ces peptides sur la croissance cellulaire. Ces peptides ont été internalisés dans les cellules 
grâce au peptide vecteur CADY2 (Kurzawa et al., 2010). CADY2 est un peptide amphipathique qui 
 267 
 
interagit avec les protéines et les peptides en formant des nanoparticules capables de traverser les 
membranes cellulaires. Après 48h de traitement, le peptide D1 s’est révélé être plus efficace que le 
peptide PISTVRE à 1µM pour inhiber la prolifération des cellules A375 (56 et 22% de réduction du 
nombre de cellules respectivement). 
3.2.6. Caractérisation in vitro 
Des variants courts et longs du peptide PISTVRE ont été conçus de façon à déterminer la séquence 
minimale permettant de cibler efficacement l’interface.  
Afin de déterminer le meilleur variant dérivant de l’hélice PISTVRE, des tests d’interaction ont été 
réalisés entre ces peptides et le peptide D1 marqué avec la sonde fluorescente TAMRA. Au vu des 
constantes de dissociation (Kd) obtenues, le variant le plus court semble être celui qui interagit le 
mieux avec le peptide D1. Ces expériences devront également être réalisées avec la cycline D1, afin 
de caractériser l’affinité et la spécificité de l’interaction entre le peptide PISTVRE et l’hélice α5 de son 
partenaire, en tenant compte de tout l’environnement autour de cette interface et toutes les 
interactions secondaires présentes à cette interface. 
4. Discussion et perspectives 
4.1. Développement d’un biosenseur fluorescent pour étudier l’activité de 
CDK4/cycline D 
Importance du PAABD 
Nous avons d’abord développé un biosenseur protéique, CDKACTRb, contenant un PAABD dérivé du 
PBD de Plk1 et une séquence substrat spécifique de CDK4. Même si les résultats obtenus in vitro et in 
extracto étaient prometteurs, nous avons envisagé une autre stratégie, le développement d’un 
biosenseur peptidique, WWRb, plus facile à synthétiser, à internaliser dans les cellules et à stocker. 
Cependant, le manque de réponse du biosenseur in extracto montre que le PAABD qu’il contient et 
qui dérive du domaine WW de Pin1 n’est pas fonctionnel dans ce système en présence de tampon de 
lyse. 
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Ce manque de fonctionnalité nous a conduits à concevoir un nouveau biosenseur peptidique, 
WWshortRb, contenant un domaine de phospho-reconnaissance plus court, WWshort. Nous avons 
montré qu’il interagissait mieux avec le peptide substrat Rb et phospho-Rb que WWlong. De plus, 
WWshortRb a montré qu’il répondait à l’activité de CDK4/cycline D in vitro et in extracto. 
Sensibilité des biosenseurs – importance de la sonde fluorescente 
Les expériences menées in vitro ont montré que le choix de la sonde fluorescente était primordial 
pour obtenir une réponse du biosenseur WWshortRb. La taille et la structure de la sonde semble 
cruciale dans ces systèmes dynamiques. TAMRA, plus petite que DyLight650 et Cy3, est la seule 
sonde permettant de rapporter le changement conformationnel du biosenseur. On peut supposer 
qu’une grosse sonde fluorescente empêche stériquement le repliement du PAABD.  
Lors de la phosphorylation du biosenseur par CDK4/cycline D, on observe une augmentation 
maximale de fluorescence de 40%. Cette limitation de l’intensité de fluorescence vient 
potentiellement du fait que TAMRA n’est pas extrêmement sensible par rapport à d’autres sondes. Il 
pourrait être intéressant de tester d’autres fluorophores comme DMN4 ou la merocyanine qui 
pourraient conduire à une augmentation plus forte de la fluorescence (Gulyani et al., 2011; Loving 
and Imperiali, 2008). Cependant, cette augmentation de fluorescence limitée ne provient peut-être 
pas de la sonde elle-même mais de l’environnement autour de l’interaction entre le PAABD et le 
susbtrat phosphorylé qui n’entraîne pas assez de changements de pH ou de polarité du solvant.   
Bien que TAMRA ne soit pas reconnu comme étant un fluorophore très sensible, le biosenseur 
WWshortRb-TAMRA permet néanmoins de comparer l’activité de CDK4 dans différentes lignées de 
mélanome et de quantifier des différences qui ne peuvent pas être mises en évidence par simple 
analyse des profils d’expression. 
Spécificité des biosenseurs 
Les études menées in extracto ont permis de démontrer que CDKACTRb rapporte spécifiquement 
l’activité de CDK4/cycline D contenu dans des extraits de mélanome. Parmi les différents inhibiteurs 
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de kinases testés, seul PD-0332991 réduit le signal fluorescent de CDKACTRb de façon dose-
dépendante. 
La fluorescence de WWshortRb est réduite lorsqu’il est incubé avec PD-0332991 et LY2835219 mais 
pas avec la Roscovitine qui inhibe CDK1, CDK2, CDK5, CDK7 et CDK9. De la même façon, on observe 
une diminution du signal fluorescent WWshortRb lorsqu’il est incubé avec des extraits de cellules de 
mélanome préalablement traités avec un siRNA ciblant CDK4. De plus, après fractionation d’un 
extrait cellulaire A375 par gel filtration, WWshortRb est capable d’identifier les fractions contenant la 
protéine CDK4. 
Application de WWshortRb pour détecter l’activité de CDK4 dans des lysats de biopsies de peau et de 
xénogreffes de mélanome 
Nous avons montré que WWshortRb rapporte l’activité de CDK4/cycline D dans des extraits 
cellulaires provenant de biopsies de peau. WWshortRb a montré une activité plus faible de CDK4 
dans des biopsies de peau présentant un psoriasis que dans des biopsies de peau saine. 
WWshortRb a été appliqué à la quantification de l’activité de CDK4/cycline D dans des lysats de 
xénogreffes de mélanome implantées chez des souris ayant été traitées ou non avec PD-0332991. 
Ces expériences nous ont permis de réaliser l’importance de normaliser les extraits cellulaires par 
rapport à la proportion de cellules cancéreuses (A375 luciférase). En effet, comme les cellules 
stromales sont aussi présentes dans la tumeur, le lysat cellulaire contient des protéines normales et 
hyperactives, telles que CDK4/cycline D. Comme chaque tumeur grossit et se comporte 
différemment, le ratio faisant état du niveau d’expression entre les protéines normales et 
hyperactives change, entraînant ainsi une normalisation erronée.  
Application de WWshortRb in cellulo 
Nous avons démontré que WWshortRb était capable de franchir seul les membranes cellulaires, bien 
que nous n’ayons identifié aucune séquence particulière qui pourrait lui conférer un caractère auto-
pénétrant. Ce résultat rend les expériences d’imagerie beaucoup plus simples puisque le biosenseur 
peptidique ne requiert, comme seule préparation, que son marquage fluorescent. Cependant la 
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stabilité in vivo du biosenseur doit être étudiée, car, n’ayant pas besoin d’une stratégie de 
vectorisation, il est complètement déprotégé vis à vis protéases. 
Les expériences de vidéo-microscopie suggèrent qu’après plusieurs heures d’acquisition, le 
biosenseur ne répond plus de manière fiable. Il semblerait donc que WWshortRb soit plus adapté à 
des applications in vitro dans lesquelles il a prouvé être très fiable. 
Conclusions et perspectives 
Nous avons démontré que le biosenseur peptidique WWshortRb était un outil efficace in vitro pour 
détecter l’activité de CDK4/cycline D, biomarqueur établi dans le mélanome. Les informations 
fournies par WWshortRb complémentent celles obtenues par sérologie et histologie et pourraient 
permettre à terme d’établir un test diagnostic pour la détection précoce du mélanome.  
De plus, étant donné que WWshortRb répond de manière sensible à l’inhibition de CDK4 par des 
inhibiteurs spécifiques de cette kinase, il représente une technologie puissante pour les programmes 
de drug discovery. Il permettrait d’évaluer la réponse au traitement et de s’assurer de l’efficacité de 
nouvelles générations d’inhibiteurs de CDK4. 
WWshortRb pourrait être appliqué à la détection de l’hyperactivité de CDK4/cycline D dans d’autres 
cancers présentant une dérégulation de la voie the p16INK4A / CDK4-6 / cycline D / Rb tels que le 
cancer du poumon non à petites cellules (NSCLC). 
WWshortRb constitue une alternative intéressante à la radioactivité ou aux approches antigéniques 
pour étudier l’activité de CDK4/cycline D in vitro. Il permet en plus de rapporter cette activité dans 
des échantillons biologiques complexes tels que le cytoplasme cellulaire ou l’environnement tumoral. 
A notre connaissance, WWshortRb est le premier outil permettant de quantifier l’activité kinase de 
CDK4 dans des biopsies de peau et dans des xénogreffes de mélanome. 
 
Cette technologie peut être améliorée sur plusieurs points, notamment au niveau de la sonde 
fluorescente et sur la stabilité du biosenseur pour les applications in vivo. Des stratégies de 
photoactivation peuvent être envisagées afin de contrôler la période d’observation de la réaction et 
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d’améliorer le ratio signal/bruit. Pour empêcher la dégradation du biosenseur par les protéases, des 
modifications chimiques de la séquence peptidique peuvent être réalisées comme l’incorporation 
d’acides aminés non-naturels ou l’incorporation de liaison pseudo-peptidiques (Gentilucci et al., 
2010). De plus, des formulations avec des vecteurs tels que les microparticules, nanoparticules, 
liposomes ou nanotubes de carbones pourraient également être testées (Patel et al., 2014). 
4.2. Identification d’inhibiteurs non compétitifs de l’ATP ciblant 
CDK4/cycline D 
A. Identification par criblage 
Mise en place d’un criblage haut débit 
Nous avons développé deux biosenseurs CDKCONF4A et CDKCONF4B qui ont été appliqués au 
criblage de deux chimiothèques. Mon travail a d’abord consisté à miniaturiser le test pour l’adapter à 
un format multi-plaques. Les conditions ont été optimisées de façon à réduire la concentration en 
réactifs et le temps de l’expérience. Ayant obtenu un Z-facteur supérieur à 0,5, nous avons procédé 
au criblage. 4% des composés de la CNE et 0,3% de ceux de la banque de Strasbourg ont été retenus 
avec les deux biosenseurs. 
Caractérisation post-criblage 
Les composés retenus ont été revalidés manuellement, à partir de poudres fraîches envoyées par les 
laboratoires d’origine. Des différences de réponse ont été observées entre le crible et la validation 
manuelle, probablement dues au fait que les poudres fraîches, à la différence des solutions 
contenues dans les plaques utilisées lors du criblage, ne contiennent que le composé pur, sans 
produits de dégradation. 
Les deux hits de Strasbourg ont été caractérisés in vitro suite à leur identification par CDKCONF4A en 
tant qu’inhibiteurs protéine-protéine. Des expériences de binding ont été menées en utilisant le 
peptide PISTVRE fluorescent, qui dérive de l’hélice PISTVRE de CDK4. Nous avons montré qu’un seul 
hit interagissait avec ce peptide. Une famille de composés dérivant de ce hit a ensuite été 
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caractérisée. Cette étude a révélé que le choix de la sonde était crucial. En effet, la première sonde 
utilisée, TP2Rho, se liait aux composés et donnait donc des résultats erronés. 
Les expériences in cellulo ont permis de démontrer que certains des dérivés, tels que RF1210 et 
LPI2252, étaient très efficaces pour réduire la prolifération de cellules cancéreuses A375. De plus, 
nous avons montré que ces deux composés étaient capables de coopérer avec d’autres inhibiteurs de 
CDK4 mais également avec des drogues utilisées fréquemment dans le traitement du cancer telles 
que le Paclitaxel et le methotrexate. Ces résultats offrent des perspectives très prometteuses dans le 
traitement du mélanome. 
Conclusions et perspectives 
Suite au criblage, nous avons identifié une famille de dérivés ayant un potentiel inhibiteur 
prometteur sur CDK4. Des simulations de dynamique moléculaire ont permis de montrer que, 
lorsque CDK4/cycline D est dans une conformation ouverte spécifique, ces composés se lient à une 
nouvelle poche, proche de l’hélice PISTVRE de CDK4. Des expériences de binding avec des mutants 
de CDK4 vont permettre de confirmer ce résultat. 
Les composés de la CNE vont également être prochainement caractérisés in vitro et in cellulo. 
Tous ces résultats permettent de mettre en évidence la puissance de la stratégie CDKCONF, basée 
sur la technologie FLiK (Fluorescent Labels in Kinases), pour identifier de nouveaux inhibiteurs non 
compétitifs de l’ATP. 
B. Conception rationnelle de peptides ciblant l’interface entre CDK4 et 
cycline D 
Conception de peptides 
Pour cibler l’interface entre CDK4 et cycline D, nous avons développé une approche basée sur la 
conception rationnelle de peptides. Nous avons conçu deux peptides, PISTVRE et D1, qui dérivent de 
l’hélice PISTVRE de CDK4 et de l’hélice α5 de cycline D respectivement. Nous avons démontré que ces 
peptides inhibent efficacement la croissance des cellules de mélanome lorsqu’ils sont administrés 
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que CADY2. De plus, des expériences de titrations de fluorescence entre des variants de PISTVRE et le 
peptide D1 suggèrent que le variant le plus court, se lie avec la meilleure affinité.  
Conclusions et perspectives 
Le mécanisme d’action des variants de PISTVRE va être déterminé par des expériences in vitro en 
utilisant le complexe CDK4/cycline D recombinant. Leur potentiel inhibiteur vis-à-vis de l’activité de 
CDK4/cycline D sera caractérisé dans des tests d’activité et de prolifération. 
Comparaison des deux stratégies 
Pendant ma thèse, j’ai développé deux stratégies différentes pour inhiber l’activité de CDK4/cycline 
D. En termes de temps et de coûts, la stratégie rationnelle est beaucoup plus intéressante. En effet, 
la miniaturisation et l’optimisation du test HTS prennent du temps et requièrent l’utilisation de 
chimiothèques qui peuvent être coûteuses. De plus, les petites molécules, comparées aux peptides, 
nécessitent des stratégies de vectorisation afin d’être internalisées dans les cellules. Cependant, la 
stratégie de screening permet l’identification de hits ayant des structures chimiques très différentes, 
offrant ainsi une grande possibilité d’optimisation. Les peptides peuvent aussi être optimisés en taille 
et la génération de mutants permet l’identification d’acides aminés essentiels.  
Enfin, notre approche de screening, couplée à de la modélisation moléculaire, a conduit à une 
découverte inattendue, l’identification d’une nouvelle poche allostérique, ce qui n’est pas possible 
avec une approche rationnelle. 
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ABSTRACT 
Uncontrolled proliferation of melanocytes results in melanoma, the most aggressive form of skin cancer, 
which further metastasizes into a deadly form of cancer. The p16INK4a-Cyclin D-CDK4/6-pRb pathway is 
dysregulated in 90% of melanomas and activation of this pathway potently cooperates with mutant BRAF 
or NRAS in transformation of melanocytes. CDK4/Cyclin D kinase hyperactivation, associated with mutation 
of CDK4, amplification of Cyclin D or loss of p16INK4a leads to increased risk of developing melanoma. This 
kinase therefore constitutes a key biomarker and an emerging pharmacological target in melanoma. Here 
we describe the design and characterization of a fluorescent peptide biosensor which reports on CDK4 
activity in vitro and in melanoma cell extracts. CDKACT4 biosensor provides sensitive means of comparing 
CDK4 activity between different melanoma cell lines, and of quantifying differences which cannot be 
identified by simple analysis of protein kinase expression levels, associated with multiple molecular 
alterations that converge on CDK4 kinase activity. This biosensor further allows to quantify response to 
CDK4 inhibitors in cell extracts, providing a direct readout of their efficacy in a fluorescence-based assay. 
Finally CDKACT4 was applied to quantify this enzymatic biomarker in skin biopsies and in melanoma 
xenograft lysates, thereby demonstrating its utility to monitor CDK4 inhibition at an early stage following 
treatment with targeted kinase inhibitors. This first-of-a kind diagnostic tool offers an alternative to 
immunological identification of serological and histological markers, for early-stage detection of melanoma 
onset, progression of the disease and response to therapeutics. 
 
Keywords: 
Fluorescent Biosensor / CDK4/Cyclin D / Kinase activity / Melanoma 
 
SIGNIFICANCE STATEMENT  
Skin cancers, in particular melanoma, constitute an important cause of death worldwide. Although 
antibody-based approaches are currently implemented for detection of several histological and serological 
melanoma-specific biomarkers, new tools are required to monitor enzymatic biomarkers whose 
hyperactivity is associated with the onset and progression of this disease. The p16INK4a-Cyclin D-CDK4/6-pRb 
pathway is dysregulated in 90% of melanomas, resulting in hyperactivity of CDK4 kinase, which promotes 
and sustains uncontrolled cell proliferation. Here we report on the design and development of a 
fluorescent peptide biosensor for quantification of CDK4 activity in melanoma cell extracts, skin biopsies 
and melanoma xenografts. This biosensor constitutes a promising tool for diagnostic and prognostic 
purposes, which affords means of monitoring cancer-associated alterations in kinase activity which are 
complementary to immunological identification of melanoma-specific biomarkers. 
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INTRODUCTION 
Skin cancers constitute an important cause of death worldwide, with an estimated 80 000 deaths a year as 
of 2010, 49 000 of which are due to melanoma. This aggressive and invasive form of skin cancer arises from 
deregulated proliferation of melanocytes, and can metastasize into a deadly form of cancer (1). Several 
morphological, histological and serological biomarkers currently serve to diagnose malignant melanoma 
and establish a prognostic profile, including melanocyte lineage and differentiation antigens such as S100-
beta, melanoma inhibitory activity (MIA) and tyrosinase, proangiogenic factors such as VEGF (Vascular 
Endothelial Growth Factor), molecules involved in cell adhesion and motility such as matrix 
metalloproteinases MMP-1 and 9, cytokines and cytokine receptors IL-6, IL-10 and sIL-2R, HLA molecules 
and other more general cancer biomarkers including C-reactive protein, albumin and lactate 
dehydrogenase (2–4). Histological analysis of skin biopsies constitutes the standard procedure for 
melanoma diagnostics, but remains poorly standardized, and is not implemented to monitor the onset and 
early-stage progression of this disease (5). Moreover, immunohistochemistry and ELISA convey information 
concerning the presence and relative abundance of biomarkers, but do not translate mutations in pathways 
that alter enzymatic activities associated with deregulated cell growth and proliferation. Hence, new tools 
are required to provide complementary information concerning enzymatic biomarkers of interest for 
diagnostic and prognostic purposes. 
More recent genetic, transcriptomic and proteomic profiling studies have led to characterization of the 
landscape of genomic mutations in cutaneous melanoma, to identification of driver mutations and 
establishment of a framework for genomic classification of melanoma into four subtypes based on the most 
prevalent significantly mutated genes (6, 7). These studies highlight molecular pathways and targets which 
offer new perspectives for the development of complementary diagnostic and therapeutic tools. In 
particular, the cyclin-dependent kinase CDK4 has been identified as an emerging pharmacological target in 
human melanoma (8–10). This serine/threonine kinase associates with D-type cyclins and integrates stimuli 
that promote exit from quiescence, entry into and progression through G1, through phosphorylation of its 
substrate, the Retinoblastoma tumour suppressor protein (pRb) (11). The p16INK4a-Cyclin D-CDK4/6-pRb 
pathway is dysregulated in 90% of melanomas and CDK4 hyperactivation may occur through various 
fashions, including mutation of CDK4 (R24C) which prevents binding of the endogenous inhibitor p16INK4a, 
amplification of Cyclin D (18% melanomas), genetic deletion or loss-of-function of its endogenous inhibitor 
p16INK4a (deletion of CDK2NA in 50-60% metastatic tumours) (12, 13). Moreover in both human and mouse 
models of melanoma, activation of the CDK4 pathway potently cooperates with mutant BRAF or NRAS in 
transformation of melanocytes (14) inferring that combination strategies utilizing inhibition of 
complementary oncogenic pathways may offer a very promising approach (9). Furthermore, recent data 
suggest that cell cycle inhibition by CDK4 inhibitors sensitizes melanoma cells to compounds that induce 
apoptosis (15). Taken together, these studies identify CDK4/Cyclin D activity as a relevant biomarker of 
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melanoma, and suggest that tools reporting on CDK4 kinase activity and assays enabling quantification of 
its hyperactivity directly from skin biopsies would offer promising means of identifying the onset of 
melanoma and monitoring progression of this disease. 
In this study we describe a fluorescent peptide biosensor that reports on CDK4/Cyclin D kinase activity 
through sensitive changes in fluorescence intensity. We show that this biosensor responds to recombinant 
CDK4/Cyclin D1 and can report on CDK4 activity in melanoma cell extracts, thereby enabling quantification 
of differences in kinase activity which cannot be identified by simple analysis of protein kinase expression 
levels, associated with molecular alterations in individual components of the p16INK4a-Cyclin D-CDK4/6-pRb 
pathway. This biosensor further reports on CDK4 kinase inhibition following treatment with small molecule 
inhibitors or siRNA, thereby allowing to assess their overall efficacy in a physiologically-relevant 
environment. Finally we show that this technology can be readily be implemented to probe CDK4 activity in 
skin biopsies and in melanoma xenograft lysates, thereby constituting an attractive tool for diagnostics, 
prediction of pathological progression and response to therapeutics targeting the CDK4 biomarker.   
 
RESULTS 
Design and characterization of a CDK4-specific protein biosensor  
Although CDK4/Cyclin D kinase constitutes an established biomarker and pharmacological target in 
melanoma, there are no means of probing its hyperactivity in a sensitive and quantitative fashion. Indeed, 
the larger part of technologies to probe this kinase activity currently rely on radioactivity or antibody-based 
approaches. Therefore, in order to probe CDK4/Cyclin D activity, we engineered a CDK4-specific protein 
biosensor derived from a previously-developed biosensor that responds to overall CDK/Cyclin activity 
through sensitive changes in fluorescence intensity (16). CDKACTRb was designed by incorporating a 
substrate sequence derived from the phosphorylation site of Retinoblastoma protein (Rb) which is 
specifically phosphorylated by CDK4/Cyclin D (S795) (17) with the phosphoamino acid binding domain 
(PAABD) derived from Polo-box domain of Plk1, devoid of cysteine residues (16) (Fig.1A). When CDKACTRb 
was labelled with a Cy3 dye on the unique cysteine proximal to the phosphorylation site of the Rb substrate 
sequence, this protein biosensor responded to recombinant CDK4/Cyclin D1 through enhancement of 
fluorescence emission (20-25%), inferring an intramolecular interaction between the PAABD and the 
phosphorylated substrate moiety that alters the local environment of the probe, as reported for the 
generic CDKACT biosensor. Moreover this fluorescence enhancement was significantly reduced upon 
addition of the CDK4-specific inhibitor PD-0332991 (Fig.1B). CDKACTRb further reported on endogenous 
CDK4 activity from A375 melanoma cell extracts in a dose-dependent fashion, since addition of increasing 
concentrations of PD-0332991 reduced the fluorescent signal of CDKACTRb accordingly (Fig.1C and 1D). 
These results further allowed to determine an IC50 value of 5.9 µM for PD-0332991 using A375 melanoma 
cell extracts (Fig.1D and Fig.S1), a value which reflects the inhibitory efficiency of this compound in a more 
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physiological context than with the purified recombinant kinase alone. In contrast, other CDK kinase 
inhibitors (Roscovitine, RO3306, AT7519) and other protein kinase inhibitors (PP2, H89, U0126) had no 
significant effect on CDKACTRb fluorescence, inferring it responds specifically to CDK4 activity (Fig.1E and 
1F). 
Development of a CDK4-specific peptide biosensor 
Preparation of the CDKACTRb protein biosensor requires expression and purification of a recombinant 
protein scaffold with limited yield and long-term storage, since it suffers from degradation over time. To 
circumvent this issue, we designed a bipartite modular peptide derivative of CDKACTRb, which can be 
readily synthesized at a large-scale and stored in a lyophilized form. This peptide derivative (WWRb) bears 
the same Rb substrate and a short PAABD derived from the WW domain of the prolyl-isomerase Pin1, 
which was previously used as a phosphorecognition domain in a hybrid biosensor (18) (Fig.2A). However, 
following labelling of this peptide biosensor on the unique cysteine at position -2 relative to the serine 
group phosphorylated by CDK4/Cyclin D, we found that it failed to respond in a robust and reproducible 
fashion (Fig.S2). We hypothesized that this might be due to a lack of proper conformation of the WW 
domain, and therefore designed a shorter artificial PAABD derived from the interface of the WW domain of 
Pin1 with a phosphopeptide substrate. Analysis of the crystal structure of this domain complexed to a 
phosphopeptide substrate (PDB 1F8A) led us to identify Arg14, Arg17, Tyr23 and Phe25, as well as Trp34 as 
critical residues for the interaction with the phosphosubstrate (GWEKRMSRSSGRVYYFNHITNASQWERPSG) 
(Fig.2B). We therefore synthesized a short peptide derivative of this WW domain (WWshort) which 
comprises these key residues in the linear order of appearance that mimicks the interface (Phe25, Arg14, 
Tyr23, Arg17) interspaced by small uncharged amino acids, and which ends with Trp34 followed by the 
same five amino acids as in the native WW domain of Pin1 (GFARVYMSRSSGWERPSG). Titration 
experiments performed with an FITC-labelled Rb substrate peptide revealed that the WWshort peptide 
indeed interacted with the phosphorylated form of Rb substrate peptide with a dissociation constant value 
of 80 +/- 37 nM, similar to the long WW peptide (118 +/- 37 nM) (Fig.2C). In comparison the WWshort and 
WWlong peptides bound the unphosphorylated substrate peptide with significantly lower dissociation 
values 628 +/- 109 nM and 675 +/- 260 nM, indicating that they preferentially bind the phosphorylated 
substrate, as expected from a PAABD (Fig.S3). Moreover, in both cases, the WWshort peptide promoted 
greater fluorescence enhancement of the fluorescently-labelled Rb substrate than its native counterpart, 
suggesting it was better suited as a PAABD for a biosensing application. We further asked whether the Rb 
substrate peptide could bind the recombinant form of CDK4. Indeed the FITC-labelled Rb substrate peptide 
bound monomeric GST-CDK4 with a dissociation constant value of 30 +/- 5 nM and its affinity increased to a 
Kd value of 7+/- 3 nM when the kinase was complexed to Cyclin D1 (Fig.2D), as expected from studies 
showing that the substrate preferentially binds the catalytic cleft of heterodimeric CDK2/Cyclin A, which is 
conformationally more favourable than that of monomeric CDK2 (19).We therefore synthesized a CDK4 
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peptide biosensor, CDKACT4, comprising the WWshort peptide followed by the Rb substrate sequence. This 
peptide biosensor was further implemented to monitor response to recombinant CDK4 kinase in vitro in 
the presence of ATP and MgCl2, following labelling of the unique cysteine within the substrate sequence 
with TAMRA. Analysis of changes in fluorescence intensity over time revealed that monomeric CDK4 bound 
the biosensor, inducing fluorescence enhancement of 40%, but that the biosensor responded to 
CDK4/Cyclin D1 complex further, with a net increase in relative fluorescence intensity (60%). The relative 
increase in fluorescence reached 75% when CDK4/CyclinD1 was preincubated with the CDK-activating 
kinase (to phosphorylate the activation loop), inferring that the kinase is catalytically more active in these 
conditions; in contrast, activity was partially reduced (55%) upon incubation with the CDK4 inhibitor PD-
0332991 (Fig.2E).  
We further implemented the TAMRA-labelled CDKACT4 peptide biosensor to probe CDK4/Cyclin D kinase 
activity in A375 melanoma cell extracts, which resulted in a robust increase in fluorescence (similar to the 
enhancement profile observed with recombinant CDK4/Cyclin D1), whereas TAMRA-labelled Rb substrate 
peptide did not exhibit any change in fluorescence (Fig.3A). In contrast, a Cy3 or Dylight-650-labelled 
CDKACT4 peptide barely responded to CDK4 activity in cell extracts, indicating that the response is 
associated with the sensitivity of the dye conjugated to the peptide (Fig.S4). The fluorescence of the 
TAMRA-CDKACT4 peptide biosensor was decreased upon treatment of cells with the CDK4 inhibitors PD-
0332991 and LY2835219 in a dose-dependent fashion, but not upon addition of Roscovitine, which 
preferentially inhibits CDK2,CDK1,CDK5, CDK7 and CDK9 (Fig.3B). Neither PD-0332991, Roscovitine, 
LY2835219 nor DMSO had any significant effect on the fluorescence of TAMRA-CDKACT4 peptide biosensor 
(Fig.S5). Likewise, the biosensor reported on a reduced CDK4 activity in A375 cells in which CDK4 protein 
levels were reduced following treatment with siRNA targeting CDK4 (Fig.3C). Finally, CDKACT4 peptide 
biosensor was implemented to identify fractions bearing CDK4 activity following fractionation of A375 cell 
extracts by gel filtration chromatography (Fig.3D). 
These results reveal that the CDKACT4 peptide biosensor, comprising a short artificial phosphorecognition 
domain derived from the WW domain of Pin1 and a substrate sequence derived from Rb, constitutes a 
specific and sensitive tool to quantify CDK4 activity in melanoma cell extracts following treatment with 
selective inhibitors or downregulation of kinase levels by RNA silencing. 
We next addressed whether CDKACT4 peptide biosensor was suited to quantify differences in CDK4 
hyperactivity in different cell lines. First, comparison of the biosensor response to cell extracts from healthy 
fibroblasts and the A375 melanoma cell line revealed a significantly greater activity in A375 cells, consistent 
with the lack of control of CDK4 in this cell line due to p16INK4a loss of function (Fig.4A and 4B). We next 
asked whether CDKACT4 could serve to measure sensitive differences in CDK4 activity between melanoma 
cell lines harbouring different molecular alterations that ultimately converge on CDK4/Cyclin D activity. 
Specifically, CDKACT4 was incubated with normalized extracts derived from cell lines harbouring different 
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combinations of wild-type or loss-of function p16INK4a (the endogenous inhibitor of CDK4), wild-type or 
mutated CDK4 (R24C mutation which prevents the binding of p16INK4a), BRaf and NRas. Fluorescent profiles 
of the CDKACT4 peptide biosensor revealed the highest CDK4 activity in A375 (CDKN2A loss of function, 
BRaf V600E), Mewo (CDKN2A loss of function, Wt CDK4) and SK-MEL28 (R24C CDK4, BRaf V600E) cell lines, 
followed by SK-MEL2 (NRas mutation (Q61R)) (Fig.4C and 4D). Quantification of the relative fluorescence 
intensity values at the plateau of response in a histogram clearly reveals significant differences in CDK4 
activity between these cell lines (Fig.4D). These response profiles are consistent with the genotypes of 
these strains in which loss of function of CDKN2A or mutation of the R24C CDK4 mutant both lead to 
unrestricted, constitutive activity of CDK4 in A375, SK-MEL28 and Mewo cell lines, in comparison with SK-
MEL2 cell line which bears wild-type CDK4, p16INK4a and pRb. Importantly, the information provided by the 
biosensor differs from the protein expression profiles revealed by Western blotting, which do not predict 
any major differences in CDK4 activity between the different melanoma cell lines (Fig.4E and 4F). 
Taken together these experiments show that the CDKACT4 peptide biosensor is a useful tool to compare 
and quantify differences in CDK4/Cyclin D kinase activity between different melanoma cell lines, which 
cannot be identified by quantification of protein kinase expression levels alone, as they reflect mutations or 
molecular alterations in components of the p16INK4a-Cyclin D-CDK4/6-pRb pathway which ultimately 
converge on CDK4 kinase activity. 
 
Quantifying CDK4/Cyclin D activity in skin biopsies and melanoma xenograft lysates 
Since the CDKACT4 peptide biosensor responded to CDK4 activity in melanoma cell extracts and reported 
differences between cell lines with different p16INK4a and CDK4 genotypes, we asked whether it could be 
applied to quantify CDK4 activity in skin biopsies. First, we assessed and calibrated its response to different 
concentrations of total healthy skin samples, relative to A375 cell extracts (Fig.5A). As with melanoma cell 
extracts, CDKACT4 fluorescence was decreased by addition of PD-0332991 (Fig.5B). We further sought to 
determine whether CDK4 activity could be detected in the dermis or epidermis, and found that it was 
essentially present in the latter (Fig.5C), consistent with the fact that rapidly dividing cells are found in the 
epidermis. 
Finally we asked whether CDKACT4 could be implemented to monitor subtle differences in CDK4 activity in 
tumour xenografts following short- and long-term administration of kinase inhibitors. To this aim, we 
implanted the melanoma cell line A375 subcutaneously into the flank of nude mice and after 24 days of 
tumour growth, mice were treated daily orally either with the CDK4 inhibitor PD-0332991 at 150 mg/kg for 
3 or 7 days, or 75 mg/kg for 7 days, or with the CDK2/5/7/9 inhibitor Roscovitine at 50 mg/kg for 5 or 11 
days. Following treatment with PD-0332991, we did not observe any growth inhibition of melanoma 
tumour xenografts (Fig. S6), nor any specific decrease in CDK4 protein levels (Fig. S7). Likewise treatment 
with Roscovitine had no major effect after 5 days, but significantly affected tumour growth after 11 days 
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(Fig. S6).  Biopsies of the xenografted tumours from three mice for each of these conditions were lysed and 
cell extracts incubated with TAMRA-labelled CDKACT4 peptide biosensor. We further normalized the 
response of CDKACT4 to that of luciferase activity of the A375 xenograft lysates, to minimize any 
differences that might be associated with tumoral heterogeneity, and found that all samples responded in a 
consistent fashion (Fig. 6 and Fig. S8). Indeed, these experiments revealed that 150 mg/kg PD-0332991 had 
no inhibitory effect on CDK4 activity after three days of treatment. However, CDK4 activity began to 
decrease slightly after 7 days of treatment with 150 mg/kg and 75 mg/kg PD-0332991. In contrast, 
treatment of A375 xenografted tumours with 50 mg/kg Roscovitine, whether for 5 or 11 days, had no 
significant effect on CDKACT4 fluorescence, although the latter treatment clearly affected tumour growth, 
consistent with the inhibitory action of this compound towards CDKs other than CDK4/6. 
Taken together our results show that CDKACT4 peptide biosensor can be implemented to quantify 
CDK4/Cyclin D kinase activity in skin biopsies and melanoma xenografts, thereby reporting on CDK4 
inhibition in a sensitive and specific fashion. Moreover our results demonstratethe utility of this technology 
to monitor inhibition of CDK4 by small molecule drugs targeting this kinase, at early stages when 
measurement of tumoral volumes does not yet reflect any detectable effect of these drugs. 
 
DISCUSSION 
The limited efficacy of current therapeutics for treatment of melanoma and the lack of diagnostic assays to 
detect the onset of this disease calls for new strategies to probe relevant melanoma-specific biomarkers at 
an early stage and monitor their response to targeted therapeutics. The development of novel technologies 
is indeed essential since melanoma can be readily treated if detected at an early stage, but is incurable 
once it metastasizes. In particular enzymatic activities associated with dysregulated molecular signaling 
pathways constitute attractive biomarkers that may reflect the molecular alterations of one or several 
upstream regulatory partners, thereby complementing existing immunological approaches. 
Fluorescent biosensors constitute potent tools for reporting on enzymatic activities in complex biological 
samples such as the cellular cytoplasm or the tumoral environment. Over the past decade, a wide variety of 
fluorescent biosensors have been developed to monitorand image enzymatic activities in living cells and 
have more recently proven to constitute attractive tools for biomedical applications (20). Indeed, several 
genetically-encoded FRET-based fluorescent biosensors have been developed to monitor aberrant kinase 
activity associated with cancer, such as the Bcr-Abl biosensor implemented to measure hyperactivity in 
cells of CML patients (21) or the Src biosensor applied to study spatial control of Src in pancreatic cancer by 
intravital FLIM-FRET imaging (22). However, these systems require transfection and time for ectopic 
expression in living cells and are therefore not adapted for diagnostic assays using cell extracts or biopsies. 
In contrast, non-genetic fluorescent reporters based on polymeric or polypeptide scaffolds are well suited 
for such applications, since they can directly be incubated with enzymes or lysates containing activities to 
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be probed, and can further be conjugated to a large choice of synthetic probes, providing a controlled 
platform which can be readily implemented to probe specific targets of interest (23). Several non-genetic 
biosensors have been engineered to monitor extracellular proteolytic activities, such as metalloproteases 
secreted at the tumour site (24, 25). Moreover a wide variety of peptide biosensors have been developed 
to probe protein kinase activities (26, 27). These include peptide biosensors conjugated to solvatochromic 
probes, which respond either directly to proximal phosphorylation within the substrate sequence of the 
biosensor by kinases such as PKA, PKC, ERK, Bcr-Abl, Lyn and Abl (28–32), or indirectly following 
interactions with phosphorecognition domains that alter biosensor fluorescence, or through 
quenching/unquenching strategies (33–35). The recent implementation of fluorescent peptide biosensors 
to monitor kinase activities in cell extracts offers promising perspectives. However, to date, none of these 
chemical tools has been applied to quantify kinase activities in skin or tumour biopsies. 
CDK4/Cyclin D kinase constitutes an established biomarker and pharmacological target in melanoma, 
hyperactivity of which is associated with mutations in the p16INK4a-Cyclin D-CDK4/6-pRb pathway. Here we 
report on a new fluorescent biosensor, which constitutes a potent tool for probing CDK4 activity in cell 
extracts, skin biopsies and melanoma xenograft lysates, thereby providing a scaled and predictive readout 
of this enzymatic cancer biomarker. Besides being the first CDK4-specific biosensor, this bipartite peptide 
offers a novel and original design comprising a substrate sequence derived from Rb and an artificial 
phosphorecognition motif derived from the interface of a WW domain. Since this biosensor responds to 
CDK4 activity through changes in fluorescence intensity, it offers a straightforward and sensitive means of 
monitoring kinase activity in a continuous fluorescence-based assay over time. We show here that 
CDKACT4 is well suited to quantify differences in CDK4 activity in lysates from different cell lines, thereby 
highlighting alterations that cannot be identified by Western blot analysis of protein kinase expression 
levels. Moreover this biosensor provides means of assessing the efficacy of CDK4 inhibitors in a more 
physiologically-relevant environment than in buffer containing purified recombinant kinase, thereby 
offering promising perspectives for drug discovery programs.  
Our work highlights the potency of fluorescent biosensors to monitor cancer-associated alterations in 
kinase activity, thereby offering an alternative to antibody-based approaches for developing diagnostic 
assays, and providing essential information for tailored therapeutic intervention. CDKACT4 biosensor 
constitutes a first-of-a kind tool for detection of a relevant enzymatic biomarker in melanoma, CDK4 kinase 
activity, and we anticipate it will enable to establish a diagnostic assay for monitoring melanoma onset, 
early-stage progression of this disease and response to therapeutics. 
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MATERIALS AND METHODS 
 
Design and engineering of CDKACTRb protein biosensor. CDKACTRb was engineered by replacing the 
substrate sequence of CDKACT derived from histone H1 (16) by a substrate sequence derived from Rb in 
which the proline at position -2 relative to the SP phosphorylation site 795 was replaced by a cysteine 
residue.  
The complete sequence of CDKACTRb is as follows:  
GEVVDSHLSDMLQQLHSVNASKPSERGLVRQEEAEDPASIPIFWVSKWVDYSDKYGLGYQLSDNSVGVLFNDSTRLILYND
GDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQI
NFFQDHTKLILSPLMAAVTYIDEKRDFRTYRLSLLEEYGSSKELASRLRYARTMVDKLLSSRSASNRLKASEFPGAGGTGLPGG
YKFCSSPLRIPG. 
 
GST-CDKACTRb was expressed in E. coli BL21pLyS following induction with 0.5 mM IPTG, at 20°C overnight, 
then purified on High Performance Glutathione Sepharose (GE Healthcare) in 50 mM Tris HCl, pH 7.4, 150 
mM NaCl, and eluted with 50 mM glutathione in the same buffer, followed by gel filtration chromatography 
on Superdex75 (GE Healthcare) in the same buffer. Following purification, CDKACTRb was labelled with a 
10-fold molar excess of Cy3-maleimide, then further purified on NAP5 columns in 50 mM Tris HCl, pH 7.4, 
150 mM NaCl, to remove excess label.  
 
Design and synthesis of CDKACT4 peptide biosensors and derived peptides. 
Peptides were synthesized by GLSBiochem and purified to 95%. 
The long WW peptide was derived from the native WW domain of Pin1 previously described by Anai et al. 
to generate a phosphopeptide hybrid biosensor (residues 6-39) (18). The shorter version was derived from 
the residues that line the interface with the phosphopeptide in the crystal structure of WW Pin1 complexed 
to a phosphopeptide substrate (PDB 1F8A). 
The Rb substrate peptide was derived from the sequence around S795. 
WW long GWEKRMSRSSGRVYYFNHITNASQWERPSG 
WW short GFARVYMSRSSGWERPSGG 
Rb substrate GGYKFCSSPLRIPG 
PhosphoRb substrate GGYKFCSpSPLRIPG 
WWRb GWEKRMSRSSGRVYYFNHITNASQWERPSG GG YKFCSSPLRIPG 
CDKACT4 GFARVYMSRSSGWERPSGG YKFCSSPLRIPG 
 
Protein expression and purification of cyclin-dependent kinases. Recombinant GST-CDK4, GST-Cyclin D1 
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and GST-CIV, the CDK-activating kinase of Saccharomyces cerevisiae, were expressed in E. coli by IPTG 
induction and purified by chromatography as described previously (36). GST-CDK4 / Cyclin D1 complex was 
formed following individual purification of each subunit and stoichiometric incubation, then further 
incubated with GST-CIV to ensure its complete activation. 
 
Fluorescence titration assays. Fluorescence titration assays were performed in 96-well plates in a 
thermostated chamber (Polarstar, BMG) at 30°C in 200 mL phosphate buffer saline with 200 nM 
concentration of FITC-labelled species (Rb peptide or Rb phosphopeptide). Changes in fluorescence 
emission were recorded at 520 nm following excitation at 495 nm. Data analysis was performed using the 
GraFit Software (Erathicus Ltd) and curve fitting was performed using a quadratic equation, as described in 
(36).  
 
Fluorescence kinase assays. Fluorescence kinase assays were performed in 96-well plates in a 
thermostated chamber (Polarstar, BMG) at 30°C in 200 mL phosphate buffer saline supplemented with 5 
mM MgCl2, 0.5 mM ATP, except when stated otherwise. Changes in TAMRA and Cy3 fluorescence emission 
were recorded at 570 nm following excitation at 544 nm. In all experiments, relative fluorescence was 
calculated following subtraction of CDKACTRb-Cy3 or CDKACT4-TAMRA fluorescence from fluorescence 
values obtained in the presence of protein kinases, inhibitors or cell extracts. Data analysis was performed 
using the GraFit Software (Erathicus Ltd). Experiments were performed in triplicate, and error bars indicate 
standard deviation from average. Histograms represent relative fluorescence intensity values after 5000s, 
unless specified otherwise.  
 
Inhibitors. Roscovitine, PD-0332991, LY2835219, AT7519, H89 and U0126 were purchased from 
Euromedex. RO3306 was purchased from CalbioChem. PP2 was purchased from Sigma. All stock solutions 
were made in DMSO and diluted in PBS to the desired concentration freshly prior to use. For animal 
experiments, PD-0332991 and Roscovitine were diluted in sodium lactate buffer 50 mM. 
  
Cell culture and extract preparation. Cell culture media, serum and antibiotics were purchased from 
Invitrogen. All cell lines were cultured in DMEM/RPMI + Glutamax supplemented with 10% FCS, 100 
units/mL penicillin (G sodium salt) and 100 µg/mL streptomycin at 37°C in an atmosphere containing 5% 
CO2.  
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Melanoma cell lines used in this study:  
  CDKN2A  CDK4  Rb BRAF  NRAS  
A375 mutated (E61Stop, Loss of function) WT WT V600E WT 
Mewo mutated (R80Stop, Loss of function) WT WT WT WT 
SK-MEL2 WT WT WT WT mutated (Q61R) 
SK-MEL28 WT R24C 
 
V600E WT 
 
siRNA targeting CDK4 were purchased from Santa Cruz (sc-29261). Internalization of siRNA in cells was 
performed using CADY peptide (37). Unsynchronized A375 cells were cultured to 60% confluence. A375 
cells were treated with complexes of siRNA (100 nM) / CADY (4 µM) (1/40 ratio) for 48h. 
Cell extracts were prepared in PBS lysis buffer containing PBS (Sigma), pH 7.4, 150 mM NaCl, 0.2% NP40, 1 
mM EDTA, 2 mM PMSF, CompleteTM protease inhibitors (Roche), and normalized following 
spectrophotometric dosage at 280 nm. 
Fractionation of A375 cell extracts prepared from 5 million cells in 500 µL PBS lysis buffer was performed by 
gel filtration chromatography on a Superose 6 10/300 GL column (GE Healthcare). 500 µL fractions were 
collected and 50 µL were used for kinase activity assays. 
 
Western blotting. Polyclonal rabbit anti-CDK4 antibody was purchased from Santa Cruz (sc-260). 
Monoclonal mouse α-tubulin antibody was purchased from Amersham (N356). Polyclonal rabbit anti-actin 
antibody was purchased from Cell Signaling (4967). 
 
Preparation of extracts from skin biopsies. Epidermis and dermis were separated by addition of 
thermolysine (0.5 mg/mL diluted in PBS (Sigma)) for 3h at 37°C. Total proteins were extracted from frozen 
skin biopsies in 50 mM Trizma Base, 0.5 M NaCl, 5 mM EDTA, 0.6% NP40 and grinding with an Ultra 
TurraxTM, then normalized following spectrophotometric dosage at 280 nm. 
 
A375 xenografts in mice. All animal experiments were conducted in agreement with the Principles of 
Laboratory Animal Care (National Institutes of Health publication no. 86-23, revised 1985) and approved by 
the regional ethics committee. Female 6 weeks old NMRI nude mice (Janvier, Le Genest- Isle, France) were 
anesthetized (isoflurane/oxygen 3.5% for induction and 1.5% thereafter) and 3.106 A375 (luciferase-
transfected) cells in 200 µL phosphate-buffered saline were implanted subcutaneously into the flank of 
mice and after 24 days of tumour growth, when tumours had reached 257 +/- 64 mm3, mice were treated 
daily orally with CDK4 inhibitor PD-0332991 at 150 mg/kg or 75 mg/kg for 7 days, or 150 mg/kg for 3 days, 
or through intraperitoneal injection with the CDK2/5/7/9 inhibitor Roscovitine at 50 mg/kg for 5 or 11 days. 
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Mice were then sacrificed and tumours were collected and frozen. Total proteins were extracted from 
tumour samples by addition of a luciferase cell culture lysis reagent (25 mM Tris-phosphate pH 7.8, 2 mM 
DTT, 2 mM EDTA, 10% glycerol, 1% Triton X-114) and grinding with an Ultra TurraxTM, then normalized to 
the proportion of cancer cells (A375 luciferase) (Victor3 V luminescence microplate reader, Perkin Elmer). 
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FIGURE LEGENDS 
Figure 1. The CDKACTRb protein biosensor responds specifically to recombinant CDK4/Cyclin D1 and 
CDK4 activity from melanoma cell extracts. (A) CDKACTRb biosensor consists of a CDK4-specific substrate 
sequence derived from pRb in which a cysteine residue was introduced at position -2 relative to the SP 
phosphorylation site (795), and a phospho amino acid-binding domain derived from the PBD of Plk1 (16) 
which recognizes the substrate sequence phosphorylated by CDK4/Cyclin D kinase. (B) Fluorescence of 50 
nM CDKACTRb-Cy3 was monitored over time upon incubation with 75 nM active recombinant CDK4/Cyclin 
D1 alone (open circles) and with 20 µM PD-0332991 (black circles). (C) Fluorescence of 25 nM CDKACTRb-
Cy3 was monitored over time upon incubation with 10 µg A375 cell extracts +/- PD-0332991 alone (open 
circles) and with 20 µM PD-0332991 (black circles). (D) Fluorescence of 25 nM CDKACTRb-Cy3 was 
monitored upon incubation with 10 µg A375 cell extracts +/- different concentrations of PD-0332991 
(CDK4/6 inhibitor), or (E) Roscovitine (CDK1/2/5/7/9 inhibitor), RO3306 (CDK1 inhibitor), AT7519 
(CDK2/4/5/9 inhibitor), (F) PP2 (Src inhibitor), U0126 (MAPK inhibitor) or H89 (PKA inhibitor). 
 
Figure 2. Design and characterization of the CDKACT4 peptide biosensor. (A) CDKACT4 peptide biosensor 
consists of a substrate sequence derived from pRb (as in CDKACTRb), and a phospho amino acid-binding 
peptide derived from the interface of Pin1 WW domain with a phosphorylated substrate peptide. (B) The 
Arg, Tyr, Phe and Trp residues at interface between Pin1 WW domain (green) that recognize a 
phosphorylated peptide (yellow) are highlighted in pink (Arg) and orange (Tyr, Phe and Trp) (PDB 1F8A). (C) 
Fluorescence titration of 200 nM FITC-labelled phospho-Rb peptide with full-length WW peptide (triangles) 
and WWshort peptide (circles). (D) Fluorescence titration of 200 nM FITC-labelled Rb substrate peptide 
with monomeric GST-CDK4 (triangles) and GST-CDK4/Cyclin D1 complex (circles). (E) Fluorescence profile of 
150 nM TAMRA-labelled CDKACT4 peptide biosensor incubated with 75 nM recombinant GST-CDK4 (black 
triangles), GST-CDK4/Cyclin D1 (black circles) or GST-CDK4/Cyclin D1 preincubated with the CDK-activating 
kinase CIV to phosphorylate Thr172 (open circles) and with 10 µM PD-0332991 (open triangles). 
 
Figure 3. Monitoring CDK4/Cyclin D activity in melanoma cell extracts. Fluorescence of 150 nM TAMRA-
labelled CDKACT4 peptide biosensor was monitored over time upon incubation with (A) 40 µg A375 cell 
extracts (circles) and compared to the 150 nM TAMRA-labelled Rb substrate peptide alone (triangles). (B) 
40 µg A375 cell extracts treated with 0 µM (open circles), 1 µM (black circles), 5 µM (open triangles), 10 µM 
(black triangles), 20 µM (open squares) PD-0332991, Roscovitine or LY2835219. (C) 40 µg A375 cell extracts 
untreated (open circles) or treated with siRNA targeting CDK4 (black circles) and Western blot of CDK4 and 
tubulin protein levels from these cell extracts.(D) Histogramme representation of CDK4 activity measured in 
fractions of A375 cell extracts purified by gel filtration chromatography (Superose 6) and Western blot of 
CDK4 levels in the same fractions. 
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Figure 4. Monitoring CDK4/Cyclin D activity in different melanoma cell lines. Fluorescence of 150 nM 
TAMRA-labelled CDKACT4 peptide biosensor was monitored over time upon incubation with (A and B) 40 
µg A375 cell extracts (circles) or fibroblasts (triangles) (C and D) 40 µg from melanoma cell lines A375 (open 
circles), Mewo (open triangles), SK-MEL2 (black triangles), SK-MEL28 (black circles). Histogramme 
quantifications in B and D represent relative fluorescence values of the assay at 5000s. (E) Western Blot of 
CDK4 levels in these different melanoma cell lines. (F) Quantification of CDK4/Actin levels. 
 
Figure 5. Quantifying CDK4/Cyclin D activity in skin biopsies. Fluorescence of 150 nM TAMRA-labelled 
CDKACT4 peptide biosensor was monitored over time upon incubation with skin biopsies. Results are 
presented as histograms corresponding to the average of fluorescent intensity measurements at 5000s in 
duplicate experiments with standard deviation bars. (A) Concentration-dependent response to healthy skin 
samples compared to 50 µg A375 cell extracts. (B) Inhibition of response to CDK4/Cyclin D activity upon 
addition of 20 µM PD-0332991 to 100 µg skin samples. (C) Differential response to 50 µg total proteins 
extracted from dermis versus epidermis. 
 
Figure 6. Response of CDKACT4 peptide biosensor to CDK4 activity in A375 xenografts treated with PD-
0332991.  
Fluorescence of 150 nM TAMRA-labelled CDKACT4 peptide biosensor, following incubation with 100 µL 
total proteins extracted from A375 tumour xenografts, normalized to luciferase activity measured in the 
same samples, and normalized to control (untreated samples) (A) from mice treated orally and daily with 
PD-0332991 at 150 mg/kg for 3 or 7 days, or with 75 mg/kg for 7 days (B) with Roscovitine at 50 mg/kg for 
5 or 11 days.  Histogrammes represent experiments performed in duplicate from three mice for each 
condition and relative to control (untreated) tumour samples. 
 
Supplementary Figure 1. Dose–dependent inhibition of CDK4/Cyclin D activity monitored thanks to the 
CDKACTRb protein biosensor. (A) Fluorescence response of 25 nM Cy3-CDKACTRb protein biosensor to 10 
µg A375 cell extracts treated with PD-0332991. (B) IC50 Plot - representation of the relative fluorescence of 
CDKACT4 biosensor at 8000 s, incubated with 10 µg A375 cell extracts and increasing concentrations of PD-
0332991. 
 
Supplementary Figure 2. Fluorescence response of 50 nM Cy3- and TAMRA-labelled WWRb peptide 
biosensor comprising the full-length native WW motif upon incubation with 20 µg A375 cell extracts alone 
(triangles) and with 20 µM PD-0332991 (circles). 
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Supplementary Figure 3. Titration of FITC-labelled unphosphorylated Rb substrate peptide with WW short 
(circles) and WW long peptide (triangles). 
 
Supplementary Figure 4. (A) Comparative response of 50 nM TAMRA-labelled (circles) and Cy3-labelled 
(triangles) CDKACT4 peptide biosensor incubated with 20 µg A375 cell extracts. (B) Comparative response 
of 150 nM TAMRA-labelled (circles) and Dylight-650-labelled (triangles) CDKACT4 peptide biosensor 
incubated with 40 µg A375 cell extracts. 
 
Supplementary Figure 5. CDKACT4 peptide biosensor does not respond to PD-0332991, Roscovitine, 
LY2835219 or DMSO. Fluorescence of 150 nM TAMRA-labelled CDKACT4 measured in the presence of 
increasing concentrations of (A) PD-0332991, (B) Roscovitine, (C) LY2835219, and (D) DMSO (no kinase or 
cell extracts). 
 
Supplementary Figure 6. Growth curves of A375 xenografts treated with PD-0332991 or Roscovitine. 
Growth curves of A375 xenografts implanted in mice and treated with PD-0332991 at 150 mg/kg for 3 or 7 
days, or with 75 mg/kg for 7 days, or Roscovitine at 50 mg/kg for 5 or 11 days. Control : mock treated mice. 
Arrows indicate time of treatment. 
 
Supplementary Figure 7. CDK4 protein levels remain constant in tumour xenografts treated with PD-
0332991 
Western blot of CDK4 levels in the A375 xenograft extracts used in the first set of tumour xenografts 
prepared for measuring CDK4 activity in Figure 6. 
 
Supplementary Figure 8. Response of CDKACT4 peptide biosensor to CDK4 activity in A375 xenografts 
treated with PD-0332991 or Roscovitine. 
Fluorescence of 150 nM TAMRA-labelled CDKACT4 peptide biosensor following incubation with 100 µL total 
proteins extracted from A375 xenografted tumour biopsies and normalized to luciferase activity measured 
in the same tumour sample, (A) from mice treated orally and daily with PD-0332991 at 150 mg/kg for 3 or 7 
days, or with 75 mg/kg for 7 days, or (B) Roscovitine for 50 mg/kg for 5 or 11 days. Each mouse sample was 
treated in duplicate. 
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ABSTRACT 
 
The p16/CDK4/Cyclin D/Rb pathway is frequently altered in human cancers, in particular melanoma. By 
designing a fluorescent biosensor of CDK4 that reports on compounds that bind the C helix of CDK4 and 
discriminates against ATP-pocket binders, we have identified a class of compounds that bind a novel 
allosteric pocket at the interface between CDK4 and Cyclin D1, thereby inhibiting kinase activity and 
inhibiting melanoma cell proliferation.  
 
XXXX 
The p16/CDK4/Cyclin D/Rb pathway is frequently altered in melanoma, resulting in a hyperactive form of 
CDK4, which therefore constitutes an attractive pharmacological target. Here we report on the 
identification of a family of small molecules that bind a novel allosteric pocket at the interface between 
CDK4 and Cyclin D, tamper with CDK4/Cyclin D kinase activity and inhibit melanoma cell proliferation.  
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INTRODUCTION 
 
Melanoma is the most aggressive form of skin cancer which is lethal when it metastasizes. Current 
melanoma drugs include ipilimumab, a monoclonal antibody which targets CTLA4 (cytotoxic T lymphocyte-
associated antigen 4) and vemurafenib which targets B-Raf mutations1,2. Nevertheless several cancers 
exhibit/develop resistance to these drugs. Therefore, novel targeted therapies are still actively sought for, 
in particular strategies involving cell cycle targets such as CDK43. Indeed the p16 INK4A/CDK4/Cyclin D/Rb 
pathway is frequently altered in melanoma, resulting in a hyperactive form of CDK4, which therefore 
constitutes an attractive pharmacological target, and several inhibitors of this kinase have recently been 
proposed for trials in melanoma therapy3–6. Moreover, in primary invasive melanoma, an increase in gene 
copy number has been reported for CDK4 (37%) and Cyclin D – CCND1 (18%) and loss of CDKN2A 
expression is a frequent event (56%), whilst the combination of gene copy variability in CDK4, CCND1 or 
CDKN2A is associated with poor survival7. 
A wide variety of ATP competitive inhibitors of CDK/cyclins have already been developed for anticancer 
therapeutics6. Whilstfirst generation pan-CDK inhibitors such as flavopiridol or R-roscovitine have shown 
disappointingly low activity and high toxicity in clinical trials due to their notorious lack of selectivity, efforts 
to develop second-generation CDK inhibitors with improved potency and selectivity have yielded 16 ATP-
competitive CDK inhibitors which are currently in clinical trials for anticancer therapy, including the CDK4 
inhibitors PD-0332991, LEE011 and LY2835219, also known as Palbociclib, Ribociclib and Abemaciclib 
respectively8,9. These CDK4 inhibitors offer promising perspectives for Rb-positive melanomas6, but are 
nonetheless poorly efficient in monotherapy, thereby calling for novel classes of drugs for combination 
therapy. Moreover, in primary invasive melanoma, response/sensitivity to PD-0332991 is associated with 
loss, methylation or mutation of p16INK4A (CDKN2A gene product) and resistance to this drug has been 
described in Rb-deficient cancers/cells7.  
Several strategies have been deployed to identify compounds that target sites other than the ATP-binding 
pocket or the catalytic site of cyclin-dependent kinases, but so far no druggable inhibitors have been 
identified10,11. Compounds that targetprotein/protein interactions (PPIs) which are essential for enzyme 
function constitute an attractive alternative, as exemplified by drugs targeting p53/Mdm2 interface12,13. We 
have previously shown that targeting the CDK2/Cyclin A interface with a peptide derived from Cyclin A 
specifically inhibited CDK2 activity without disrupting the complex, and efficiently reduced cancer cell 
proliferation in vitro14. More recent studies further demonstrate that targeting the interface between a CDK 
and a partner protein constitutes a relevant alternative to ATP-competitive inhibitors15,16. Consequently, 
the identification of low-molecular-weight compounds that would tamper with the main interface between 
CDK4 and Cyclin D should constitute a selective means of targeting this kinase and offer novel therapeutic 
perspectives for melanoma.  
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The interaction between CDK4 and Cyclin D is essentially mediated by the PISTVRE helix in the N-terminal 
lobe of CDK4 and the complementary alpha 5 helix of Cyclin D, which is critical for assembly of the 
functional heterodimeric kinase17,18 (Figure 1A). In order to identify compounds that would bind the 
PISTVRE helix, we engineered a fluorescent biosensor derived from the kinase scaffold of CDK4 in which 
cysteine residues 78 and 135 were specifically labelled with the fluorescent dye Cy3, thereby spanning the 
chemical space surrounding the PISTVRE helix (Figure 1B). The CDK4-PISTVRE biosensor is insensitive to 
ATP-competitive inhibitors such as PD-0332991 but responds robustly to Cyclin D1, promoting fluorescence 
enhancement of the Cy3 probes (Figure 1C, Suppl. Fig. 1). As such this biosensor constitutes a highly 
sensitive probe for discriminating against ATP competitive inhibitors and identifying compounds which 
selectively bind the region surrounding the PISTVRE interface. This biosensor was successfully applied to 
screen a library of small chemical compounds (FRED Describe) leading to identification of a compound, 
LPI2251, which enhanced fluorescence of the biosensor to a similar extent as Cyclin D1 (Figure 1D).  
Since the p16/CDK4/Cyclin D/Rb pathway is notoriously deregulated in melanoma, we asked whether this 
compound and two of its derivatives (LPI2252 and RF1210) could inhibit proliferation of the A375 
melanoma cell line (Figure 1E, Suppl. Fig. 4, 5). Both LPI2251 and LPI2252 inhibited melanoma cell 
proliferation to a similar extent as the gold star reference PD-0332991, but RF1210 was more efficient with 
an IG50 13.6 µM compared to 17.6, 17.9 and 18.7 µM for LPI2251, LPI2252 and PD-0332991, respectively. In 
contrast, neither of these compounds displayed any significant inhibition of fibroblasts (Suppl. Fig. 6). We 
further characterized the inhibitory potential of RF1210 towards different cell lines, bearing either wild-
type p16, BRAF and CDK4 (Mewo cells), the NRAS Q61R mutation (SK-MEL2 cell line), the R24C CDK4 and 
BRAF V600E mutation (SKMEL28 cell line) or a loss of function mutation of CDKN2A (p16) and the V600E 
BRaf mutation, but otherwise wild-type CDK4 (A375 cells). This study revealed that RF1210 was most 
efficient against SKMEL2 cells, with IG50 10.1 µM, followed by MV3 with an IG50 10.8 µM, SKMEL28 with an 
IG50 12 µM and A375 cells with IG50 13.6 µM.  (Fig 1F, Suppl. Fig. 7 & 8). 
Finally we asked whether the RF1210 might cooperate with other CDK4 inhibitors in promoting efficient 
inhibition of melanoma cell proliferation (Fig. 1G, Suppl. Fig. 9 & 10). Indeed, at suboptimal concentrations 
of 10 µM RF1210 and 10 µM PD-0332991, the combination of these compounds proved to inhibit 
proliferation of A375 cells more efficiently (72% inhibition) than either compound alone (46% inhibition by 
10 µM RF1210 and 36% inhibition by 10 µM PD-0332991). Likewise, combined administration of RF1210 
with LY2835219 or LEE011 at suboptimal concentrations (15 µM) inhibited A375 proliferation more 
efficiently than either compound alone (73 and 92% inhibition compared to 46% by 10 µM RF1210, 20.5% 
by 15 µM LY2835219 and 59% inhibition by 15 µM LEE011). Finally to completely validate that RF1210 had 
such significant effect on melanoma cell proliferation through inhibition of CDK4/Cyclin D activity, we 
examined the status of Rb phosphorylation.  
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To verify whether these compounds affected CDK4 kinase activity, we asked whether treatment of cells 
with LPI2252 and RF1210 induced a reduction in phosphorylation of Retinoblastoma (Rb), the major 
substrate of CDK4, by Western blotting of treated cell extracts.  
 
In an attempt to identify the binding site of these inhibitors and gain insight into their mechanism of action, 
molecular modelling docking experiments were performed. This study revealed binding of the compounds 
within a pocket that lies beneath the PISTVRE alpha helix of CDK4 (Figure 2A). We further mutagenized 
CDK4-PISTVRE biosensor at the bottom face of the helix and compared binding of RF1210, LPI2251 and 
LPI2252. This experiment revealed a significantly reduced binding affinity of the CDK4 inhibitors to these 
mutants (Figure 2C). Moreover, we synthesized a peptide derived from the PISTVRE helix of CDK4 and 
characterized its affinity for CDK4 inhibitors in fluorescence titration assays using a peptide derived from 
the complementary interface, the alpha 5 helix of Cyclin D1 as a positive control  (Figure 2D). All three 
compounds, LPI2251, LPI2252 and RF1210 enhanced the fluorescence of fluorescently-labelled PISTVRE 
significantly. We repeated this experiment with mutant forms of the PISTVRE peptide, in which 
hydrophobic residues were replaced by charges, and found that mutant fluorescently-labelled PISTVRE 
peptide no longer bound the small molecule inhibitors of CDK4.   
Finally we asked whether LPI2251, LPI2252 and RF1210 interfered either directly or indirectly with ATP, 
cyclin partner or substrate binding. To this aim CDK4 was preincubated with each of these compounds, 
then used to evaluate binding of the Rb substrate, ATP (mant-ATP) in fluorescence titration assays (Figure 
2E). 
Taken together these data highlight a new allosteric pocket in CDK4 as well as a novel class of CDK4 
inhibitors which specifically bind this pocket (LPI2251, LPI2252 and RF1210).  
 
Concluding remarks  
Melanoma is an aggressive and lethal form of skin cancer when it metastasizes in which the 
p16INK4A/CDK4/Cyclin D/Rb pathway is frequently altered, resulting in a hyperactive form of CDK4 kinase. 
Several ATP-competitive inhibitors of CDK4 tested in clinical trials exhibit promising perspectives for Rb-
positive melanomas. However, response to these inhibitors is associated with loss, or functional 
downregulation of p16INK4A, most likely because this endogenous inhibitor of CDK4/Cyclin D prevents 
their binding within the ATP pocket of CDK4. As such, and since the classical mechanism of action of ATP-
competitive inhibitors is notorious for its lack of selectivity, ATP being required for the ensemble of protein 
kinases as well as for several other enzymes and chaperones, alternative strategies to target CDK4 kinase 
function should provide new avenues to develop therapeutics for melanoma. Here we report on a novel 
class of CDK4 inhibitors which we identified thanks to a fluorescent biosensor that discriminates against 
ATP-competitive inhibitors, which preferentially retains compounds that bind the chemical space around 
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the alpha helix of CDK4. These compounds are the first small molecules reported to target the alpha helix 
of CDK4 through binding to a newly identified pocket beneath the PISTVRE helix. We show here that these 
compounds bind the PISTVRE helix of CDK4 and interfere with ATP, partner and substrate binding. 
Moreover, these compounds inhibit melanoma cell proliferation with an efficacy in the same range as PD-
0332991, and further synergize with the latter at sub-IC50 concentrations. Our work clearly suggests that 
dual targeting of CDK4 kinase with an ATP-competitive and a non-ATP-competitive inhibitor may provide a 
more effective means of targeting its function in melanoma, thereby offering new therapeutic perspectives 
to target the p16/CDK4/Cyclin D/Rb pathway in this deadly disease.  
 
FIGURE LEGENDS 
FIGURE 1 – Identification of compounds that target the PISTVRE helix of CDK4 and inhibit melanoma cell 
proliferation. A. Structure of CDK4/Cyclin D highlighting the interface between the PISTVRE helix of CDK4 
and the alpha 5 helix of Cyclin D1. B. Schematic representation of CDK4-PISTVRE biosensor and C. its 
response to Cyclin D1 and PD-0332991. D. Fluorescence response of CDK4-PISTVRE to positive (Cyclin D) 
and negative (peptide) controls, PD-0332991 and LPI2251 in the screen. E. Proliferation inhibition assays of 
LPI2251, LPI2252 and RF1210 in A375 cells. F. Proliferation inhibition assays of RF1210 in different 
melanoma cell lines: A375 cells (CDKN2A loss of function, BRaf V600E), SKMEL28 (wt CDKN2A, R24C CDK4, 
BRaf V600E), SKMEL2 (NRas mutation (Q61R)), Mewo (CDKN2A loss of function, Wt CDK4) and fibroblasts. 
G. Comparison of inhibition potential of RF1210, PD-0332991 and coadministrated compounds at sub IG50 
concentrations. H. Comparison of inhibition potential of RF1210, Paclitaxel and coadministrated 
compounds atsub IG50 concentrations. I. Western blot of phosphoRb status in cell extracts treated with 
inhibitors as described in G and H.  
 
FIGURE 2 – Identification of the binding site and mechanism of action of RF1210, LPI2251 and LPI2252.  
A. Molecular Docking of RF1210, LPI2251 and LPI2252 onto CDK4/Cyclin D1. B. Structural representation of 
RF1210, LPI2251 and LPI2252. C. Fluorescence binding assay of inhibitors to TP2-Rho-PISTVRE peptide and 
mutants of the PISTVRE helix. D. Fluorescence binding assay of inhibitors to a CDK4-derived PISTVRE 
peptide and its mutants. E. Fluorescence titration of CDK4 and CDK4-inhibitor complexes with mant-ATP. F. 
Fluorescence titration of CDK4 and CDK4-inhibitor complexes with FITC-Rb substrate peptide. G. 
Fluorescence titration of CDK4-PISTVRE and CDK4-PISTVRE/inhibitor complexes with Cyclin D. 
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SUPPLEMENTAL FIGURES & TABLES 
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Supplementary Figure 1 – Optimization of concentrations and Kinetics for the Screen 
A. 25 nM Cy3-labelled CDK4-PISTVRE biosensor was incubated with 2 µM positive control (recombinant 
Cyclin D1) or negative control (irrelevant peptide) and fluorescence emission intensity of Cy3 was 
monitored over time. B. Different concentrations of CDK4-PISTVRE-Cy3 labelled biosensor were incubated 
with 2 µM controls and fluorescence emission intensity of Cy3 was measured at 5h. C. 25 nM CDK4-
PISTVRE-Cy3 labelled biosensor was incubated with different concentrations of controls and fluorescence 
emission intensity of Cy3 was measured at 5h. Experiments were performed in duplicate and error bars 
indicate the standard deviation of positive and negative controls.  
 
Supplementary Figure 2 – Dose response of CDKCONF4A-Cy3 to LPI2251 variants 
 
Supplementary Figure 3 – Fluorescence emission spectra of LPI2251 derivatives - do not fluoresce following 
excitation at 510 nm 
 
Supplementary Figure 4 – A375 melanoma cell proliferation assays performed with LPI2251, LPI2252, 
RF1210 and PD-0332991  
 
Supplementary Figure 5 – A375 melanoma cell proliferation assays performed with LEE011, LY2835219, 
Paclitaxel and Methotrexate  
 
Supplementary Figure 6 – Fibroblast proliferation assays performed with LPI2251, LPI2252, RF1210 and PD-
0332991  
 
Supplementary Figure 7 – Comparative cell proliferation assays performed with RF1210 and PD-0332991 
on A375 and MV3 melanoma cell lines  
 
Supplementary Figure 8 – Comparative cell proliferation assays performed with RF1210 and PD-0332991 
on SKMEL2 and SKMEL-28 melanoma cell lines  
 
Supplementary Figure 9 – A375 cell proliferation assays performed with RF1210, PD-0332991 or 
LY2835219, either alone or combined at sub IG50 concentrations 
 
Supplementary Figure 10 – A375 cell proliferation assays performed with LPI2252, PD-0332991 or 
LY2835219, either alone or combined at sub IG50 concentrations 
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Supplementary Figure 11 – A375 cell proliferation assays performed after 48h with 10 µM RF1210, 15 µM 
LEE011, 15 µM LY2835219, 15 µM Paclitaxel, 15 µM Methotrexate, 10 µM PD-0332991 either alone or 
combined at sub IG50 concentrations 
 
Supplementary Figure 12 – A375 cell proliferation assays performed after 48h with 10 µM LPI2252, 15 µM 
LEE011, 15 µM LY2835219, 15 µM Paclitaxel, 15 µM Methotrexate, 10 µM PD-0332991 either alone or 
combined at sub IG50 concentrations 
 
Online methods - Experimental section 
Design and engineering of CDK4 PISTVRE biosensor and mutants. The cDNA sequence of mouse CDK4 was 
cloned into the pGex6P1 vector (GE Healthcare) 5’BamHI 3’ EcoRI. Cysteine residues 202 and 215 were 
mutagenized to serine, so as to yield a mutant bearing only two cysteine residues, 78 and 135, spanning the 
PISTVRE helix of CDK4. The « bottom » V51E S52R L59R L60R L63R and « top » T53K V54E V57E A58E A65E 
of CDK4-PISTVRE biosensor were further generated by site directed mutagenesis. Site-directed mutagenesis 
was performed according to the QuickStart protocole (Strategene) and all mutants were completely 
sequenced to verify the presence of the desired mutation and absence of any other undesired mutations or 
stop codons. 
 
Protein expression and purification of cyclin-dependent kinases. Recombinant GST-CDK4 and Cyclin D 
were expressed in E. coli by IPTG induction and purified by chromatography as described previously14, first 
on a GST-Trap column, then by gel filtration chromatography.  
 
Fluorescence titration experiments 
Fluorescence titration assays were performed in 96-well plates using a Clariostar spectrofluorimeter (BMG) 
in 200 mL PBS (Sigma), 150 mM NaCl. The fluorescence of Cy3-labelled CDK4-PISTVRE biosensor with 
recombinant Cyclin D, PD-0332991 or small molecules was acquired at 570 nm following excitation at 550 
nm. The fluorescence of TP2-Rho-labelled PISTVRE peptide with D1 peptide (derived from the 
complementary interface in Cyclin D1), with a control peptide, PD-0332991 or small molecules was 
acquired at 510 nm following excitation at 614 nm. Data analysis was performed using the GraFit Software 
(Erathicus Ltd). Experiments were performed in triplicate, and error bars indicate standard deviation from 
average. 
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Peptide synthesis and labelling 
PISTVRE (GGGCPISTVRAVALLRRL), D1 (SIRPEELLQMELLLVNKLKWNLC) and control 
(VESSDTIDNVKSKIQDKEGC) peptides were purchased from GLS Biochem, (Shanghai, China), and were 
labelled on their unique cysteine with TP2-Rho-maleimide (F.Mahuteau) then further purified on NAP-5 
columns (GE Healthcare) as described previously19. 
 
Small molecule inhibitors 
PD-0332991 (Palbociclib), LEE011 (Ribociclib), LY2835219 (Abemaciclib), Vemurafenib, Cisplatin, Paclitaxel 
and Methotrexate were all purchased from Euromedex and resuspended in DMSO, according to the 
manufacturer’s advice.  
 
CDK4 kinase activity assays 
CDK4 kinase activity assays were performed using GST-CDK4 kinase incubated with A375 cell extracts as a 
source of active CDK4/Cyclin D complexes which phosphorylate and increase the fluorescence of the 
CDKACT biosensor20. As a control, kinase activity assays were performed with PD-0332991. Fluorescence 
kinase assays were performed as described previously20 in 96-well plates in a thermostated chamber using 
a ClariostarTM spectrofluorimeter (BMG) at 30°C in 200mL PBS (Sigma) supplemented with 5 mM MgCl2, 
0.5mM ATP. The fluorescence of Cy3-labelled CDKACT was monitored over time. In all experiments, relative 
fluorescence was calculated following subtraction of CDKACT-Cy3 fluorescence from fluorescence values 
obtained in the presence of CDK4/Cyclin D kinase incubated with or without inhibitors. Data analysis was 
performed using the GraFit Software (Erathicus Ltd). Experiments were performed in triplicate, and error 
bars indicate standard deviation from average. 
 
Automated high throughput screen conditions and hit validation 
Prior to the HTS, stability assays and downscaling experiments were performed to establish the best 
conditions for a miniaturized assay in 96-well plates and optimized so as to obtain a robust and 
reproducible signal. Performance criteria for reproducibility, sensitivity (in the presence of DMSO), 
tolerance and robustness were established with the ATP-competitive inhibitor of CDK4 PD-0332991, and a 
control peptide that barely affected Cy3-labelled CDK4-PISTVRE biosensor fluorescence and the 2 mM Cyclin 
D, as a positive control, that promotes significant enhancement of Cy3-labelled CDK4-PISTVRE biosensor 
fluorescence. Optimal screening conditions were established as follows: 25 nM freshly purified Cy3-labelled 
CDK4-PISTVRE biosensor in 50 mM KH2PO4/K2HPO4, pH 6.5, 500 mM NaCl, 1% DMSO, for 5 hours at room 
temperature in the dark. Prescreen Conditions: amplification by positive control (Cyclin D) 1.8 fold 
enhancement. Prescreen Zfactor = 0.89. 
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The screen itself was performed in 96-well black Greiner Bio One plates. Compounds from the library were 
used at 10-5 M final concentration against 25 nM Cy3-labelled CDK4-PISTVRE biosensorin 50 mM 
KH2PO4/K2HPO4, pH 6.5, 500 mM NaCl and fluorescence emission of Cy3 was measured at 570 nm following 
excitation at 550 nm after 3 hours. The screen was performed on a TECAN Freedom Evo Robot. In parallel, 
the intrinsic fluorescence of the library compounds at 570 nm following excitation at 550 nm was 
determined, to eliminate autofluorescent compounds. The increase in fluorescence was calculated with 
reference to the basal fluorescence of Cy3-labelled CDK4-PISTVRE biosensor alone and is expressed as the 
percentage of increase. A molecule was considered a hit when it was not autofluorescent, yet induced 
amplification of Cy3-labelled CDK4-PISTVRE biosensor fluorescence 3 times or greater the standard 
deviation of CDK4-PISTVRE biosensorfluorescence alone (or p=0.01). 
Hits identified in the screen were retested manually in quadruplet to confirm they were positive hits with a 
fresh batch of Cy3-labelled CDK4-PISTVRE biosensor and stock solutions of the library compounds in DMSO.  
 
Cell culture and extract preparation 
Melanoma cell lines used in this study: 
  CDKN2A  CDK4  Rb BRAF  NRAS  
A375 mutated (E61Stop, Loss of function) WT WT V600E WT 
Mewo mutated (R80Stop, Loss of function) WT WT WT WT 
MV3      
SKMEL2 WT WT WT WT mutated (Q61R) 
SKMEL28 WT R24C 
 
V600E WT 
 
Cell culture media, serum and antibiotics were purchased from Life Technologies. Cells were cultured in 
DMEM/RPMI + Glutamax supplemented with 10% FCS, 100 units/mL penicillin (G sodium salt) and 100 
µg/mL streptomycin at 37°C in an atmosphere containing 5% CO2. 
Cell extracts were prepared in PBS lysis buffer pH 7.4, 0.2% NP40, 1 mM EDTA, 2 mM PMSF, CompleteTM 
protease inhibitors (Roche), and normalized following spectrophotometric dosage at 280 nm.  
 
Chemical Synthesis of Small Molecule Inhibitors - FRED 
Small Molecules … 
Library …. 
 
DOCKING Experiments - Nicolas 
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Supplementary Figure 1 – Optimization of concentrations and Kinetics for the Screen
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Supplementary Figure 2 – Dose response of CDK4-PISTVRE-Cy3 to LPI2251 variants
Supplementary Figure 3 – Fluorescence emission spectra of PISTVRE-TP2-Rho and LPI
derivatives
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Supplementary Figure 4 – Proliferation assays in melanoma A375 cell line
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Supplementary Figure 5 – Proliferation assays in melanoma A375 cell line
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Supplementary Figure 6 – Proliferation assays in fibroblasts
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Supplementary Figure 7 – Proliferation assays – Comparison PD-0332991 & RF1210 in different 
melanoma cell lines
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Supplementary Figure 8 – Proliferation assays – Comparison PD-0332991 & RF1210 in different 
melanoma cell lines
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Supplementary Figure 9 – Synergy assays with RF1210 – A375 cells
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Supplementary Figure 10 – Synergy assays with LPI2252 – A375 cells
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Supplementary Figure 11 – Synergy assays – A375 cells
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Supplementary Tables – Summary of IG50 values determined for melanoma cell lines
IG50 (PD-0332991) (µM) IG50 (RF1210) (µM)
A375 18.7 +/- 0.4 13.6 +/- 0.4
MV3 11.0 +/- 0.8 10.8 +/- 4.4
SKMEL2 10.7 +/- 1.6 10.1 +/- 1.0
SKMEL28 11.5 +/- 3.2 12.0 +/- 0.2
A375 IG50 (µM)
RF1210 13.6 +/- 0.4
LPI2251 17.6 +/- 0.5
LPI2252 17.9 +/- 2.2
PD-0332991 18.7 +/- 0.4
CDKN2A CDK4 Rb BRAF NRAS 
A375 mutated (E61Stop. Loss of function) WT WT V600E WT
Mewo mutated (R80Stop. Loss of function) WT WT WT WT
MV3 ND ND ND WT WT
SK-MEL2 WT WT WT WT mutated (Q61R)
SK-MEL28 WT R24C WT V600E WT
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